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Loss of rad51 in zebrafish (Danio rerio): 
a novel Fanconi anaemia model 
Jan Botthof 
Abstract  
RAD$% is an indispensable homologous recombination protein, necessary for strand 
invasion and crossing over. It has recently been designated as a Fanconi anaemia (FA) 
gene, following the discovery of two patients carrying dominant negative mutations. FA 
is a hereditary DNA repair disorder characterised by various congenital abnormalities, 
progressive bone marrow failure and cancer predisposition. The cellular and molecular 
pathology of FA is poorly understood, resulting in a severe lack of eﬀective treatment 
options. In this thesis, I describe the ﬁrst viable vertebrate model of RAD$% loss. 
Phenotypic characterisation of zebraﬁsh rad$% loss-of-function mutants showed that 
they develop key features of FA, including hypocellular kidney marrow, sensitivity to 
crosslinking agents and decreased size. Taking advantage of the unique properties of the 
zebraﬁsh model, I show that some of these symptoms stem from both decreased 
proliferation, as well as increased apoptosis of embryonic haematopoietic stem and 
progenitor cells. Co-mutation of p$L was able to rescue the haematopoietic defects seen 
in the single mutants, but led to tumour development, underscoring the role of rad$% as 
a tumour suppressor. I further demonstrate that prolonged inﬂammatory stress can 
exacerbate the haematological impairment, leading to an additional decrease in kidney 
marrow cell numbers. In contrast, prolonged aldehyde-derived stress did not induce 
symptoms in the mutant ﬁsh. These ﬁndings strengthen the assignment of RAD$% as a 
Fanconi gene and provide more evidence for the notion that aberrant p$L signalling 
during embryogenesis leads to the haematological defects seen later in life in FA. It also 
strengthens the evidence for the involvement of haematopoietic stress, such as 
inﬂammation, in the development of bone marrow failure. Further research on this 
novel zebraﬁsh FA model will lead to a deeper understanding of the molecular basis of 
bone marrow failure in FA and the cellular role of RAD$%.  
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Blut ist ein ganz besondrer Saft. 
[Blood is juice of a very special kind.] 
—“Mephistopheles” in Faust I by Johann Wolfgang von Goethe (%lQl) 
 
Table of contents 
	vi	
Table of contents 
Abstract ....................................................................................................................... i 
Declaration ................................................................................................................. ii 
Acknowledgements .................................................................................................. iii 
Table of contents ...................................................................................................... vi 
List of figures ............................................................................................................. x 
List of tables ............................................................................................................ xii 
List of abbreviations ................................................................................................ xiii 
1 Introduction ............................................................................................................. 1 
1.1 The history of Fanconi anaemia ..................................................................... 1 
1.2 Symptoms ......................................................................................................... 2 
1.2.1 Congenital features ..................................................................................... 2 
1.2.2 Haematological features ............................................................................. 5 
1.2.3 FA and cancer ............................................................................................. 6 
1.3 Incidence .......................................................................................................... 7 
1.4 Prognosis .......................................................................................................... 7 
1.5 Treatment ......................................................................................................... 8 
1.5.1 Supportive therapies ................................................................................... 9 
1.5.1.1 Non-targeted therapies ........................................................................ 9 
1.5.1.2 Targeted therapies/small molecules ................................................... 10 
1.5.2 Potentially curative therapies .................................................................... 10 
1.5.2.1 Bone marrow transplantation ............................................................. 10 
1.5.2.2 Gene therapy ...................................................................................... 12 
1.5.3 Novel challenges and future perspective .................................................. 13 
1.6 Fanconi anaemia genes ................................................................................ 13 
1.6.1 Types of FA genes .................................................................................... 14 
1.6.2 Assignment of FA genes ........................................................................... 15 
1.6.3 Genotype-phenotype variability ................................................................ 16 
1.7 Cellular pathology and bone marrow failure in Fanconi anaemia ............ 17 
1.7.1 Fanconi anaemia is caused by a HSPC defect ......................................... 18 
1.7.2 HSPC defects start during embryonic/foetal development ...................... 19 
1.7.3 Signalling pathways mediating HSPC defects .......................................... 19 
1.7.4 Aldehyde hypersensitivity ......................................................................... 21 
1.7.5 Oxidative stress ......................................................................................... 21 
1.7.6 Autophagy defects .................................................................................... 22 
1.7.7 Abnormal inflammatory signalling ............................................................. 23 
1.7.8 Telomere defects in Fanconi anaemia ...................................................... 23 
1.7.9 Replication fork protection ........................................................................ 24 
1.7.10 Cytokinesis .............................................................................................. 25 
1.7.11 Aberrant TGFb signalling ......................................................................... 25 
1.7.12 Additional functions of the Fanconi anaemia pathway ........................... 26 
1.7.13 Summary ................................................................................................. 26 
Table of contents 
 vii 
1.8 The Fanconi anaemia pathway ..................................................................... 26 
1.8.1 Interstrand crosslink removal .................................................................... 30 
1.8.1.1 Crosslink recognition .......................................................................... 30 
1.8.1.2 Nucleolytic incision ............................................................................. 31 
1.8.1.3 Translesion synthesis ......................................................................... 31 
1.9 Homologous recombination ......................................................................... 32 
1.9.1 Presynaptic phase ..................................................................................... 32 
1.9.2 Synaptic phase ......................................................................................... 34 
1.9.3 Postsynaptic phase ................................................................................... 34 
1.9.3.1 Double Holliday junction resolution .................................................... 35 
1.9.3.2 Synthesis-dependent strand annealing .............................................. 35 
1.9.3.3 Break-induced replication .................................................................. 35 
1.10 RAD51 ........................................................................................................... 37 
1.10.1 Evolution ................................................................................................. 37 
1.10.2 Structure-function relationship ............................................................... 37 
1.10.3 Function in meiosis and lymphopoiesis .................................................. 39 
1.10.4 RAD51 in Fanconi anaemia ..................................................................... 39 
1.11 Zebrafish as a model organism in haematology ....................................... 42 
1.11.1 Historical developments .......................................................................... 42 
1.11.2 Zebrafish haematopoiesis ....................................................................... 43 
1.11.3 The Fanconi anaemia pathway in zebrafish ............................................ 45 
1.12 Aims .............................................................................................................. 48 
2 Materials and methods ........................................................................................ 49 
2.1 Zebrafish care and strains ............................................................................ 49 
2.2 Genomic DNA extraction and genotyping ................................................... 49 
2.3 Western blotting ............................................................................................. 50 
2.4 Immunostaining ............................................................................................. 51 
2.5 Microscopy ..................................................................................................... 52 
2.6 Embryo irradiation ......................................................................................... 52 
2.7 Chromosome spreads ................................................................................... 52 
2.8 NHEJ inhibition .............................................................................................. 53 
2.9 CRISPR-Cas9 ................................................................................................. 53 
2.10 Fish photography ......................................................................................... 53 
2.11 Semen collection ......................................................................................... 53 
2.12 Histology ....................................................................................................... 54 
2.13 RNA extraction and RT-qPCR .................................................................... 54 
2.14 Single-cell suspension and cell counts ..................................................... 55 
2.15 Kidney flow cytometry ................................................................................. 56 
2.16 AnnexinV-propidium iodide assay .............................................................. 58 
2.17 BrdU incorporation assays ......................................................................... 59 
2.17.1 Adult fish ................................................................................................. 59 
2.17.2 Embryos .................................................................................................. 60 
2.18 Blood smears ............................................................................................... 61 
2.19 Antisense probe synthesis .......................................................................... 61 
2.20 In-situ hybridisation (ISH) ........................................................................... 62 
2.21 Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labelling 
(TUNEL) ................................................................................................................. 63 
Table of contents 
	viii	
2.22 Sudan black staining ................................................................................... 63 
2.23 Bulk RNA-Seq .............................................................................................. 64 
2.24 Stem cell transplantation ............................................................................ 66 
2.24.1 Genotyping of rag2E450fs recipients .......................................................... 66 
2.24.2 Transplantation ....................................................................................... 66 
2.25 Treatments to trigger stress haematopoiesis ........................................... 66 
2.25.1 Dose estimations ..................................................................................... 66 
2.25.2 Long-term pI:pC injections ..................................................................... 67 
2.25.3 Long-term pI:pC injections with BrdU .................................................... 67 
2.25.4 Long-term acetaldehyde injections ......................................................... 67 
2.25.5 Ethanol treatment .................................................................................... 67 
2.26 Statistical analysis ....................................................................................... 67 
2.27 Data visualisation ......................................................................................... 68 
3 Characterisation of rad51 mutant zebrafish ...................................................... 69 
3.1 Introduction .................................................................................................... 69 
3.1.1 Models of rad51 deficiency ....................................................................... 69 
3.1.2 FA model systems ..................................................................................... 70 
3.2 Results ............................................................................................................ 73 
3.2.1 Embryonic non-haematopoietic phenotypes ............................................ 73 
3.2.1.1 The rad51sa23805 allele leads to complete loss of functional Rad51 
protein ............................................................................................................ 73 
3.2.1.2 Embryos lacking Rad51 develop micropthalmia ................................ 75 
3.2.1.3 The embryonic DNA damage response is impaired in rad51 mutant 
embryos .......................................................................................................... 75 
3.2.1.4 Rad51b partially compensates for Rad51 loss .................................. 81 
3.2.2 Adult non-haematological phenotypes ..................................................... 82 
3.2.2.1 Rad51 mutants display congenital defects resembling FA ................ 82 
3.2.2.2 Lack of rad51 leads to excess DNA damage in exposed tissues ...... 85 
3.2.3 Haematological phenotypes ..................................................................... 86 
3.2.3.1 Adult rad51 mutants display a hypocellular kidney marrow ............... 86 
3.2.3.2 Rad51 mutants develop macrocytic erythrocytes with ageing .......... 89 
3.2.3.3 Apoptosis is not increased in the WKM of adult rad51-/- fish ............. 90 
3.2.3.4 Establishing a BrdU pulse-chase system in adult zebrafish .............. 91 
3.2.3.5 Proliferation is paradoxically increased in the WKM of rad51-/- fish ... 92 
3.2.3.6 Rad51 mutants form fewer HSPCs during embryonic development . 94 
3.2.3.7 Most mature blood cells are unaffected in rad51-/- embryos ............. 96 
3.2.3.8 Haematopoietic stem cell transplantation experiments ..................... 98 
3.2.3.9 RNA-Seq reveals a differential p53 response in different cell types 102 
3.3 Discussion .................................................................................................... 104 
4 BMF in FA: molecular signalling ........................................................................ 111 
4.1 Introduction .................................................................................................. 111 
4.1.1 The p53 protein and pathway ................................................................. 111 
4.1.2 The role of p53 in HSPCs ........................................................................ 112 
4.1.3 Zebrafish p53 .......................................................................................... 113 
4.1.4 The role of p53 in FA ............................................................................... 114 
4.2 Results .......................................................................................................... 116 
4.2.1 Expression in embryos and adults .......................................................... 116 
Table of contents 
 ix 
4.2.2 Characterisation of rad51, p53 double mutants ..................................... 117 
4.2.3 Co-mutation of p53 partially rescues congenital phenotypes ................ 117 
4.2.4 Double mutant fish develop tumours ...................................................... 118 
4.2.5 Haematological defects in rad51-/- embryos are rescued when p53 is     
co-mutated ....................................................................................................... 119 
4.2.6 Co-mutation of p53 also rescues adult WKM defects ............................ 121 
4.2.7 Loss of p53 on its own can also affect haematopoiesis ......................... 122 
4.3 Discussion .................................................................................................... 126 
5 BMF in FA: initial triggers .................................................................................. 129 
5.1 Introduction .................................................................................................. 129 
5.1.1 Inflammation in FA pathogenesis ............................................................ 129 
5.1.1.1 The effects of inflammation on HSCs ............................................... 130 
5.1.1.2 Cytokine hypersensitivity .................................................................. 131 
5.1.1.3 Cytokine overproduction .................................................................. 131 
5.1.2 Aldehydes in FA pathogenesis ................................................................ 132 
5.1.2.1 Sources of aldehydes ....................................................................... 132 
5.1.2.2 Aldehyde scavengers ....................................................................... 133 
5.1.2.3 DNA damage induced by aldehydes ................................................ 133 
5.1.2.4 Evidence for aldehydes as main damaging molecules in FA 
pathogenesis ................................................................................................ 134 
5.2 Results .......................................................................................................... 135 
5.2.1 Modelling the influence of prolonged inflammation in FA ....................... 135 
5.2.1.1 Establishing a zebrafish model of prolonged inflammation .............. 135 
5.2.1.2 Prolonged inflammation exacerbates the phenotype of rad51     
mutant fish .................................................................................................... 137 
5.2.2 Modelling the role of acetaldehyde-induced damage in FA ................... 144 
5.2.2.1 Acetaldehyde dose estimation ......................................................... 144 
5.2.2.2 Aldehyde-derived stress in rad51 mutant zebrafish ......................... 144 
5.2.2.3 Alcohol-derived stress in rad51 mutant embryos ............................ 146 
5.3 Discussion .................................................................................................... 148 
6 Discussion ........................................................................................................... 153 
6.1 Insights into the aetiology of FA ................................................................. 153 
6.1.1 A model for BMF in FA ............................................................................ 153 
6.1.2 Implications for FA patients .................................................................... 155 
6.1.3 Limitations and open questions .............................................................. 156 
6.1.4 Future research on my FA model ............................................................ 157 
6.2 Looking beyond FA ...................................................................................... 158 
6.2.1 A novel system to study Rad51 .............................................................. 158 
6.2.2 Zebrafish sex determination and meiosis ............................................... 159 
6.3 Conclusion .................................................................................................... 159 
References ............................................................................................................. 161 
Appendix ................................................................................................................ 199	
Figures 
	x	
Figures 
Figure 1.1: FA patients have various congenital abnormalities ................................... 3 
Figure 1.2: FA patients are sensitive to crosslinking agents. ...................................... 5 
Figure 1.3: Summary of FA treatment approaches. .................................................... 9 
Figure 1.4: Mutations in a subset of Fanconi genes cause almost all cases of FA .. 15 
Figure 1.5: Summary of the different mechanisms that have been proposed as the 
trigger of BMF in FA. .......................................................................................... 18 
Figure 1.6: Overview of ICL repair by the FA pathway .............................................. 28 
Figure 1.7: Ways of resolving HR .............................................................................. 36 
Figure 1.8: RAD51 crystal structures. ....................................................................... 38 
Figure 1.9: Location of the FA associated mutations on the RAD51 filament .......... 41 
Figure 1.10: Locations of haematopoiesis in the zebrafish embryo .......................... 44 
Figure 1.11: Sites of haematopoiesis in adult zebrafish ............................................ 45 
	
Figure 2.1: General FACS gating scheme ................................................................. 56 
Figure 2.2: Selection of the erythrocytic lineage ....................................................... 57 
Figure 2.3: Selection of the thrombocytic lineage ..................................................... 57 
Figure 2.4: Identification of different blood lineages using the forward and side 
scatter parameters ............................................................................................. 58 
Figure 2.5: Gating for apoptotic cells ........................................................................ 59 
Figure 2.6: Gating for BrdU+ cells on fixed cells ....................................................... 60 
Figure 2.7: Gating strategy for the RNA-Seq experiment ......................................... 64 
 
Figure 3.1: The rad51sa23805 allele leads to complete loss of functional Rad51 protein
 ........................................................................................................................... 74 
Figure 3.2: Embryos with rad51 mutation are micropthalmic ................................... 75 
Figure 3.3: Loss of rad51 leads to DNA damage sensitivity ..................................... 76 
Figure 3.4: rad51 mutation leads to crosslinker sensitivity ....................................... 79 
Figure 3.5: Outcrossing increases mutant survival ................................................... 79 
Figure 3.6: Rad51 is expressed in single-cell stage embryos ................................... 80 
Figure 3.7: NHEJ inhibition does not lead to synthetic lethality in rad51 mutants .... 81 
Figure 3.8: Adult rad51 mutant fish are smaller than their wild type siblings ............ 83 
Figure 3.9: rad51 mutant fish are all infertile males ................................................... 84 
Figure 3.10: The intestine is unaffected in rad51 mutant fish ................................... 85 
Figure 3.11: qPCR analysis of different tissues ........................................................ 86 
Figure 3.12: WKM cell number is halved in mutants ................................................. 87 
Figure 3.13: Ageing causes a shift towards myeloid cells in the WKM ..................... 88 
Figure 3.14: Mutants develop macrocytic erythrocytes ............................................ 90 
Figure 3.15: Apoptosis is not increased in the WKM of rad51 mutants .................... 91 
Figure 3.16: Establishing a BrdU pulse-chase system in zebrafish .......................... 92 
Figure 3.17: Proliferation is increased in the WKM of rad51 mutants ....................... 93 
Figure 3.18: The rad51sa23805 HSPC defect starts during embryonic development ... 95 
Figure 3.19: The number of lymphocytes is decreased in embryonic rad51     
mutants, whereas other lineages are unaffected ............................................... 97 
Figure 3.20: Establishing an irradiation dose for transplantation .............................. 99 
Figures 
 xi 
Figure 3.21: Initial trial transplantation trial ............................................................. 101 
Figure 3.22: The GFPlow population of Tg(cd41:EGFP) WKM lacks long-term 
engraftment potential ....................................................................................... 102 
	
Figure 4.1: The expression of p53 differs between embryos and adult fish ........... 116 
Figure 4.2: Co-mutation of rad51 and p53 can rescue some congenital     
phenotypes seen in the single mutants ........................................................... 118 
Figure 4.3: Double mutants are susceptible to tumourigenesis .............................. 119 
Figure 4.4: The embryonic HSPC defects in rad51sa23805 fish are rescued in a p53 
mutant background .......................................................................................... 120 
Figure 4.5: The adult WKM defects in rad51sa23805 fish are rescued in a p53 mutant 
background ...................................................................................................... 121 
Figure 4.6: p53 co-mutation reverts the blood lineage bias seen in single        
mutants ............................................................................................................ 122 
Figure 4.7: p53 mutation can increase HSPC numbers independently from rad51 
mutation ........................................................................................................... 123 
Figure 4.8: Neutrophils are increased in p53 mutant embryos ............................... 124 
	
Figure 5.1: A bolus injection of pI:pC can induce the expression of marker genes    
for inflammation ............................................................................................... 136 
Figure 5.2: Long-term pI:pC injection trial .............................................................. 137 
Figure 5.3: Repeated pI:pC injections elicit a different inflammatory response      
than single injections ........................................................................................ 138 
Figure 5.4: Prolonged inflammation leads to an increase of monocytes in the PB 139 
Figure 5.5: Prolonged inflammation leads to an exacerbation of the mutant 
phenotype ........................................................................................................ 141 
Figure 5.6: The p53 pathway responds differently to prolonged inflammation in     
WT and mutant fish .......................................................................................... 142 
Figure 5.7: Prolonged inflammation can abrogate the excess proliferation in the 
mutant WKM .................................................................................................... 143 
Figure 5.8: Mutation in rad51 does not lead to acetaldehyde sensitivity ................ 145 
Figure 5.9: Ethanol does not affect rad51 mutant embryos more strongly than     
their WT siblings ............................................................................................... 147 
	
Figure 6.1: Proposed model of FA pathogenesis .................................................... 154 
Tables 
	xii	
Tables 
Table 1.1: Summary of congenital features observed in FA patients ......................... 4 
Table 1.2: Fanconi genes in humans ......................................................................... 14 
Table 1.3: Conservation of the FA gene network among several common model 
organisms ........................................................................................................... 46 
 
Table 2.1: KASP Primers used for genotyping. ......................................................... 50 
Table 2.2: List of antibodies ...................................................................................... 51 
Table 2.3: Primers used for qPCR analysis. .............................................................. 55 
Table 2.4: Vectors used to generate ISH probes ...................................................... 62 
Table 2.5: Cycling conditions for cDNA synthesis .................................................... 65 
Table 2.6: Cycling conditions for PCR amplification ................................................. 65 
 
Table 3.1: Co-mutation of rad51 and rad51b is lethal ............................................... 82 
 
Table 4.1: Quantification of the staining data presented in Figure 4.4 ................... 120 
Abbreviations 
 xiii 
Abbreviations 
AAA+ ATPases associated with diverse cellular activities 
AD autosomal dominant 
ADP adenosine diphosphate 
AGM aorta-gonad mesonephros  
ALDH aldehyde dehydrogenase 
ALM Anterior lateral plate mesoderm 
ALT alternative lengthening of telomeres 
AML acute myeloid leukaemia 
ANOVA analysis of variance 
AP alkaline phosphatase 
AR autosomal recessive 
ASCE additional strand conserved E 
ATP adenosine triphosphate 
ATR ataxia telangiectasia and RAD3-related kinase 
AV annexin V 
BIR break-induced repair 
BM bone marrow 
BMF bone marrow failure 
BMT bone marrow transplantation 
bp basepair 
BSA bovine serum albumin 
CHT caudal haematopoietic tissue 
CI confidence interval 
CPT camptothecin 
Abbreviations 
	xiv	
CRISPR Clustered regularly interspaced short palindromic repeats 
DAMP danger-associated molecular patterns 
DAPI 4',6-diamidino-2-phenylindole 
DEB diepoxybutane 
dHJ double Holliday junction 
DiQ 1,5-isoquinolinediole 
DMSO dimethylsulphoxide  
DNA deoxyribonucleic acid 
DNAP DNA polymerase 
dpf days post fertilisation 
dpi days post injection 
dpt days post transplantation 
DSB double-stranded break 
dsDNA double-stranded DNA 
DTT dithiothreitol 
dUTP deoxyuridine triphosphate 
EGFP enhanced GFP 
ENU N-ethyl-N-nitrosourea 
ERCC External RNA Controls Consortium 
ES embryonic stem  
EtOH ethanol 
FA Fanconi anaemia 
FACS fluorescence-activated cell sorting 
FBS foetal bovine serum 
FSC forward scatter 
G-CSF granulocyte-colony stimulating factor 
Abbreviations 
 xv 
GFP green fluorescent protein 
GO gene ontology 
GSH glutathione-SH 
GVHD graft versus host disease 
H&E haematoxylin and eosin 
HIV human immunodeficiency virus 
HJ Holliday junction 
HLA human leukocyte antigen 
hpf hours post fertilisation 
hpi hours post injection 
HPV human papilloma virus 
HR homologous recombination 
HSC haematopoietic stem cell 
HSCT haematopoietic stem cell transplantation 
HSPC haematopoietic stem and progenitor cells 
I injected 
ICL interstrand crosslink 
ICM intermediary cell mass 
IL interleukin 
IP intraperitoneal 
IS immunostaining 
ISH in-situ hybridisation 
IVF-PGD in-vitro fertilisation-preimplantation genetic diagnostics 
KASP competitive allele-specific PCR 
KEGG Kyoto Encyclopedia of Genes and Genomes 
KO knockout 
Abbreviations 
	xvi	
LOF loss of function 
LPM lateral plate mesoderm 
LPS lipopolysaccharide 
LT-HSC long-term haematopoietic stem cell 
MAPK mitogen activated protein kinase 
MBT mid-blastula transition 
MDS myelodysplastic syndrome 
MeOH methanol 
MMC mitomycin C 
MPNST malignant peripheral nerve sheath tumour 
N2-ethyl-dG N2-ethyl-2-deoxyguanosine 
NBT/BCIP nitro-blue tetrazolium and 5-bromo-4-chloro-3’-indolyphosphate 
NER nucleotide excision repair 
NHEJ non-homologous end joining 
NI non-injected 
NK natural killer  
PAMP pathogen-associated molecular pattern 
PARP poly ADP ribose polymerase  
PB peripheral blood 
PBI peripheral blood island 
PBS phosphate buﬀered saline 
PCR polymerase chain reaction 
PDB Protein Database 
PdG 1,N2-propano-2-deoxyguanosine 
PFA paraformaldehyde 
pH2AX phospho-histone H2AX 
Abbreviations 
 xvii 
PI propidium iodide 
pI:pC polyinosinic:polycytidylic acid 
PLM posterior lateral mesoderm 
PTW phosphate buﬀered saline with Tween 
QC quality control 
RNA ribonucleic acid 
RNS reactive nitrogen species 
ROS reactive oxygen species 
RT room temperature 
SCC squamous cell carcinoma 
SCT stem cell transplantation 
SD standard deviation 
SDS-PAGE sodium dodecyl sulphate–polyacrylamide gel electrophoresis 
SDSA synthesis-dependent strand annealing 
SEM standard error of the mean 
siRNA small interfering RNA 
SSC side scatter 
ssDNA single-stranded DNA 
TBST tris-buﬀered saline with Tween 
TGF transforming growth factor 
TLR Toll-like receptor 
TLS translesion synthesis 
TNF tumour necrosis factor 
TPM transcripts per million 
TUNEL terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labelling 
VDA ventral dorsal aorta 
Abbreviations 
	xviii
WB Western blot 
WBC white blood cell 
WKM whole kidney marrow 
wpt weeks post transplantation 
WT wild type 
XLR X-linked recessive 
ZMP zebrafish mutation project 
 
1 — Introduction	
 1 
1 Introduction 
1.1 The history of Fanconi anaemia 
The haematological disorder Fanconi anaemia was ﬁrst described by the Swiss physician 
Guido Fanconi in %mX]. In his initial paper called “Familiäre infantile perniziösartige 
Anämie (perniziöses Blutbild und Konstitution)” [“Familial infantile pernicious anaemia 
(pernicious blood count and constitution)”]%, he described a family with ﬁve children. 
Among them, three boys suﬀered from the disease. Fanconi’s meticulous description 
already contained all the main features of the disease and suggested a hereditary cause 
– an exceptionally impressive feat considering the limitations of the day. 
The aﬀected boys showed what would later be considered typical congenital features of 
Fanconi anaemia, including microcephaly, café-au-lait-spots, hypoplastic testes and 
delayed development. The haematological symptoms of the patients consisted of 
anaemia with macrocytic erythrocytes and leukocytopenia, stemming from bone 
marrow dysfunction. Heavy bleeding, especially under the skin, was already apparent 
before anaemia developed, indicating early thrombocytopenia. All three boys died of 
their disease after a series of infections (the lack of leukocytes presumably made them 
susceptible to pathogens), culminating in bone marrow failure%. 
A further case reported by Uehlinger in %mXmX made Fanconi realise that the disease 
aﬀects all blood lineages, i.e. that it leads to pancytopenia. Later research led him to the 
erroneous conclusion that the malady is caused by chromosomal translocationL, as the 
phenotype appeared to him to be too variable to be caused by one gene and aﬀected 
families were not consanguineous. Subsequent discoveries disproved him, showing that 
the disease is caused by recessively inherited mutations in several genes (except for 
FANCB, which is X-linkedY and some very rare dominant negative mutations).  
In the early %m]Qs, the ﬁrst steps toward a molecular understanding of the disease were 
underway. As shown by groups in the US and Japan, all Fanconi patients were sensitive 
to crosslinking agents, which leads to the accumulation of chromosomal damage$,P.  
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It took a further two decades of study until the ﬁrst FA complementation group was 
linked to a gene, namely FANCC ]. However, this alone was not enough to explain the 
aetiology of the disease, as an understanding of the functional role of the Fanconi genes 
was lacking. This issue was resolved in the early XQQQs, when the fundamental role of 
the Fanconi pathway in DNA repair was unravelledl,m. 
However, even though patients show strikingly increased DNA damage and the Fanconi 
genes play a major role in DNA repair, there are still divergent explanations as to what 
the major cause of bone marrow failure is. An important theory has long been that 
Fanconi anaemia cells are more sensitive to certain inﬂammatory cytokines%Q,%%, but other 
groups favour DNA damage by small aldehydes as the cause%X–%$. More recently, there 
has also been new evidence that Fanconi genes are involved in autophagy%P,%], telomere 
defects%l and various other pathways. Overall, there is still no complete clarity about 
how all of these features are causally related to the observed gene mutations and how 
they lead to the congenital defects and bone marrow failure seen in Fanconi anaemia. 
1.2 Symptoms 
Despite being called Fanconi “anaemia”, the symptoms of the disease are wide ranging 
and aﬀect many more tissues than blood. In general, the symptoms can be classiﬁed into 
three diﬀerent categories: congenital (i.e. birth) defects, haematological features and 
cancer predisposition.  
1.2.1 Congenital features 
About ]$% of FA patients suﬀer from some form of physical abnormality from birth%m. 
There is a wide variety of symptoms, with a large range in severity. The most common 
features include short stature, café-au-lait-spots on the skin and skeletal deformities, 
often aﬀecting the thumbs and other ﬁngers (See Figure %.% for example images of an FA 
patient and Table %.% for a comprehensive list of all known congenital symptoms and 
incidence rates). Typically, FA is diagnosed during early childhood. However, some 
individuals may not display any obvious symptoms until adulthood, where FA is 
occasionally discovered in people hypersensitive to chemo- and radiotherapy, but 
otherwise healthyXQ,X%. Other patients suﬀer from severe disabilities throughout their life. 
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Intriguingly, children with severe congenital features tend to suﬀer from bone marrow 
failure earlier in lifeXX. This inconsistency in the severity of symptoms has been linked to 
the high genetic variability of the disorderXX, which will be discussed later in this text.  
 
Figure (.(: FA patients have various congenital abnormalities. The images portrayed here are of a 
three-year-old toddler suﬀering from FA, showing typical symptoms. Visible on the left is the short stature 
for his age, a proportionally small head and a dislocated hip. In the middle, the small eyes and triangular 
face are apparent. In the top right image, hypo- and hyperpigmented areas “café-au-lait-spots” are visible. 
Shown in the bottom right are typical skeletal deformities aﬀecting the hands, “dangling” thumbs. 
Reproduced with permission by Elsevier from Shimamura and Alter XQ%Q%m. 
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Table (.(: Summary of congenital features observed in FA patients. Based largely on Shimamura and 
Alter XQ%Q%m, with additions indicated in the text. SD = standard deviation. 
Abnormality Details Frequency  
Low birth weight  5% 
Microsomia >60% are more than 2SD shorter than peers
23. Only 10% of patients 
are taller than average.  40% 
Skin 
Generalised hyperpigmentation, café au lait spots, hypopigmented 
areas. Up to 12% of patients may develop Sweet’s syndrome/acute 
neutrophilic dermatosis (red plaques and nodules). 
40% 
Skeletal: upper 
limbs, unilateral or 
bilateral 
Thumbs: Absent or hypoplastic, bifid, duplicated, rudimentary, 
attached by a thread, triphalangeal, long, low set 
Radii: Absent or hypoplastic (only with abnormal thumbs), absent or 
weak pulse 
Hands: Flat thenar eminence, absent first metacarpal, clinodactyly, 
polydactyly 
Ulnae: Dysplastic, short 
Thumbs: 35% 
Radii: 7% 
Hands: 5% 
Ulnae: 1% 
Skeletal: Lower 
limbs 
Feet: Toe syndactyly, abnormal toes, club feet 
Legs: Congenital hip dislocation 5% 
Skeletal: Neck Sprengel deformity, Klippel-Fiel anomaly, short, low hairline, webbed 1% 
Skeletal: Spine Spina bifida, scoliosis, hemivertebrae, abnormal ribs, coccygeal aplasia 2% 
Craniofacial: Head Microcephaly 20% 
Craniofacial: Face Triangular, birdlike, dysmorphic, micrognathia, mid-face hypoplasia 2% 
Eyes Small, cataracts, astigmatism, strabismus, epicanthal folds, hypo- and hypertelorism, ptosis 20% 
Renal Kidneys: horseshoe, ectopic or pelvic, abnormal, hypoplastic or dysplastic, absent; hydronephrosis or hydroureter 20% 
Gonads: Males Hypospadias, micropenis; undescended testes, absent testes. Fertility is reduced in males due to hypo or azoospermia. 25-64%
24  
Gonads: Females bicornuate uterus, malposition, small ovaries. Pregnancy in females is possible, regardless of SCT status25,26 2% 
Developmental 
delay Intellectual disability, developmental delay 10% 
Ears 
Hearing loss (usually conductive secondary to middle ear bony 
anomalies); abnormal shape (dysplastic, atretic, narrow ear canal 
[i.e., external auditory meatus], abnormal pinna) 
10-50%27,28  
Cardiopulmonary 
Congenital heart defect: patent ductus arteriosus, atrial septal defect, 
ventricular septal defect, coarctation of the aorta, truncus arteriosus, 
situs inversus 
6% 
Gastrointestinal Oesophageal, duodenal, jejunal atresia; imperforate anus; tracheoesophageal fistula; annular pancreas; malrotation of the gut 5% 
Central nervous 
system 
Small pituitary, pituitary stalk interruption syndrome, absent corpus 
callosum, cerebellar hypoplasia, hydrocephalus, dilated ventricles 3% 
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One very important, but not immediately visible, defect in FA is the sensitivity of patient 
cells to crosslinking agents such as diepoxybutane (DEB) or mitomycin C (MMC) (Figure 
%.X), which is an absolute diagnostic criterion%m.  
 
Figure (.=: FA patients are sensitive to crosslinking agents. Shown are examples of FA patient 
chromosome spreads in response to MMC (left) and DEB (right). Visible characteristic are gaps, breaks 
and radial formations, which are pointed out with arrows. Reproduced with permission by Elsevier from 
Shimamura and Alter XQ%Q%m. 
1.2.2 Haematological features 
Almost all FA patients develop haematological abnormalities at some point of their life. 
Progressive bone marrow failure (BMF, deﬁned as the inability to make at least one 
blood lineage at levels required for survival) occurs in mQ% of patients by age YQ, with 
the median age of onset being about sevenXm,LQ. The range is very large however; babies 
may develop BMF%m,L%, whereas some patients can be symptom free until adulthoodXQ,X%,Xm, 
again highlighting the high variability of disease onset and severity of symptoms.  
Early haematological signs of FA before complete BMF can be quite variable as well. 
More than mQ% of FA patients develop macrocytosis early in life, which normally goes 
hand in hand with the aberrant expression of foetal haemoglobinLX. Thrombocytopenia 
is also common and often occurs as the ﬁrst haematological abnormality. It is frequently 
linked to macrocytosis as wellLQ. Thrombocytopenia is often noticed ﬁrst, due to the 
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spontaneous bleeding it can causeLX. These uni-lineage cytopenias normally gradually 
develop into pancytopenia, followed by complete BMFLQ. On examination of the bone 
marrow, it usually appears hypocellular for the age of the patient, which is correlated 
with a decrease of the haematopoietic precursors. However, these cells typically appear 
morphologically normal, unless myelodysplastic syndrome (MDS) or acute myeloid 
leukaemia (AML) is developing%m. 
1.2.3 FA and cancer 
Patients who survive to adulthood without BMF, or have undergone stem cell 
transplantation, are at a high risk of developing both haematological, as well as solid 
malignancies. AML is particularly common, with a $QQ-fold increase in risk in FA 
patients compared to healthy controlsLL–L$. The overall incidence of leukaemia and MDS 
reaches m and ]% respectivelyLP. The cumulative incidence of leukaemia at age YQ is 
LL%Xm and the median age of onset is %%, a few years after the median onset of BMFLL. 
Another study has estimated the mean age of development for leukaemias to be %Y and 
of MDS to be %]L]. When looking at these numbers, it should be considered that most 
FA patients will develop BMF beforehand, i.e. they never progress to haematological 
malignancies solely because their original bone marrow is gone.  
The risk of developing solid tumours is also increased markedly – the cumulative 
incidence of solid tumours reaches Xl% at age YQXm. This ﬁgure becomes even more 
dramatic if only patients alive at age YQ are considered – it goes up to PP%Xm, as many 
patients die of other causes before developing solid tumours. The mean age of solid 
tumour development is XLL]. Overall, BMF develops earliest, followed by leukaemias and 
solid cancers lastLL. The most common neoplasms in FA are squamous cell carcinomas 
(SCCs) of the head and neck, the anogenital region and the skin, followed by liver cancer 
and othersXm. Other cancers with signiﬁcantly increased risk include cervical cancer 
(%QQ-fold increase) and vulvar cancer (more than %QQQ-fold increase)LL,LP,Ll.  
As SCCs are the most common type of solid malignancy, a lot of research has been 
focussing on the causative factors in SCC development. Human papilloma virus (HPV) 
is a common cause of SCCsLm. Some studies have suggested that FA patients are at an 
increased risk of HPV-linked SCCsXm, whereas others have found no such linkYQ. 
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However, HPV vaccination is still recommended for all FA aﬀected childrenLX, especially 
as HPV infections are very common in FA patientsY%. 
Even though several of the FA genes are also breast cancer susceptibility genes 
(FANCS/BRCA%, FANCD%/BRCA>, FANCN/PALB>, FANCJ/BRIP% and FANCO/RAD$%C), 
breast and ovarian cancer are rather rare in FA patients. This might be due to the 
hypogonadism seen in many FA patientsYX.  
1.3 Incidence 
For a long time, the incidence of FA has been estimated to be %:LPQQQQ live birthsYL. This 
original model used a carrier frequency of %:LQQ and an autosomal recessive mode of 
inheritance to determine this number. Newer data suggests a much higher carrier 
frequency in the United States of %:%l%, leading to a predicted incidence of about 
%:%QQQQQ live birthsYY.  
Curiously, FA is more prevalent in males than females (%.X:%), a fact that cannot be solely 
explained by the X-linked inheritance of FANCB mutations%m. 
In some communities, carrier frequencies are signiﬁcantly higher than in the general 
population. Ashkenazi Jews have a carrier frequency greater than %:%QQ, with some 
unique mutations to this ethnic group due to several founder mutationsYY–YP. Some sub-
Saharan African ethnic groups also carry FA genes at a similar frequency, leading to an 
incidence of about %:YQQQQ live births, due to a founder mutation in Bantu-speaking 
populationsY]. Afrikaners (white South-Africans predominantly descended from Dutch 
and German settlers) also have a very high carrier frequency of about %:lQ, which is 
thought to stem from a founder eﬀect in the originally very small populationYl. The 
highest incidence of FA has been reported for a population of Spanish gypsies (carrier 
frequency %:PY-%:]Q). Like the other groups, this is due to a founder mutation about PQQ 
years agoYm. 
1.4 Prognosis 
The median age of diagnosis for FA is P.$ years%m, but as mentioned previously, adults do 
occasionally get diagnosed when they do not suﬀer from obvious congenital defects or 
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BMFXQ,X%,Xm. The median survival time was XY years in a XQQL study of the International 
Fanconi anaemia registryXm. A XQ%Q study using the National Cancer Institute cohort 
found a signiﬁcantly higher median survival of LL yearsL$, with some patients living into 
their ﬁfties. Indeed, one patient was only diagnosed at the age of $$ following their death 
from chemotherapy$Q and another patient was diagnosed at age $$ after being 
considered as a bone marrow donor for an aﬀected sibling%m. 
It is possible that some of the improvement in survival is due to better diagnosis of less 
severe cases, which might have been missed previously (a lead time bias). It cannot be 
discounted however, that the longer survival is at least partially a result of reﬁned 
treatment methods, which will be discussed below. 
1.5 Treatment 
As mentioned previously, FA is a phenotypically extremely diverse disorder, with a wide 
range of symptoms. Because of this, the treatment of FA can never be limited to the 
haematological symptoms, but must involve the expertise of many specialists. This may 
include hand surgeons for repair of congenital bone defects or head and neck cancer 
specialists for tumour surveillanceX%.  
Currently, the decision to undertake treatment is mainly made on the basis of laboratory 
measurements of the blood. The present standard of care suggests that treatment is 
initiated when haemoglobin (Hb) < l g/dl, platelets < LQQQQ/µl and neutrophil count 
 < $QQ/µl. Treatment may be started earlier if problems such as anaemia, bleeding or 
infection occur$%.  
Treatment modalities can be grouped into supportive therapies (trying to improve blood 
counts without addressing the underlying stem cell defect) and potentially curative 
therapies (repair or replacement of the HSCs) (Figure %.L).  
1 — Introduction	
 9 
 
Figure (.?: Summary of FA treatment approaches. Treatment modalities have been grouped into 
supportive (orange) and curative (green therapies). It is also indicated whether therapies are currently 
available (blue) or still being developed for clinical use (yellow). 
1.5.1 Supportive therapies 
1.5.1.1 Non-targeted therapies 
The main supportive treatment modality are blood transfusions, which have been made 
possible by modern blood banking. This has helped greatly to deal with anaemia and 
bleeding caused by thrombocytopenia, but infections due to neutropenia are still a 
problem$X.  
Another class of supportive drugs are haematopoietic growth factors, which stimulate 
the division of speciﬁc HSPC subsets$L. These proteins have been used successfully to 
treat neutropenia, but granulocyte-colony stimulating factor (G-CSF) in particular has 
been associated with increased risk of leukaemia$Y,$$.  
Androgens, such as oxymetholone, are used for the treatment of cytopenias in BMF in 
patients for which haematopoietic stem cell transplantation (HSCT) is not an option$P–
$m. Similar to growth factors, they stimulate the production of mature blood cells$L. This 
therapy has been linked to increased liver cancer and other side eﬀects, such as 
virilisation and hirsutism$P. In some patients, low-dose androgen therapy might 
FA therapies
Supportive Curative
Androgens Growth 
factorsTransfusions HSC transplantation
Gene therapySmall
molecules
Currently available
Not in use yet
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completely eliminate the need for a transplantLX. However, as it decreases the chances 
of successful subsequent transplantationPQ, it is more appropriate for patients in which 
this is not an option. 
1.5.1.2 Targeted therapies/small molecules 
Targeted therapies speciﬁcally aim to correct the pathways thought to be causative in 
BMF. They straddle the line between curative and supportive therapies – while they do 
not ﬁx the underlying cause, they may eventually prevent BMF until the natural death 
of the patient. Small molecules have been used successfully to alleviate FA symptoms in 
mouse models by targeting oxidative stressP%,PX. Other potential drug targets that have 
been suggested are pLl kinase inhibition to target cytokine hypersensitivityPL,PY and 
transforming growth factor (TGF)b inhibitionP$, which is particularly promising as 
inhibitors are in clinical trials for other diseasesPP,P]. However, none of these treatments 
have reached routine clinical use yet. 
1.5.2 Potentially curative therapies 
1.5.2.1 Bone marrow transplantation 
The only currently available curative therapy is haematopoietic stem cell transplantation 
(HSCT)X%,Pl. The ﬁrst transplantations of human leukocyte antigen (HLA)-identical 
donor marrow were carried out in the late %m]Qs and early %mlQsPm. This was followed by 
the development of cord-blood transplantations for FA in %mlm]Q. Changes in the 
conditioning regimens have markedly improved survival to mY% ﬁve years post-
transplantation]% in a study of alternative donor HSCT, which is a major improvement 
compared to the ~LQ% survival in earlier trialsPl,]X. This low success rate mainly 
stemmed from graft failure and graft versus host disease (GVHD)Pl,]%,]L. 
Another recent Dutch study also nicely illustrates how gradual improvements in therapy 
over the last YQ years have elevated survival post HSCT to over mQ% in children (mean 
age m.] years)]Y. Particularly the introduction of the drug ﬂudarabine to the standard 
conditioning regimen before transplantation considerably increased survival. The 
removal of irradiation was also helpful, as it is badly tolerated by FA patients]$. Thus, 
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the current Dutch regimen of ﬂudarabine and cyclophosphamide is highly successful 
and comparable to the recent American treatment regimens. 
Even mismatched donor transplantation can have a success rate approaching mQ% in FA 
aﬀected children (mean age %%.% years) if a more intensive treatment regimen is 
followed]P. Adverse eﬀects, such as GVHD were more common in this study. However, 
ﬁnding a suitable donor if no sibling is available limits the use of HSCT severely, 
especially as siblings need to be unaﬀected by FA]],]l. Therefore, using HLA-mismatched 
donors is a good alternative for these patients. 
An interesting advance to work around this limitation in the treatment of FA is the 
generation of so-called “saviour siblings”. This refers to children from carrier couples 
selected via in-vitro fertilisation and pre-implantation genetic diagnosis (IVF-PGD) to 
be non-carriers. HSCs can be harvested from the umbilical cord of this unaﬀected child 
to treat its sick sibling]m. However, apart from the ethical concerns with this technique, 
there are severe technical limitations. Most problematic is the extremely low IVF success 
rate per cycle (< $%), as only healthy (and HLA matched) embryos can be used. This is 
particularly diﬃcult to solve, as maternal age tends to be high, which increases the risk 
of aneuploidylQ.  
Despite being a potentially very eﬀective treatment, bone marrow transplantation 
(BMT) is not wholly without risks. Apart from the immediate side eﬀects due to the 
conditioning regimen, there is some evidence that BMT increases the risk of tumour 
developmentLL,l%. There is also a risk of developing chronic or acute GVHD, 
immunodeﬁciency and various organ dysfunctions as a result of treatmentlX. 
The best time to transplant patients is currently being debated in the ﬁeld. It is however 
agreed that it should be done before the development of MDS or AML, as it becomes 
considerably more challenging once malignant changes have occurred]], but BMT itself 
also carries considerable risk. This is reﬂected in the low overall ﬁve-year survival in 
older patients ranging from LL to lQ% in several studieslL–lP. Some people even advocate 
HSCT before the development of BMF. A recent paper presented a decision analysis 
model to help deciding whether a patient should be pre-emptively transplantedl]. This 
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model recommends pre-emptive transplantation only in children below ﬁve years of age, 
as later treatment-related mortality increases. This problem also applies to treatments 
seeking to delay BMT, such as androgen therapy, as older transplant recipients have 
worse outcomesLX,]Y. A particularly striking example is a recent study which showed a 
ﬁve-year survival of only $Y% in adult recipients (mean age XY), in stark contrast to the 
much higher survival discussed in younger recipients earlier in the textll. 
1.5.2.2 Gene therapy 
In the future, the treatment of FA might become less dependent on the availability of 
donors, as gene therapy approaches become feasible and the patient’s own cells can be 
used instead. FA should be very suitable for a gene therapy approach, as it is easy to 
identify which gene is defective in the patient and there is only one mutated gene per 
patient. Furthermore, FA is a haematological disease. This means HSCs can be easily 
obtained from the patient and transplanted back, enabling an ex-vivo gene therapy 
approach as an alternative to targeting cells while they are in the bodylm. The rapid 
advances in genome editing techniques such as the CRISPR-Casm system will probably 
lead to fast adoption in the clinic. Indeed, CRISPR-Casm has already been used to correct 
FA genes in-vitromQ. 
Other eﬀorts have focussed on correcting the mutations by supplying FA cells with a 
working copy of the mutant genem%–ml. An especially interesting recent publication 
integrated FANCA into the AAVS% locusml and transduced this construct into patient-
derived ﬁbroblasts using a retroviral vector. The cells were then reprogrammed to 
induced pluripotent stem cells (iPSCs), followed by diﬀerentiation into HSCs. Even 
though these FA ﬁbroblasts were harder to de-diﬀerentiate to iPSCs than “normal” cells, 
they showed comparable expression and methylation of pluripotency genes. 
Furthermore, the iPSCs were able to form teratomas in mice, a common test for 
pluripotency. Patient-derived reprogrammed HSCs could potentially be transplanted 
back into the patient. Interestingly, FA cells are normally refractory to reprogramming, 
indicating that the FA pathway is important in maintaining “stemness”mm,%QQ. 
Reprogramming ﬁbroblasts would be a good option if a patient does not have enough 
HSCs left to correct, which has caused issues with other gene therapy approaches%Q%,%QX. 
However, retroviral vectors have considerable problems with transducing HSCs. This 
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issue was very problematic in a trial of gene therapy for FAm%, leading to the treatment 
being relatively ineﬀective in alleviating patient symptoms. Furthermore, there are 
safety concerns about the vectorsm%, making genome editing based approaches more 
attractive in comparison. It remains to be seen whether more recently generated, 
improved retroviral vectors show better eﬃcacy in the clinic mX,mL. 
HSC numbers in each patient will be very important. As CDLY+ HSCs may be depleted 
very early, it is possible to have too few for gene correction%Q%. This might lead to two 
diﬀerent treatment approaches: if enough CDLY+ cells are available, it would be 
preferable to ﬁx the FA gene deﬁciency in these cells directly. In patients where this is 
not the case, reprogramming with an intermediate iPSC step might be the only possible 
solution, although reprogramming clearly introduces additional time, cost and safety 
considerations.  
1.5.3 Novel challenges and future perspective 
The current treatment regimens for FA are insuﬃcient, as they suﬀer from lack of long-
term eﬀectivity (growth factors), have severe side eﬀects (androgens) or are only 
possible when a suitable donor is found (HSCT). Because of this, a better understanding 
of the molecular mechanisms of the disease are necessary to develop better therapeutics 
until gene therapy becomes a widespread, cost-eﬀective treatment method.  
Improvements in the treatment of BMF will lead to new therapeutic challenges. As the 
lifespan of FA patients increases, the management of long-term complications stemming 
from HSCT and cancers in non-haematological tissues increases%QL. Cancer treatments 
are particularly problematic, as chemo- or radiation therapy are often tolerated badly or 
lead to more malignancies due to the DNA damage sensitivity of the patients]$. As these 
long-term complications become more common, new treatments will need to be 
developed. 
1.6 Fanconi anaemia genes 
There are currently X% FA genes recognised in the Fanconi Anaemia Mutation 
Database%QY (Table %.X). Most patients have mutations in a subset of FA genes, which 
make up the majority of FA mutations. Particularly FANCA and FANCC mutations are 
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common, whereas some other complementation groups only have one or two known 
patients (See Table %.X and Figure %.Y). The main function of the FA genes is described 
below in the description of interstrand crosslink (ICL) repair by the FA pathway gene 
products. 
Table (.=: Fanconi genes in humans. Shown are their alternative names, chromosomal location, 
inheritance mode and patient number. These statistics are mainly based on the LOVD database%Q$, adding 
in the newly discovered FANCV and U genes. AD = autosomal dominant, AR = autosomal recessive, 
XLR = X-linked recessive. 
Gene Alternate name 
Chromosome 
/band Inheritance 
Patients  
(total number) 
Patients  
(%) 
FANCA  16/q24.3 AR 1752 63.4 
FANCB  X/p22.2 XLR 40 2.0 
FANCC  9/q22.3 AR 323 11.4 
FANCD1 BRCA2 13/q12-q13 AR 73 2.4 
FANCD2  3/p25.3 AR 85 2.7 
FANCE  6/p22-p21 AR 48 2.1 
FANCF  11/p15 AR 47 1.5 
FANCG XRCC9 9/p13 AR 262 8.7 
FANCI  15/q26.1 AR 32 1.4 
FANCJ BRIP1, BACH1 17/q22.2 AR 57 1.9 
FANCL  2/p16.1 AR 12 0.5 
FANCM  14/q21.3 AR 8 0.3 
FANCN PALB2 16/p12.1 AR 18 0.5 
FANCO RAD51C 17/q25.1 AR 6 0.1 
FANCP SLX4 16/p13.3 AR 14 0.4 
FANCQ ERCC4 16/p13.3 AR 4 0.1 
FANCR RAD51 15/q15.1 AD 2 0.1 
FANCS BRCA1 17/q21.31 AR 1 0.1 
FANCT UBE2T 1/q32.1 AR 6 0.2 
FANCU ERCC2 7/q36.1 AR 1 0.1 
FANCV REV7 1/p36.22 AR 1 0.1 
1.6.1 Types of FA genes 
The Fanconi anaemia genes can be classiﬁed into two groups: bona-ﬁde FA genes, where 
at least two patients developed BMF during the course of their disease and FA-like genes, 
which recapitulate the main features of FA, but where no patient with BMF has been 
observed%QP. Four of the genes can be classiﬁed as FA-like: FANCO/RAD$%C, 
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FANCR/RAD$%, FANCS/BRCA% and FANCU/XRCC>. However, as there are very few 
patients for each of these genotypes (as few as one for FANCS and FANCU), it cannot be 
concluded that mutations in these genes invariably will not cause BMF, as many FA 
patients of other complementation groups never progress to BMF, or do so very late in 
life.  
 
Figure (.@: Mutations in a subset of Fanconi genes cause almost all cases of FA. This pie chart 
demonstrates the predominance of FANCA, FANCC and FANCG among FA patients. The data is based on 
Table %.X. Shown individually in this chart are all complementation groups mutated in more than two 
percent of all patients. 
1.6.2 Assignment of FA genes 
Typically, a FA gene is assigned if the wild type version can correct the phenotype (i.e. 
features such as crosslinker sensitivity) in patient-derived cells. This process is not 
always straightforward, as illustrated by the case of FANCM. Even though it was initially 
described as a bona-ﬁde FA gene%Q] and sits at the core of the FA complex%Ql, it has 
recently been cast into doubt as to whether it actually qualiﬁes as FA gene at all. This is 
because the patient in which it was described also carries homozygous FANCA 
mutations%Qm, complementation of which can rescue the phenotype. Furthermore, there 
are homozygous carriers for loss of function FANCM mutations who do not show any 
symptoms of FA (albeit increased risk for breast cancer)%%Q. Because of this, it has been 
proposed to exclude it from the list of FA genes%QP. Nevertheless, Fancm mutant mice 
recapitulate many features of FA%%%. Together with its central role in the FA core complex, 
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this suggests that mutations in this gene at least have the potential to cause an FA 
phenotype. 
A similar situation previously led to wrong assignment of the complementation group 
FANC-H, which turned out to be caused by mutations in FANCA%%X. This also explains 
the lack of a FANCH gene.  
1.6.3 Genotype-phenotype variability 
The large number of genes and the variations of diﬀerent mutations within each gene 
means that the genetic causes of FA are very heterogeneous. This contributes to the 
variety of phenotypes seen. The inﬂuence of diﬀerent gene mutations is particularly 
visible when the distribution of FA patients in the diﬀerent mutation groups is 
considered. For example, FANCD%/BRCA> mutant patients make up around X% of all FA 
patients. From the carrier frequency in the general population, it can be estimated that 
if all homozygous FANCD% mutant embryos survived to birth, the proportion of the 
FANCD% group would make up about $Q% of all FA patientsXX. Other FA mutations are 
also found much less commonly than would be expected if they were compatible with 
life. There is only one known patient to survive with homozygous FANCS/BRCA% 
mutations%%L, indicating that complete loss-of-function mutations are usually lethal and 
only very speciﬁc, hypomorphic mutations can be tolerated and still lead to the 
development of FA. Similarly, there are only two patients with FANCR/RAD$% 
mutations%%Y,%%$, with very speciﬁc mutations, as other mutations presumably lead to an 
early embryonic death. 
However, if a patient survives to term, there is considerable evidence that it is less 
important which gene is mutated, but rather what kind of mutation the patient carries 
– point mutations are usually less severe, whereas frameshifts or deletions tend to be 
very detrimentalXX. This is because point mutations are more likely to be hypomorphic, 
rather than complete loss-of-function mutations in comparison to frameshifts and 
deletions. An example of the variable phenotypes can be seen in patients carrying 
FANCC mutations. Patients with mutations in intron Y (IVSY+YA>T) or point mutations 
in exon %Y (RY$lX and L$$YP) have a signiﬁcantly worse prognosis, with a median onset 
of BMF at X.] and X.% years of age respectively. This is very early in comparison to other 
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FANCC mutations, which have a median onset of BMF around age seven, similar to other 
complementation groups%%P. 
The situation is further complicated by the fact that even in siblings with identical 
mutations, symptoms can be quite disparate, illustrating the importance of modiﬁers 
within the genetic backgroundXX. The eﬀect of other alleles on the phenotype of FA 
patients is well demonstrated for the ALDH> gene, described in-depth in section $.%.X.Y. 
Another example for non-FA genes inﬂuencing disease phenotype are glutathione S-
transferase (GSTM%) polymorphisms, which have been linked to considerably earlier 
(three vs. seven years) BMF in FANCC patients%%]. 
There are some FA mutations that lead to an especially increased risk of cancer 
development, particularly genes of the BRCA networkXX. Almost %QQ% of patients with 
FANCD%/BRCA> or FANCN/PALB> develop malignancies (mostly leukaemias) during 
their early childhood, before BMF%%l–%X%. Furthermore, FANCS/BRCA%, FANCD%/BRCA>, 
FANCN/PALB>, FANCJ/BRIP% and FANCO/RAD$%C are breast cancer susceptibility 
genes when heterozygous%XX–%XP. Apart from these associations, there is little evidence 
that particular FA gene mutations lead to speciﬁc tumours in the diﬀerent 
complementation groups.  
1.7 Cellular pathology and bone marrow failure in 
Fanconi anaemia 
Even though FA has been recognised as a disease for almost a century, there are still 
surprisingly many questions about why the majority of patients eventually suﬀer from 
BMF. Many hypotheses exist about the underlying cause, but most of them accept that 
the HSPCs are exhausted. The debate centres on what the main factor is in this stem cell 
depletion. FA has been likened to a premature ageing disorder, as many of the defects 
discussed below (e.g. cytokine overproduction and defective mitochondria) also 
commonly occur during normal ageing%X]. In particular, it shares many features with the 
premature ageing and BMF syndrome dyskeratosis congenita, including many of the 
congenital abnormalities and blood defects%X]. It has also been likened to a segmental 
progeroid syndrome of the bloodXX. The discussion in this section will be limited to the 
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haematopoietic defects contributing to eventual exhaustion of the HSPCs and will not 
cover congenital symptoms. Some of the main hypotheses proposed to explain the 
defects seen in FA are summarised in Figure %.$. 
 
Figure (.B: Summary of the diﬀerent mechanisms that have been proposed as the trigger of BMF 
in FA. The diﬀerent hypotheses are shown here as a Venn diagram. Mitochondrial (Mt) dysfunction has 
been linked to both DNA damage, as well as increased cytokine expression and therefore represents an 
overlap between those two options. All of these signals are thought to trigger apoptosis and cell cycle 
arrest, leading to HSC exhaustion. 
1.7.1 Fanconi anaemia is caused by a HSPC defect 
All blood lineages are aﬀected in FA, which indicates that there is a general HSPC 
dysfunction, rather than a defect in diﬀerentiation of a uni/oligopotent progenitor%QL. 
Moreover, FA patients generally display low CDLY+ cell numbers in the bone marrowm%,%Q%. 
This is further corroborated by FA mouse models, many of which also show decreased 
HSPC numbers%$,PX,%Xl–%L% and decreased engraftment ability upon transplantation%LX,%LL. 
Forcing HSPCs to enter the cell cycle by various means is able to cause BMF in mouse 
models%LY. Further evidence comes from cell culture models. FA patient-derived 
ﬁbroblasts are refractory to reprogrammingmm,%QQ, suggesting that they cannot maintain 
pluripotency. Similarly, knocking down FA genes in embryonic stem (ES) cells leads to 
lineage defects%L$, indicating FA genes are necessary to maintain stemness and 
multilineage potential.  
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1.7.2 HSPC defects start during embryonic/foetal development 
It is normal for HSPC numbers to decrease during normal ageing%LL, but elderly people 
do not usually suﬀer from BMF (albeit BMF is more common in elderly people than in 
children), in stark contrast to FA patients who almost invariably suﬀer from BMF during 
early childhood. This diﬀerence could be explained by three diﬀerent possibilities. The 
ﬁrst option is that patients start out with a decreased number of stem cells, which are 
depleted at the same rate as in healthy humans. The second option is that FA patients 
start with normal HSC numbers, but that the rate of depletion is increased, either to 
changes to the HSCs themselves or to their microenvironment. Finally, patients may 
suﬀer from a combination of these factors. The second option appears unlikely, as bone 
marrow cellularity is already reduced very shortly after birth%LL. In addition, foetal liver 
HSPCs derived from Fancd>-/- and Fanc-/- mice show decreased engraftment abilities 
when transplanted%LP,%L]. Taken together, these papers suggest that the haematopoietic 
defects seen in FA already start during embryonic haematopoiesis. 
1.7.3 Signalling pathways mediating HSPC defects 
Experiments looking at the foetal livers of Fanconi mice elucidated that the p$L/pX% axis 
plays an important role in the lowered number of HSPCs. Levels of pX% are dramatically 
increased, suggesting an early proliferation defect leading to GQ/G% arrest%LL. Cultured 
Fancg-/- HSPCs also engraft signiﬁcantly less well, a defect which can be rescued upon 
p$R silencing%LL. However, knocking out p>% in Fancd>-/- mice cannot rescue the 
haematopoietic phenotype (neither engraftment following transplantation nor 
proliferation defects were rescued), but in fact exacerbates it%Ll. This argues against the 
role of pX%, but it is possible that another p$L target mediates the defects. 
Another connection between p$L and the FA pathway is that p$L actively downregulates 
the transcription of FA pathway genes%Lm. This could lead to a harmful vicious circle. 
DNA damage induces p$L, leading to the repression of FA genes. As the damage cannot 
be repaired due to the lack of repair proteins, the induction of p$L is increased further, 
exacerbating the problem rather than solving it. In combination, the upregulation of p$L 
in response to defective DNA repair%LL and the downregulation of the pathway in 
response to p$L suggests a positive feedback loop%Lm. 
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Even though the role of p$L is generally accepted by most of the ﬁeld, there is evidence 
to the contrary. A study looking at foetal defects in Fancd>-/- mice found that while there 
are indeed proliferation defects, these are mediated via pLl instead of p$L%L], in stark 
contrast to the results obtained by Ceccaldi et al.%LL. It is possible that the use of diﬀerent 
FA models (Fancg and Fancd>) contributed to these diﬀerences, as well as diﬀerent 
genetic backgrounds. Nevertheless, both models still predict decreased proliferation and 
increased apoptosis in the early embryonic HSCs within the foetal liver. 
Nevertheless, it is clear that foetal FA HSPCs already show various impairments. As 
described above, FA has been likened to a premature ageing syndrome%X], so a 
comparison between the defects in aged and FA HSPCs is warranted. Indeed, a p$L-
dependent response to DNA damage and cellular stress has been implicated in HSC 
ageing in humans and mice%YQ–%YX. These defects can cause genomic instability, BMF and 
haematopoietic malignancies in the elderly%YQ,%Y%, akin to what is seen much earlier in FA 
patients. It may be that HSC number is not dependent on successful DNA repair, but 
their functionality is. These damaged HSCs are ﬁne until they are forced to leave 
quiescence. This leads to their eventual exhaustion, as their self-renewal capacity is 
impaired. Such defects are especially problematic in times of stress where HSCs have to 
leave quiescence to replenish the blood%LY,%YQ. In agreement with this, HSCs with 
hyperactive p$L are more similar to aged cells and have impaired functional properties. 
Moreover, the overall number of HSCs in p$L hyperactive mice is decreased and the 
remaining cells have to excessively proliferate to maintain working haematopoiesis%YL. 
DNA repair in general seems to be required to maintain the pool of HSPCs, as LigS-/- (a 
gene in the non-homologous end joining (NHEJ) pathway) mice show decreased bone 
marrow cellularity, coupled with increased proliferation to maintain blood production%YY. 
It seems as if increased proliferation in response to reduced HSPC compartment is a 
general reaction in mice, which leads to a vicious circle. The already diminished HSPCs 
have to enter the cell cycle more often, thus slowly completely depleting the pool. 
While it is clear that FA HSPCs are impaired in their functionality, it is less clear how 
the pathways leading to these defects are triggered. There are many hypotheses, the 
most common of which are discussed below. Broadly speaking, they can be grouped into 
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mechanisms where DNA damage is the primary cause of HSC exhaustion and those in 
which DNA damage is just coincident with other cellular defects, which are the ultimate 
trigger of cell death.  
1.7.4 Aldehyde hypersensitivity 
As discussed previously, the main (and best studied) function of the Fanconi pathway is 
the removal of ICLs from DNA. It is uncertain however what damaging agent is the 
predominant cause of ICLs in FA patients. The Patel group in Cambridge has 
accumulated considerable evidence in the past few years that the main damaging 
molecules are small aldehydes, which are generated during normal metabolism and are 
found in many dietary sources%Y$. The evidence for aldehyde hypersensitivity of FA cells 
stems from cell culture experiments%X,%Y,%YP,%Y], mouse models%L–%$,%L% and epidemiological 
data%Yl,%Ym. The details of this hypothesis are outlined in detail in chapter Y, where I 
consider the eﬀect of aldehyde-induced stress on my zebraﬁsh FA model. 
1.7.5 Oxidative stress 
Even though there is a lot of genetic evidence for the role of aldehydes in causing DNA 
damage in FA, they are not the only damaging agent that can cause ICLs. There is 
considerable evidence that the FA pathway also serves to remove lesions induced by 
oxidation. The FA pathway assembles in response to oxidative stress%$Q and some FA 
proteins are directly involved in mechanisms to reduce oxidative stress%$%–%$L. There is cell 
culture evidence that oxygen can cause chromosomal aberrations in FA cell lines%$Y and 
that FA cells grow better when cultured in hypoxic conditions%$$, which are 
disadvantageous to normal cells. Furthermore, FA cells gain more mutations when 
cultured under conditions of oxidative stress%$P. Additionally, double mutant Fancc-/-, 
Sod-/- (superoxide dismutase) mice show hypocellular bone marrow and 
erythro/leukocytopenia, indicating that these mutations can cooperate to induce a 
stronger phenotype%$]. However, the number of phenotypic HSCs in these double 
mutants is normal, even though they show clear functional defects. Birth defects are also 
not observed, in contrast to the phenotypes seen in FA mice also carrying mutations in 
aldehyde metabolising enzymes. Oxidative stress overproduction in FA cells has been 
linked to mitochondrial defects%$l and lack of some FA proteins has been associated with 
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mitochondrial dysfunction%$m. This connects oxidative stress with another hypothesis on 
why FA HSCs get depleted: defective autophagy. 
1.7.6 Autophagy defects 
Autophagy is the process by which a cell recycles its unnecessary cellular constituents, 
both to gain energy in times of starvation and to remove damaged components. In 
particular, damaged mitochondria have to be removed from the cell. Mitochondria 
sustain a lot of damage, as they continually generate oxidative stress in the form of 
reactive oxygen species (ROS) as a side eﬀect from the electron transport chain, which 
necessitates a turnover within about %Q-X$ days. Elimination of defective mitochondria 
is important, because otherwise mitochondrial DNA damage accumulates. This leads to 
a cell full of dysfunctional mitochondria, eventual bioenergetics failure and death of the 
cell. The importance of this process has led to the term “mitophagy” for the autophagic 
removal of mitochondria%PQ. 
Defects in autophagy can lead to HSC attrition via the accumulation of damaged 
mitochondria and increased oxidative stress, which can eventually lead to bone marrow 
failure%P%. Indeed, the importance of autophagy in the maintenance of HSC functionality 
during ageing has been highlighted in a recent publication%PX, which showed that defects 
in autophagy lead to impaired energy metabolism and are associated with loss of 
quiescence and stemness.  
Evidence for mitochondrial dysfunction in FA comes from the fact that FA cells have a 
shift in metabolism towards glycolysis at the expense of oxidative phosphorylation%PL. 
Many FancdX interacting proteins are localised to mitochondria, suggesting a function 
in that compartment%PY. In addition to that, several FA genes (FANCC, FANCF and 
FANCI) were recently identiﬁed as potential autophagy regulators in a genome-wide 
small interfering RNA (siRNA) screen%P$. This discovery was initially surprising, as the 
canonical function of FA genes occurs solely in the nucleus. However, a combination of 
cell culture and in-vivo work showed that essentially all FA genes also have a cytosolic 
role in facilitating autophagy%P. Another group validated these results and showed that 
defective autophagy in FA is due to defective mitochondrial ﬁssion%]. Loss of mitophagy 
led to both increased oxidative stress via inﬂammosome activation, as well as ROS 
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generation, since defective mitochondria were not removed eﬃciently%P. Furthermore, 
the involvement of mitochondria in cell death%PP could be an additional factor leading to 
HSC depletion in FA. These facts are especially intriguing, because this indicates that 
defective autophagy is both linked to increased oxidative stress, as well as increased 
inﬂammation; it could thus serve as the connecting point between the diﬀerent 
hypotheses.  
1.7.7 Abnormal inflammatory signalling 
Inﬂammation is deﬁned as a response to abnormal conditions, such as tissue damage or 
infection. Chronic inﬂammation in particular is linked to tissue dysfunction. One of the 
important features of inﬂammation is the local production of inﬂammatory cytokines 
by tissue-resident cells such as macrophages, which serve to recruit more immune cells 
to the site of inﬂammation and other things%P]. FA pathogenesis has been linked to 
inﬂammatory cytokines in multiple publications. There are two complementary aspects 
to this; FA bone marrow cells have shown both cytokine hypersensitivityP$,%LY,%Pl,%Pm, as 
well as increased production of inﬂammatory cytokines%%,%]Q–%]Y. Both of these 
mechanisms might cooperate to induce BMF by increasing HSC cycling. The details of 
this are discussed in chapter Y, where I investigate the role of inﬂammatory stress in 
BMF. 
1.7.8 Telomere defects in Fanconi anaemia 
Telomere defects are common in diseases involving aplastic anaemia, with one third of 
all acquired aplastic anaemia patients showing shortened telomeres%l. In agreement with 
this general trend, FA patients often display shortened telomeres, which tend to be 
about $Q% as long as the average telomeres of healthy people of the same age. This puts 
them in the shorter, but still normal range of telomere length, in contrast to dyskeratosis 
congenital (DC) patients, who have much shorter telomeres yet%]$. However, while 
patients do show clear telomere defects, mouse models of FA generally fail to 
recapitulate this. Neither Fancc, Fancg nor Fancj mutant mice show any telomere 
shortening when unchallenged%]P–%]l. The fact that mouse telomeres tend to be 
considerably longer than human telomeres%]], as well as the shorter lifespan of mice may 
be contributing factors to this diﬀerence. The role of FA genes in alternative lengthening 
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of telomeres (ALT) was demonstrated using a gene knockdown approach. The 
researchers used siRNA in cultured cells relying on ALT to lengthen telomeres to show 
that at least FANCA, FANCC and FANCD> are necessary for ALT to occur. Another FA 
protein with an important role in telomere preservation is FANCP/SLXY, which 
participates in the negative regulation of telomere length, regulation of telomere 
recombination and the prevention of telomere defects%]m–%l%. Moreover, all the FA genes 
that are also homologous recombination (HR) genes are required for telomere 
replication and capping%lX, so loss of HR proteins should aﬀect telomeres even more than 
loss of core FA proteins. Cells lacking RAD$% have shortened telomeres, as double 
stranded breaks remain unrepaired and hence telomeric DNA is lost. This is thought to 
be as replication forks have trouble progressing through telomeric DNA, leading to 
stalled replication forks%lL,%lY. The HR protein RAD$%-BRCA%/X axis is necessary for 
replication fork protection in conjunction with FANCDX, linking the FA pathway and 
HR in replication fork protection, as discussed in more depth below%l$. Consistent with 
this, HR-deﬁcient cells also have more fragile telomeres%lL,%lY. It was previously thought 
that RAD$% also plays a role in the ALT mechanism of telomere lengthening, but a recent 
publication disputes this%lP. Overall, FA proteins play a role both in the ALT mechanism, 
as well as normal telomere lengthening.  
1.7.9 Replication fork protection 
The FA pathway and the RAD$%-BRCA%/X axis are also involved in normal replication 
fork protection. The ﬁrst observations suggesting this possibility were undertaken when 
FA cells were treated with hydroxyurea, which does not cause ICLs, but does cause 
replication fork stalling, leading to the activation of the FA pathway%l]. Fittingly, FA 
pathway deﬁcient cell lines%l$, as well as cells derived from Fancc-/- mice%ll show 
increased instability at stalled replication forks. It has been shown that both the Fanconi 
core complex, including FANCDX-I are involved with fork stabilisation%l$, as well as the 
HR proteins BRCAX and RAD$%%l$,%lm. As deﬁciency of the core complex genes can be 
compensated by overexpression of RAD$%%l$, it is likely that the core complex recruits 
BRCA%/X and RAD$% as in ICL repair and the RAD$% protein complex then protects the 
fork from excess processing by nucleases, such as DNAX/WRN%%Y,%lm. Interestingly, 
FANCDX recruits the nuclease FAN% via its ubiquitin modiﬁcation%mQ,%m%, which was 
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previously thought to be necessary for ICL repair to stalled replication forks, where it is 
indispensable for fork stabilisation rather than crosslink removal%mX,%mL. This is 
corroborated by several earlier papers showing that FAN% is not strictly necessary for ICL 
repair%mY–%mP and by the fact that FAN% loss in humans and mice does not lead to Fanconi 
anaemia, but rather a kidney disease called karyomegalic interstitial nephritis%mX,%m$. It is 
currently unknown why the kidney is more sensitive to the loss of FAN% than other 
tissues%m$. 
Other Fanconi proteins also play a role in the resolution of stalled replication forks; 
FANCJ is necessary for replication fork restarting%m]. This suggests that the whole 
pathway is involved with this process, as well as ICL repair. 
1.7.10 Cytokinesis 
Apart from protecting stalled replication forks, FA proteins also play other roles during 
cell division. Indeed, cytokinesis failure contributing to BMF has been observed in FA 
cells%ml. Several FA proteins have been shown to protect chromosomal fragile sites%l]. 
The FA proteins cooperate with bloom syndrome protein (BLM) to repair damaged 
chromosomes during mitosis and promote the eﬃcient separation of the sister 
chromatids%mm,XQQ. Furthermore, FA proteins can also associate with the mitotic 
apparatus, where they are necessary to prevent aneuploidyXQ%. 
1.7.11 Aberrant TGFb signalling 
The FA pathway has extensive crosstalk with other DNA repair mechanismsXQX. Most 
importantly, it has been associated with suppression of the error-prone DNA repair 
mechanism NHEJ. Suppression of this pathway in FA-deﬁcient cells can rescue some of 
the defects normally seenXQL–XQ$. It has recently been shown that this switch to NHEJ is 
mediated via increased TGFb signalling. In addition, compounds inhibiting TGFb 
signalling can alleviate many of the defects seen in FA HSPCs, most importantly the 
aberrant p$L signalling. Interestingly, blocking TGFb also rescued defects seen in FA 
cells upon inﬂammatory stress and aldehyde mediated DNA damage, suggesting that 
the TGFb pathway is a shared mediator leading to stem cell depletionP$. This indicates 
that TGFb might be a master regulator in BMF and an attractive drug targetXQP. Early 
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mouse studies on FA mice have already started, showing that two radiation mitigator 
drugs have the potential to modulate TGFb inductionXQ]. 
1.7.12 Additional functions of the Fanconi anaemia pathway 
The FA pathway is also involved in other cellular mechanisms, for which there is less 
evidence than the pathways described above. The FA complex has been implicated in 
the removal of aberrant DNA:RNA hybrids (R-loops)XQl. There is also limited evidence 
that FA cells are impaired in the epigenetic regulation of gene expression, similar to 
cancer-related changesXQm.  
1.7.13 Summary 
FA proteins are involved in a multitude of cellular processes, many of which have been 
proposed to trigger the p$L/pX% signalling that ultimately causes BMF (Figure %.$). It is 
currently unclear which one of these factors (if any) is dominant in patients and 
eventually causes the depletion of HSCs in FA patients. However, multiple mechanisms 
common to several of the proposed causes of BMF have started to emerge, adding some 
pieces to the puzzle of why the bone marrow fails in FA patients. A better understanding 
of these changes will be necessary to develop novel treatments to lengthen the lifespan 
without BMF, potentially negating the need for costly and arduous BMT.  
1.8 The Fanconi anaemia pathway 
The DNA in each cell is constantly being damaged by various forms of insults, ranging 
from ultraviolet radiation to small oxygen radicalsX%Q, leading to up to %Q$ lesions per cell 
per dayX%%. One particularly problematic form of damage are ICLs, in which both strands 
of DNA are connected by covalent bonds, rather than the normal hydrogen bonds 
between the basesX%X. ICLs may lead to DNA breakages or chromosomal rearrangements 
if they are not repaired correctlyX%L. A single ICL can potentially kill a cell if it cannot be 
repaired or bypassed. This is especially challenging, as ICLs are hard to repair due to the 
involvement of both strands of the DNA double helixX%Y. This poses a huge challenge 
during DNA replication, because both strands need to be separated to act as a 
templateX%X. As outlined above, one of the main hypotheses as to what causes ICLs in FA 
are small aldehydes, stemming from normal metabolic reactions. The Patel group in 
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Cambridge has done a lot of work on FA mouse models, and shown that stress caused 
by acetaldehyde and formaldehyde may be responsible for many of the Fanconi 
features%X–%$. Alcohol may be an especially big contributor, as it is metabolised to 
acetaldehyde%Y$. FA patients carrying hypomorphic or null mutations in the more active 
mitochondrial aldehyde dehydrogenase (as is common in many Asian populations) tend 
to have stronger symptoms for this reason%Yl,%Ym,X%$.  
The main pathway to remove ICLs completely is via the FA pathway, coupled to 
replication during S-phaseX%P. Other repair mechanisms that are available to the cell, 
such as nucleotide excision repair (NER), cannot fully remove ICLsX%], with the sole 
exception of the NEILL pathway. This glycosylase has recently been shown in Xenopus 
egg extracts to be able to remove at least some forms of ICLs (primarily less bulky ones), 
whereas the FA pathway in conjunction with HR is able to remove all types of ICLsX%l. 
Because of this new data on NEILL, it has been proposed that other DNA glycosylases 
might also be able to remove certain types of ICLsX%m. Indeed, a recent publication 
highlighted another DNA glycosylase in bacteria that can also remove ICLs, showing the 
potential of this class of enzymes to participate in ICL repairXXQ. As exciting as these new 
discoveries may be, this section will deal exclusively with the mechanisms of the 
canonical FA pathway. 
There are four basic steps of repair using the FA pathwayXX% (Figure %.P). First, the lesion 
has to be recognised. This step is carried out by the FA core complex. Subsequently, the 
DNA is incised, which is done by genes related to nucleotide excision repair. The newly 
made gap in the DNA is now ﬁlled and the crosslink bypassed by translesion DNA 
polymerases. Finally, the strands are connected back together and the lesion removed 
by homologous recombination. 
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Figure (.E: Overview of ICL repair by the FA pathway. Recognition of the lesion and activation of the 
FA pathway (A). FANCM recognises the lesion (red line connecting the DNA strands) and activates RPA 
ﬁlament formation and ATR activation. ATR in turn phosphorylates FANCDX-I, FANCS/BRCA% and 
members of the FA core complex. Phosphorylation patterns are based on information from Wang et al. 
XQQlXXX. Vital phosphates are shown in deep red, optional ones in grey. At the same time, nucleases such 
as WRN and DNAX, process the ends of the DNA for later HR. In the next step, the core complex 
monoubiquitylates FANCDX, in association with the EX ubiquitin-conjugating enzyme FANCT/UBEXT 
(B). This process is reversible by the enzyme USP%. FANCDX-I binds to DNA and stabilises the RAD$% 
ﬁlament, whose formation was catalysed by a complex containing FANCS/BRCA% and FANCD%/BRCAX.	
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This ﬁlament blocks excess processing of the DNA ends by DNAX. Once FANCDX-I has been ubiquitylated, 
it triggers nucleolytic incision by the SLX tri-nuclease complex (C), which cuts the DNA strand around 
the ICL. As soon as the DNA is incised, translesion synthesis mediated by several DNA polymerases can 
repair one strand across the lesion (D), leading to one intact DNA strand and another strand with a 
double-stranded break. In the ﬁnal step of ICL repair, HR mediated among other things by RAD$% (E), 
repairs the second strand of the DNA.  
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1.8.1 Interstrand crosslink removal 
1.8.1.1 Crosslink recognition 
The FA pathway is triggered when two replication forks collide at an ICL during DNA 
replication in S-phaseXXL,XXY. FANCM recognises the lesion, binds the crosslink and acts 
as an anchor for the rest of the FA core complex (Figure %.PA). Because of this, it can be 
considered the “FA signalosome anchor”%Ql. In addition to the FA proteins recruited 
subsequently, it is constitutively bound to its partners FAAPXY/FAXY and MHF%-XXX$–XX]. 
Apart from functioning as the signalosome anchor, FANCM also triggers an ataxia 
telangiectasia and RADL-related (ATR) kinase response and CHK% dependent 
signallingXXl–XLQ. Targets of ATR and CHK% include FANCMXL% itself, as well as other 
Fanconi proteins, such as FANCIXLX and FANCEXLL. FANCM is also able to recruit RPA, 
which smooths out the DNA, to the lesionXLY. Once FANCM is bound, the rest of the 
core complex assembles, which is a mixture of bona-ﬁde FA proteins and accessory 
proteins. There are %Y currently known members of the core complex (FANCA, FANCB, 
FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, FANCT, FAAPXQ/FAXQ, 
FAAPXY/FAXY, FAAP%QQ/FA%QQ, MHF% and MHFX)XL$. The whole core complex acts as 
a scaﬀold for the EX ubiquitin-conjugating enzyme FANCT/UBEXT and the EL ubiquitin 
ligase FANCL, which monoubiquitylates the FANCDX-FANCI heterodimer on the 
FANCDX subunit$X,XLP–XLm (Figure %.PB). FANCB and FAAP%QQ are bound to FANCL and 
modulate its activity%Q],XYQ,XY%. FANCE’s function during this process appears to be the 
direct binding of FANCDX and holding it in place for the reaction to occurl,XYX–XYY. The 
role of many other FA genes in FANCDX ubiquitylation is poorly deﬁned, even that of 
the most commonly mutated gene in FA, FANCAXY$. FANCI may also be ubiquitylated, 
which might increase the eﬃciency of the signalling pathway, but is not essentialXYP. It 
is unclear whether this happens at the same time as FANCDX modiﬁcation and whether 
the same proteins are responsibleXY$. It has however been proposed that a dimeric 
FANCB-FAAP%QQ-FANCL complex monoubiquitylates the FANCDX-I complex in a 
symmetric concurrent mannerXY$,XY]. The ubiquitin on FANCDX can be removed by the 
USP%-UAF% heterodimer, adding extra regulationXYl,XYm. There are other modiﬁcations 
that happen to the FANCDX-I dimer apart from ubiquitin modiﬁcation. Before this 
ubiquitylation event, FANCDX-I is also phosphorylated by ATRXYP,X$Q. This 
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phosphorylation might be necessary for the localisation to chromatinXYP. Besides these 
modiﬁcations, sumoylation of the complex has also been reported. This appears to 
regulate removal of the complex from chromatin, to limit incisions to the site of damage 
and decrease oﬀ-target cutsX$%. As can be seen from the stringent regulation of this phase, 
FANCDX-I activation is a key step in controlling ICL repair. Next, the FANCDX-I 
heterodimer binds the DNA at the stalled replication fork and triggers the next phase of 
ICL repair: nucleolytic incisionX%P. 
1.8.1.2 Nucleolytic incision 
SLXY/FANCP is recruited to the chromatin, which directly binds the ubiquitin on 
FANCDXX$X,X$L. In turn, FANCP recruits several structure-speciﬁc nucleases. These 
include the ERCCY (FANCQ/XPF)-ERCC% complexX$Y,X$$, MUSl%-EME%X$P and SLX%X$P. 
New data suggests that SLXY, SLX%, MUSl%-EME% and XPF-ERCC% form the SMX tri-
nuclease, which functions as complex responsible for nucleolytic incision during ICL 
repairX$]. In this complex, MUSl%-EME% seems to be the main nuclease, whereas SLXY 
and XPF-ERCC% tend to have more of a regulatory role in replication fork cleavage. 
SLXY’s role seems to be to relax the substrate speciﬁcity of MUSl%-EME% and XPF-ERCC% 
stimulates cleavage in an unknown way, independent of its nuclease activityX$]. Cleavage 
around the ICL by MUSl%-EME% leads to a double-stranded gap in the DNA (Figure %.PC). 
At this step, the nuclease FAN% binds FANCDX as well to protect the replication fork, 
but its role in ICL removal itself is disputed%mX,%mL. This situation is described in detail in 
section %.].m on the role of FA proteins in replication fork protection. 
1.8.1.3 Translesion synthesis 
The next step in the repair process is to replicate the DNA around the lesion, a process 
termed “translesion synthesis”XL$,X$l (Figure %.PD). There are three steps to this process: 
approach, insertion and extension. Approach refers to the DNA synthesis up to, but not 
including, the nucleotide opposite the lesion. The approach steps are catalysed by REV% 
and DNAPζ (REVL-])X$m. REV% is a deoxycytidyl transferaseXPQ,XP% and plays an important 
role in regulating translesion synthesis (TLS) polymerase activityXPX,XPL. 
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Insertion refers to the insertion of a nucleotide directly opposite to the lesion. The 
nuclease catalysing the insertion is still unknown, but DNAPhXPY and DNAPn, which 
binds RAD$% and FANCDX-ubiquitin, have been suggested%%Y,%%$. This step is very error-
prone and can reach up to %% misincorporated nucleotidesXP$. 
The last step of translesion synthesis, extension, is catalysed by DNAPζXPY,XP$. This results 
in an intact DNA strand, which can be used as a template for homologous recombination 
(Figure %.PE), as well as one strand containing a double-stranded break. The importance 
of this step has recently been underlined by the discovery of a Fanconi patient carrying 
biallelic REVV mutations, leading to the designation of REVV as FANCVXPP.  
1.9 Homologous recombination 
Homologous recombination (HR) is the last phase of ICL repair, as well as a major 
pathway to repair double-stranded DNA (dsDNA) breaks outside of ICL repairX%P. The 
process can be divided into three fundamental phases: the presynaptic phase, the 
synaptic phase and the postsynaptic phaseXP]. In the presynaptic phase, the DNA is 
prepared for RAD$% ﬁlament formation and the RAD$% monomers are assembled into a 
ﬁlament. In the synaptic phase, homologous DNA is searched and strand exchange 
catalysed by RAD$%. In the postsynaptic phase, the gaps left by strand exchange are ﬁlled, 
leading to the completion of DNA repair. Note that some of the proteins involved diﬀer 
when HR is used for other purposes, such as meiosis. This section will only discuss HR 
in the context of ICL repair. Rather than occurring after the processes mediated via the 
FA core complex, the early steps of HR have been shown to happen at the same time as 
some steps in the Fanconi pathway%%Y (Figure %.P).  
1.9.1 Presynaptic phase 
The ﬁrst step of HR is the $’-L’ resection started by the MRE%%-RAD$Q-NBS% (MRN) 
complex in conjunction with CTIP and further continued by EXO%, BLM, WRN and 
DNAXXPl (Figure %.PA). The multitude of proteins involved stems from the fact that there 
are two diﬀerent pathways that can lead to resected DNA, with either EXO% or DNAX 
acting as the nucleaseXPm, however for the purposes of ICL repair, these are equivalent. 
The newly formed single-stranded DNA (ssDNA) is bound by RPA, which serves to 
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straighten out the DNAX]Q. The resecting nucleases can resect the DNA too much, 
impairing DNA repair. Initially this was thought to be caused by MRE%%, but now it is 
known to be mediated by DNAX%%Y. While these nuclease complexes incise the DNA from 
both sides, RAD$% protects the DNA from excess processing from the nucleases, 
meaning it must already be coating the DNA beforehand%%Y,%%$,%l$,%lm (Figure %.PB). Proteins 
necessary for loading RAD$% onto the DNA include BRCA% and X (FANCS and FANCD%), 
FANCN/PALBX and FANCJ/BRIP%, which cooperate to load it into the ssDNA, replacing 
RPA in the processX]%–X]Y. This underscores the importance of replication fork protection 
for the successful ICL repair, as lack of either of these proteins can cause FA. In the 
cytoplasm, RAD$% is usually found in oligomeric form, bound to BRCAXX]$. The 
following model has been proposed for BRCAX’s role in loading RAD$% onto the DNAX]P: 
BRCAX disrupts RAD$% oligomers by binding it via its BRC repeats. In this step, the TRX 
region of BRCAX is phosphorylated. Once a DSB has been detected, BRCAX is 
dephosphorylated and RAD$% loaded onto the DNA. The interaction of the 
dephosphorylated TRX region with the RAD$% ﬁlaments stabilises the newly formed 
ﬁlament structureX]]–X]m. Once HR has ﬁnished, BRCAX is phosphorylated completely, 
helping with the disassembly of the RAD$% ﬁlament. The FA proteins FANCJ/BRIP% and 
FANCN/PALBX are important in this process by facilitating BRCA% functionality and the 
BRCA%-BRCAX interaction respectively. BRCA% is itself necessary to recruit BRCAX to the 
DNAX]%–X]L,XlQ. BODL% is also required to stabilise RAD$% at these forks and if lost, confers 
crosslinking sensitivity on the cellXl%. This process requires several accessory proteins, 
which positively and negatively regulate RAD$% function by mediating strand assembly 
or stabilising the RAD$% ﬁlament. These include RAD$%B, FANCO/RAD$%C, RAD$%D, 
FANCU/XRCCX, XRCCL, RAD$X, SWS%, SWSAP%, RAD$Y, RAD$YB, SWI$, and SFRXlX, 
as well as the ones mentioned above in the text. These interactions demonstrate the high 
amount or regulation required to carry out this processXlX. The importance of FA 
proteins in regulating this process is clear when the number involved in RAD$% ﬁlament 
formation and stabilisation is considered. Overall, resection results in single-stranded 
ends ready for the next phase, synapsis.  
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1.9.2 Synaptic phase 
RAD$% molecules coat the ssDNA to form a nucleoprotein ﬁlamentXlL that stretches the 
DNA out and promotes strand invasion into a homologous duplex strand, followed by 
strand exchange (synapsis)XlY (Figure %.PE). Renkawitz et al. have proposed a uniﬁed 
model for how RAD$% searches for homologous DNA in the cell that they have termed 
“accelerated random search model”XP]. In this model, the RAD$% coated strand starts out 
by probing the surrounding DNA on the broken chromosome by undergoing very short 
strand invasions. If no homologous DNA is found, the DNA further away is probed. 
However, probing eﬃciency decreases as a function of distance very rapidly, as regions 
further away are encountered much less frequently by chance. This process might be 
accelerated by sliding of the RAD$% ﬁlament along the DNA, as the ﬁlament would not 
constantly have to dissociate and associate to probe large tracts of DNA. Sampling of 
multiple non-contiguous segments of DNA by one ﬁlament may also help with speeding 
up the process. Using such a process would ensure that homology search by RAD$% is 
eﬃcient, as the DNA close to the break is searched ﬁrst, but the mechanism can still 
cover a large swath of the genome. Once homologous DNA is found, strand exchange 
can occur. Strand exchange leads to a DNA formation called the “D-loop”, in which the 
invading strand primes DNA synthesisXl$. As soon as RAD$% has fulﬁlled its function, it 
hydrolyses ATP to ADP, which leads to a conformational shift allowing dissociation from 
the DNAXlP,Xl]. 
1.9.3 Postsynaptic phase 
The postsynaptic phase, also termed the resolution phase, begins with DNA synthesis 
from the broken L’ end formed during the synaptic phase. The resulting structure can 
either be resolved via a double Holliday junction (dHJ) with crossover or non-crossover 
products, or the synthesis-dependent, strand annealing (SDSA) pathway, which 
prevents crossovers. Alternatively, a new replication fork can also be formed in a process 
called break-induced replication (BIR), which has the disadvantage that it can lead to 
loss of heterozygosityXl$. There are usually no crossovers in somatic cells, whereas they 
are common during meiosisXl$. In yeast cells, dHJ formation is blocked by Rad$%, which 
biases the process to the SDSA pathway, where no crossovers occurXll. This agrees with 
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experimental evidence showing that the SDSA pathway is preferred in-vivoXlm. However, 
dHJs can occasionally occur in somatic cells nonethelessXmQ. 
1.9.3.1 Double Holliday junction resolution 
The dHJ resolution model (Figure %.]A), ﬁrst proposed in this form by Szostak et al. in 
%mlLXm%, is the classical model of how HR is ﬁnished. After strand invasion, the invading 
strand primes DNA synthesis from its L’ end. D-loop extension allows the displaced 
complementary strand to anneal and its L’ end now also serves as a starting point for 
replication. The ends of the newly made DNA are now ligated, which leads to the 
formation of the dHJ. Ultimately, several nucleases can lead to the resolution of the dHJ, 
resulting in either crossover or non-crossover products. As both strands of DNA prime 
DNA synthesis here, the mechanism uses semi-conservative DNA replicationXmX. 
1.9.3.2 Synthesis-dependent strand annealing 
The basic process of SDSA (Figure %.]B) was ﬁrst described in a TY Phage system by 
Formosa and Alberts in %mlPXmL. As in dHJ resolution, it starts with extension of the 
invading strand at its L’ end. However, instead of also extending the displaced 
complementary strand at this step, the invading strand is further extended, leading to a 
translocating D-loop. The ﬁrst strand being elongated is thereby displaced from its 
template strand by branch migration, as the “DNA bubble” moves along the DNA during 
extension. The second end is captured when the complementary ssDNA of the ﬁrst 
strand is exposed by branch migration, which then anneals to the tail of the second 
strand as the D-loop collapses. The DNA on this strand can now be completely replicated 
and the breaks ligated. This process conserves the intact strand completely, thus newly 
made DNA is only on the repaired strand and the process is conservativeXmX. This also 
prevents crossovers, unless second end capture happens by the second strand annealing 
to the D-loop, which can form another dHJ. However, this alternative way of completing 
SDSA and the resulting crossovers are extremely rareXlm, so SDSA usually produces non-
crossover products. 
1.9.3.3 Break-induced replication 
The BIR pathway (Figure %.]C) of resolving HR intermediates can occur when one of the 
resected DSBs is homologous to the intact DNA. Here, the invading DNA strand serves 
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as starting point for a new complete replication fork, which has a leading and lagging 
strand as usually in the cellXmY, whereas the other HR resolution methods only use the 
machinery for the leading strand. It is semi-conservative, like dHJ resolutionXmX and 
requires the resolution of a single Holliday junction (HJ) to be completedXm$. 
 
Figure (.K: Ways of resolving HR. Newly made DNA is shown in red. (A) Classical dHJ resolution. A 
RAD$%-coated DNA strand invades a homologous DNA duplex. A D-loop forms and is extended until the 
other broken strand can anneal, followed by the extension of this second strand. This extension leads to 
the formation of a dHJ, which can be resolved by cutting at several sites, indicated by diﬀerent arrows. 
Depending on how the dHJ is cut (and the junction translocated), there can be crossover and non-
crossover products. As indicated in the products, newly made DNA can be found on both new 
chromosomes, indicating the semi-conservative nature of this process. (B) SDSA pathway. As in dHJ 
resolution, RAD$%-coated DNA invades a homologous duplex and forms a D-loop. However, in contrast 
to dHJ resolution, the D-loop is extended much longer, leading to a migrating DNA bubble. The newly 
made DNA can then hybridise with the broken end on the other DNA strand, acting as a template for 
repair of the other side of the break. Thus, newly made DNA is only found on one chromosome, making 
this way of repair conservative. (C) BIR pathway. Strand invasion triggers the generation of two completely 
new replication forks, with leading and lagging strand DNA synthesis. In the end, a single HJ is resolved 
to give rise to the repaired DNA strands. Both contain newly synthesised DNA (red), i.e. the process is 
semi-conservative. 
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1.10 RAD51 
The RAD$% protein is one of the main components of the HR pathway. It plays a vital 
role in recombination, both for DNA repair, as well as in meiosis. It is in fact so 
important, that knocking out Rad$% in mice leads to early embryonic lethalityXmP,Xm]. This 
section will discuss the evolution, structure and mechanism of RAD$%, with a focus on 
its role in the aetiology of FA. 
1.10.1 Evolution 
The human RAD$% protein was discovered as a homologue to the yeast recombinase 
Rad$%, which in turn is a homologue of bacterial RecAXlL,Xml,Xmm. The basic structure is 
highly conserved between all three proteins, particularly the “homologous core 
region”Xml,LQQ. The yeast and human proteins are lL% identicalLQQ. Because of this 
similarity, most of the functional and structural studies of the enzymes have been 
carried out on the yeast and bacterial versions. When applicable, diﬀerences to the 
human protein will be highlighted, otherwise the proteins will be treated as 
interchangeable. These three proteins form part of a larger evolutionary family called 
the RecA/RAD$% like proteins. This family shares a common RecA/RAD$% core domain 
containing an ATP-binding Walker A and B motif LQ%. The family is an evolutionarily 
ancient group, being found in eubacteria, eukaryotes and archaeaLQ%,LQX. Apart from 
RAD$% itself, it contains many of the RAD$% accessory proteins that play a role in the FA 
pathway and HR, including RAD$%B, C and D, as well as XRCCX and L, all of which have 
more than X$% identity on the protein levelLQL. The RecA/RAD$% group is part of the 
larger, ATPases associated with diverse cellular activities (AAA+) and additional strand 
conserved E (ASCE) family, which shares a common catalytic mechanismLQY. 
1.10.2 Structure-function relationship 
RAD$%’s structure is highly similar to the bacterial RecA structure, yet there are some 
key diﬀerences in its domain architecture. In contrast to RecA, RAD$% starts with an N-
terminal domain containing a helix-hairpin-helix domain, which mediates DNA binding. 
This is followed by the conserved RecA/RAD$% domain, which makes up the bulk of the 
protein. RAD$% ends with this domain, whereas RecA has an additional C-terminal 
domain, which facilitates DNA binding like the N-terminal RAD$% domainLQ%. 
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Crystallographic analysis showed that the catalytic domain of RAD$% and RecA are 
topologically identical and can be superimposed with negligible deviation between the 
structuresLQ$. The RecA domain is made up of an eight-stranded β-sheet ﬂanked by α-
helices. ATP binds near the C-terminus of a β-sheet, with its phosphates close to the N-
terminus of an α-helixLQP. When bound to DNA, the RAD$% ﬁlament encases it in a 
helical ﬁlament with %QL Å pitch, a rise of %P.% Å and a twist of $P.X°, consisting of P.Y 
protomers per turnLQ] (Figure %.l).  
 
Figure (.O: RADB( crystal structures. RAD$% ﬁlament wound around ssDNA (not shown), forming a 
protomer seen from the side (A) and from the front (B) The individual RAD$% protomers are coloured 
diﬀerently. The helical shape of the ﬁlament is clearly apparent. DNA would normally ﬁt into the channel 
in the middle, as visible in (B). Based on the crystal structures by Short et al. XQ%PLQ]. PDB: $JCZ. 
These ﬁlaments are necessary to facilitate strand exchangeXlY, akin to bacterial RecA. 
Just like RecA interacts closely with the bacterial ssDNA binding protein SSB, Rad$% 
works together with RPA, which smooths out secondary structure in ssDNA and 
signiﬁcantly stimulates Rad$% ﬁlament formationLQl. RAD$% has two DNA binding sites, 
one of which is necessary to bind the invading DNA strand, the other necessary to 
weakly bind DNA being probed for homology. Once homologous DNA is found, the 
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strand to be displaced is bound more tightly, allowing formation of the strand exchange 
complexLQm. Upon completion of strand exchange, RAD$% hydrolyses the bound ATP to 
ADP and the resulting conformational change leads to dissociation from the DNAXlP,Xl]. 
Even though this mechanism is highly conserved, there are several small diﬀerences in 
the function of RecA and Rad$%. RecA preferentially binds ssDNA or partially ssDNAL%Q, 
whereas Rad$% can bind under various conditionsXlY,Xml,L%%, including dsDNA. 
Furthermore, strand transfer occurs in opposite directions; RecA transfers $’-L’, whereas 
Rad$% transfers L’-$’. 
1.10.3 Function in meiosis and lymphopoiesis 
Apart from its roles in somatic recombination, Rad$% is also seen on chromosomal DNA 
during meiotic prophase, where it facilitates cross overs between chromosomesL%X–L%Y. 
However, here it does not act directly to catalyse strand exchange, but rather acts as an 
accessory factor to the highly similar protein DMC%, which catalyses meiotic strand 
exchangeL%$. Because of this function, it is highly expressed in meiotic germ cells. 
Similarly, lymphoid tissues undergo considerable amounts of somatic recombination to 
generate diverse antibodies and T-cell receptors, leading to high expression of Rad$% 
thereLQQ,L%P,L%]. In somatic cells, Rad$% foci are normally only seen following DNA 
damageL%X.  
1.10.4 RAD51 in Fanconi anaemia 
Recently, there have been two case reports of patients suﬀering from Fanconi anaemia-
like symptoms linked to mutations in the RAD$%%%Y,%%$. One patient was a girl suﬀering 
from radial dysplasia, absent right thumb, pelvic left kidney, microcephaly and 
micropthalmia, café-au-lait-spots and increased DNA damage in response to 
crosslinking agents. This patient had above average intelligence%%Y. The other patient 
displayed growth retardation, microcephaly, hydrocephalus, thumb abnormalities, 
imperforate anus and an abnormal left testicle. This patient displayed mild mental 
retardation, with an IQ of about ]Q%%$. Importantly, neither patient has yet developed 
BMF by age %L and XL respectively%%Y,%%$. The discovery of patients carrying mutations in 
RAD$% was surprising, as loss-of-function mutations of Rad$% in mice invariably leads to 
early embryonic lethalityXmP,Xm]. This discrepancy was explained by the fact that both 
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patients only carry one mutant copy of the gene, which acts in a dominant negative 
fashion. HR is still functional in both patients, allowing survival to birth%%Y,%%$. One 
mutation leads to the change of threonine %L% to proline (T%L%P) in the Walker A motif, 
leading to increased speed of ATP hydrolysis. The mutation causes the formation of 
unstable ﬁlaments and impairs the functionality of RAD$% in protecting the broken-
down replication fork from excess processing by DNAX-WRN, which makes the 
appropriate repair of ICLs impossible. Interestingly, this patient upregulates the wild 
type form of the protein, seemingly to compensate for the mutant allele%%Y. The other 
mutation leads to a change in alanine XmL to threonine (AXmLT), which leads to 
decreased, rather than increased ATPase function, but impairs DNA binding and also 
leads to unstable ﬁlament formation%%$, presumably also impairing replication fork 
protection and thus ICL repair. Intriguingly, mapping of the mutations to a model of 
RAD$% in the ﬁlament revealed that both mutations map to the interface between the 
individual RAD$% protomersLQ] (Figure %.m). Phenylalanine %Xm on one protomer 
interacts with histidine XmY from the adjacent protomer to stabilise the interaction 
between them. As shown in Figure %.m, the disease-causing mutations map very closely 
to these key amino acids. In the case of the T%L%P mutation, a conformational distortion 
of the α-carbon backbone might lead to the F%Xm side chain, being oriented wrongly, 
obstructing the interaction with HXmY. The AXmLT mutation on the other hand might 
interfere with the orientation of histidine XmY itself, similarly destabilising the interface. 
It is intriguing that both mutations in very diﬀerent parts of the primary structure map 
to the same location in the protein complex, leading to such similar defects. It is unclear 
what role the changed ATPase eﬃciencies play in this model, as the defects in ﬁlament 
formation seem to be mediated by abnormal protomer-protomer interactions rather 
than aberrant ATP hydrolysisLQ].  
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Figure (.Q: Location of the FA associated mutations on the RADB( ﬁlament. The two diﬀerent 
protomers are shown as cartoons in light blue and light green respectively. The side chains of FA-relevant 
amino acids are shown as stick models. F%Xm is in green, T%L% in red, AXmL in yellow and HXmY in blue. The 
interaction between F%Xm and HXmY can be seen in the middle between the protomers. It is apparent that 
the disease-causing T%L%P and AXmLT mutations are in close proximity on the ﬁlament, even though they 
are far apart on a single protomer and the primary amino acid sequence. Based on the crystal structures 
by Short et al. XQ%PLQ]. PDB: $JCZ. 
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1.11 Zebrafish as a model organism in haematology  
Zebraﬁsh (Danio rerio) are teleost ﬁsh in the cyprinid family (the carp or minnow family) 
of the class Actinopterygii (ray-ﬁnned ﬁsh), which are a subgroup of the Osteichthyes 
(bony ﬁsh)L%l. Their original range lies in the South-eastern Himalaya regionL%m. They live 
in various diﬀerent habitats, but most of them are associated with aquatic vegetation, 
such as rice ﬁeldsLXQ. The average natural life span of the zebraﬁsh is unknown, but can 
exceed ﬁve years in rare cases in laboratoriesLXQ. Teleosts, the group to which zebraﬁsh 
belong, underwent a genome duplication event. This complex genome might be an 
explanation why teleosts are the most species-rich vertebratesLX%,LXX. 
1.11.1 Historical developments 
The ﬁrst known use of teleost ﬁsh for scientiﬁc research goes back to %mth century Austria. 
Joseph Oellacher, a physician, discovered the intra-embryonic generation of blood in 
trout embryos, whereas in other vertebrates haematopoiesis initially starts in the yolkLXL. 
Zebraﬁsh were ﬁrst mentioned in the literature as a scientiﬁc model in %mPLLXY. Again, 
the paper was concerned with the early stages of haematopoiesis. It seems ﬁtting that 
both the ﬁrst paper using teleosts, as well as the ﬁrst paper using zebraﬁsh investigated 
blood formation, considering how popular the zebraﬁsh model has proven to be with 
haematologists. Later, George Streisinger at the University of Oregon was the ﬁrst to 
popularise the use of zebraﬁsh as a model organism. Their high fecundity, small size and 
moderate space requirementsL%l, as well as their transparent embryosLX$ made them ideal 
for use in research, so many laboratories started to set up their own colonies. 
More recently, there have been many advances enabling even more sophisticated work 
on zebraﬁsh. Their genome has been sequenced, which revealed that at least ]Q% of the 
human genome have at least one orthologue among the ~XPQQQ genes in the zebraﬁsh 
genome, including most known disease-causing genesLXP. The zebraﬁsh mutation 
project (ZMP) at the Sanger InstituteLX] is one of several resources to obtain various 
mutant lines. The CRISPR-Casm system has been adapted successfully for zebraﬁshLXl,LXm, 
including a tissue-speciﬁc variantLLQ. This technique has for example been used to 
supplement the Sanger ZMP pipelineLL%. Overall, the availability of these techniques and 
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the intrinsic advantages of the ﬁsh model make the zebraﬁsh very attractive organisms 
for research purposes. 
1.11.2 Zebrafish haematopoiesis 
Haematopoiesis is highly conserved between ﬁsh and mammalsLX$,LLX,LLL. As in mammals, 
there are two waves of haematopoiesis, called “primitive” and “deﬁnitive” waveLLX,LLL.  
The primitive wave (Figure %.%QA) starts from %X hours post fertilisation (hpf) in the 
intermediary cell mass (ICM). It is a transient wave making erythrocytesLLY and 
leukocytes, which consist of mostly macrophages, but also some neutrophilsLL$–LL]. From 
%X-%P hpf, erythroid and myeloid cells are made exclusively in the anterior lateral 
mesoderm and posterior lateral mesoderm respectively. Between %P and Yl hpf, there is 
additional generation of primitive neutrophils and thrombocytes in the peripheral blood 
islands (PBI)LLL. The primitive wave is only relevant for very early embryogenesis, so the 
focus here will lie on the deﬁnitive wave. 
The deﬁnitive wave (Figure %.%QB) starts around LL hpf, when long-term haematopoietic 
stem cells (LT-HSCs) are formed from endothelial cells of the ventral wall of the dorsal 
aorta (VDA) in the anterior gonad mesonephros (AGM). Stem cells bud oﬀ from the 
VDA until approximately $Y hpf, with peak activity at Yl hpf LLl–LY%. This is dependent 
on the blood ﬂow from the earlier primitive waveLYX. These newly made HSCs 
subsequently move to the caudal haematopoietic tissue (CHT), which serves as an 
intermediate place of haematopoiesis in which the HSCs expand greatly, akin to the 
foetal liverLYL. The CHT contributes to haematopoiesis roughly between X and P dpf LLX. 
At L dpf, the thymus is colonized by lymphoblasts stemming from the AGM and CHTLYY. 
The function of this organ is to serve as the production place of mature T-lymphocytes 
in the embryo and adult. Cells expressing the recombination-activating genes rag% and 
rag>, necessary for immunoglobulin and T-cell receptor production, can be seen there 
as early as L.$ dpf LY$. From Y dpf onwards, the pronephros, which later forms the fully 
mature mesonephros, is colonized by cells from the AGM and CHTLYL,LYP. The 
mesonephros is the fully mature form of the kidney in zebraﬁsh, whereas in mammals 
it is completely replaced by the metanephros and atrophiesLY].  
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Figure (.(S: Locations of haematopoiesis in the zebraﬁsh embryo. (A) Sites of the primitive wave in 
the zebraﬁsh embryo. LPM = lateral plate mesoderm, ALM = anterior lateral mesoderm, PLM = posterior 
lateral mesoderm, PBI = peripheral blood island. (B) Sites of the deﬁnitive wave in the zebraﬁsh embryo. 
AGM = aorta-gonad-mesenephros, CHT = caudal haematopoietic tissue. 
In adult ﬁsh (Figure %.%%), haematopoiesis occurs in the kidney marrow, which is the 
equivalent of the mammalian bone marrowLLL. They have all major blood lineages found 
in humans, but some small diﬀerences do exist. Their erythrocytes are nucleated, but 
they undergo globin switching just like mammalian red blood cellsLYl. Instead of 
platelets, they have thrombocytes, which are functionally identical but also nucleated. 
No megakaryocytes exist in zebraﬁshLYm. Granulocytes, such as neutrophils are also 
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foundL$Q,L$%. Other myeloid cells, such as monocytes/macrophagesLLP, dendritic cellsL$X 
and mast cellsL$L exist as well. The lymphocytic lineage is present too, with B-cellsL$Y, T-
cellsLY$, as well as natural killer (NK) cellsL$$–L$]. 
 
Figure (.((: Sites of haematopoiesis in adult zebraﬁsh. Zebraﬁsh have all major blood lineages found 
in humans, which are mostly made in the kidney. T-lymphocytes are an exception, as they are formed in 
the thymus. 
1.11.3 The Fanconi anaemia pathway in zebrafish 
The Fanconi gene network is generally conserved in the zebraﬁsh, with the exception of 
BRCA%/FANCSL$l (Table %.L). There is evidence that the whole system must have evolved 
very early, at least before the divergence of ray ﬁn and lobe ﬁn ﬁsh approximately Y$Q 
million years agoL$m,LPQ. FA genes seem to have reverted back to a single copy after the 
teleost genome duplication event. This is because none (bar one) of them is duplicated, 
which would be very unlikely to have happened by chance, considering the number of 
genes involved and that roughly LQ% of the zebraﬁsh genome is duplicated. This 
suggests the stochastics of the individual proteins are very importantL$m. A recently 
discovered potential FA gene (REVV/FANCV) is in fact duplicatedXPP. However, it has not 
been fully shown to be a bona-ﬁde Fanconi gene and is not involved in the core Fanconi 
complex. This indicates that at least in the core complex the stochasticity of the proteins 
KidneyThymus
ErythrocytesThrombocytes NeutrophilsEosinophilsMonocytes
T-Lymphocytes
B-Lymphocytes
NK cells
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is vital for the successful survival of an organism. This conservation of the pathway and 
the fact that they are vertebrates with similar organs to humans, make zebraﬁsh good 
for modelling FAL$m. 
Table (.?: Conservation of the FA gene network among several common model organisms. O 
indicates conservation, whereas X indicates the absence of this gene. A clear divide in conservation 
between lower organisms and vertebrates is seen. Zebraﬁsh have all the FA genes that humans do, apart 
from FANCS/BRCA%. Data in this table is mostly based on Dong et al. XQ%$L$l, with additional information 
from FANCV and U added via ENSEMBL searches. 
	
Species Fanconi Gene 
Homo sapiens 
(FANC...) A B C D E F G I J K L M N O P Q R S T U V 
Mus musculus O O O O O O O O O O O O O O O O O O O O O 
Xenopus laevis O O O O O O O O O O O O O O O O O O O O O 
Danio rerio O O O O O O O O O O O O O O O O O X O O O 
Drosophila 
melanogaster X X X X O X X X O X O O X O X O O X O X O 
Caenorhabditis 
elegans X X X O O X X X O O X X X O O O O X O X X 
Saccharomyces 
cerevisiae X X X X X X X X X O X O X O O O O X X X X 
 
Most of the Fanconi anaemia research on zebraﬁsh so far has been carried out on 
embryos. Titus et al. showed that FA genes are mainly expressed in the developing 
nervous system, as well as the gonadsL$m. Just like in humans%LL, there is a connection 
between loss of the Fanconi pathway and excess p$R activation. This was shown by 
knocking down fancd> in zebraﬁsh embryos using morpholinos followed by irradiation. 
This led to a small eye and head phenotype, which could be rescued by p$R knockdownLP%. 
Interestingly, it seems like Fanconi genes are very important in early development and 
are maternally provided because of thatL$m,LP%. This is again consistent with the idea that 
the stem cell defect seen in FA is already apparent during embryonic development%LL. 
There are currently two zebraﬁsh models in which Fanconi anaemia genes are lost; one 
involving loss of fanclLPX and one involving brca>LPL,LPY (this model was independently 
described by two diﬀerent groups at almost the same time). Both models showed sex 
reversal with complete lack of female ﬁsh. This feature successfully rescued with p$R co-
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mutationLPL,LPY. A functional FA pathway seems to be necessary for the development of 
females and, explaining why the FA genes are highly expressed in the gonads of 
developing ﬁsh. Interestingly, fancl mutant males are fertileLPX, indicating that HR, but 
not the FA pathway is necessary for successful male meiosis. 
Interestingly, none of the mutants have been analysed in-depth for features of Fanconi 
anaemia. While brca> mutant ﬁsh display increased sensitivity to crosslinking 
agentsLPL,LPY, as do FA patients, there are no reports of any haematological abnormalities. 
This suggests the blood phenotype (if there is any) is subtle. This reﬂects the situation 
seen in mouse models of the disease, described in section L.%.X. The lack of adult 
zebraﬁsh without a characterised blood phenotype compelled me to study 
haematopoiesis in my rad$% mutants more closely, leading to the ﬁrst description of a 
zebraﬁsh FA model using adult ﬁsh.  
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1.12 Aims 
As discussed above, there are still signiﬁcant gaps in our understanding of the causes of 
FA, as well as in our understanding of the in-vivo role of Rad$%. In this thesis, I try to 
address these issues by pursuing the following aims:  
%. Characterising the haematological and non-haematological phenotype of rad$% 
mutant zebraﬁsh 
X. Using the zebraﬁsh FA model to better understand the cellular and molecular 
basis of FA 
L. Elucidating the eﬀect of increased stress haematopoiesis on the haematological 
phenotype of the rad$% mutant ﬁsh to gain a better understanding of the role of 
stress in the aetiology of FA 
In the next chapter, the methods used to answer these questions are outlined. Chapters 
L-$ describe and discuss the experiments conducted during this study. In the sixth and 
ﬁnal chapter, these results are placed into the overall context of FA research.
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2 Materials and methods  
2.1 Zebrafish care and strains 
Fish lines were maintained in the Sanger Institute zebraﬁsh facility according to EU, 
Home Oﬃce and Animals Scientiﬁc Procedures Act %mlP regulations. Wild type ﬁsh 
were of the Tübingen long ﬁn strain. The rad$%sa>RWX$ line was obtained from the 
Wellcome Trust Sanger Institute Zebraﬁsh mutation projectLX]. The rad$%b mutant line 
was generated using the CRISPR-Casm technique as described below. The tp$Rzdf% lineLP$ 
was generously provided by Sebastian Gerety. The rag>ES$Xfs lineLPP was kindly provided 
by David Langenau. Apart from the mutant lines, I also used Tg(itga>b:EGFP)LP] (itga>b 
is an orthologue of human CDS%), Tg(gata%a:EGFP)LPl and Tg(sdf%a:dsRed)LPm ﬁsh (sdf%a 
is also called cxcl%>a). Lines were crossed as indicated in the main text. Embryos were 
incubated at Xl.$°C in egg water (Q.%l g/l of synthetic sea salt in sterile HXO). When 
transparent embryos were required for assays, they were placed into egg water 
containing Q.QQY$% %-phenyl-X-thiourea (Sigma-Aldrich) at about ]-l hpf to inhibit 
melanocyte formation as described previouslyL]Q. For breeding, adult ﬁsh were kept in 
small separate tanks with a mesh insert and removable barriers to control the exact time 
of the mating. 
2.2 Genomic DNA extraction and genotyping 
Adult ﬁsh were anaesthetised in Q.QX% L-amino-benzoic acid ethyl ester (tricaine) 
(Sigma-Aldrich) and the tip of the tail removed and sorted into mP-well plates. For 
embryos, either the head or the tail was kept for genotyping and also sorted into mP-well 
plates. DNA was extracted using the Hot Shot method. Samples were treated with 
alkaline lysis buﬀer (X$ mM NaOH and Q.X mM EDTA) at m$°C for LQ minutes to lyse 
cells and extract the DNA. This solution was neutralized by adding an equal volume of 
neutralization buﬀer (YQ mM tris-HCl). I then used KASP (a commercial variant of 
competitive allele-speciﬁc PCR) genotyping assays (KBioscience) according to the 
manufacturer’s protocol. The primers used for genotyping can be found in Table X.%. 
Primers were acquired from Sigma-Aldrich or LGC genomics. Individual primers were 
mixed as follows: XY µl primer % and X each, PQ µl common primer and mX µl HXO. 
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Analysis was carried out on a PHERAstar Plus (BMGlabtech) using KlusterCaller 
software (KBioscience). 
Table =.(: KASP Primers used for genotyping. Primers for rad$%l% were ordered commercially from LGC 
genomics, hence the sequence is not known. All primers are listed in $’-L’ direction. 
Allele Primer 1 Primer 2 Common 
tp53zdf1 
GAAGGTGACCAAGTT
CATGCTGATGGGCC
TGCGGTTCA  
GAAGGTCGGAGTCA
ACGGATTGGATGGG
CCTGCGGTTCT  
ACAACTGTGCTACTA
AACTACATGTGCA 
rad51sa23805  
GAAGGTGACCAAGTT
CATGCTCCTTCAACA
CTGACCATCAAACAC 
GAAGGTCGGAGTCA
ACGGATTGCCTTCAA
CACTGACCATCAAAC
AT 
GGTCATCATAGCGG
AGGCCTGAT 
rad51l1 Proprietary from LGC genomics  	
 
2.3 Western blotting 
Tissues for western blotting were dissected from ﬁsh and lysed in lysis buﬀer ($Q mM 
tris pH ].Y, %QQ mM NaCl, $ mM MgClX, Q.$% NPYQ, % mM dithiothreitol (DTT)) with 
one tablet of proteinase inhibitor (Roche Diagnostics) per %Q ml of buﬀer for LQ minutes. 
Samples were then centrifuged at %YQQQ rpm for %Q minutes and the supernatant 
collected. The protein concentration was quantiﬁed using the Bradford assay. Each 
sample was diluted to the same concentration and stored at -lQ°C. Lithium dodecyl 
sulphate loading buﬀer to %X ﬁnal concentration and X$ µl/ml β-mercaptoethanol were 
added to the samples, which were then run on %X% NuPAGE polyacrylamide gels 
(Thermo Fisher Scientiﬁc) at mQ V for XQ minutes and then at %XQ V until the marker 
reached the bottom of the gel. Proteins were transferred onto methanol-activated 
polyvinylidene ﬂuoride membranes at LQQ mA for %.$ hours and blocked overnight in 
X% bovine serum albumin (BSA)/tris-buﬀered saline with Tween (TBST) ($Q mM tris 
pH ].Y, Q.Q$% Tween XQ (Sigma-Aldrich)). The membrane was then probed with the 
primary antibody (%:%QQQ) for % hour, followed by horseradish peroxidase (HRP)-
conjugated anti-mouse or goat secondary antibody for % hour. The membrane was 
washed extensively in TBST after each probing step. The signal was revealed using 
SuperSignal West Femto Maximum Sensitivity substrate (Thermo Scientiﬁc) and 
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for Y$ minutes at $Q°C using pre-warmed stripping buﬀer (%X.$ ml tris-HCl pH P.l Q.$ 
M, XQ ml %Q% SDS, Q.l ml β-mercaptoethanol, P].$ ml HXO), followed by X hours of 
rinsing under running tap water and a ten-minute wash in TBST. Details on the 
antibodies used can be found in Table X.X. 
Table =.=: List of antibodies. IS = immunostaining, WB = western blotting. 
Target Species Conjugate Company Catalogue No. Dilution used 
Rad51 rabbit none Abcam  ab137323  1:1000 (WB),  1:200 (IS) 
Rad51 rabbit none AnaSpec 55838 1:200 
BrdU rabbit fluorescein Roche 11202693001 1:100 
pH2AX rabbit none - - 1:1000 
Beta-
actin mouse none 
Sigma-
Aldrich  012M4821  1:1000 
Mouse 
IgG rabbit HRP Abcam ab97046  1:50000 
Rabbit 
IgG goat HRP 
Molecular 
Probes G21234  1:50000 
 
2.4 Immunostaining 
Embryos were ﬁxed at X dpf in Y% paraformaldehyde (PFA) in phosphate buﬀered saline 
(PBS) for X hours at room temperature, followed by extensive PBS + Tween XQ (PTW) 
washes. Samples were digested in Q.l µl/ml proteinase K for LQ minutes at RT, followed 
by reﬁxation in Y% PFA at room temperature (RT) and PTW washes. This step was 
omitted for freshly fertilised embryos. The samples were blocked in blocking solution 
(%Q% foetal bovine serum (FBS), %% dimethylsulphoxide (DMSO), Q.%% Triton X-%QQ in 
PBS) for % hour at RT followed by overnight incubation with rabbit primary antibody in 
blocking solution (%:XQQ) at Y°C. The embryos were then washed extensively in blocking 
solution and incubated with AFYll-conjugated secondary antibody for L hours at RT. 
The stained embryos were washed in PBS and optionally incubated for X days at RT in % 
ng/ml Hoechst dye LLLYX. Details on the antibodies can be found in Table X.X. 
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2.5 Microscopy 
Pictures of ﬂat mounted tails and live embryos were taken using a Zeiss Axio Zoom.V%P 
using Zen Imaging software. Pictures of stained slides were taken using a Leica DM 
YQQQB using %QX and XQX non-immersion objectives and a PLX oil immersion objective 
as appropriate. An Olympus DP]X camera was used for image acquisition in conjunction 
with Olympus cellSens software. Chromosome spreads were imaged using a Leica DM 
$QQQB microscope with a %QQX oil immersion objective and SmartCapture software 
(Digital Scientiﬁc UK). Confocal images were acquired on a Leica SP-$ confocal 
microscope using a YQX water immersion lens and Leica LAS-AF software. 
Measurements on pictures, as well as maximum projections for ﬂuorescence images 
were made using ImageJ software. 
2.6 Embryo irradiation 
Embryos were irradiated at XY hpf in a Gammacell %QQQ Elite Blood Irradiator (MDS 
Nordiron) at ]$Q cGy. Depending on the batch were then either collected and ﬁxed after 
L hours for immunostaining, or kept until X dpf. At X dpf, comparison pictures were 
taken and embryos scored for phenotypic abnormalities. 
2.7 Chromosome spreads 
Embryos were treated with $ µg/ml mitomycin C (MMC), % µg/ml diepoxybutane (DEB), 
%Q µM %,$-isoquinolinediol (DiQ) or %Q nM camptothecin (CPT) (Sigma-Aldrich) in egg 
water between Y and XY hpf, followed by treatment with Y mg/ml colchicine (Sigma-
Aldrich) in egg water for mQ minutes. The embryos were then transferred to %.%% sodium 
citrate and the yolk dissected away for %Q minutes. Dissected embryos were kept in 
sodium citrate on ice for another %Q minutes, followed by overnight ﬁxation in L:% 
methanol (MeOH):acetic acid. The heads of the embryos were then separated and kept 
for genotyping. The individual tails were dissociated in $Q% acetic acid by vigorously 
dissociating the tissue with dissecting forceps. The dissociated cells were then pipetted 
onto pre-warmed slides kept in a water bath at $Q°C. After several seconds, a few drops 
of MeOH were added to stop the reaction. Following that, the slides were transferred 
into a drying chamber at $Q°C. After complete drying of the samples, coverslips were 
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mounted onto slides using VECTASHIELD antifade mounting medium with Y',P-
diamidino-X-phenylindole (DAPI, Vector Laboratories). Coverslips were ﬁxed to the 
slide using nail varnish.  
2.8 NHEJ inhibition 
Non-homologous end joining was inhibited using the DNA ligase IV inhibitor SCR-] 
(Sigma-Aldrich). SCR-] was added to egg water at a range of concentrations (%Q, X$ and 
]$ µM). Embryos were incubated in these solutions between Y and XY hpf, at which point 
they were photographed and scored for abnormalities, followed by genotyping. 
2.9 CRISPR-Cas9 
Mutations in rad$%l% were induced at exon two, leading to a seven basepair (bp) deletion 
(Y]l-YlYdelTGGGTCC in the cDNA). The targeted DNA sequence was $’-
GGATGTCCTGTCGGTCACCCAGG-L’. The sequence of the ssDNA oligonucleotides was 
$’-TAGGATGTCCTGTCGGTCACCC-L’ and $’-AAACGGGTGACCGACAGGACAT-L’ 
(Sigma-Aldrich). These were annealed and ligated with pDRX]Y vector (Addgene) 
linearised with BsaI (New England Biolabs) to make a guide RNA (gRNA) expression 
vector. gRNA was prepared with MAXIscript T] kit (Life Technologies) using the DraI-
linearised gRNA expression vector as a template, while Casm mRNA was synthesised 
using the mMESSAGE mMACHINE T] kit (Ambion) and an pMLMLP%L expression 
vector (Addgene) linearised with PmeI (New England Biolabs). Zebraﬁsh embryos were 
injected at the %-cell stage with %X.$ pg of gRNA and %PQ pg of Casm mRNA. The presence 
of mutations was screened using Illumina miSeq. 
2.10 Fish photography 
Pictures of anaesthetised adult ﬁsh were taken using a Canon Eos ]$QD with a Canon 
Eos EF-S PQmm macro lens. The size was measured using ImageJ. 
2.11 Semen collection 
Adult male ﬁsh were anaesthetised using tricaine. Unconscious ﬁsh were dried oﬀ and 
placed on their backs in pre-made polyurethane foam moulds, allowing access to the 
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ventral side of the ﬁsh. Remaining water was dried oﬀ using a cotton bud. A %Q µl 
capillary was placed near the urogenital pore and the ﬁsh stroked gently from the 
anterior to the posterior end to stimulate the release of semen. Pictures of the capillaries 
were taken and used to estimate the volume of the emission. The cloudiness of the 
sample was used to determine the presence of spermatozoa. 
2.12 Histology 
Tissues for histology were ﬁxed in Y% PFA overnight and if necessary, treated with %Q% 
EDTA for decalciﬁcation over several days. Samples were processed by a Tissue-Tek 
VIPP tissue processor (Sakura) and embedded in paraﬃn. Sections were obtained at $ 
µm thickness using a Leica RMXXL$ rotary microtome. Slides were stained using 
standard Harris haematoxylin and eosin (H&E) staining (Sigma-Aldrich) and 
coverslipped on a Leica ST$Q%Q-CV$QLQ workstation. 
2.13 RNA extraction and RT-qPCR 
RNA was extracted using RNeasy columns (Qiagen) In brief, kidney samples were lysed 
in L$Q µl RLT buﬀer and vortexed vigorously. An equal volume of ]Q% ethanol (EtOH) 
was added to each tube and the mixed sample transferred to silica columns. The samples 
were centrifuged at maximum speed for %$ seconds to bind to the column. This was 
followed by one wash with ]QQ µl RW% buﬀer and two washes with $QQ µl RPE buﬀer, 
interspersed by %$ second centrifugations at maximum speed. After the last wash, the 
columns were centrifuged for X minutes at maximum speed. Following that, the columns 
were transferred into fresh collection tubes and centrifuged at the same speed again for 
% minute. Finally, the tubes were placed into fresh RNAse free Eppendorf tubes and the 
RNA eluted by adding LQ µl of HXO, followed by centrifugation at lQQQ g for % minute. 
Eluted RNA was stored at -lQ°C until use. cDNA was generated using either the 
SuperScript III or the SuperScript VILO kit (Thermo Fisher). For SuperScript III, X µl of 
cDNA, Xµl of Enzyme %Q µl of buﬀer and P µl of HXO was added per tube. The tube was 
then incubated at X$°C for %Q minutes, $Q°C for LQ minutes and l$°C for $ minutes. RNA 
was removed by adding % µl RNAse H and incubating at L]°C for XQ minutes. For 
SuperScript VILO, each tube contained X µl of RNA, $ µl of VILO reaction mix and %L µl 
of HXO. Tubes were incubated at X$°C for %Q minutes, Y$°C for LQ minutes and l$°C for 
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$ minutes. Following cDNA synthesis, samples were diluted threefold using HXO. qPCR 
was carried out using $ µl SYBR Green master mix (Thermo Fisher), Q.%$ µl of %Q µM of 
forward and reverse primer each, X.] µl HXO and X µl cDNA per sample in a QuantStudio 
L RT-PCR system (Thermo Fisher). Primers for qPCR analysis can be found in Table X.L. 
Samples were run in duplicates and analysed using the DDCt methodL]%. The mean Ct 
value of the housekeeping genes %Ws, actb% and eif%a was used for normalisation. 
Statistical tests were carried out on the DCt values, as recommended in Yuan et al.L]X.    
X-DDCt values were graphed with the geometric mean ±m$% conﬁdence intervals to 
estimate the fold change.  
Table =.?: Primers used for qPCR analysis. All primers are listed in $’-L’ direction. 
Target Forward Reverse Reference 
18S TCGCTAGTTGGCATCGTTTATG CGGAGGTTCGAAGACGATCA  
actb1 CGAGCAGGAGATGGGAACC CAACGGAAACGCTCATTGC  
brca2 AGCCAGACTTGTCCACAGAC AGGCACACAGATAGCTCCTC  
csf1r ATGACCATACCCAACTTTCC AGTTTGTTGGTCTGGATGTG 373 
eif1a TGGCAAGGTCACAAAGTCTG TCCGATGGGTTTTAATCAGC  
gadd45ab AACATGAGACGTCTGGCAGA AGATTGATGACTGGCACCCA  
il1b GCTGGAGATCCAAACGGATA ATACGCGGTGCTGATAAACC 374 
il8 GTCGCTGCATTGAAACAGAA AGGGGTCCAGACAGATCTCC 374 
lig4 CTGGCGCCGTTTAACTTTCT GTGCAGAGGTGAATGAACGG  
marco ACGACAGCTTCGATAATTTG AAAATACTGCTCTCGGTTCC 373 
p21 GTGTCAGGAAAAGCAGCAGA GACGCTTCTTGGCTTGGTAG  
p53 CGAGCCACTGCCATCTATAAG TGCCCTCCACTCTTATCAAATG  
prkdc TGAGTCTGACCGGGATGATC GCTGCATTCTCTGGCTGTAC  
rad52 AGGATATGGGGTCAGCGAAG GGCTCCAAATCGCTACGTTT  
rb1 GTATCTCTCTCCTGTCCGGC CTGGATGTGAGGTCAGCAGA  
xrcc4 GGAGGAAGTACGGAAGATGAAC CTGCATTCTGGCATCTCTTCT  
 
2.14 Single-cell suspension and cell counts 
Single-cell suspensions were made as follows. Dissected zebraﬁsh kidneys were placed 
in $% FBS in PBS on ice and sequentially passed through a YQ µm cell strainer (Corning) 
using a plunger, followed by a second ﬁltration using a XQ µm cell strainer (Partec). Cells 
were counted using Neubauer improved haemocytometers.  
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2.15 Kidney flow cytometry 
Single-cell suspensions were made as described above. Flow cytometry/ﬂuorescence 
activated cell sorting (FACS) was carried out on a BD LSRFortessa, a MoFlo XDP 
(Beckman Coulter) or a BD Inﬂux (BD Biosciences). Debris was excluded using the 
forward (FSC) and side scatter (SSC) parameters (Figure X.%A). Single cells were selected 
using FSC-A and FSC-W (Figure X.%B). Dead cells were excluded using (Sigma-Aldrich) 
or propidium iodide (PI) at %:%QQQ dilution (Figure X.%C and D).  
 
Figure =.(: General FACS gating scheme. (A) Separation of cells from smaller debris using the FSC and 
SSC parameters. (B) Selection of single cells using the FSC-A and FSC-W parameters. (C and D) Selection 
of viable cells using PI on a PI- control (C) and a PI+ sample (D). Selection of viable cells using DAPI would 
work analogously, just using a diﬀerent channel for detection. 
Erythrocytes and committed erythrocytic progenitors were selected using the 
Tg(gata%a:EGFP) transgenic lineLPl (Figure X.X). 
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Figure =.=: Selection of the erythrocytic lineage. (A) Gating for Tg(gata%a:EGFP)+ cells on a non-
transgenic control. (B) The same gate applied to a transgenic ﬁsh. 
Cells of the thrombocytic lineage were selected by using the Tg(itga>b:EGFP) lineLP] 
(Figure X.L). In this line, thrombocytic progenitors are labelled in the GFPlow population 
and mature thrombocytes are labelled in the GFPhigh populationL]$ (Figure X.LC). 
 
Figure =.?: Selection of the thrombocytic lineage. (A) Gating for Tg(itga>b:EGFP)+ cells on a non- 
transgenic ﬁsh. (B) The same gating applied to a transgenic ﬁsh. (C) GFP+ cells are split into GFPlow 
(thrombocytic progenitors) and GFPhigh (mature thrombocytes) cells by selecting for two equally-sized 
gates at the $Q% ﬂuorescence mark. 
Other blood lineages were selected on the basis of their FSC and SSC parameters, as ﬁrst 
described by Traver et al.L]P. I used this gating considering new RNA-Seq informationL]] 
that allowed me to redeﬁne the identity of some of the populations (Figure X.Y).  
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Figure =.@: Identiﬁcation of diﬀerent blood lineages using the forward and side scatter 
parameters. Ery = Erythrocytes, Prog = Progenitors, My = Myeloid cells, Mono = Monocytes. 
2.16 AnnexinV-propidium iodide assay 
I used the Alexa Fluor Yll Annexin V/Dead Cell Apoptosis Kit (Thermo Fisher) per the 
manufacturer’s instructions. In brief, kidney single cell suspensions were made as 
described above. Cells were spun down for L minutes at LQQQ rpm and resuspended in 
%QQ µl annexin buﬀer. One sample was split up to have controls without any stain, a 
control without PI and a control without antibody. All other samples received $ µl 
annexin V antibody conjugated to AFYll (Roche), as well as % µl of %QQ µg/ml PI. After 
%$ minutes of staining in the dark at RT, YQQ µl of annexin binding buﬀer were added to 
each sample to stop the reaction. The samples were then ﬁltered using XQ µm ﬁlters and 
analysed using FACS. Gating was set using the controls (Figure X.$).  
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Figure =.B: Gating for apoptotic cells. (A) Gating set on an unstained control, (B) gating on an AV-GFP 
and PI-stained control. Viable cells are in the bottom left (QY), apoptotic cells in the top left (Q%) and 
dead cells are in the two gates on the right (QX and L). 
2.17 BrdU incorporation assays  
2.17.1 Adult fish 
Fish were subjected to intraperitoneal (IP) injection with %Q µl %Q mg/ml $-bromo-X'-
deoxyuridine (BrdU, Sigma-Aldrich) and culled after the time speciﬁed in the text. The 
kidney and blood were extracted and single-cell suspensions made as described earlier. 
These suspensions were spun down at %$QQ rpm and ﬁxed in ]Q% ethanol (EtOH) 
overnight. The samples were then treated with XM HCl for % hour, followed by washes 
in tris (pH m.$) and PBS (pH P.l). The washed cells were incubated with anti-BrdU 
ﬂuorescein-conjugated antibody at %:%QQ in blocking solution (%Q% FBS, %% DMSO, Q.%% 
Triton X-%QQ) for X hours, after which the cells were resuspended in PBS. Samples were 
ﬁltered again using XQ µm ﬁlters (Partec) and analysed using FACS (Figure X.P). Details 
on the antibody can be found in Table X.X. 
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Figure =.E: Gating for BrdU+ cells on ﬁxed cells. (A) Selection for cells, (B) singlets, (C) and BrdU+ cells. 
(D) Same gating as in iii, but on a BrdU-injected sample. 
2.17.2 Embryos 
Embryos were dechorionated while chilled on ice for %$ minutes. This was followed by a 
XQ-minute incubation in %Q mM BrdU dissolved in egg water on ice. They were placed 
at Xl.$°C for L hours, followed by ﬁxation in Y% PFA at Y°C overnight. They were then 
dehydrated in an increasing series of MeOH and stored at -XQ°C in %QQ% MeOH. After 
rehydration in a decreasing MeOH series, heads were cut oﬀ for genotyping. For X dpf 
embryos, the whole tails were then pooled according to genotype, whereas for Y dpf 
embryos the CHT was cut out and pooled the same way. Samples were treated with %Q 
mM DTT in %X Danieau’s solution for LQ minutes at room temperature. They were then 
incubated in %X liberase (Roche Diagnostics) in PBS for L hours at L]°C with regular 
vortexing. The reaction was stopped by replacing the solution with $% FBS/PBS after 
spinning the tissue down at LQQQ rpm for L minutes. Single cell suspensions were made 
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as described above, followed by ﬁxation in ]Q% ethanol overnight. From here on, the 
staining process and analysis was identical to cells obtained from adults (see above). 
2.18 Blood smears  
Blood smears were carried out by severing the head of a culled ﬁsh on a microscope slide 
and smearing the blood along the length of the slide. After drying overnight, cells were 
ﬁxed in -XQ°C cold methanol (MeOH) for L minutes at room temperature and stained 
in May-Grünwald solution (Sigma-Aldrich) diluted %:% in HXO for %Q minutes at RT. This 
was followed by Giemsa solution diluted $:% in HXO for XQ minutes at RT. Excess stain 
was removed by washing in HXO. 
Diﬀerential counts on blood smears were carried out using ImageJ. Ten pictures of each 
bloodsmear were taken and all cells from each picture counted blindly. Leukocyte 
numbers were normalised by dividing the number of leukocytes by the total number of 
cells. 
2.19 Antisense probe synthesis 
Template DNA for the probe was ampliﬁed by PCR and inserted into a plasmid. Plasmids 
were used to transform OneShot ready Cells (Life Technologies) according to the 
manufacturer’s instruction. Transformed cells were then spread on plates carrying the 
appropriate antibiotic and incubated overnight at L]°C. Single colonies were picked and 
used to seed X$ ml Luria-Bertani broth containing the appropriate antibiotic, which was 
incubated at L]°C shaking overnight. The plasmid was extracted using a Qiagen 
MIDIPrep kit, according to the manufacturer’s instructions. Depending on the 
orientation of the insert and possible restriction sites, % µg plasmid was digested using 
LQQ U/µl of the appropriate restriction enzyme (New England Biolabs) using the 
corresponding New England Biolabs buﬀer at L]°C overnight. The product of this 
reaction was used to transcribe antisense probe using TL or T] enzyme at L]°C for L 
hours. The appropriate enzyme was selected according to the used vector and insert 
orientation (Table X.Y). The probe was then puriﬁed using an RNeasy kit (Qiagen), 
according to the manufacturers instruction. The resulting riboprobe was mixed %:% with 
hybridisation buﬀer ($Q% formamide (Sigma-Aldrich), $X saline-sodium citrate, %$Q 
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µg/ml heparin, $ mg/ml Torula RNA (Sigma-Aldrich) and Q.X% Tween XQ) and stored 
at -XQ°C. 
Table =.@: Vectors used to generate ISH probes. Prom = promoter. Sizes are in basepairs. All primers 
are listed in $’-L’ direction. 
Gene Forward primer 
Reverse 
primer 
Vector 
name 
Insert 
size  Antibiotic Enzyme Prom 
Other 
info 
cmyb N/A N/A 
pCMV-
SPORT 
6.1 
3271 Ampicillin NruI T7 
IMAGE 
clone ID: 
6790859 
ea1-
globin 
ATGAGT
CTCTCT
GCCAA
AGAC 
TTATCT
GTACTT
CTCAG
ACAT 
pCR-
Blunt II-
TOPO 
440 Kanamycin SpeI T7  
mpx N/A N/A pBK-CMV 2830 Kanamycin SalI T7 
IMAGE. 
clone ID: 
6790891 
rag1 
TGTAAC
CAACA
CCTGA
ACCCA 
CCATCT
TCTCAT
CATAG
CCTGT
G 
pCR4-
TOPO 1200 
Ampicillin 
Kanamycin NotI T3  
2.20 In-situ hybridisation (ISH) 
Embryos were ﬁxed in Y% PFA at Y°C overnight. They were then dehydrated in an 
increasing series of MeOH (X$, $Q, ]$ and %QQ%) followed by storage at -XQ°C in %QQ% 
MeOH. After rehydration in a decreasing MeOH series, they were digested using %.P 
µl/ml proteinase K (Roche Diagnostics) in HXO for one hour, followed by reﬁxation in 
Y% PFA for XQ minutes. Samples were then incubated in hybridisation buﬀer for one 
hour at $P°C. This was exchanged for antisense probe diluted in hybridisation buﬀer 
(L:XQQ), which was heated to lQ°C for %$ minutes beforehand. The probe was left on 
overnight, followed by three Y$-minute washes with preheated ($P°C) washing 
solutions: ﬁrst, XX saline-sodium citrate/PTW, Q.%% Tween XQ, $Q% hybridisation buﬀer, 
second, XX saline-sodium citrate/PTW, Q.X% Tween XQ and third, Q.XX saline-sodium 
citrate/PTW, Q.X% Tween XQ. The samples were then blocked using blocking solution 
($% FBS in PTW). Anti-digoxygenin-alkaline phosphatase (AP) conjugated antibody 
(Roche Diagnostics) was added at %:XQQQ in blocking solution and incubated at Y°C 
overnight. Samples were washed several times using PTW, followed by a washing 
solution (Q.% M NaCl, Q.% M tris-HCl at pH m.$, Q.Q$ M MgClX and Q.%% Tween XQ) for 
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LQ minutes, changing the solution once. One tablet of NBT/BCIP (nitro-blue 
tetrazolium and $-bromo-Y-chloro-L'-indolyphosphate) (Roche Diagnostics) was 
dissolved in %Q ml washing solution and added to the samples. Samples were incubated 
in the dark until suﬃcient staining was reached. Stained embryos were then washed 
extensively in PTW and subsequently stored in lQ% glycerol. Embryos were sorted into 
high, medium and low staining categories before the head was removed from the 
embryo to use its tissue for genotyping. The tail was then ﬂat mounted on a microscope 
slide for photography. 
2.21 Terminal deoxynucleotidyl transferase (TdT) 
dUTP nick-end labelling (TUNEL) 
Embryos for TUNEL assays were ﬁxed in Y% PFA at X dpf, transferred to MeOH and 
rehydrated as for ISH described above. The embryos were then digested for %Q minutes 
with Q.l µl/ml Proteinase K, followed by reﬁxation for XQ minutes in Y% PFA. After 
washing the PFA oﬀ with extensive PTW washes, embryos were stained using the Roche 
Cell Death kit. A master mix of %Q µl enzyme solution and mQ µl label solution was 
prepared for each sample and added. They were incubated at L]°C for LQ min, followed 
by quick PTW washes to remove the label solution. All liquid was removed and the 
samples heated to lQ°C for %Q minutes to inactivate endogenous AP. Embryos were 
quickly washed with PTW, followed by a % hour wash in blocking solution ($% FBS in 
PTW). After that, embryos were incubated in XQQ µl blocking solution with AP-
conjugated anti-ﬂuorescein antibody (%:XQQQ) overnight at Y°C. AP staining was 
revealed as for ISH, letting the embryos develop for LQ minutes in NBT/BCIP. Embryos 
were genotyped, followed by blinded scoring of %Q wild type and %Q mutant embryos per 
clutch by counting TUNEL foci in the CHT region of the tail. Details on the antibody 
can be found in Table X.X. 
2.22 Sudan black staining 
Embryos were ﬁxed in glutaraldehyde for XQ minutes at RT. Fixed embryos were 
incubated in Sudan black for XQ minutes at RT. Stained embryos were washed in ]Q% 
EtOH until only neutrophilic granules were stained, followed by storage in lQ% glycerol.  
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2.23 Bulk RNA-Seq 
Kidney cell suspensions were made as described above. I used two rad$%+/+ and rad$%-/- 
ﬁsh each in a Tg(itga>b:EGFP) background. A BD Inﬂux (BD Biosciences) ﬂow cytometer 
was used to sort the cells according to ﬂuorescence and their forward and side scatter 
properties. As described above, I sorted cells into GFPlow thrombocyte progenitors 
(Figure X.L), erythrocytes, progenitors, myeloid cells/neutrophils and monocytes. I 
modiﬁed the gating slightly to take only the more mature erythrocytes, which tend to 
be higher in SSC value (Figure X.]). After excluding debris, dead cells (using PI as a stain) 
and doublets, $Q cells of each gate were sorted per well, sorting $ wells per cell type for 
each ﬁsh. Each well contained X.L μl of Q.X% Triton X-%QQ supplemented with % U/μl 
SUPERase In RNase inhibitor (Ambion).  
 
Figure =.K: Gating strategy for the RNA-Seq experiment. This is a modiﬁcation of the scheme 
presented in Figure XX, but with a more stringent gate for mature erythrocytes. Ery = Erythrocytes, 
Prog = Progenitors, My = Myeloid cells, Mono = Monocytes. 
The whole transcriptome was ampliﬁed and libraries for sequencing were prepared 
using the Smart-seqX protocolL]l,L]m using External RNA Controls Consortium (ERCC) 
spike in controls. In short, cDNA was made by reverse transcription using SMARTScribe 
enzyme (Clontech) (see cycling conditions in Table X.$), an oligo-dT primer and a 
template-switching oligo. This step was followed by PCR ampliﬁcation of the cDNA (see 
cycling conditions in Table X.P) and a clean-up of the PCR product using Ampure XP 
beads (Beckman Coulter). Finally, libraries were generated using the Nextera XT DNA 
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sample preparation kit (Illumina) and a ﬁnal clean-up using beads. The resulting pooled 
libraries were sequenced on the Illumina Hi-SeqX$QQ platform.  
Table =.B: Cycling conditions for cDNA synthesis. Steps X-Y were repeated XY times. 
Step Temperature (°C) Time (seconds) 
1 98 180 
2 98 20 
3 67 15 
4 72 360 
5 72 300 
6 4 until required 
 
Table =.E: Cycling conditions for PCR ampliﬁcation. Steps X-$ were repeated %X times. 
Step Temperature (°C) Time (seconds) 
1 72 180 
2 95 30 
3 95 10 
4 55 30 
5 72 60 
6 72 300 
7 10 until required 
 
Reads were aligned to the zebraﬁsh reference genome (Ensemble BioMart version lL) 
combined with the ERCC spike-ins sequences. Alignment and quantiﬁcation was 
performed using SailﬁshLlQ version Q.m.Q with the default parameters using paired-end 
mode (parameter –l IU). Transcript Per Million (TPM) values reported by Sailﬁsh were 
used for the quality control (QC) of the samples. All wells passed the QC since were 
found to contain more than %,QQQ expressed genes (TPM>%) and less than PQ% of ERCC 
or Mitochondrial content. In order to perform the diﬀerential expression analysis 
between wild type and mutant samples for each of the ﬁve diﬀerent gating strategies, 
estimated counts for each well were used as input to the DEseqX R package (version 
%.%Y.%)Ll%. For each of the ﬁve diﬀerent gating strategies, statistically signiﬁcant genes that 
scored P < .QQ% were used to perform Gene Ontology (GO) enrichment analysis. I 
searched the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway databaseLlX 
using EnrichRLlL with the human orthologues of the zebraﬁsh genes.  
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2.24 Stem cell transplantation  
2.24.1 Genotyping of rag2E450fs recipients 
Recipient ﬁsh for transplantation were from the rag>ES$Xfs line generated by the 
Langenau laboratoryLPP. Fish were genotyped using PCR followed by restriction enzyme 
digestion. For PCR, the KOD Hot-Start kit from Novagen was used at standard cycling 
conditions. DNA was ampliﬁed using the forward primer 
$ʹ-ACTGCTCTAGTTGCAATTCCT-L’ and the reverse primer 
$ʹ-AGCTGGGGTCATCTTCAGT-L’ to produce a $l$-bp fragment. This was        digested 
using the restriction enzyme XcmI at L]°C overnight followed by gel electrophoresis. 
WT ﬁsh produce one band at $l$ bp. Heterozygotes produce three bands at $l$, L]X 
and X%X bp. Homozygous mutants produce two bands at L]X and X%X bp. 
2.24.2 Transplantation 
Rag>-/- ﬁsh were normally irradiated sub-lethally with a %Q Gy dose from an IBL YL]C 
irradiator using a caesium %L] source. Two days after irradiation, the ﬁsh were injected 
intraperitoneally with %QQQ GFPlow cells in %Q µl $% FBS/PBS. These were obtained from 
the kidneys of donor adults of the appropriate genotype carrying the Tg(itga>b:EGFP) 
transgene. Optionally, $QQ stromal cells from Tg(sdf%a:dsRed) were added as well. Donor 
cells were sorted using FACS as described above. The ﬁsh were analysed for engraftment 
using FACS Y or %P weeks post transplantation. Any ﬂuorescent cells in the kidney or 
peripheral blood of recipient ﬁsh were scored as engraftment. 
2.25 Treatments to trigger stress haematopoiesis 
2.25.1 Dose estimations 
To estimate the tolerated maximum dose of the substances used, I injected diﬀerent 
concentrations of acetaldehyde (Sigma-Aldrich) or polyinosinic:polydytidylic acid 
(pI:pC) (Sigma-Aldrich), followed by optional qPCR analysis of appropriate marker 
genes in diﬀerent tissues at P hpi to show eﬃcacy. The respective concentration and 
markers are indicated in the text. 
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2.25.2 Long-term pI:pC injections 
Fish were injected with %Q mg/ml pI:pC once a week, totalling four injections. Fish were 
culled three days after the last injection. Blood smears from the peripheral blood were 
obtained and the kidney was removed for later analysis. Kidneys were processed to 
single cell suspensions for FACS, as described above. Cells were analysed using an Inﬂux 
cytometer (BD Biosciences). Remaining cell suspensions after sorting were spun down 
and kept at -lQ°C for later gene expression analysis with qPCR.  
2.25.3 Long-term pI:pC injections with BrdU 
As in the other experiments, %Q mg/ml pI:pC and %Q mg/ml BrdU were used. BrdU was 
dissolved either in PBS or pI:pC solution. Depending on the experimental group, ﬁsh 
were injected with PBS only, BrdU only, pI:pC only or pI:pC + BrdU. The injection 
containing BrdU was always the last a ﬁsh received, and BrdU-injected ﬁsh were culled 
% day after the injection. Tissues were processed according to the normal BrdU staining 
protocol described above. 
2.25.4 Long-term acetaldehyde injections 
These injections followed the same scheme as the pI:pC injections, but substituted pI:pC 
for %% acetaldehyde (Sigma-Aldrich) in PBS. Fish were culled after four injections, 
followed by cell counts, FACS and qPCR analysis on the kidney tissue.  
2.25.5 Ethanol treatment 
Embryos were grown in egg water containing %.$% ethanol between Y and XY hpf. After 
this period, they were allowed to recover in normal egg water until Y dpf. At this point, 
images were taken for scoring of the phenotype. 
2.26 Statistical analysis 
The data was analysed using Microsoft Excel, InVivoStat $.L and GraphPad Prism P 
software. Statistical methods were used as required and are indicated in the text. If 
necessary, results were corrected for multiple testing using appropriate methods as 
indicated in the text. Unless otherwise indicated, a (corrected) P-value < .Q$ was 
considered statistically signiﬁcant.  
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2.27 Data visualisation 
Flow cytometry data was analysed using FlowJo (Treestar). Graphs were generated in 
GraphPad Prism P. Molecular images were created in PyMol using data deposited in the 
protein data bank (PDB, http://www.rcsb.org/pdb/home/home.do). Images were 
adjusted using Adobe Photoshop CC. Figures were assembled using Adobe Illustrator 
CC.
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3 Characterisation of rad51 mutant 
zebrafish 
3.1 Introduction 
3.1.1 Models of rad51 deficiency 
Initially, the study of RAD$% in eukaryotes was limited to yeast. Mutant yeast strains 
were generated in both budding (Saccharomyces cerevisiae) and ﬁssion yeast 
(Schizosaccharomyces pombe), the classical workhorses of molecular biology. In both 
cases, this led to proliferation defects, radiation hypersensitivity and mitotic, as well as 
meiotic impairment. However, despite these severe impairments, the RAD$% mutant 
strains were nevertheless completely viableXmm,LlY,Ll$.  
After these early insights using yeast, two groups independently generated murine Rad$% 
mutation models to study the role of the gene in mammals, publishing their papers only 
a few months apart. The ﬁrst paper described the replacement of the ﬁfth exon in Rad$% 
with a neomycin cassette using a gene targeting approach, leading to a disrupted RecA 
domainXm]. They generated mice carrying the mutant allele and incrossed them to breed 
a total of %Yl pups. However, none of these was a homozygous mutant for the Rad$% 
allele. Further work using in-vitro fertilisation allowed them to show that Rad$%-/- mice 
die early during embryonic development. 
The second paper to be publishedXmP also used a gene targeting approach, this time 
deleting nucleotides Y%L-$LQ of the Rad$% gene. They also did not ﬁnd any homozygous 
mutant pups among ]$ oﬀspring. Their analysis showed that Rad$% mutants develop 
normally until embryonic day EP, but are much smaller at E].$, at which point the 
mother’s body starts to resorb them. This decrease in size was caused by a proliferation 
defect starting at E$.$, which was accompanied by increased apoptosis starting from 
E].$, as determined by BrdU incorporation and TUNEL assays respectively. These 
proliferation defects also extended to murine ES cells carrying the mutation, together 
with increased radiosensitivity. Furthermore, embryo-derived Rad$% mutant cells rarely 
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entered the cell cycle and when they did, they often displayed an abnormal number of 
chromosomes. Most importantly, they showed that co-mutation with Tp$R was able to 
rescue the mutation partially, as double mutants were able to survive until Em.$. The 
unexpected lethality of the mutation suggests that vertebrate cells are much more 
reliant on functional HR than lower organisms such as yeast, possibly due to the much 
larger genome, explaining the early embryonic death of the mutant mice. 
Since then, neither conditional, nor hypomorphic, or mosaic rad$% knockout mice have 
been generated to work around the embryonic lethality seen in full knockouts. While 
no published attempts of creating rad$% knockouts in other vertebrate species exist, 
there is some evidence from in-vitro experiments suggesting that the cell death 
phenotype observed in mice is also present in other species. A study on the chicken cell 
line DTYQ showed that loss of Rad$% leads to massive proliferation defects coupled to 
chromosomal damage, culminating in cell deathLlP. 
In summary, these results show that lack of functional Rad$% is tolerable in lower 
eukaryotes, but leads to excess cell death and proliferation defects in at least some 
vertebrates, precluding the development of useful model systems to study the role of 
Rad$% in vertebrate cells. 
3.1.2 FA model systems 
In contrast to the situation for RAD$% models, there are multiple vertebrate in-vitro and 
in-vivo model systems for the study of FA. Nevertheless, their number is quite limited 
and their appropriateness often disputed. This lack of suitable genetic systems is a severe 
drawback to the study of the FA pathway in mammalsXL$.  
Several patient-derived FA cell lines for in-vitro work exist, but their number is small. 
Indeed, the FA cell line repository at Oregon Health & Science University 
(http://www.ohsu.edu/research/fanconi-anemia/celllines.cfm/) only contains six 
human and eight mouse FA ﬁbroblast lines (two of these are control lines). Furthermore, 
uncertainty about their physiological relevance and lack of speciﬁcity pose further 
problems to the validity of conclusions derived from these systemsXL$. 
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On the in-vivo front, almost all work has been on murine FA mutants. A rare, non-
murine system is the Xenopus system established by the Walter group in Harvard. They 
used it to elucidate many of the molecular details during ICL repair%lm,X%P,X%l. The Xenopus 
system is mostly used for experiments on egg extract, making it mainly useful for in-
vitro approaches. However, few other groups are focussing on this model with regards 
to FA.  
There has also been limited in-vivo work in the FA ﬁeld on zebraﬁsh embryosL$m,LP%, but 
this model system has rarely been utilised outside of some initial studies. As both the 
Xenopus, as well as the zebraﬁsh model are rarely used, most of the work remains limited 
to murine systems. 
Mice carrying mutations in Fanca-pLl], as well as FancrXmP,Xm] and Fancs%%L are currently 
available. Even though FA mutants for almost all FA genes exist (multiple diﬀerent 
mutation sites are available for some of the alleles), there are some signiﬁcant drawbacks 
to the use of murine FA models, the main issue being the low overlap between the 
murine and human disease phenotypeXL$,L$l,Ll],Lll, as well as a large variability of the 
phenotype depending on the genetic background of the miceLl].  
While mice carrying FA mutations do not always develop congenital abnormalities, 
many of them do. Most commonly seen are small size, micropthalmia, reduced fertility 
and sub-Mendelian birth ratiosL$l,Ll]. These features do not cover all the congenital 
features described in patients (see section %.X.% for an in-depth discussion), but the 
symptoms that are present resemble their human equivalent reasonably well. Genes 
with such phenotypes include FancaLlm, FanccLmQ, Fancd>Lm%, FanclLmX, Fancm%%% and 
FancpX$L. However, not all mutations cause such defects; for example, homozygous 
Fancg mice show none of these featuresLmL,LmY. Another important feature of FA, cancer 
predisposition, is also recapitulated in many of the murine models. FancaLlm, Fancd>Lm%, 
Fancf Lm$ and Fancs%%L mice have been reported to form a variety of malignancies, ranging 
from leukaemias to epithelial tumours. As is described above for patients, severe 
mutations in many of the FA genes are usually lethal. Complete embryonic lethality is 
seen for Fancl (in a pure %Xm/Sv background)LmX, FancnLmP,Lm], FancoLml,Lmm, FancrXmP,Xm], as 
well as null Fancd% and Fancs mutantsYQQ. The most characteristic feature of FA in 
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patients are the progressively worsening blood abnormalities leading to eventual 
complete failure of the bone marrow. However, almost all murine FA models show little 
to no haematopoietic features at all, unless they are challenged to undergo stress 
haematopoiesis by treatment with inﬂammation inducing or DNA damaging agents. 
Such treatments can even lead to complete BMF%Q,P$,%LQ,%LY,Ll],Lll. This disparity is 
presumably due to physiological diﬀerences between mice and humans (e.g. diﬀerences 
in life span, speed of metabolism), as well as the highly controlled environment and diet 
that laboratory mice experience, which may expose them to fewer DNA damaging agents. 
The only exceptions to the lack of blood defects unless challenged are hypomorphic 
Fancd% mutants, which display HSC proliferation defectsYQ%, Fancd> mutants, which have 
a decreased number of HSCs%Xl and Fancp mutants, which show a reduction in white 
blood cells and plateletsX$L. The only murine FA model showing spontaneous BMF is a 
conditional Fancs/Brca% knockout model%%L. These conditional knockouts avoid the 
complete embryonic lethality of conventional Fancs mutationsYQQ. Brca% mutant mice 
develop macrocytic anaemia as early as one month after birth and have decreased WBC 
counts. This then progresses to spontaneous BMF in ~LQ% of the mice. Cancers 
(leukaemias and lymphomas) are also common, occurring in ~Y$% of the animals. These 
haematopoietic defects were linked to reduced HSPC number and function%%L. Due to 
the problems of recapitulating FA features in model systems, there is a signiﬁcant need 
for the development of better model systems both for in-vitro and in-vivo research. I 
attempted to ﬁll this gap with the rad$% zebraﬁsh model. 
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3.2 Results 
3.2.1 Embryonic non-haematopoietic phenotypes 
3.2.1.1 The rad51sa23805 allele leads to complete loss of functional Rad51 protein  
To study the eﬀects of Rad$% deﬁciency, I obtained zebraﬁsh carrying the rad$%sa>RWX$ 
allele from the Wellcome Trust Sanger Institute Zebraﬁsh Mutation Project (ZMP). The 
founding mutation was generated by ENU mutagenesis, as described in previouslyYQX. 
The rad$%sa>RWX$ allele has a C>T mutation at codon XQL in exon ], leading to a premature 
stop codon in the catalytically important AAA+ ATPase domain (Figure L.%A). To 
conﬁrm the absence of full length Rad$% protein in homozygous rad$% mutants, I carried 
out Western blotting on testis tissue. This organ was chosen as Rad$% has been 
previously described to be highly expressed in germ cells of other speciesL%P, which I 
could conﬁrm in zebraﬁsh based on data from an unrelated RNA-Seq experimentL]]. The 
Western blot conclusively showed that full-length Rad$% is lost in rad$%-/- ﬁsh (Figure 
L.%B). I was unable to detect any new smaller bands, which would have indicated a 
truncated form of the protein. To verify the speciﬁcity of the antibody and thus the 
validity of the Western blotting results, immunostaining was carried out. This 
experiment, carried out by Ewa Bielczyk-Maczyńska (E.B.-M), used an anti-Rad$% 
antibody to detect Rad$% foci in irradiated rad$%+/- incross embryos, followed by 
genotyping (Figure L.%C). This strategy was used, as the formation of Rad$% foci is 
necessary for the repair of double-stranded breaks arising from irradiation-induced 
DNA damage. As expected, Rad$% foci appeared after irradiation in rad$%+/+ embryos, 
demonstrating the functionality of the antibody. In contrast, rad$%-/- embryos did not 
develop any Rad$% foci, indicating that the protein is lost (Figure L.%Ci and ii). The results 
of this experiment thus conﬁrmed the Western blots and validated that rad$%-/- ﬁsh 
completely lack functional Rad$%.  
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Figure ?.(: The rad$%sa'()*$ allele leads to complete loss of functional RadB( protein. (A) The sa>RWX$ 
allele contains a premature stop codon in exon seven, which leads to a truncation of the full-length Rad$% 
protein in the middle of the catalytically important AAA+ ATPase domain. (B) Western blot of testis tissue 
showing that the Rad$% protein is completely lost. (C) Immunostaining against Rad$% on embryos before 
and after irradiation. Quantiﬁcation of Rad$% foci following irradiation (i) showed that mutants lack any 
Rad$% protein Foci are indicated using arrows in example images (ii). Mann-Whitney test, P = .QQQX, 
n+/+ = l, n-/- = l. Images were obtained using a YQX water immersion objective Data shown in C was 
obtained by E.B.-M. 
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3.2.1.2 Embryos lacking Rad51 develop micropthalmia 
Two of the most common features of FA are decreased height and micropthalmia. To 
investigate this, the body and eye size of $ dpf embryos were measured (Figure L.XA). 
While rad$%-/- embryos were the same overall size as their wild type (WT) siblings (Figure 
L.XB) at $ dpf, their eyes were about ]% smaller on average (Figure L.XC), already 
resembling the micropthalmia commonly seen in FA patients. 
 
Figure ?.=: Embryos with rad$% mutation are micropthalmic. (A) Representative $ dpf embryos. 
Magniﬁcation = %PX. Measurement of total body length (B) showed no diﬀerence between WT and mutant 
embryos, but eye size (C) was signiﬁcantly diﬀerent between WT and mutant ﬁsh. Two-tailed Student’s 
t-test, P = .QQQ%, n+/+ = X%, n-/- = %L. Bars represent mean ± SEM in both graphs. Data shown in this ﬁgure 
was obtained by E.B.-M. 
3.2.1.3 The embryonic DNA damage response is impaired in rad51 mutant 
embryos 
After conﬁrming the loss of Rad$%, the next aim was to characterise the eﬀects this would 
have on the DNA damage response during embryonic development. DNA damage 
remains unrepaired in rad$% mutants, as immunostaining of a rad$%+/- incross using a 
phospho-histone HXAX (pHXAX, a marker of double stranded breaks) antibody at X dpf 
showed (Figure L.LA). Unrepaired DNA damage had a detrimental eﬀect on the 
developing organism. Embryos lacking rad$% developed small eyes and heads in response 
to gamma radiation at X dpf (Figure L.LB), presumably because the rapidly dividing cells 
of the central nervous system are especially susceptible to DNA damage, leading to 
excess apoptosis. This strongly exacerbated the already decreased eye size in untreated 
embryos (Figure L.XC) and also decreased the overall body size of the embryos, which 
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was previously unaﬀected (Figure L.XB), making the irradiated phenotype easily 
recognisable by eye (Figure L.LBi).  
 
Figure ?.?: Loss of rad$% leads to DNA damage sensitivity. (A) Immunostaining for pHXAX in wild 
type and mutant embryos with representative embryos (i) and quantiﬁcation of foci (ii). White arrows 
indicate example foci. Images were obtained with a YQX water immersion objective. Two-tailed Student’s 
t-test, P < .QQQ%, n+/+ = l, n-/- = %%. Bars represent mean ± SEM. (B) Comparison of the response of Yl hpf 
wild type and mutant embryos to irradiation (i). The black arrow indicates the small head and eye 
phenotype, which is quantiﬁed in ii. Magniﬁcation = %PX. Two-tailed Fisher’s exact test pooling wild types 
and heterozygotes as control group, P < .QQ%, n = P]. Data shown in this ﬁgure was obtained by E.B.-M. 
Next, I tested the response of the rad$%-/- embryos to several DNA damaging drugs. After 
assessing the maximum tolerated dose for each drug on WT zebraﬁsh embryos (deﬁned 
as the highest tolerable concentration without any noticeable developmental 
abnormalities at XY hpf), I treated the embryos with the drugs between Y and XY hpf, 
followed by chromosome spreads and genotyping of the individual embryos. I utilised 
two agents that are widely used in the diagnosis of FA, DEB and MMC, which induce 
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interstrand crosslinks, as well as the topoisomerase I inhibitor CPT and the PARP% 
inhibitor DiQ. Chromosomes were blindly photographed and karyotyped by me, 
followed by genotyping to determine the mutation status of each spread. My results 
indicated that embryos lacking functional Rad$% cannot successfully repair ICLs, leading 
to characteristic chromosome breaks and radial structures seen exclusively in rad$%-/- 
embryos (Figure L.YA and B) upon DEB and MMC treatment, consistent with an FA-like 
phenotype and further demonstrating the DNA damage susceptibility of rad$% mutants. 
MMC seemed to induce more premature chromatid separation events than DEB. CPT 
induced many DNA breaks, but relatively few radial structures (Figure L.YC), showing 
the lack of functional HR. Treatment with DiQ however, induced little damage in both 
WT and mutant embryos (Figure L.YD), indicating that PARP% inhibition does not 
disproportionally aﬀect rad$% mutants. 
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Figure ?.@: rad$% mutation leads to crosslinker sensitivity. (A) Chromosome spreads of XY hpf wild 
type and mutant embryos treated with % µg/ml DEB for XQ hours. White arrows indicate characteristic 
damage (chromosome breaks and radial structures) in response to crosslinking agents (i). Quantiﬁcation 
of the damage (ii). Mann-Whitney test, P = .QQQY, n+/+ = X$, n-/- = XP. (B) Chromosome spreads of XY hpf 
wild type and mutant embryos treated with $ µg/ml MMC for XQ hours. White arrows indicate premature 
chromatid separation events (i). Quantiﬁcation of the damage (ii). Mann-Whitney test, P = .QQ%, n+/+ = %P, 
n-/- = %m. (C) Chromosome spreads of XY hpf wild type and mutant embryos treated with % nM CPT for XQ 
hours. White arrows indicate breaks and radial structures in response to topoisomerase inhibition (i). 
Quantiﬁcation of the damage (ii). Mann-Whitney test, P < .QQQ%, n+/+ = %X, n-/- = %]. (D) Chromosome 
spreads of XY hpf wild type and mutant embryos treated with %Q µM DiQ for XQ hours (i). Quantiﬁcation 
of the damage (ii). Mann-Whitney test, P = .%L, n+/+ = %Y, n-/- = Xm. All images were obtained using a %QQX 
oil immersion objective. Bars represent mean ± SEM in all graphs. 
 
Figure ?.B: Outcrossing increases mutant survival. The percentage of mutants at L mpf in each cross 
(X$% expected) is plotted against the cross number. A lower number tends to indicate less outcrossing, 
as older, more inbred lines get replaced by more outcrossed parent lines. The regression line shows a 
linear ﬁt of the data. A signiﬁcant regression equation was found. F (%, %X) = %X.l], P = .QQY, RX = Q.$X. 
I continued my investigation by growing rad$% mutants to adulthood. In contrast to mice 
lacking Rad$%, these ﬁsh survived to adulthood. In my ﬁrst crosses, I observed sub-
Mendelian survival of the rad$%-/- ﬁsh. However, after several rounds of outcrossing, this 
eﬀect went away (Figure L.$). This means that rad$% mutants do not inherently have a 
sub-Mendelian birth ratio, but might be more susceptible to the presence of other, 
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harmful mutations. Outcrossing was presumably able to prevent such deleterious 
mutations from accumulating and therefore brought survival back to expected levels.  
Next, I investigated potential reasons for the survival of zebraﬁsh rad$% mutants to 
adulthood in contrast to the early death of mice lacking Rad$%XmP,Xm]. Early embryonic 
development is highly dependent on maternally-derived RNA and proteinsYQL. Indeed, 
zebraﬁsh development is reliant on maternally-derived factors until the mid-blastula 
transition (MBT) at approximately Y hpf YQY. The ﬁrst RNAs start being expressed at X 
hpf, reaching full activation of the zygotic genome around L.] hpf YQ$. One possible 
reason for the survival of rad$%-/- zebraﬁsh embryos is a diﬀerence in the contribution of 
maternal RNA between mice and ﬁsh. I examined Rad$% expression using 
immunostaining with two diﬀerent primary anti-Rad$% antibodies in freshly fertilised 
eggs stemming from a rad$%+/- incross (Figure L.P), as any protein present so early must 
stem from the mother. Embryos displayed a diﬀuse, but clearly recognisable signal 
corresponding to Rad$% in the cytoplasm. As embryos at this stage are not amenable to 
genotyping due to the low amount of DNA, I assumed a Mendelian ratio of mutants (one 
quarter) for the interpretation of the experiment. As all embryos stained with primary 
antibody (Figure L.PB and C) showed considerably higher staining than the secondary 
antibody only controls (Figure L.PA), I concluded that maternal contribution of Rad$% 
cannot be ruled out as a cause for the viability of rad$% mutants to adulthood. 
 
Figure ?.E: RadB( is expressed in single-cell stage embryos. Representative Rad$% immunostained 
embryos derived from a rad$%+/- incross. (A) Secondary only, n = %%, (B) Abcam primary, n = $%, (C) AnaSpec 
primary, n = L]. Magniﬁcation = PQX. 
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Finally, I considered the role of NHEJ in the survival of the mutant ﬁsh. To do that, I 
treated an incross of rad$%+/- parents with a range of diﬀerent concentrations of SCR-], 
a DNA ligase IV inhibitor and scored the embryos at XY hpf (Figure L.]). At the lowest 
concentration, embryos were completely unaﬀected, whereas at the higher 
concentration all embryos died. At no concentration were the mutant embryos more 
sensitive than their WT siblings, indicating that NHEJ is dispensable for the survival of 
rad$%-/- embryos. 
 
Figure ?.K: NHEJ inhibition does not lead to synthetic lethality in rad$% mutants. Morphology of XY 
hpf embryos treated with varying concentrations of SCR-] for XQ hours. For each concentration, n = YQ 
treated embryos. Magniﬁcation = %PX. 
3.2.1.4 Rad51b	partially compensates for Rad51 loss 
In addition to the rad$% mutants, E.B.-M. generated a rad$%l% (the zebraﬁsh orthologue 
of human RAD$%B) mutant using CRISPR with a frameshift mutation in exon X. As both 
mutants were viable and blood defects subtle in the case of rad$% and not present at all 
in rad$%b mutants, I decided to generate double rad$%, rad$%b mutants to study potential 
compound eﬀects of the mutations. I carried out two independent matings of rad$%+/-, 
rad$%b+/- ﬁsh, with a total of XQY ﬁsh surviving until L months post fertilisation (mpf) for 
genotyping. However, among these XQY ﬁsh there were no double mutants, even though 
%X.]$ would have been expected due to Mendelian inheritance (Table L.%). I repeated the 
same cross and collected embryos at Y dpf. Again, zero out of YY embryos were double 
mutants, even though X.]$ would have been expected. Finally, I repeated the cross and 
genotyped at P hpf (the earliest point the genotyping works reliably). Out of Y] embryos, 
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none were double mutants. This early embryonic synthetic lethality of co-mutation 
indicates that rad$% and rad$%b have at least partially redundant functionality, which may 
explain the viability of the single mutants. 
Table ?.(: Co-mutation of rad$% and rad$%b is lethal. Punnet square of the genotyping results at L mpf 
stemming from two independent rad$%+/-, rad$%b+/- incrosses. Actual numbers are in black, whereas 
expected numbers according to Mendel’s rules are in blue. The lack of double mutants is highlighted in 
red. Overall n = XQY. 
  rad51  
  +/+ +/- -/-  
ra
d5
1b
 
+/+ 1/12.75 18/25.5 11/12.75 30/51 
+/- 25/25.5 64/51 14/25.5 103/102 
-/- 48/12.75 23/25.5 0/12.75 71/51 
  74/51 105/102 25/51  
          
      n = 204   
 
3.2.2 Adult non-haematological phenotypes 
After having shown that rad$% mutants are viable to adulthood, presumably due to 
maternal eﬀects, I proceeded with characterising the phenotype of the ﬁsh during 
adulthood. 
3.2.2.1 Rad51 mutants display congenital defects resembling FA 
Just as for embryos, I measured the size of juvenile and adult rad$% mutants (Figure L.l). 
This revealed that in contrast to embryos, there was a size diﬀerence between WT and 
mutant ﬁsh starting in the juvenile period, which was maintained over the whole 
observed lifespan of the ﬁsh. Importantly, all adult ﬁsh appeared to be males, 
presumably due to sex determination defects during the juvenile phase. This was not 
due to female ﬁsh dying, as mutants were born at the expected ratio, indicating sex 
reversal. Zebraﬁsh sex determination is explained in more detail in section L.L.  
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Figure ?.O: Adult rad$% mutant ﬁsh are smaller than their wild type siblings. (A) Representative 
images of mutant and WT ﬁsh at XL dpf (i). Magniﬁcation = %PX. Graph showing diﬀerence in size between 
the genotypes (ii). Two-tailed Student’s t-test (P = .QQ%P), n+/+ = %%, n-/- = ]. Scale bar = % mm. (B) 
Comparison of mutant and wild type ﬁsh at Y mpf (i). Graph showing diﬀerence in size between the 
genotypes (ii). Two-tailed Student’s t-test (P = .QQY), n+/+ = Xl, n-/- = %m. Scale bar = % cm. (C) 
Representative images of mutant and WT ﬁsh at l mpf (i). Graph showing diﬀerence in size between the 
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genotypes (ii). Two-tailed Student’s t-test (P = .QXL), n+/+ = Xm, n-/- = L%. Scale bar = % cm. Bars represent 
mean ± SEM in all graphs. 
None of my attempts to breed these rad$%-/- males resulted in any oﬀspring, as all 
resulting eggs were unfertilised. Mating behaviour was not aﬀected, as seen by a large 
number of unfertilised eggs whenever matings were attempted. I then tried to obtain 
sperm from the rad$% mutants. As can be seen in Figure L.mA, wild type ﬁsh had milky, 
thick sperm, whereas mutant ﬁsh only yielded thin, watery secretions, explaining their 
inability to father oﬀspring. To investigate the cause of this lack of sperm, I obtained 
histological sections of Y mpf rad$% mutant testes, which were stained with standard 
H&E staining for visualisation (Figure L.mB). As can be seen on these micrographs, ﬁsh 
lacking rad$% cannot form mature spermatozoa, leading to many empty spaces in the 
testes. 
 
Figure ?.Q: rad$% mutant ﬁsh are all infertile males. (A) Capillaries used to obtain sperm from wild 
type and mutant ﬁsh. Numbers indicate the number of ﬁsh giving sperm among the ﬁsh tested. Two-
tailed Fisher’s exact test, P = .QQQX. n+/+ = m. n-/- = %L. (B) H&E stained histological sections of Y mpf wild 
type and mutant kidneys using a XQX objective. The arrow points out the area where mature spermatozoa 
reside. Scale bar = %QQ µm. 
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Other tissues appeared normal during dissection. For a more detailed look, I obtained 
histological sections of the intestine (Figure L.%Q), which has highly proliferative cells 
that turn over very quickly. I reasoned that it might therefore be more aﬀected by 
increased DNA damage sensitivity than many other tissues. However, no clear diﬀerence 
could be seen between WT and mutant intestine tissue, suggesting that this tissue has 
normal functionality. 
 
Figure ?.(S: The intestine is unaﬀected in rad$% mutant ﬁsh. Representative H&E stained histological 
sections of Y mpf wild type and mutant intestines using a %QX objective. Scale bar = %QQ µm. 
3.2.2.2 Lack of rad51 leads to excess DNA damage in exposed tissues 
To look at other genes linked to the FA pathway, I obtained tissue from the brain, eyes, 
ﬁn and heart of rad$%+/+ and -/- ﬁsh, extracted the RNA and generated cDNA for qPCR. I 
considered a DNA damage marker (gaddS$ab), NHEJ related genes (ligS, prkdc, xrccS), 
genes encoding Rad$% binding proteins (brca> and rad$>), cell cycle genes (rb%), as well 
as genes of the p$L pathway (p>% and p$R). Most genes were unchanged, but interestingly 
the skin showed a roughly tenfold, statistically signiﬁcant upregulation of the gaddS$ab 
gene (Figure L.%%), which is a marker for DNA damage. This shows that lack of Rad$% 
leads to increased DNA damage in adults as well, but this is only noticeable on the tissue 
level in organs exposed to a lot of DNA damage.
Intestine 4 mpf
+/+ -/-
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Figure ?.((: qPCR analysis of diﬀerent tissues. (A) Brain. n+/+ = L. n-/- = L. (B) Eye. n+/+ = Y. n-/- = $. (C) 
Fin. n+/+ = Y. n-/- = $. (D) Heart. n+/+ = Y. n-/- = $. Individual plots shown refer to the relative expression in 
mutants, the line at % represents the geometric mean of the WT ﬁsh. Bars represent the geometric mean 
± m$% conﬁdence interval to estimate fold changes. All P-values stem from two-tailed Student’s t-tests 
with Bonferroni correction for multiple testing. 
3.2.3 Haematological phenotypes 
3.2.3.1 Adult rad51 mutants display a hypocellular kidney marrow 
The key features of FA are progressive marrow defects, leading to gradually worsening 
haematological impairments and eventual complete BMF. Because of this, I investigated 
the zebraﬁsh kidney marrow (WKM) for defects. I observed the morphology of the WKM 
by obtaining histological sections of the kidney stained with H&E (Figure L.%XA). This 
allowed me to determine that the WKM was morphologically normal, without any 
obvious empty spaces or dysplastic cells. However, during the dissection of the kidney I 
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noticed that the rad$%-/- kidneys appeared considerably smaller than the WT kidneys 
(Figure L.%XBi). I quantiﬁed this size diﬀerence between Y and %L mpf by counting WKM 
cellularity with a haemocytometer (Figure L.%XBii). This showed that mutants had 
roughly half as many cells in the kidney as WT ﬁsh and that this diﬀerence was 
maintained at the same level over the whole life of the ﬁsh. Interestingly, both WT and 
mutant WKM cellularity decreased signiﬁcantly with age, a change which I did not 
expect.  
 
Figure ?.(=: WKM cell number is halved in mutants. (A) Representative images of H&E stained 
histological sections of Y mpf wild type and mutant kidneys using a XQX objective. Muscle (red arrow), 
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ducts/tubules (green arrow) and haematopoietic kidney marrow (black arrow) can be seen. Scale bar = %QQ 
µm. (B) Fixed l mpf wild type and mutant kidneys (i). Magniﬁcation = l.$X. Quantiﬁcation of the number 
of total cells per freshly isolated kidney at diﬀerent ages using a haemocytometer (ii). Two-way ANOVA 
was used and type III model ﬁt. The test showed a signiﬁcant inﬂuence of age (F (%, $Q) = %l.XL, P < .QQQ%) 
and mutation status (F (%,$Q) = %Q.l], P = .QQ%l) on phenotype, but no interaction between these two 
factors (F (%,$Q) = %.$Y, P = .XX). Y mpf n+/+ = P, n-/- = P; l mpf; n+/+ = %P, n-/- = %P; %L mpf n+/+ = P, n-/- = Y. 
Bars represent mean ± SEM. 
Next, I investigated the eﬀect of age on the proportion of the diﬀerent blood lineages 
present in the WKM (Figure L.%L). During ageing, the ratio of the diﬀerent blood lineages 
in the WKM shifted towards the myeloid lineage (Figure L.%LB). However, this eﬀect was 
stronger in mutants than in their WT siblings (Figure L.%LB). 
 
Figure ?.(?: Ageing causes a shift towards myeloid cells in the WKM. (A) Percentage of erythrocytes 
in the WKM. Two-way ANOVA revealed a signiﬁcant diﬀerence due to mutation status (F (%, LQ) = %$.], 
P = .QQQY) and of age (F (X,LQ) = %Q.Pm, P = .QQQL), as well as an interaction between mutation status and 
age (F (X,LQ) = l.YP P < .QQ%X). (B) Percentage of myeloid cells in the WKM. Two-way ANOVA revealed a 
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signiﬁcant diﬀerence due to mutation status (F (%, LQ) = X$.YP, P = .QQQ$) and of age (F (X, LQ) = %Q.$X, 
P = .QQQL), as well as an interaction between mutation status and age (F (X, LQ) = Y.$XY P < .Q%m). (C) 
Percentage of monocytes in the WKM. Two-way ANOVA revealed a signiﬁcant diﬀerence due to mutation 
status (F (%, LQ) = %l.]P, P = .QQQX), but not due to age (F (X, LQ) = %.l], P = .%]) or an interaction between 
the two (F (X, LQ) = X.l], P = .Q]X). (D) Percentage of progenitors in the WKM. Two-way ANOVA revealed 
a signiﬁcant diﬀerence due to age (F (X, LQ) = Y.lL, P = .Q%$), but not due to mutation status (F (%, LQ) = .QX, 
P = .lm) or an interaction between the two (F (X, LQ) = %.X$, P = .L). For all graphs: Y mpf n+/+ = P, n-/- = P; 
l mpf n+/+ = P, n-/- = ]; %L mpf n+/+ = ], n-/- = Y. Bars represent mean ± SEM in all graphs. 
3.2.3.2 Rad51 mutants develop macrocytic erythrocytes with ageing 
Subsequently I considered changes in the peripheral blood (PB). Neither WT nor mutant 
ﬁsh ever developed clear signs of anaemia (such as pallor) and neither did I ﬁnd a higher 
death rate of mutants during the observed life span. To get a more quantiﬁable picture 
of the PB, I measured the number of erythrocytes in the PB at Y mpf and found no 
signiﬁcant diﬀerence (Figure L.%YA). To consider morphological defects as well, I 
obtained blood smears at diﬀerent ages and quantiﬁed the nuclear and overall size of 
the erythrocytes (Figure L.%YB). This showed that cytoplasmic volume increased over 
time in the mutants (Figure L.%YBi and ii). Changes were particularly visible when I 
calculated the ratio of the cytoplasmic to nuclear volume (Figure L.%YBiii). The ratio was 
essentially constant in both WT and mutant ﬁsh until %L mpf, at which points the value 
increased considerably and signiﬁcantly in the mutants only. This revealed that while 
the mutants did not develop acute anaemia until %L mpf, they nevertheless developed 
macrocytic erythrocytes, an early sign of haematological impairments. 
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Figure ?.(@: Mutants develop macrocytic erythrocytes. (A) Quantiﬁcation of peripheral blood (PB) 
cells in wild type and mutant ﬁsh at Y mpf. Two-tailed Student’s t-test, P = .ml, n+/+ = P, n-/- = P. (B) 
Comparison of erythrocytes seen in blood smears of %L mpf wild type (top) and mutant ﬁsh (bottom) (i). 
Scale bar = %Q µm. Quantiﬁcation of the erythrocyte area (ii). There was a statistically signiﬁcant 
interaction between age and mutation status (F (%, Xl) = %X.lm P = .QQ%X), no signiﬁcant inﬂuence of age 
(F (%, Xl) = %lQ.]P, P = .LmX) and no signiﬁcant inﬂuence of mutation status (F (%, Xl) = X.ll, P = .%QP). 
Quantiﬁcation of the cytoplasmic/nuclear ratio (iii). There was a statistically signiﬁcant interaction 
between age and mutation status (F (%, Xl) = YYm.] P = QQ%.), no signiﬁcant inﬂuence of age (F (%, 
Xl) = XP.Ll, P = Lm) and no signiﬁcant inﬂuence of mutation status (F (%, Xl) = %QQ.PX, P = .%). All data in 
B was analysed using two-way ANOVA and a type III model ﬁt. P-values shown on the graphs stem from 
post-hoc Tukey multiple comparison tests. Y mpf n+/+ = P, n-/- = P; l mpf n+/+ = $;                n-/- = $, %L mpf 
n+/+ = P, n-/- = Y. Bars represent mean ± SEM in all graphs.  
3.2.3.3 Apoptosis is not increased in the WKM of adult rad51-/- fish 
After establishing that rad$% mutant ﬁsh develop kidney marrow hypocellularity, I aimed 
to gain a more mechanistic understanding of why this decrease happens in rad$% 
mutants. The number of cells in the kidney is determined by the balance between the 
number of stem cells generated during development and the balance between apoptosis 
and proliferation during adulthood. I ﬁrst assessed whether this diﬀerence was due to 
excess apoptosis in adult rad$%-/- ﬁsh by carrying out Annexin V-Propidium Iodide 
staining on the dissected WKM followed by FACS (Figure L.%$). In this assay, cells about 
to undergo apoptosis are labelled because they express the protein marker annexin V, 
which is upregulated during apoptosis. This experiment revealed that there was no 
diﬀerence in the number of apoptotic cells between WT and mutant ﬁsh at Y mpf	(Figure 
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L.%$B). Accordingly, apoptosis in the WKM of adult ﬁsh can be ruled out as a cause for 
the decreased WKM cellularity. 
 
Figure ?.(B: Apoptosis is not increased in the WKM of rad$% mutants. (A) FACS proﬁles from an 
annexin V-PI assay to detect apoptotic cells. Representative results of WT (left) and mutant (right) WKM 
are shown. Apoptotic cells are found in Q%. (B) Quantiﬁcation of apoptotic cells in the WKM. Two-tailed 
Student’s t-test, P = .XY, n+/+ = Y, n-/- = Y. Bars represent mean ± SEM. 
3.2.3.4 Establishing a BrdU pulse-chase system in adult zebrafish 
After excluding apoptosis as a possible cause for the decreased WKM cellularity, I 
focussed on the proliferation rate of the HSPCs. To do this, I developed a novel BrdU 
injection assay using adult zebraﬁsh, which allowed me to label newly generated cells. 
BrdU is a nucleoside analogue of thymidine. Upon injection, it is transported into all 
tissues by the blood, where it is incorporated into the DNA of dividing cells, replacing 
thymine. This allows the labelling of recently generated cells using BrdU-speciﬁc 
antibodies, which are conjugated to ﬂuorophores or other labels. These can then be 
detected by ﬂow cytometry or other methods. Before carrying out experiments on the 
mutant ﬁsh line, I aimed to establish the protocol on WT ﬁsh ﬁrst. I started an initial 
trial experiment, in which I injected ﬁsh with %Q µl %Q mg/ml BrdU intraperitoneally and 
culled them four hours, six hours, one day, seven days, %Y days and Xl days post injection 
(dpi) (Figure L.%PA). After staining the WKM cells using anti-BrdU-ﬂuorescein 
antibodies, I obtained FACS data to quantify the number of BrdU+ cells. This showed 
that BrdU+ cells started appearing very quickly in the WKM and PB, even after only Y 
hours post injection (hpi). Peak labelling in the WKM was reached at % dpi, whereas it 
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was ] dpi for the PB, although the error bars were very large due to the low number of 
ﬁsh used. At Xl dpi, there were only very few BrdU+ cells present in the WKM. (Figure 
L.%PB). Because labelling in the WKM was highest at % dpi and almost undetectable at Xl 
dpi, I limited my analysis of the mutant line to this period.  
 
Figure ?.(E: Establishing a BrdU pulse-chase system in zebraﬁsh. (A) In a pilot experiment, I injected 
two WT ﬁsh for each time point (Y and P hours, %, ], %Y and Xl days post injection) with %Q mg/ml BrdU. 
(B) FACS analysis for BrdU incorporation. Percentage of BrdU-labelled cells in the WKM (i) and the PB 
(ii). n = X at each time point. Bars represent mean ± SEM in both graphs. 
3.2.3.5 Proliferation is paradoxically increased in the WKM of rad51-/- fish  
In my experimental design to compare WT and mutant ﬁsh, both groups were injected 
with BrdU and culled at %, ] or %Y dpi, followed by analysis for BrdU incorporation in the 
WKM and PB using FACS (Figure L.%]A). The results indicated that rad$%-/- ﬁsh rapidly 
accumulated BrdU+ cells in the WKM following injection, which were then diluted 
quickly to reach the same level as in the WT (Figure L.%]Bi), as the initial BrdU label was 
diluted in further divisions. In the PB, BrdU+ erythrocytes appeared much quicker in the 
circulation in the mutants, but this level plateaued soon after (Figure L.%]Bii). Conversely, 
WT ﬁsh initially had fewer BrdU+ cells in the PB, but then slowly reached the same level 
as the mutants (Figure L.%]Bii). Together, these results show that HSPCs in rad$%-/- ﬁsh 
are proliferating signiﬁcantly more than HSPCs in WT ﬁsh, even though overall WKM 
cellularity was reduced. Hence a decrease in proliferation cannot explain the lowered 
cell number in rad$%-/- ﬁsh. 
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To accumulate more evidence for an increase in proliferation, I focussed on transgenic 
lines in which newly made blood cells are labelled (Figure %]C and D). In the 
Tg(gata%a:EGFP) line, newly made erythrocytes are labelledLPl. In agreement with my 
previous data, rad$% mutants had about twofold more GFP+ cells in the kidney at Y mpf 
(Figure L.%]C), as shown by FACS analysis.  
In the Tg(itga>b/cdS%:EGFP) lineLP], thrombocytic progenitors and mature 
thrombocytes are labelled in the GFPlow and GFPhigh populations respectivelyL]$. My 
analysis showed that at Y mpf, rad$%-/- ﬁsh had about twice as many GFPlow thrombocytic 
progenitors than the WT ﬁsh, but the number of mature thrombocytes was not changed 
(Figure L.%]D). This shows that the progenitors of multiple lineages were dividing more 
quickly, i.e. the increase in proliferation was not driven by only one lineage. 
 
Figure ?.(K: Proliferation is increased in the WKM of rad$% mutants. (A) Schematic of the 
experimental design for the BrdU incorporation experiments. Fish were injected once with %Q mg/ml BrdU 
and culled after %, ] or %Y days to obtain the blood and kidney marrow for antibody staining and FACS 
analysis. (B) FACS results quantifying BrdU-labelled cells. (i) Percentage of BrdU+ cells in the kidney. Two-
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sided Student’s t-test, P = .QXY at % dpi and P>.Q$ at %Y dpi. % dpi n+/+ = $, n-/- = P; ] dpi  n+/+ = P, n-/- = P; %Y 
dpi n+/+ = $, n-/- = $. (ii)Percentage of BrdU+ cells in the peripheral blood. Two-sided Student’s t-test, 
P = .QQ%$ at % dpi and P = .PY at %Y dpi. % dpi n+/+ = $, n-/- = P; ] dpi n+/+ = P, n-/- = $; %Y dpi n+/+ = $, n-/- = $. 
(C) Percentage of gata%:GFP+ cells in the kidney at Y mpf. Two-sided Student’s t-test, P = .QX$,  n+/+ = P,   
n-/- = P. (D)  Percentage of GFPlow and GFPhigh cdS%:GFP+ cells in the kidney at Y mpf, labelling 
thrombocytic progenitors and mature thrombocytes respectively. Two-tailed Student’s t-test. 
Thrombocytic progenitors: P = .QXL, mature thrombocytes: P = n.s., n+/+ = %Q, n-/- = %Q. Bars represent 
mean ± SEM in all graphs. 
As neither apoptosis, nor proliferation during adulthood could explain the hypocellular 
kidney marrow, I characterised the embryonic haematological development of the rad$% 
mutants in detail. 
3.2.3.6 Rad51 mutants form fewer HSPCs during embryonic development  
To assess embryonic HSPC levels, I carried out a cmyb in-situ hybridisation, which 
speciﬁcally labels HSPCs, on an incross from rad$%+/- parents at X and Y dpf (Figure L.%lA 
and B). After staining the embryos, they were blindly sorted into high, medium and low 
staining categories (XQ embryos per category). The head and tail of each embryo were 
separated, followed by genotyping using the head tissue and photography of the tail, 
allowing me to connect ISH staining to genotype without biasing the sorting results. 
This revealed a small, but noticeable decrease in rad$% mutants at X dpf (Figure L.%lA), 
which was exacerbated at Y dpf (Figure L.%lB). To ﬁnd out the cause of this decrease, I 
carried out a BrdU incorporation assay on the embryos, genotyped them and assessed 
proliferation levels (Figure L.%lC and D). This showed that there was a statistically 
signiﬁcant decrease in proliferation at X dpf (roughly twofold) (Figure L.%lC), but not at 
Y dpf (Figure L.%lD), although there was still a trend towards lower proliferation. This 
means that the main diﬀerence in proliferation happens very early between X-Y dpf. I 
also assessed the levels of apoptosis at X dpf, using a TUNEL assay (Figure L.%lE and F) 
This time point was chosen as it corresponds to the time point where I saw the largest 
diﬀerence in proliferation. This showed that apoptosis was signiﬁcantly increased (also 
roughly twofold) in rad$%-/- embryos at X dpf (Figure L.%lF). Thus, the lower level of HSPC 
formation in rad$% mutants stems from a combination of decreased proliferation and 
increased apoptosis during early embryonic development.  
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Figure ?.(O: The rad$%sa'()*$ HSPC defect starts during embryonic development. (A) Representative 
X dpf embryos stained using a cmyb ISH probe (i) and quantiﬁcation of distribution of genotypes in the 
diﬀerent staining categories (ii). The arrow shows HSPCs. n = %%m from two clutches. (B) Quantiﬁcation of 
BrdU+ cells in the tail at X dpf. Two-tailed Student’s t-test, P = .QYX, n+/+ = L, n-/- = L. (C) Representative Y 
dpf embryos stained using a cmyb ISH probe (i) and quantiﬁcation of distribution of genotypes in the 
diﬀerent staining categories (ii). The arrow shows HSPCs. Representative images of the three diﬀerent 
staining categories are shown in (i) and a quantiﬁcation of the diﬀerent genotypes in (ii). n = %%m from two 
clutches. n = %XQ from two clutches. (D) Quantiﬁcation of BrdU+ cells in the CHT at Y dpf. Two-tailed 
Student’s t-test, P = .L, n+/+ = Y, n-/- = Y. Bars represent mean ± SEM in B and D. (E) Representative images 
of TUNEL-stained X dpf embryos from a rad$%+/- incross. Dotted lines indicate the area of the CHT that 
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was scored. Arrows indicate example TUNEL+ cells. (F) Quantiﬁcation of three clutches of TUNEL-stained 
X dpf rad$%+/- incrosses. Each clutch was scored blindly and consisted of %Q +/+ and %Q -/- embryos each. 
Bars represent mean ± SEM. 
3.2.3.7 Most mature blood cells are unaffected in rad51-/- embryos 
In addition to the HSPCs, I characterised the mature blood cells in the embryo using 
ISH, all at $ dpf. As before, embryos were stained and then blindly sorted into diﬀerent 
staining categories, followed by photography and genotyping. Erythrocytes were 
assessed using the embryonic α%-globin gene (ea%), lymphocytes using the 
recombination-activating gene (rag%) and myeloid cells using myeloperoxidase (mpx) 
expression (Figure L.%m). These ISH results indicated a drastic decrease in lymphocytes 
in mutant embryos, resulting in large numbers of mutants in the medium and low 
staining category (Figure %mA). In contrast, there was very little, if any diﬀerences 
between WT and mutant embryos (Figure L.%mB) for erythrocytes and a slight increase, 
if anything, for myeloid cells (Figure L.%mC). I veriﬁed the validity of the mpx ISH results 
by carrying Sudan black staining, which very speciﬁcally labels neutrophilic granulesYQP, 
on $ dpf embryos (Figure L.%mD). Embryos were stained, genotyped and photographed. 
Ten embryos of each genotype were blindly scored; meaning the number of neutrophils 
was counted in each tail (Figure L.%mD). This did not indicate a statistically signiﬁcant 
diﬀerence between WT and mutant ﬁsh either, consistent with ISH results. This 
conﬁrmed the validity of the ISH approach for assessing the number of blood cells 
during embryonic deﬁnitive haematopoiesis. Taken together, these results mean that 
while HSPC numbers are aﬀected during embryogenesis, most mature blood cells can 
be produced at normal numbers. Lymphocytes are an exception, since they require 
recombination to mature (see discussion in section L.L). 
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Figure ?.(Q: The number of lymphocytes is decreased in embryonic rad$% mutants, whereas other 
lineages are unaﬀected. (A) Representative $ dpf embryos stained using a rag% ISH probe (i) and 
quantiﬁcation of distribution of genotypes in the diﬀerent staining categories (ii). The arrow shows 
lymphocytes. n = $m from one clutch. (B) Representative $ dpf embryos stained using an ea% globin ISH 
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probe (i) and quantiﬁcation of distribution of genotypes in the diﬀerent staining categories (ii). The arrow 
shows erythrocytes. n = $] from one clutch. (C) Representative $ dpf embryos stained using an mpx ISH 
probe (i) and quantiﬁcation of distribution of genotypes in the diﬀerent staining categories (ii). The arrow 
shows neutrophils. n = PQ from one clutch. (D) Representative $ dpf embryos stained using Sudan black 
(i) and quantiﬁcation of the number of neutrophils in WT and mutant embryos (ii). The arrow shows 
neutrophils. Two-tailed Student’s t-test, P = .X], n+/+ = %Q, n-/- = %Q. Bars represent mean ± SEM. 
3.2.3.8 Haematopoietic stem cell transplantation experiments 
Transplantation experiments are a widely-used method to determine the engraftment 
and self-renewal capacity of HSPCsYQ]. This method is also commonly employed to 
assess whether HSPCs are functionally impairedXQ],YQl,YQm. Transplantation time-spans 
between Y and %P weeks are widely used to investigate the engraftment potential of 
progenitor cells and stem cells respectively. To determine these properties in the mutant 
ﬁsh, I aimed to establish a zebraﬁsh transplantation protocol for the functional analysis 
of HSPCs in our laboratory. To this end, I employed the recently generated rag>ES$Xfs 
(homozygous carriers of this allele will be termed rag>-/- in this text) mutant line, which 
has a reduced number of functional B- and T-lymphocytes and therefore allows 
successful engraftment of non-immune matched cells even at sub-lethal doses of 
radiationLPP.  
As a ﬁrst step to establish a transplantation protocol, I assessed the eﬀect of varying 
doses of radiation (%Q, XQ, LQ and YQ Gy) on the survival of ﬁve rag>+/- zebraﬁsh (chosen 
as I did not have enough mutants) (Figure L.XQA). One ﬁsh of each group had to be 
culled due to side eﬀects. In general, ﬁsh irradiated with lower doses (%Q and XQ Gy) 
were livelier and appeared healthier. Three days post irradiation, I culled the ﬁsh and 
assessed cell numbers, as well as the proportion of diﬀerent blood lineages in the kidney 
using haemocytometers and FACS (Figure L.XQB-F). From these studies, I ascertained 
that a dose of around %Q Gy was necessary to aﬀect the number of progenitors (arguably 
the most important, as this would free niche space) and monocytes, whereas myeloid 
lineages were only aﬀected from XQ Gy. Total cellularity was reduced at %Q and XQ Gy, 
but this eﬀect only became statistically signiﬁcant at LQ Gy. Due to concerns about side 
eﬀects with higher doses of radiation and as progenitors were already aﬀected at %Q Gy, 
I limited the radiation dose to %$ Gy for my next trial experiment.
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Figure ?.=S: Establishing an irradiation dose for transplantation. (A) Schematic of the experiment. 
Fish heterozygous for rag>eS$Xfs were irradiated with diﬀerent doses of gamma radiation. After a three-day 
recovery, the number of cells in the WKM was counted and the diﬀerent blood lineages assessed using 
FACS. (B) Total number of cells in the WKM. P = .QQ]. (C) Number of erythrocytes in the WKM. P = n.s. 
(D) Number of progenitors in the WKM. P < .QQQ%. (E) Number of myeloid cells in the WKM. P < .QQQ%. 
(F) Number of monocytes in the WKM. P < .QQQ%. All data was analysed using one-way ANOVA and the 
resulting P-values are shown in the legend. P-values shown on the graphs stem from post-hoc Bonferroni 
multiple comparisons tests between the individual groups. For all graphs, nCtrl = $, n%Q Gy = Y, nXQ Gy = L,             
nLQ Gy = L, nYQ Gy = Y. Bars represent mean ± SEM in all graphs. Ctrl = non-irradiated control ﬁsh. 
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Next, I wanted to introduce HSPC transplantation to the experiment and test the eﬃcacy 
of the %$ Gy dose. I utilised the Tg(itga>b:EGFP) line, which has previously been shown 
to contain transplantable stem cellsLLm. HSCs are enriched in the GFPlow populationL]$. I 
planned to irradiate m mpf rag>-/- ﬁsh and transplant %QQQ GFPlow cells intraperitoneally. 
In total, I irradiated ten ﬁsh at %$ Gy. One ﬁsh had to be culled three days post irradiation 
due to loss of balance and inability to swim. At four days post irradiation, another two 
ﬁsh had to be culled due to the same symptoms. The surviving ﬁsh were divided into 
two groups of four ﬁsh each. Both groups received $QQ Tg(sdf%a:dsRed)-labelled stromal 
cells to improve engraftment of the HSCs. The groups diﬀered in the number of GFPlow 
cells that were administered at the same time as the stromal cells. One group received 
%QQ GFPlow cells each, whereas each ﬁsh in the other group received %QQQ.The stromal 
cells were omitted in later experiments due to issues with transgene silencing in the 
kidney marrow. At one day post transplantation (dpt), one of the low-dose recipients 
was found dead. At Y dpt, a ﬁsh in the high dose group was found dead. At ] dpt yet 
another ﬁsh of the low-dose group died, followed by another ﬁsh in the high dose group 
at l dpt. At %% dpt another ﬁsh of the low-dose group had to be culled due to problems 
with maintaining balance while swimming. Finally, at %Y dpt another ﬁsh high dose 
group died. This led me to stop the experiment and cull the remaining two ﬁsh (one 
from the low and one from the high dose group) for analysis using FACS. Neither of the 
ﬁsh showed any engrafted cells. As I later learned via personal communication from 
David Langenau, whose laboratory created this line, rag> mutant ﬁsh tend to become 
very ill between P-l mpf, explaining the phenotype of the mutant ﬁsh, as they were m 
mpf at the start of the experiment. As a precaution, I only used L-Y mpf ﬁsh in 
subsequent experiments and limited the radiation dose to %Q Gy to prevent any further 
deaths. I reasoned that ablating haematopoietic progenitors (as is possible with a %Q Gy 
dose (Figure L.XQD)) would be suﬃcient for transplantation in the absence of T-
lymphocytes.  
I then carried out another transplantation trial. I started by irradiating nine rag>-/- ﬁsh 
with %Q Gy (Figure L.X%A). One had to be culled shortly afterwards due to side eﬀects 
from the radiation. The remaining eight ﬁsh were injected with %QQQ GFPlow cells two 
days later to allow the ﬁsh some time for recovery. At Y weeks post transplantation (wpt), 
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I assessed engraftment of the cells using FACS analysis of the PB and WKM. Fish were 
scored as engrafted if they showed clearly ﬂuorescent cells in either the PB or WKM 
(Figure L.X%B) Of all injected ﬁsh, six out of eight retained ﬂuorescent cells, 
corresponding to a ]$% engraftment rate, although the number of engrafted cells varied 
greatly between the ﬁsh, ranging from two to several dozens of cells. 
 
Figure ?.=(: Initial trial transplantation trial. (A) Transplantation scheme. Fish mutant for rag> were 
irradiated with %Q Gy. After a three-day recovery, they were transplanted with %QQQ GFPlow cells stemming 
from Y mpf WT Tg(itga>b:EGFP) ﬁsh. Four weeks later, ﬁsh were culled and assessed for engraftment in 
the WKM and PB. (B) Typical FACS proﬁle of the WKM (i) and PB (b) of a transplanted ﬁsh, showing the 
presence of GFP+ cells indicating engraftment. n = l. 
After completing these preliminary trials, I sought to use this technique to characterise 
the rad$% mutant line. To do this, I irradiated ten mutant and WT ﬁsh each at %Q Gy, 
followed by transplantation of %QQQ GFPlow cells per ﬁsh. After %P weeks, I culled the 
recipients and assessed the WKM and PB for engraftment (Figure L.XXA). However, none 
of the ﬁsh retained any GFP+ cells (Figure L.XXB), suggesting that the transplanted cells 
did not contain any long-term engraftment potential, although the low number of ﬁsh 
means this can only be considered a very preliminary result. This lack of engraftment 
made it impossible for me to discern any diﬀerences between WT and mutant HSPCs in 
terms of their engraftment potential. Due to ﬁnancial and time constraints, I did not 
pursue this avenue of research further. 
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Figure ?.==: The GFPlow population of Tg(itga'b:EGFP) WKM lacks long-term engraftment 
potential. (A) Transplantation scheme. Fish mutant for rag> were irradiated with %Q Gy. After three days 
of recovery, they were transplanted with %QQQ GFPlow cells stemming from Y mpf rad$% WT or mutant ﬁsh. 
%P weeks later, ﬁsh were culled and assessed for engraftment in the WKM and PB. (B) Typical FACS proﬁle 
of the WKM (i) and PB (ii) of a transplanted ﬁsh, showing the lack of GFP+ cells indicating engraftment. 
n+/+ = $, n-/- = $. 
3.2.3.9 RNA-Seq reveals a differential p53 response in different cell types 
To complement my data, I carried out bulk RNA-Seq on the diﬀerent cell types of the 
WKM. I used the same sorting approach as in one of our other publicationsL]] (see 
section X.XL for a detailed description of the gating). By using that method, one can 
separate the major mature blood lineages, including HSPCs (progenitors). The basic 
principle of this technique is that the diﬀerent blood cell types in the zebraﬁsh kidney 
diﬀer by their FSC and SSC parameters, allowing a rough determination of cell type. I 
was able to improve upon this method by verifying the identity of the diﬀerent cell types 
using single-cell RNA-Seq, GO enrichment and cytospin analysis, as described 
previouslyL]], reassigning some of the gates. Lymphocytes and thrombocytes cannot be 
sorted based on the FSC and SSC parameters due to their low abundance in the WKM, 
so I focussed on erythrocytes, HSPCs, myeloid cells (mainly neutrophils) and monocytes. 
The erythroid and myeloid gate were almost exclusively made up by these cell types as 
shown by cytospins, but the monocyte and progenitor gates displayed considerably 
more heterogeneity. Additionally, I enriched for thrombocytic progenitors by using the 
Tg(itga>b:EGFP) line, sorting GFPlow cells.  In total, I sorted four wells with $Q cells each 
per gate, for two WT and mutant ﬁsh. Following sorting, samples were prepared using 
the SmartSeqX protocolL]l,L]m by L.F. and sequenced.  
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Sequencing data was processed and by E.A. Due to the size of the tables, the results are 
presented in the appendix. Following read-alignment and quality control, the reads of 
the diﬀerent genotypes were pooled to compare WT and mutant gene expression, which 
was split up into up- and downregulated genes (Tables A%-%Q). I then used EnrichRLlL to 
search the KEGG pathway databaseLlX using diﬀerentially expressed genes with a non-
adjusted P < .QQ% to discover pathways that are diﬀerentially expressed between WT and 
mutant cells. Up- and downregulated genes were searched separately. An adjusted P-
value of .Q$ was used as cut-oﬀ for signiﬁcance in the gene ontology (GO) term analysis.  
Erythrocytes and Tg(itga>b:EGFP) GFPlow thrombocytic progenitors showed no 
signiﬁcant enrichment among up- and downregulated genes (Tables A%%-%Y). 
For monocytes, an upregulation of ribosomal pathways (associated with proliferation) 
and p$L signalling were found (Table A%$). For the downregulated genes, only non-
speciﬁc terms related to secretion were found (Table A%P). 
For neutrophils, no GO terms were signiﬁcant among the upregulated genes (Table A%]). 
However, for the downregulated genes, oxidative phosphorylation, lysosomal genes and 
antigen processing/presentation were signiﬁcant (Table A%l).  
Finally, I considered the gate containing mostly progenitors/HSPCs. Among the 
upregulated genes, both the p$L signalling pathway, as well as ribosomal genes were 
enriched (Table A%m). For the downregulated genes on the other hand, a lot GO terms 
related to secretory pathways were found to be signiﬁcantly enriched (Table AXQ). 
Overall, this analysis highlighted alterations in pathways controlling proliferation and 
p$L signalling in the mutants, but many of the other changes were not easily relatable 
to the phenotype of the ﬁsh. The implications of these ﬁndings are discussed in more 
detail below. 
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3.3 Discussion 
In the initial characterisation of the rad$% mutant zebraﬁsh line, I demonstrated that the 
mutation leads to a complete loss of protein and that while mutants are able to survive 
to adulthood, they are all infertile males. In terms of their FA-related phenotypes, I 
showed that mutant ﬁsh develop both haematological and non-haematological features 
resembling FA. 
To characterise the response to DNA damage, rad$% mutant embryos were exposed to 
gamma radiation, which led to the development of small eyes and heads, exacerbating 
the micropthalmia seen without the use of DNA damaging agents. A similar phenotype 
was seen in zebraﬁsh embryos where fancd> was knocked down using morpholinosLP%. 
It is also reﬂective of the micropthalmia/microcephaly seen in some FA patients%m and 
some FA mouse modelsLm%,Y%Q, demonstrating the sensitivity of the rapidly dividing 
central nervous system to DNA damage. To counteract this, zebraﬁsh embryos have a 
high expression of FA genes in the developing head and eyes, especially between the %$ 
somite and early long pec stages of developmentL$m. 
I also observed FA-typical chromosomal abnormalities in response to crosslinking 
agents commonly used in the diagnosis of FA (DEB and MMC). Similar results have been 
obtained for fancd> morphantsLP%, brca> mutantsLPL,LPY, as well as fancl mutantsLPX. 
In addition, inhibition of topoisomerase I by CPT also led to increased DNA damage, 
consistent with defective HR repair. 
In contrast, my results show that loss of rad$% does not lead to higher sensitivity to PARP 
inhibitors. Previous research on mammalian cells showed that BRCA%/> mutant cells are 
more sensitive to PARP inhibition. One model proposes that this is due to the 
importance of PARP% in reactivating stalled replication forks in HR-deﬁcient cellsY%%. 
That model is not compatible with my data, suggesting that PARP-BRCA synthetic 
lethality stems from functions unrelated to HR. PARP% is highly conserved between 
zebraﬁsh and humans (~]Q%). A small molecule inhibitor such as DiQ should therefore 
be able to enter the zebraﬁsh embryos and inhibit the enzyme the same way as in human 
cells. Further evidence for this is provided by the lethality of high doses of this drug in 
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WT and rad$% mutant ﬁsh. In addition, the drug has previously been successfully used 
on adult zebraﬁshY%X. However, I was unable to obtain brca> mutant zebraﬁsh to use as 
a positive control for DNA damage in response to PARP inhibition. This should be taken 
into account when interpreting my ﬁndings. 
The survival of the rad$% mutants to adulthood came as a surprise, since murine Rad$% 
mutants die during early embryonic developmentXmP,Xm]. This early embryonic death 
shows that Rad$% has vital functions during early mammalian development. However, 
murine and zebraﬁsh development have considerable diﬀerences, the most obvious of 
which is the external development of zebraﬁsh compared to the uterine development of 
mice. Another big diﬀerence is the timing at which zygotic genes dominate development 
compared to maternal genes. In mice, zygotic genes are switched on around one to two 
divisions, whereas zebraﬁsh embryos undergo about ten rounds of divisions before 
zygotic transcripts are predominantYQ$. This corresponds to the mid-blastula transition 
at about L.] hpf YQY. The immunostaining results showing that maternal Rad$% protein is 
present in all embryos regardless of mutation status mean that it is likely that maternal 
RNA rescue allows the survival of rad$%-/- embryos. There is evidence that fancd> mRNA 
is also maternally providedLP%, strengthening the hypothesis further. In agreement with 
this data, immature oocytes of adult zebraﬁsh have been shown to have a high 
expression of FA genesL$m. This contrasts with human data, where FANCDX protein was 
not found in oocytesY%L. If the same is the case for RAD$%, this would explain the species 
diﬀerences in survival. A similar rescue has been proposed for brca> mutant zebraﬁshLPL. 
However, as it is impossible to generate fertile mutant females, I ultimately could not 
do an experiment that irrefutably proves maternal RNA/protein is what allows the 
survival. 
I then proceeded with the characterisation of the adult mutants. My initial ﬁnding of 
sub-Mendelian birth ratios, which could be raised back to normal by outcrossing, 
indicates that my ﬁsh carried other mutations, which were recessive-lethal in 
combination with rad$% mutations. I showed that surviving mutants have a decreased 
body size in comparison to their WT siblings, similar to the short stature seen in many 
FA patients%m and some mouse modelsX$L,Llm–Lm%. Together with the decreased eye size in 
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embryos and infertility, the rad$% mutant line recapitulated key congenital features of 
FA. 
Another intriguing ﬁnding of my research was that all mutants reared to adulthood were 
infertile males. I was able to conclude that this was due to sex reversal (i.e. mutants that 
should have developed as females became males), rather than female mutants dying, as 
the number of mutant ﬁsh was in accordance with Mendel’s rules. This phenomenon 
has previously been described for brca>-/- ﬁshLPL,LPY. Interestingly ﬁsh carrying 
homozygous mutations in the FA core complex gene fancl are also all males, but fertileLPX. 
Together, this evidence indicates that FA genes are necessary for the development of 
female zebraﬁsh. HR genes are additionally necessary for successful meiosis in male 
zebraﬁsh, besides being vital for the development of females. The requirement of DNA 
repair genes for sex determination is due to the complicated sex determination system 
in zebraﬁsh, which consists of a mixture of environmental determination coupled to a 
polygenic sex determination system. During the larval period, zebraﬁsh develop a 
juvenile ovary. If the ﬁsh is to become a male, the oocytes are eliminated by apoptosisY%Y. 
Fish lacking FA genes have an increased rate of p$L-driven apoptosis of the oocytes 
caused by unrepaired DNA damage, as demonstrated in the fancl modelLPX, leading to 
the development of all male mutants. The same is true for brca> mutant ﬁshLPL,LPY and 
presumably for rad$% as well, considering the role of BrcaX in loading Rad$% onto the 
DNA. It is possible that the common infertility in FA patients might stem from similar 
meiotic defects in part of the patient population. 
I then utilised qPCR to investigate the expressions of genes linked to the DNA damage 
response. Intriguingly, gaddS$ab, a marker for double-stranded breaksY%$, was 
upregulated exclusively in ﬁn tissue. This could stem from higher exposure of the skin 
to damaging agents due to its role as a barrier. It could also be that the DNA damage 
response pathways are slightly diﬀerent in the various tissues, leading to failure of 
detection of DNA damage using gaddS$ab as a marker gene. 
In my characterisation of the haematological phenotype of the adult rad$% mutants, I 
found that they exhibit decreased numbers of blood cells in the WKM and gradually 
develop macrocytic erythrocytes in the PB. I then showed that this decrease in WKM 
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cellularity was not caused by increased apoptosis or decreased proliferation of the adult 
cells. Paradoxically, mutant ﬁsh even displayed increased proliferation in the WKM. As 
this increased rate did not lead to increased cell numbers in the WKM, the newly made 
cells must be released into the PB. This suggests that the increased proliferation is a way 
to compensate for the WKM hypocellularity – a decreased number of haematopoietic 
progenitors proliferating at the normal rate would presumably not be enough to 
maintain homeostasis. In agreement with this, the ﬁsh were not anaemic. This ﬁts with 
research done on Fancd>-/- mice, which showed increased cycling of HSPCsPX. This rapid 
division might also be the cause of the macrocytic erythrocytes, as macrocytosis can be 
an early sign for the impairment of the haematopoietic system and is commonly seen 
before BMF in FA patientsY%P. As I only observed my ﬁsh until %L mpf, I do not know 
whether the ﬁsh ever develop anaemia in the PB or BMF at a later age. This would be an 
interesting area for further study. However, as most mouse FA models do not develop 
BMF during their natural life span%%L,L$l,Ll], it is possible that my ﬁsh would also never 
progress to that stage. It is important to note that the two known patients carrying 
RAD$% mutations, have not progressed to BMF so far%%Y,%%$ and that rare patients carrying 
mutations in other FA genes can live surprisingly long without ever experiencing blood-
related pathologies%m,$Q. Despite not showing overall anaemia, I saw an exacerbated shift 
to myeloid cells in the WKM, which is a common sign of ageingY%]. This ﬁts with the 
view of FA as a segmental progeroid disorder, aﬀecting only the bloodXX,%X]. Overall, the 
combination of key congenital and haematological symptoms in out model strengthens 
addition of RAD$% to the Fanconi genes as FANCR.  
A similar decrease in the number of blood-forming cells was seen in mice carrying 
homozygous mutations for the non-homologous end joining protein LigS. These mice 
displayed decreased BM cell numbers and just like my ﬁsh, they had an approximately 
twofold increase in proliferation of the LT-HSCs%YY. This shows that both major pathways 
for the repair of double stranded breaks are important in maintaining HSCs, underlining 
the necessity of DNA repair in preserving the number of HSCs. It also suggests that 
hyperproliferation of HSPCs could be a common way to account for hypocellularity in 
the bone marrow.  
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Since the decrease in WKM cellularity could not be explained by defects seen in the 
adult ﬁsh, I turned to embryonic haematopoiesis to explain the changes seen later in life. 
My results showed a decrease in the number of HSPCs in embryos, caused by reduced 
proliferation with concurrently increased apoptosis. It was previously proposed by other 
groups that the number of HSCs in FA patients is already decreased at birth due to 
embryonic impairments%LL,%LP,%L]. However, my results are the ﬁrst to demonstrate in an 
in-vivo model that the HSCs of FA patients are already decreased during embryonic 
development. In contrast to the work by Jean Soulier’s group%LL, who proposed decreased 
proliferation of HSCs as the main cause of cell number decreases in FA, I observed both 
decreased proliferation, as well as increased apoptosis. 
When examining the mature blood cells during embryonic development, I found that 
erythroid and myeloid cells were unaﬀected, whereas rag%+ T-lymphocytes in the thymus 
were drastically reduced. Lymphocytes undergo V(D)J recombination to generate a wide 
variety of receptors/antibodies during maturation. After V(D)J rearrangement, somatic 
diversiﬁcation makes the receptors/antibodies even more diverse. One mechanism to 
do that is gene conversion. Data from rabbit cells suggests that Rad$% is a vital 
component of that processY%l,Y%m. Other publications have implicated Rad$% in B-cell class 
switching, rather than somatic hypermutationYXQ. Interestingly, my data suggests that 
these processes seem to be necessary for the generation of suﬃcient numbers of 
lymphocytes, rather than an additional step to generate more cellular diversity. It would 
be interesting to investigate whether cells that cannot undergo somatic diversiﬁcation 
are dysfunctional, or whether there is another reason for the decrease in lymphocytes. 
The simultaneous decrease in HSPCs, but lack of changes in mature cells (bar the special 
case lymphocytes), indicates that there is no direct correlation between the number of 
stem and mature cells during embryonic development. 
It is possible that this is also true during adulthood, indicating that there is no 
relationship between the number of HSCs and the number of mature blood cells in the 
PB. This is in agreement with studies showing that the number of functional HSCs 
declines with ageingYX%,YXX, even though the number of phenotypic HSCs increasesYXL–YXl, 
because otherwise all elderly people should suﬀer from various cytopenias, which is not 
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the case. These observations also ﬁt with a previous study that proposed that HSCs plays 
a minor role in the maintenance of normal (i.e. when not stressed) haematopoiesisYXm. 
Next, I wanted to determine whether the HSPC defects were cell-intrinsic, i.e. caused 
only by the cells themselves, or extrinsic, i.e. determined the environment of the HSPCs 
in their niche. To do this, I carried out transplantation experiments, using WT and 
mutant cells from Tg(itga>b:EGFP) carrying donors. However, my results showed no 
engraftment for WT ﬁsh at %P wpt, making the comparison of WT and mutant 
engraftment impossible. I believe that this failure to engraft was due to a combination 
of the low amount of irradiation used in my trial and the low proportion of long-term 
repopulating cells in the GFPlow subpopulation. In contrast, Ma et al.LLm, who used lethal 
irradiation, reported good engraftment at %P wpt. When they used %QQQ GFPlow cells, 
with carrier marrow ($-l X %Q$ cells) they achieved %m% engraftment at %P wpt (when 
dead ﬁsh are included in the analysis). Considering the low number of ﬁsh that were 
transplanted, it is conceivable that I just did not see any engraftment by chance. An 
interesting avenue for future research would be to repeat this experiment using a higher 
dose of radiation and more GFPlow cells. I have since reﬁned the transplantation 
technique utilising the Tg(runx%+>R:mCherry) transgenic lineLLl, routinely resulting in 
>lQ% engraftment at %P wptL]], indicating a higher proportion of HSCs in this transgenic 
line. A lack of time and ﬁnancial resources prevented me from using this improved 
technique for the study of the rad$% mutant ﬁsh.  
Finally, I considered transcriptional changes in the diﬀerent blood lineages using bulk 
RNA-Seq. I was able to investigate erythrocytes, myeloid cells, monocytes, HSPCs and 
GFPlow thrombocytic progenitors, but lymphocytes could not be considered due to their 
rarity in the kidney. My analysis revealed surprisingly few changes in the diﬀerent blood 
lineages of mutant ﬁsh. The experimental design pooling only $Q cells per well might 
have caused this by increasing the variability within each biological replicate. This factor 
possibly contributed to the low number of diﬀerentially expressed genes. For future 
experiments, a higher number of cells per well would be preferable. However, even 
though the experimental design increased the ambiguity of my data, I was still able to 
detect diﬀerential responses to Rad$% loss in the diﬀerent cell types. Of note is the 
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enrichment of antigen processing genes and oxidative phosphorylation among 
downregulated genes in neutrophils, which may suggest a less mature state of the cells. 
Most interestingly, both ribosomal genes, as well as the p$L signalling pathway were 
enriched among upregulated genes in HSPCs. The increase in ribosomal genes is 
interesting, as a previous publication of my research group identiﬁed high expression of 
ribosomal constituents to be associated with more immature cellsL]], indicating that 
HSPCs in rad$% mutant ﬁsh contain proportionally more immature cells than the WT 
WKM, indicating diﬀerentiation defects. In addition, the upregulation of p$L target 
genes indicates that the p$L pathway is being activated, ﬁtting with increased 
haematopoietic stress. The role of p$L-driven signalling in FA pathogenesis will be 
discussed in detail in the next chapter. 
In summary, rad$% mutant ﬁsh developed both congenital, as well as haematological 
symptoms resembling key features of FA. It can also be concluded that the assignment 
of RAD$% as FANCR is appropriate. As brca> and fancl knockout ﬁsh have not been 
characterised in terms of haematological abnormalitiesLPX–LPY, the rad$% mutant line can 
therefore be considered the ﬁrst characterised adult zebraﬁsh FA model. After having 
established the appropriateness of my model, I went on to utilise it to understand the 
molecular pathology underlying FA.
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4 BMF in FA: molecular signalling  
4.1 Introduction 
4.1.1 The p53 protein and pathway 
The p$L protein is possibly the most famous protein in cancer biology, if not biology in 
general. Its moniker “p$L” stems from the fact that it appears to have a mass of $L kDa 
when run on an SDS-PAGE gel. In fact, its real molecular weight is only about YL.] kDa 
(at least for the full-length form). This discrepancy is due to proline-rich regions in the 
protein, which impede migration through the gelYLQ. This vital protein is encoded by the 
TP$R gene in humans, which has orthologues in almost all vertebrate speciesYL%. Here, I 
will be using p$L and TP$L interchangeably. 
The original discovery of p$L happened in the late %m]Qs during the study of cells 
transformed by Simian vacuolating virus YQ (SVYQ). In these cells, p$L was identiﬁed as 
the binding partner of the SVYQ T antigenYLX. Subsequent experiments showed it to be 
highly expressed in cancer cells, whereas comparatively small amounts were found in 
non-transformed cellsYLL,YLY. Due to this high expression in transformed cells and 
somewhat common dominant-negative mutations, initial reports erroneously 
considered it an oncogene rather than a tumour suppressorYLQ. Following the cloning of 
the TP$R gene in mice and humans for the ﬁrst time in the early %mlQsYL$,YLP, evidence 
for the protein’s role as a tumour suppressor started accumulating in the mid-%mlQs. At 
that point, it was shown that P$R was commonly mutated in cancer cell lines and cancer 
patients, a hallmark of a tumour suppressor geneYL]–YY%. Further evidence came from 
overexpression experiments, which showed that P$R overexpression can suppress 
transformationYYX. Finally, the discovery that germline P$R loss-of-function mutations 
lead to the Li-Fraumeni cancer predisposition syndrome conclusively showed that p$L 
acts as a tumour suppressor rather than as an oncogeneYYL,YYY. It is indeed one of the 
most commonly mutated genes in cancer, with a mutation rate ranging between %Q and 
%QQ% depending on the type of cancerYY$. Compared to solid tumours, P$R mutations 
are relatively rare in haematological malignanciesYYP. 
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The p$L protein has various roles in the cell, which are reviewed in-depth 
elsewhereYY],YYl. Its main function is as a transcription factor, controlling genes such as 
the proliferation suppressor P>% and pro-apoptotic proteins such as BAXYYm,Y$Q. Many of 
its other targets are also involved in processes regulating cellular growth, metabolism 
and apoptosisYLQ. It does not only promote transcription, but conversely can also repress 
genesY$%.  
Apart from its function in the nucleus as a transcription regulator, it also carries out 
many diﬀerent non-transcriptional roles all over the cell. For example, p$L plays a vital 
role in the membrane permeabilisation of mitochondria during apoptosis%PP. 
Both transcriptional, as well as non-transcriptional roles of p$L are involved in the 
response to genome stressY$X,Y$L. Because of this induction of p$L in response to damage 
to the DNA, it has been termed “guardian of the genome”Y$Y. 
The signalling pathways involving p$L are very diverse and there are few cellular 
mechanisms that do not involve it at least indirectly. Just to give some examples, p$L is 
involved in the antioxidant responseY$$, it acts as a negative regulator of inﬂammationY$P 
and mediates the toxic eﬀects of radiation in haematopoietic tissuesY$P–Y$l. 
Due to the vital role of the p$L protein in the protection of genomic integrity, there is a 
complicated regulatory network controlling its activity. One of the most important 
regulatory player on which many signals converge is MDMXYLQ. This protein acts as an 
EL ubiquitin ligase for p$L, contributing to the fast turnover of p$L. MDMX also 
functions in ubiquitin-independent modes to block the interaction of p$L with the rest 
of the transcriptional machineryY$m. It acts is conjunction with another important p$L 
regulator, MDMY, which can pose as a cofactor for MDMXYPQ. A combination of these 
and other mechanisms allow the ﬁne-tuning of p$L activity to the appropriate level.  
4.1.2 The role of p53 in HSPCs 
As in other tissues, p$L plays a large role in regulating the activity of haematopoietic 
cells. Depending on the cellular context, p$L may regulate the exit of HSPCs from the 
cell cycle, the apoptotic response or DNA repairYP%–YP]. The regulation of these factors by 
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p$L plays an important role in the ageing process of the haematopoietic system%YQ–
%YX,%YY,YPl.  
The p$L pathway seems to be particularly important in regulating quiescence and the 
cell cycle of HSCsYPm. Quiescence is, among other things, vital to maintain HSC 
functionality and proliferation of HSCs gradually leads to functional impairment during 
ageing%LY,YX%,Y]Q,Y]%. As p$L suppresses cell cycle entry, it is not surprising that Tp$R 
knockout mice have a two- to threefold larger HSC pool. This was linked to decreased 
cycling time and outcompetition of wild type cells in-vitro. However, these HSCs show 
a reduced repopulation ability, indicating functional impairmentYPL,Y]X–Y]Y. Similar 
results were obtained using pharmacological inhibition of p$L activity. These 
interventions lead to increased cell cycling and a decreased recovery time following 
BMTY]$,Y]P. 
Another important function of p$L is to regulate the decision of whether a cell undergoes 
apoptosis. While apoptosis is usually beneﬁcial to the organism (such as killing cells 
with DNA damage to prevent tumours), there are situations where it can be detrimental 
to the haematopoietic system. Aberrant p$L signalling may lead to genome instability 
and BMF%YQ,Y]]. For example, the toxicity of ionising radiation to the bone marrow is 
mediated via p$L, whereas in other tissues such as the small intestine, p$L signalling 
post irradiation can serve as a survival signalY$P–Y$l,Y]l. This is why the bone marrow is 
extremely sensitive to ionising radiation. This sensitivity can also be used medically, as 
it allows the selective ablation of the bone marrow prior to HSC transplantation.  
A further example of the sensitivity of the bone marrow to p$L-driven apoptosis is the 
anaemia seen in the ribosomopathy Diamond-Blackfan anaemia, where p$L-driven 
signalling in response to ribosomal stress leads to apoptosis of the erythroid progenitors. 
Similar mechanisms have been proposed for other ribosomopathiesY]m.  
4.1.3 Zebrafish p53 
The zebraﬁsh genome contains an orthologue of the human TP$R gene, with which it 
shares about Y$% identity on the nucleotide level. Zebraﬁsh tp$R is particularly highly 
expressed during early development before Yl hpf, demonstrating the importance of 
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this gene during embryogenesisYlQ. Despite this, zebraﬁsh lacking p$R survive to 
adulthood without any problemsLP$,Yl%. The role of tp$R mutations in the adult zebraﬁsh 
has also been studied. Homozygous ﬁsh carrying mutations in the DNA-binding domain 
(tp$RM>%SK) were studied in-depth for abnormalities. The only noticeable eﬀect of p$R 
mutation at the organismal level was the development of malignant peripheral nerve 
sheath tumours (MPNSTs) in slightly fewer than LQ% of the adult ﬁsh, with the ﬁrst 
tumours appearing about l mpf LP$. Mice carrying mutations in Tp$R show similar 
features, albeit with diﬀerent tumour typesYlX. Apart from gross organismal defects, the 
ﬁsh showed many abnormalities in cellular signalling due to the loss of functional p$LLP$. 
Overall, these similarities to the situation in mice and humans demonstrates the 
suitability of the zebraﬁsh model to study p$L signalling. 
4.1.4 The role of p53 in FA 
There have been many studies looking at p$L-driven signalling in FA cell lines, animal 
models and patient samples. Early studies were quite ambiguous, with many 
contradictory results. Some studies found that p$L-mediated apoptosis following 
gamma irradiation is impaired in FA cells (i.e. cells were less likely to undergo apoptosis 
than normalYlL,YlY), whereas others found that p$L-driven apoptosis is at least partly 
responsible for apoptosis in Fancc mutant mice. Similarly, some groups showed that p$L 
can induce the expression of FA genes such as FANCC%$P, whereas others showed that 
p$L downregulates the FA pathway%Lm. Apoptosis driven by p$L has also been implicated 
in germ cell defects in FA patientsYl$. In addition, loss of p$L has been shown to 
accelerate tumour development in Fancd> and Fancc knockout miceYlP,Yl], as well as 
brca> mutant zebraﬁshLPL,LPY,Yll. 
A more deﬁned role for p$L in FA emerged in XQ%X, when Ceccaldi et al. proposed that 
an excessive p$L/pX% response drives the bone marrow failure in FA patients%LL. First, 
they proved that the p$L protein is excessively induced in response to DNA damage in 
patient-derived FA cells. They then went on to show that this leads to pX%-mediated cell 
cycle arrest. Engraftment defects upon transplantation of Fancg-/- cells were also rescued 
upon p$R knockdown, with similar results obtained for p$R knockdown on human FA 
cells. Because the defects seen in FA start early in life, they reasoned that an overactive 
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p$L/pX% response in the foetal liver leads to a small initial HSC pool. Later in life, 
additional stress leads to further decreases in the stem cell pool, eventually exhausting 
it and causing BMF. This ﬁts nicely with previous data from the group showing that FA 
patients with lower p$R expression have less severe symptomsYlm. However, data from 
p>%, Fancd> double knockout mice shows that these defects do not seem to be mediated 
via pX%, as the phenotype of this line was exacerbated rather than alleviated as 
expected%Ll. In addition, another paper has shown that HSC defects in the foetal liver of 
Fancd>-/- mice are independent of apoptosis of p$L activation, claiming that overly active 
MAPK (pLl) is the main factor mediating blood abnormalities%L]. In conclusion, there is 
still no complete certainty about the role of p$L-driven signalling in the pathogenesis of 
FA, even though there are strong indications that it is one of the main drivers of BMF. 
In this part of this study, I investigated the role of p$L in the phenotype of the rad$% 
mutant line. I show that haematological phenotypes were completely rescued upon p$R 
co-mutation, adding further evidence that p$L plays a critical role in FA pathogenesis. 
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4.2 Results 
4.2.1 Expression in embryos and adults 
To look at the role of p$R signalling in the abnormal phenotype of the rad$% mutants, an 
in-situ hybridisation using a tp$R-speciﬁc riboprobe was carried out at X dpf. Expression 
of p$R in unchallenged rad$% mutants was noticeably increased in the head region of the 
embryo (Figure Y.%A), underscoring the susceptibility of the developing nervous system.  
Paradoxically, when I carried out qPCR analysis on the tissues of adult rad$% mutants, 
p$R expression was consistently decreased in the kidneys of the mutants (Figure Y.%B), 
suggesting that there is a functional need for the decrease in p$R in most blood cells. 
Alternatively, there could be a selective advantage for cells expressing low levels of p$R, 
either due to cells expressing high levels undergoing apoptosis, or because cells 
expressing low levels might proliferate at a higher rate. 
 
Figure @.(: The expression of p$( diﬀers between embryos and adult ﬁsh. (A) ISH of X dpf embryos 
using a p$R ISH probe. Upregulation of the transcript in the head region of the embryos is visible. n+/+ = Xl, 
n-/- = %m (B) Expression of tp$R in the adult WKM as assessed by qPCR analysis. The expression was roughly 
halved compared to the WT ﬁsh. Two-tailed Student’s t-test, P = .QQ]. n+/+ = Y, n-/- = $. Bars represent the 
geometric mean ± m$% CI to estimate fold changes. Data shown in A was obtained by E.B.-M  
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4.2.2 Characterisation of rad51, p53 double mutants 
I then decided to cross the rad$% line with the tp$Rzdf%/tp$RM>%SK line (p$R-/-), in which the 
p$R gene is dysfunctional because of a MX%YK mutationLP$, to generate double mutants 
for the study of the compound eﬀects of combining these mutations. There were 
multiple compelling arguments to do this. For one, p$R driven signalling has been 
implicated in the pathogenesis of FA%LL, so I reasoned co-mutation might rescue some of 
the phenotypes I observed. Moreover, co-mutation of brca> and p$R was able to 
successfully rescue the sex reversal seen in these ﬁsh and led to a high rate of cancer 
developmentLPL,LPY,Yll. Finally, the upregulation of p$R in rad$%-/- embryos (Figure Y.%A) 
led me to believe that p$L plays an important role in the phenotype of the mutant ﬁsh.  
4.2.3 Co-mutation of p53 partially rescues congenital phenotypes 
In my initial characterisation of the oﬀspring of rad$%+/-, p$R+/- incrosses, I observed 
several female (four out of twelve ﬁsh) ﬁsh among the double mutants (Figure Y.XA). 
This was most likely caused by decreased apoptosis in the immature germ cells, allowing 
the development of oocytes and consequently ovaries. Zebraﬁsh sex determination and 
the role of p$L in this process is described in more detail in sections L.L and Y.L 
respectively. Fertility was not rescued, as I was unable to outcross both female and male 
double mutants to WT ﬁsh even after several attempted matings. The female gonads 
looked normal despite the infertility (Figure Y.XB), but in the males, the infertility 
matched with histological evidence showing lack of mature spermatozoa in the testes 
(Figure Y.XC). 
Size measurements of my ﬁsh showed that both rad$% single and rad$%, p$R double 
mutants were smaller than their wild type siblings, in contrast to p$R single mutants, 
which were of normal size (Figure Y.XD). This indicates that the small size of rad$% single 
mutants was unlinked to p$L signalling. 
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Figure @.=: Co-mutation of rad$% and p$( can rescue some congenital phenotypes seen in the 
single mutants. (A) Male (top) and female (bottom) double mutants. (B) Histological sections of a        
p$R-/- ovary (left) and a p$R, rad$%-/- ovary (right) at Y mpf using a %QX objective. Oocytes of diﬀerent 
maturation stages are apparent in both genotypes. Scale bar = %QQ µm. (C) Histological sections of a        
p$R-/- testis (left) and a p$R, rad$%-/- testis at Y mpf using a XQX objective. (right). Arrows indicate mature 
spermatozoa (or lack thereof). Scale bar = %QQ µm(D) Graph showing the size of WT and double mutant 
adults at Y mpf, showing a small, but measurable diﬀerence. np$R+/+ rad$%+/+ = X], np$R-/- rad$%-/- = m. Two-tailed 
Student’s t-test, P = .QQl. Bars represent mean ± SEM. 
4.2.4 Double mutant fish develop tumours 
Intriguingly, one third of the double mutants (three out of nine ﬁsh left to age) 
developed tumours. The earliest tumour appeared at $ mpf and took the form of a 
tumour in the eye socket which led to the eye “bulging” out of its socket (Figure Y.LA). 
Two more tumours were detected upon histological examination at l mpf and these 
were located around the ovaries (Figure Y.LB). Further investigation of the histological 
slides revealed that the tumours resembled MPNSTs (common tumours in zebraﬁsh in 
general), with very characteristic “spindle-like” cells (Figure Y.LA and B). Conversely, 
p$R-/- ﬁsh have a higher latency of developing tumours (l months) and only reach a 
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comparable tumour incidence at %P mpfLP$, indicating a compound eﬀect of the rad$%  
and p$R mutations. 
 
Figure @.?: Double mutants are susceptible to tumourigenesis. (A) Tumour found directly behind 
the eye of a $ mpf ﬁsh (i) and accompanying H&E stained histological sections of the tumour (ii) using 
X.$ and PLX oil immersion objectives. In the insert characteristic spindle cells, consistent with a MPNST 
are readily apparent. (B) (i) and (ii) MPNSTs found upon histological examination two diﬀerent l mpf 
female double mutants. Arrows indicate the tumour mass next to the normal ovary tissue. Overall, three 
out of nine aged double mutants developed tumours. Scale bar = $QQ µm and %Q µm in the overall images 
and the inserts respectively. 
4.2.5 Haematological defects in rad51-/- embryos are rescued when 
p53 is co-mutated 
I then went on to characterise the haematological phenotypes of the double mutants. As 
I saw a striking decrease in cmyb+ cells in the CHT of Y dpf rad$% single mutants, I carried 
out an ISH on p$R+/-, rad$%+/- incrosses, which was scored blindly as described above. 
Representative CHTs are shown in (Figure Y.Y) and a quantiﬁcation of staining intensity 
in (Table Y.%). It is apparent in these images that while rad$%-/- embryos had considerably 
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decreased cmyb expression, this defect was absent in p$R-/-, rad$%-/- embryos, which had 
similar staining to WT embryos. 
 
Figure @.@: The embryonic HSPC defects in rad$%sa'()*$ ﬁsh are rescued in a p$( mutant 
background. Representative images of Y dpf embryos resulting from incrosses of p$R+/-, rad$%+/- parents 
stained using a cmyb-speciﬁc probe. The total number of embryos used (all genotypes) n = XL] from Y 
clutches. For information about all genotypes please see Table Y.%. 
Table @.(: Quantiﬁcation of the staining data presented in Figure @.@. Three independent clutches 
with n = PQ were pooled to generate this table, leading to an overall n = XL] when accounting for 
unsuccessful genotyping. p$R-/-, rad$%+/+ ﬁsh are underrepresented in the high staining group (highlighted 
in orange), whereas p$R-/-, rad$%-/- embryos (blue) stained similar to WTs.  
  Staining intensity 
  High  Medium Low 
Ge
no
ty
pe
 
rad51+/+, p53+/+ 5 9 3 
rad51+/+, p53+/- 13 13 5 
rad51+/+, p53-/- 5 4 6 
rad51+/-, p53+/+ 6 8 12 
rad51+/-, p53+/- 25 17 17 
rad51+/-, p53-/- 15 14 7 
rad51-/-, p53+/+ 1 6 6 
rad51-/-, p53+/- 4 6 19 
rad51-/-, p53-/- 6 3 2 
     
Unsuccessful genotyping  3   
Successful genotyping 237   
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4.2.6 Co-mutation of p53 also rescues adult WKM defects 
Next, I investigated whether HSPC proliferation in the WKM of Y mpf ﬁsh would also 
be rescued by p$R co-mutation. To do this, I carried out the same BrdU incorporation 
assay described in section L.X.L.$. As I did not have enough double mutants for a time 
course and BrdU incorporation was the highest at % dpi in the previous experiment, I 
focussed on this day for the analysis of BrdU incorporation. Strikingly, proliferation rates 
were reduced back to WT levels in the double mutants, rather than doubled as in the 
rad$% single mutants (Figure Y.$A). 
To see whether these changes would translate to a rescue of WKM cellularity, I carried 
out cell counts of the rad$%, p$R mutant ﬁsh. This experiment showed that kidney 
marrow cellularity reverted to WT levels upon co-mutation (Figure Y.$B). Interestingly, 
rather than having increased WKM cellularity, p$R single mutants had the same cell 
number as WT ﬁsh (Figure Y.$B). The relative proportion of diﬀerent blood cell lineages 
in the kidney was similarly unaﬀected (Figure Y.P). 
 
Figure @.B: The adult WKM defects in rad$%sa'()*$ ﬁsh are rescued in a p$( mutant background. (A) 
Percentage of BrdU+ cells in Y mpf kidneys at % dpi. Two-tailed Student’s t-test, P = .]P, np$R+/+ rad$%+/+ = $,     
np$R-/- rad$%-/- = $. (B) Number of total cells per kidney at Y mpf quantiﬁed using a haemocytometer. Analysis 
using one-way ANOVA (F (L, YL = %Q.Y$), P < .QQQ%), individual p-values shown in the ﬁgure are from 
Tukey’s, post-hoc test, np$R+/+ rad$%+/+ = %P, np$R+/+ rad$%-/- = %P, np$R-/- rad$%+/+ = P, np$R-/- rad$%-/- = l. Bars represent 
mean ± SEM in both graphs. 
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Figure @.E: p$( co-mutation reverts the blood lineage bias seen in single mutants. FACS results 
showing results WT and p$R-/-, rad$%-/- ﬁsh at l mpf in terms of the proportions of diﬀerent cell lineages 
present in the WKM. Shown are erythrocytes (A), progenitors (B), myeloid cells (C) and monocytes D. For 
all graphs, np$R+/+ rad$%+/+ = Y, np$R-/- rad$%-/- = l. Bars represent mean ± SEM. 
In summary, p$R co-mutation completely rescued all haematological phenotypes 
investigated, suggesting that the deleterious eﬀects of rad$% mutation are mediated via 
a p$L-driven mechanism. Interestingly, not all phenotypic features were rescued; neither 
size defects, nor infertility were ﬁxed by co-mutating p$R. This indicates that some FA 
features may be p$L-driven, whereas others are not. 
4.2.7 Loss of p53 on its own can also affect haematopoiesis 
I carried out a cmyb ISH in which rad$%+/-, p$R-/- ﬁsh were incrossed (Figure Y.]A), to see 
whether rad$% loss would still have an eﬀect in a p$R mutant background. The results of 
this experiment were inconclusive – there were slightly more rad$% mutants in the low 
staining group, but the eﬀect was not nearly as strong as in a p$R+/+ background, 
providing further evidence for the rescue of the HSPC defects. To clarify whether p$R 
loss on its own can aﬀect HSPC numbers, I carried out a cmyb ISH on a p$R+/-, rad$%+/+ 
incross (Figure Y.]B). This showed that p$R mutation alone was able to increase the 
number of HSPCs in comparison to WT embryos, in contrast to the adult situation, 
where p$R mutation on its own was unable to increase WKM cell numbers (Figure Y.$). 
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Figure @.K: p$( mutation can increase HSPC numbers independently from rad$% mutation. (A) 
Representative images of Y dpf embryos resulting from incrosses of p$R-/-, rad$%+/- parents stained using a 
cmyb-speciﬁc probe (i) and quantiﬁcation of the data (ii). The arrow shows HSPCs. n = %%m from two 
clutches. (B) Representative images of Y dpf embryos resulting from incrosses of p$R+/- parents stained 
using a cmyb-speciﬁc probe (i) and quantiﬁcation of the data (ii). The arrow shows HSPCs. n = %XQ from 
two clutches. 
I also considered the mature blood lineages during the deﬁnitive wave of embryonic 
haematopoiesis. Neutrophils were increased upon p$R mutation in $ dpf embryos 
(Figure Y.l A and B), but erythrocytes and lymphocytes were unaﬀected (Figure Y.l C 
and D). These results imply that p$R mutation on its own can aﬀect the haematopoietic 
lineage output in zebraﬁsh. 
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Figure @.O: Neutrophils are increased in p$( mutant embryos. (A) Representative embryos stemming 
from a p$R+/- incross stained using an mpx ISH probe (i) and quantiﬁcation of distribution of genotypes in 
the diﬀerent staining categories (ii). The arrow shows neutrophils. n = %%m from two clutches. (B) 
Representative embryos stemming from a p$R+/- incross stained using Sudan black (i) and quantiﬁcation 
of the number of neutrophils in WT and mutant embryos (ii). The arrow shows neutrophils. Two-tailed 
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t-test, P = .QY. n+/+ = Xm, n-/- = Xm. Bars represent mean ± SEM. (C) Representative embryos stemming from 
a p$R+/- incross stained using an ea% globin ISH probe (i) and quantiﬁcation of distribution of genotypes in 
the diﬀerent staining categories (ii). The arrow shows erythrocytes. n = %Pm from three clutches. (D) 
Representative embryos stemming from a p$R+/- incross stained using a rag% ISH probe (i) and 
quantiﬁcation of distribution of genotypes in the diﬀerent staining categories (ii). The arrow shows 
lymphocytes. n = %%$ from two clutches. 
	  
4 — BMF in FA: molecular signalling 
	
	126
4.3 Discussion 
In this part of the thesis, I showed that p$L-driven signalling mediates many of the 
defects seen in rad$% mutant zebraﬁsh, including sex reversal and WKM hypocellularity 
and that co-mutation of p$R can rescue many, but not all, of the observed abnormalities.  
When considering the expression of p$R, I found an increase in the developing nervous 
system. This ﬁts with the small eye and head phenotype observed upon irradiation. It 
also agrees with the frequent micropthalmia/microcephaly, as well as occasional mental 
disability seen in FA patients in the clinic%m and similar symptoms seen in mouse 
modelsL$l,Ll]. This is most likely due to the rapid proliferation of cells in the developing 
nervous systemYmQ. Curiously, in adult WKM, p$R expression was consistently decreased, 
which is very counterintuitive at ﬁrst glance. A similar phenotype was observed in LigS 
mutant mice, which develop BM hypocellularity and a hyperproliferative phenotype of 
the HSPCs to compensate for this%YY. I believe that the most likely explanation for this 
downregulation is the need to suppress further p$L signalling to maintain kidney 
homeostasis, i.e. to generate enough blood cells to stay alive. Interestingly, my RNA-Seq 
results presented in the previous chapter suggest that p$L-driven signalling might still 
be upregulated in certain subsets cells enriched for HSPCs in the WKM. It may well be 
the case that decreased p$L signalling is necessary for the survival of the more mature, 
rapidly dividing progenitor cells, but this is speculative. It is unclear how this diﬀerential 
expression between the diﬀerent blood lineages is regulated. Furthermore, the 
limitations of my RNA-Seq experiment should be taken into account when interpreting 
these ﬁndings. 
I then went on to generate rad$%, p$R double mutants. I observed that the sex reversal 
and haematopoietic defects were rescued in these ﬁsh, whereas the small size and 
infertility of males were not rescued. In addition, double mutants developed tumours at 
a high rate. 
The rescue of sex reversal, but not of infertility is equivalent to what has been observed 
in brca> and brca>, p$R mutant ﬁshLPL,LPY and is due to the premature apoptosis of 
oocytes, coupled to defective meiosis in immature sperm cells. Interestingly, fancl 
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mutant zebraﬁsh also display sex reversal that can be rescued upon p$R co-mutation, 
but the mutant males are fertile due to their intact meiosisLPX. This demonstrates the 
necessity of the FA proteins for zebraﬁsh sex development and that they are dispensable 
for meiosis. In contrast, Rad$% is required for both sex development, as well as meiosis. 
Infertility is also a common symptom of FA%m and it is intriguing to speculate whether 
some of these cases are due to meiotic defects in the germ cells, at least where FA genes 
are mutated that also function in HR. However, due to the diﬀerences in sex 
determination between humans and zebraﬁsh, the applicability of these results to 
humans remains to be explored. 
I also showed that rad$%, p$R mutant ﬁsh develop malignant peripheral nerve sheath 
tumours. This is the same kind of tumour commonly found in p$R single mutantsLP$ and 
brca>, p$R double mutantsLPL,LPY,Yll. In contrast to single mutants, double mutants 
developed the tumours much earlier, starting at $ mpf. The ﬁrst tumours in single 
mutants have been reported to arise from %Q mpf onwards, rising to about LQ% incidence 
at %P.$ mpf LP$, whereas the rad$%-/-, p$R-/- ﬁsh reached this rate at l mpf. This shows that 
loss of rad$% can speed up tumour development and demonstrates its role as a tumour 
suppressor gene. Interestingly, two out of three of the tumours I observed were found 
in ovarian tissue, which agrees with ﬁndings on brca> knockout ﬁshLPL,LPY,Yll. BRCA%/> 
are well known ovarian cancer predisposition genesYm%,YmX. Furthermore, the RAD$% 
paralogues RAD$%B, C and D have also been implicated as risk factors for ovarian 
cancer%XX,YmL,YmY. Some studies have found a correlation between RAD$% polymorphisms 
and ovarian cancerYm$, whereas a more robust meta-analysis found no correlationYmP. My 
data suggests that another look at hypomorphic RAD$% alleles and ovarian cancer risk 
may be warranted. Overall it is clear however, that defects in the repair of doubles 
stranded breaks play an important role in the development of ovarian cancer. 
In terms of haematological features, co-mutation of p$R rescued HSC numbers in 
embryos. This translated to normal WKM cell numbers during adulthood, as well as 
normalised proliferation rates. These ﬁndings provide further evidence for the work 
presented by Ceccaldi et al. in XQ%X%LL, who proposed a model in which excess p$L 
signalling during embryonic development leads to the later defects in FA. The 
normalisation in proliferation suggests that the increased cycling in rad$% single mutants 
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is indeed to compensate for lower WKM cellularity, rather than due to increased 
unrepaired DNA damage. This is as p$R co-mutation normalised WKM cellularity, but 
should have no inﬂuence on the amount of damage a cell receives. My results clearly 
show that embryonic abnormalities lead to decreased HSC counts in FA patients, rather 
than just depletion after birth caused by stressors such as DNA damage. 
My conclusions disagree with the ﬁndings reported by Yoon et al.%L], who proposed that 
p$L-driven pathways play little to no role in FA pathogenesis and that pLl MAPK 
inhibition can stimulate FA HSC engraftment after transplantation. While it is plausible 
that MAPK inhibition could alleviate engraftment defects (in particular since pLl is a 
known regulator of HSC metabolism and proliferationYm]), the data presented showing 
no involvement of p$L was unconvincing. The authors concluded the irrelevance of p$L 
on the basis that the two downstream target genes they investigated (Puma and Noxa) 
were unchanged. Furthermore, they claimed that HSC proliferation was not impaired 
based on very broadly labelled haematopoietic cells, potentially missing proliferation 
defects in actual stem cells. Overall, I ﬁnd the evidence from genetic ablation of p$L to 
be more convincing. 
Finally, I considered the role of p$L on its own in HSPC numbers, showing that p$R 
mutation can increase the number of embryonic HSPCs and neutrophils, but does not 
aﬀect WKM cell numbers during adulthood. This is in agreement with work on murine 
models, in which loss-of-function (LOF) mutations of p$R led to two- to threefold 
increases in the number of HSCs, which were however functionally impairedYPL,Y]X,Y]L. 
Conversely, hyperactivation of p$L can lead to decreased HSC numbers in aged mice%YL. 
It is unclear why only embryonic HSPCs and neutrophils were aﬀected, but no other 
lineages. Together, this underscores the vital role p$L plays in the regulation of HSC 
number and activity. It also highlights potential diﬀerences between embryonic and 
adult haematopoiesis. 
In conclusion, my results conﬁrm previous in-vitro work implicating p$L in FA 
pathogenesis in an in-vivo context, as well as highlighting its general role in 
haematopoiesis.
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5 BMF in FA: initial triggers 
5.1 Introduction 
After investigating the signalling pathways that lead to apoptosis and senescence in FA 
cells, I focussed my attention on the initial causes of these signals. As alluded to in earlier 
parts of this thesis, there are many hypotheses as to why the bone marrow fails in FA. 
Essentially, every molecular abnormality seen in FA cells has been proposed as the cause 
for the progressive BM dysfunction that most FA patients eventually succumb to. In this 
study, I explore two of the major hypotheses, which are almost complete opposites. On 
one hand we have inﬂammation, which has been proposed to drive HSC proliferation 
and thereby cause their eventual exhaustion. On the other hand, there is aldehyde-
induced DNA damage, which is thought to induce senescence and apoptosis of HSCs. I 
will discuss previous work on both hypotheses in turn, followed by an experimental 
investigation into both.  
5.1.1 Inflammation in FA pathogenesis 
The term inﬂammation describes the biological reaction in response to a disruption in 
tissue homeostasis%P]. Inﬂammation commonly includes tissue destruction and 
recruitment of blood constituents (plasma protein, ﬂuid and leukocytes) into perturbed 
tissues. The entry of cells into the tissue is mediated via changes in the vasculature. 
These include vasodilation, increased permeability of the vascular system and increased 
blood ﬂow. In combination, this leads to the classical symptoms of local inﬂammation, 
as already deﬁned by Galen: calor, dolor, rubor, tumour (heat/fever, pain, reddening and 
swelling)Yml.  
The main causes of inﬂammation are infection, injury, trauma and exposure to foreign 
particles (e.g. ﬁne dust in the lung leading to chronic inﬂammation)Yml. It is not 
completely clear why diﬀerent stimuli such as infection and traumatic injury should give 
rise to very similar responses. There are two hypotheses as to why that might be the case. 
The ﬁrst proposes that infections often follow traumatic injury, so it would be favourable 
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to respond to any injury with inﬂammationYmm. The other suggests that pathogens and 
wounding just trigger similar molecular signalling pathways$QQ. 
There are several steps in the inﬂammatory response, which have been highly conserved 
during evolutionYml. First, pathogen-associated molecular patterns (PAMPs) are 
recognised by cells at the site of infection. Next, these cells release alarmins or danger-
associated molecular patterns (DAMPs), which alert the innate immune system. 
Immune cells start producing inﬂammatory cytokines, such as interleukin (IL)%b, ILP or 
tumour necrosis factor (TNF)α. Molecules like these lead to the recruitment of 
neutrophils, monocytes and other cells to the site of infection. At the site of infection, 
neutrophils create a cytotoxic environment by degranulating, which leads to the release 
of ROS and reactive nitrogen species (RNS), as well as proteinases. In this environment, 
both host and invading cells are killed or attenuated. Macrophages remove infected host 
cells and invaders. Normally, inﬂammation is resolved once the immediate cause has 
been removed. If this does not happen, unregulated inﬂammation can lead to unwanted 
side eﬀects, including collateral damage to the tissue and pathological changesYml. 
5.1.1.1 The effects of inflammation on HSCs 
One of the major characteristics of inﬂammation is that more eﬀector cells are needed 
at the site of tissue injury. This means that haematopoietic progenitors have to cycle 
more to provide a suﬃcient number of cells to ﬁght oﬀ injection. It has recently been 
shown that HSCs are directly aﬀected by inﬂammatory signalling$Q%. Among others, 
interferons, IL%, TNF, Toll-like receptor (TLR) -ligands and G-CSF can stimulate 
proliferation and diﬀerentiation of HSCs$Q%–$QY, which can come at the expense of HSC 
self-renewal$Q$. It has been shown that HSCs are negatively aﬀected when they leave 
quiescence in the sense that they gradually lose their functionality every time they are 
activatedYX%. This is why chronic inﬂammation may be deleterious to HSCs – the excess 
cycling can bring them out of quiescenceP$,%LY,$QP and lead to p$L-dependent apoptosis 
even in WT cells$QY. Moreover, FA cells are also thought to be both more sensitive to 
inﬂammation, as well as to express more inﬂammatory cytokines. In addition to 
becoming less functional with each division, they are aﬀected even more strongly, as 
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they cannot repair DNA damage that accumulates during DNA replicationP$,%LY,$QP. Both 
of these aspects are discussed in turn below. 
5.1.1.2 Cytokine hypersensitivity 
There is substantial evidence that FA cells react excessively to inﬂammatory stress 
mediated via pro-inﬂammatory cytokines. Previous research has especially focussed on 
the role of TNFα and interferon gamma (IFNγ). In cell culture experiments, TNFα can 
elicit cytotoxicity%Pl,$Q] and can induce apoptotic and necrotic cell death%Q,$Ql,$Qm. The 
FANCC protein has been implicated in regulating the apoptotic response to TNFα and 
Fas ligand%Pl. Furthermore, it has been implicated in regulating protein kinase R 
activation, as well as interacting with HSP]Q and STAT%, which plays an important role 
in IFN signalling%Pm,$Q],$%Q. 
Apart from this in-vitro evidence for cytokine hypersensitivity, there has also been 
considerable work done on animal models. Inﬂammatory stress induced by pI:pC can 
induce BMF in FA miceP$,%LY. Similar results can be obtained by using the vaccine 
adjuvant alum, which triggers repeated emergency granulopoiesis leading to BMF in FA 
mice$%%, as well as with TNFα$%X and IFNγ$%L. Increased TNFα also induces leukaemic 
clonal evolution in murine FA stem cells upon transplantation$%Y, demonstrating the role 
of inﬂammation in the development of malignancies. 
5.1.1.3 Cytokine overproduction 
Macrophages derived from the BM of FA mice have been shown to overproduce TNFα 
and IL%bPL,%]Q. FANCC has been implicated to regulate TNFα production in monocytes 
by suppressing TLRl activity%]%. Moreover, FANCDX can regulate the expression of TNFα 
by binding to its promoter$%$. In a mouse study of FA, it was shown that the LINE-% 
retrotransposon becomes hyperactive in FA, which leads to the accumulation of excess 
nucleic acids in the cytoplasm. These are recognised by receptors that normally sense 
PAMPs, leading to the production of excess inﬂammatory cytokines%]X. Apart from this 
experimental data, there is also support from clinical research suggesting an 
overproduction of inﬂammatory cytokines in FA. Patients express considerably higher 
amounts of TNFα%]L,%]Y,$%P and IL%b$%]. However, in contrast to these studies, Matsui et al. 
did not ﬁnd overproduction of inﬂammatory cytokines in FA patients when their cells 
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were unchallenged. Challenge with lipopolysaccharide (LPS) led to an increase in 
cytokines, but this was also seen in healthy controls, suggesting that cytokine 
overproduction is just a general feature of BM dysfunction and not speciﬁc to FA$%l. In 
agreement with this, irradiation of mice induces high levels of TNFα, which mediates 
apoptosis in the bone marrow that can be rescued upon TNFα co-mutation$%m. 
It is currently disputed whether cytokine hypersensitivity and DNA repair defects are 
linked in FA$XQ, although there is limited evidence that cytokine overproduction and ICL 
sensitivity are unlinked at least in macrophages$X%.  
My results investigating the role of inﬂammation in the pathogenesis in FA suggest that 
increased cytokine sensitivity plays a contributing role in BMF, but intrinsic cytokine 
overproduction does not. These results are described in detail in section $.X.%. 
5.1.2 Aldehydes in FA pathogenesis 
As discussed previously, the main (and best studied) function of the Fanconi pathway is 
the removal of ICLs from DNA. It is uncertain however what damaging agent is the 
predominant cause of ICLs in FA patients. The Patel group in Cambridge has 
accumulated considerable evidence in the past few years that the main damaging 
molecules are small aldehydes. This section will deal with the diﬀerent types of 
aldehydes relevant to biology and how they might contribute to FA pathogenesis. 
5.1.2.1 Sources of aldehydes 
Aldehydes are ubiquitous molecules deﬁned by their reactive aldehyde functional group. 
They can be reduced to alcohols or oxidised to organic acids. They are a very diverse 
group of molecules, found in nature and the chemical industry alike. While a lot of 
aldehydes are safe to ingest and are even found in food, many substances of this class 
are quite toxic due to their reactivity with macromolecules. It is impossible to avoid toxic 
aldehydes completely. Environmental sources, such as motor vehicle emissions, 
cigarette smoke, industrial chemicals and even rainwater contain large amounts of 
aldehydes, in particular formaldehyde and acetaldehyde. Our diet is also a major source 
of aldehydes. Acetaldehyde is found naturally in many fruits and vegetables. 
Cinnamaldehyde gives cinnamon its characteristic fragrance, while benzaldehyde gives 
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almonds their ﬂavour. Many food components become metabolised to aldehydes as well. 
The clearest examples are of course alcohols such as methanol in fruits, which is 
converted to formaldehyde, and ethanol from alcoholic beverages, which is converted 
to acetaldehyde. Other metabolic reactions also lead to acetaldehyde products. Lipids 
may be peroxidised to aldehydes, carbohydrates oxidised to glyoxal or methylglyoxal 
and amines oxidised to various aldehydes. Myeloperoxidase found in neutrophils can 
also catalyse the formation of various aldehydes. Many drugs are already aldehydes or 
may be metabolised to aldehydes. Examples include the HIV drug Abacavir and some 
anticancer drugs that are metabolised to acrolein by PY$Q%Y$. 
5.1.2.2 Aldehyde scavengers 
Due to the ubiquitous nature of aldehydes, a wide range of aldehyde scavenging 
enzymes has evolved. There are nine aldehyde oxidising enzymes, seven aldehyde 
reducing enzymes and three glutathione (GSH) dependent enzymes%Y$.  
Most aldehyde oxidases can be found in the aldehyde dehydrogenase (ALDH) family. 
This includes the slow cytosolic ALDH% and the much faster mitochondrial ALDHX, 
which is often dysfunctional in Asian ethnic groups. Among other things, these enzymes 
process acetaldehyde to acetate. Aldehyde reducing enzymes includes alcohol 
dehydrogenases. Furthermore, there are GSH-dependent enzymes like ADH$, which 
processes formaldehyde%Y$. 
5.1.2.3 DNA damage induced by aldehydes 
Many of these aldehydes are mutagenic and genotoxic. That is because they can form 
various forms of adducts on DNA. The simplest (and best studied) case is acetaldehyde. 
There are two main forms of adducts induced by acetaldehyde on the DNA. One option 
is NX-ethyl-X-deoxyguanosine (NX-ethyl-dG), formed from acetaldehyde and 
deoxyguanosine. However, this adduct is not particularly mutagenic, as it can be 
bypassed by translesion polymerases such as DNAPδ and η, with high ﬁdelity. Another, 
more dangerous adduct is %,NX-propano-X-deoxyguanosine (PdG), which is much more 
mutagenic and genotoxic. PdG can be a precursor for interstrand DNA-DNA or DNA-
protein crosslinks, which are the substrates of the FA pathway. PdG itself can be 
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removed by nucleotide excision repair. Other aldehydes can form similar types of 
adducts in principle$XX. 
5.1.2.4 Evidence for aldehydes as main damaging molecules in FA 
pathogenesis 
FA pathway deﬁcient cells are hypersensitive to both acetaldehyde, as well as 
formaldehyde in culture%X,%Y,%YP,%Y]. Moreover, mutations in fancd> and adh$ (the gene 
encoding for the alcohol dehydrogenase necessary for formaldehyde metabolism) are 
synthetic lethal in chicken DTYQ cells%X. 
Further evidence for the importance of aldehydes in the pathogenesis of FA stems from 
mouse models. Co-mutating Fancd> and Aldh> (acetaldehyde dehydrogenase) results in 
embryonic lethality in Aldh>-/- mothers, but embryos can be carried to term in AldhX+/- 
mothers. However, the surviving Fancd>-/- Aldh>-/- all invariably develop acute 
leukaemia or BMF due to a PQQ-fold reduction in HSPC numbers%Y,%$. Similar results were 
obtained in Fanca-/- Aldh>-/- mice%L. Loss of Adh$ in conjunction with FA mutations led 
to even more serious defects in double mutant mice, with invariable BMF due to a m$Q-
fold reduction in HSPCs%L%. This indicates that several types of aldehydes can induce 
similar damage. 
Lastly, there is also epidemiological evidence for the importance of aldehydes in FA. In 
humans, there are several diﬀerent alleles of ALDH>. In Southeast Asia, a dominant 
negative, inactive isoform of is common. Carriers of this allele show the so-called “Asian 
ﬂushing” syndrome in response to alcohol, as the alcohol can be processed to 
acetaldehyde quickly, but the further metabolism is slow, leading to accumulation of the 
toxic acetaldehyde$XL. FA patients with this form of ALDH> show a more severe 
phenotype, i.e. they have earlier BMF and stronger congenital features%Yl,%Ym. This again 
underlines the importance of the pathway during early development. 
My own results investigating the role of aldehyde-induced DNA damage in-vivo do not 
suggest a major role in the development of BMF. These results are described in detail in 
section $.X.X and the diﬀerence in outcome when compared to the mouse models of 
aldehyde-induced damage is examined in the discussion of this chapter (section $.L). 
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5.2 Results 
5.2.1 Modelling the influence of prolonged inflammation in FA 
5.2.1.1 Establishing a zebrafish model of prolonged inflammation 
To investigate the role of inﬂammation in BMF, I developed a model for prolonged 
inﬂammation in zebraﬁsh. To do this, I ﬁrst selected an appropriate compound to 
induce inﬂammation. In the literature, various molecules are used, but pI:pC appealed 
most to me, as it is very stable, non-toxic and has previously been used successfully to 
induce inﬂammatory stimuli in ﬁsh and other species$XY–$X]. I ﬁrst began by assessing 
the maximum tolerated single dose of pI:pC when intraperitoneally injected into WT 
ﬁsh. I determined that even the highest soluble concentration of pI:pC in PBS (%Q 
mg/ml) is well tolerated by the ﬁsh when %Q µl are injected. In parallel, I began assessing 
the eﬃcacy of the injections in terms of eliciting a robust inﬂammatory response (Figure 
$.%A). I began by looking at the expression of several genes linked to inﬂammation (il%b, 
ilW, tnfa, p$R) in the kidney at P hpi (Figure $.%B). These results revealed a robust 
upregulation of the interleukins, as well as an upregulation of p$R. The expression of 
TNFα was unchanged. Because of this upregulation of inﬂammatory genes, I concluded 
that bolus pI:pC injections are eﬃcacious at triggering inﬂammation in zebraﬁsh. 
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Figure B.(:	A bolus injection of pI:pC can induce the expression of marker genes for inﬂammation. 
(A) Injection scheme for the experiments. Fish were injected with %Q µl %Q mg/ml pI:pC and culled at P 
hpi to extract tissue for qPCR analysis. (B) Expression of inﬂammatory markers in the WKM at P hpi. (i) 
il%b. P = .QQm. (ii) ilW. P = .Q%$. (iii) p$R. P = .QYm. (iv) tnfa. P = .Ll. PBS; n = P, pI:pC; n = P. P-values stem 
from two-sided Student’s t-test and bars represent the geometric mean ± m$% CI in all graphs. 
After establishing that single injections can robustly induce acute inﬂammation, I aimed 
to expand this model to prolonged inﬂammation. My initial test was scheduled to span 
four weeks, with weekly injections totalling to ﬁve rounds of injections, with culling, 
followed by qPCR and FACS analysis three days after the last injection. While the initial 
injections were tolerated well, after four rounds of injections, some ﬁsh started showing 
signs of bleeding and inﬂammation at the site of injection, with two out of ﬁve even 
dying due to the eﬀects of this stress (Figure $.XA). Because of this, the experiment had 
to be stopped early and ﬁsh were culled ﬁve days after the last injection. Again, RNA 
from the WKM and intestine was used for qPCR analysis, showing increases in several 
inﬂammatory markers (Figure $.XB). However, the results were not statistically 
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signiﬁcant, presumably due to the long time between the last injection and obtaining 
the tissue in combination with a decreased number of ﬁsh due to the unexpected deaths. 
Nevertheless, together with the very strong side eﬀects seen in the injected ﬁsh, these 
results were encouraging enough to begin applying my model to the rad$% mutant line. 
 
Figure B.=: Long-term pI:pC injection trial. (A) Outline of the injection schedule. Fish were injected 
with %Q µl %Q mg/ml pI:pC once a week, totalling four injections, followed by culling ﬁve days after the 
fourth injection. In lighter colours, the initially planned experiment is outlined, continuing with a ﬁfth 
injection and culling at three days after the last injection. (B) qPCR analysis of inﬂammatory genes, again 
showing increases in two out of three ﬁsh (i) il%b. P = .Q]X. (ii) ilW, P = .%%. (iii) p$R, P = .%LL. (iv) tnfa, P = .%%. 
All were tested using a two-sided Student’s t-test, nNI = Y, nI = L. Bars represent the geometric mean ± m$% 
CI in all graphs, except for Bi and ii, where the m$% CI is too large to be displayed without skewing the 
graph.  
5.2.1.2 Prolonged inflammation exacerbates the phenotype of rad51 mutant 
fish 
I modiﬁed my injection schedule to take into account the severe side eﬀects seen during 
the ﬁrst trial, leading to a schedule of four weekly injections followed by culling three 
days after the last injection (Figure $.LA) (i.e. one injection fewer than planned before). 
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Overall, the experiment consisted of four groups: non-injected rad$%+/+ ﬁsh, non-injected 
rad$%-/- ﬁsh, pI:pC injected rad$%+/+ ﬁsh and pI:pC injected rad$%-/- ﬁsh. Following the 
injection period, all ﬁsh were culled. From the dead ﬁsh, I obtained blood smears for 
observing changes in the PB as well as, kidneys for cell counts, FACS and qPCR. 
I conﬁrmed the successful eﬀect of the injections by assessing il%b and ilW expression 
following the experimental schedule outlined in Figure $.LA. Interestingly, both markers 
were decreased upon injection (Figure $.LB), indicating an unexpected downregulation 
of cytokines involved in acute inﬂammation at this time point after injection This was 
in stark contrast to my previous experiments, where I used a bolus pI:pC injection on 
WT ﬁsh and assessed the expression of il%b and ilW at P hpi (Figure $.%). This showed a 
robust response in both WT and mutant ﬁsh (Figure $.LB). Importantly, there was no 
diﬀerence in the expression of inﬂammatory genes between uninjected WT and mutant 
ﬁsh (Figure $.LB).  
 
Figure B.?: Repeated pI:pC injections elicit a diﬀerent inﬂammatory response than single 
injections. (A) Schematic of the experimental design. Both wild type and rad$%-/- ﬁsh were injected every 
seven days with %Q µl %Q mg/ml pI:pC, four injections in total. All ﬁsh were culled three days after the last 
injection. Control ﬁsh were not injected (B) Expression of acute inﬂammatory markers il%b (i) and ilW (ii) 
after my injection schedule. (i) Two-way ANOVA showed a statistically signiﬁcant eﬀect of injection status 
(F (%, LX) = %].], P = .QQQX), but not of mutation status (F (%, LX) = %.m], P = .%]), or an interaction between 
the two (F (%, LX) = .Yl$, P = .Ym). (ii) Two-way ANOVA showed a statistically signiﬁcant eﬀect of injection 
status (F (%, LX) = LX.]Y, P < .QQQ%), but not of mutation status (F (%, LX) = .XP, P = .P%, or an interaction 
between the two (F (%, LX) = %.$$, P = .XX). In both graphs, P-values shown stem from post-hoc Tukey 
multiple comparison tests. rad$%+/+, nNI = %Q, nI = m; rad$%-/-, nNI = l, nI = m. Bars represent the geometric 
mean ± m$% CI. 
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To assess changes in the PB, I obtained blood smears during the culling. Slides were then 
blindly scored for the diﬀerent blood lineages (See example images in the panels labelled 
“i” in Figure $.Y for examples of diﬀerent blood cell types scored). This showed a 
statistically signiﬁcant increase in monocytes upon injection in both WT and mutant 
ﬁsh (Figure $.YA). There were no changes in the other blood lineages considered (Figure 
$.YB-D).
 
Figure B.@: Prolonged inﬂammation leads to an increase of monocytes in the PB. (A) Changes in 
the monocytes. (i) Example pictures of cells scored as monocytes. Visible are large cells, with large nuclei. 
They occasionally contained large vacuoles in the cytoplasm. (ii) Quantiﬁcation of monocytes in the PB. 
Two-way ANOVA revealed an inﬂuence of injection status (F (%, L%) = P.lm], P = .%LL), but no inﬂuence of 
mutation status (F (%, L%) = .%L, P = .]X) or an interaction between these factors (F (%, L%) = .%l, P = .P]). (B) 
Changes in the neutrophils. (i) Example pictures of cells scored as neutrophils. Visible are large cells with 
a normally multi-lobed nucleus. (ii) Quantiﬁcation of neutrophils in the PB. Two-way ANOVA found no 
statistically signiﬁcant diﬀerence between the groups in terms of injection status (F (%, L%) = X, P = %].), 
mutation status (F (%, L%) = %.Y, P = .XY), or an interaction between the two (F (%, L%) = .mm, P = .LL). (C) 
Changes in the lymphocytes. (i) Example pictures of cells scored as lymphocytes. Visible are small cells 
with large nuclei. (ii) Quantiﬁcation of lymphocytes in the PB. Two-way ANOVA found no statistically 
signiﬁcant diﬀerence between the groups in terms of injection status (F (%, L%) = %%, P = .]Y), mutation 
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status (F (%, L%) = X.%P, P = %$.), or an interaction between the two (F (%, L%) = .X], P = .P%). (D) Changes in 
the eosinophils. (i) Example pictures of cells scored as eosinophils. Visible are large cells with a 
comparatively small nucleus and a strongly stained, granular cytoplasm. (ii) Quantiﬁcation of eosinophils 
in the PB. Two-way ANOVA found no statistically signiﬁcant diﬀerence between the groups in terms of 
injection status (F (%, L%) = L.PP, P = .QP$), mutation status (F (%, L%) = .X], P = .P%), or an interaction 
between the two (F (%, L%) = .%%, P = .]$). Bars represent mean ± SEM in all graphs. rad$%+/+ nNI = m, nI = l; 
rad$%-/- nNI = l, nI = m. Pictures were taken using a PLX oil immersion objective. Scale bars = %Q µm. 
For the FACS analysis, I used standard gating that allows one to diﬀerentiate between 
the diﬀerent blood lineages in the kidneyL]] (Figure X.Y), with slight modiﬁcations from 
the original procedure to account for monocytes and HSPCs. This gating was similar to 
the one used for my RNA-Seq experiment discussed previously (see section L.X.L.m for 
details). The FACS results were then combined with absolute cell counts of the WKM, 
to obtain an estimate of the absolute number of each investigated blood lineage (Figure 
$.$A). 
Interestingly, WT ﬁsh expanded their monocyte population at the expense of the 
erythrocytes, whereas rad$%-/- ﬁsh displayed a decrease in erythrocytes without being 
able to increase the monocytic population (Figure $.$A). In agreement with this, WT 
ﬁsh increased the expression of the monocyte markers marco and csfr% in the WKM upon 
injection (Figure $.$B).  
Furthermore, overall kidney cellularity was decreased upon pI:pC injection in rad$% 
mutants, but not in WT ﬁsh (Figure $.$C). This shows that prolonged inﬂammatory 
stress can indeed exacerbate the kidney hypocellularity of the mutant ﬁsh even further, 
providing further evidence for the role of inﬂammation in BMF of FA patients.  
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Figure B.B: Prolonged inﬂammation leads to an exacerbation of the mutant phenotype. (A) 
Absolute number of cells belonging to diﬀerent blood lineages in the kidney gained by combining FACS 
data with the cell counts shown in A. Statistical tests were carried out individually for each cell type, using 
two-way ANOVA. P-value shown on the graph stems from a post-hoc Šidak multiple comparison test, 
comparing non-injected to injected ﬁsh within each genotype. rad$%+/+, nNI = %Q, nI = m; rad$%-/-, nNI = l, 
nI = m. Erythrocytes: There was a signiﬁcant eﬀect of injection status (F (%,LX) = %L.PP, P = .QQQl), a 
signiﬁcant eﬀect of mutation status (F (%,LX) = $.m, P = .QX%), but no signiﬁcant interaction between the 
two (F (%,LX) = .Qm, P = .]]). Progenitors: There was a signiﬁcant eﬀect of mutation status (F (%,LX) = %$.QY, 
P = .QQQ$), but not of injection status (F (%,LX) = .$Y, P = .Y]) or an interaction between the two 
(F (%,LX) = .XY, P = .PL). Myeloid cells: There was a signiﬁcant eﬀect of injection status (F (%,LX) = m.Y, 
P = .QQY), a signiﬁcant eﬀect of mutation status (F (%,LX) = %L.lY, P = .QQQl), but no signiﬁcant interaction 
between the two (F (%,LX) = .QQ], P = .mL). Monocytes: There was a signiﬁcant eﬀect of injection status 
(F (%,LX) = Y.P], P = .QLl), a signiﬁcant eﬀect of mutation status (F (%,LX) = %%.LP, P = QQX.), but no 
signiﬁcant interaction between the two (F (%,LX) = X.lm, P = .Qml). Bars represent mean ±SEM. (B) 
Expression of the monocyte/macrophage markers csf%r (i) and marco (ii) in the WKM. (i) Expression of 
csf%r. Two-tailed ANOVA showed a statistically signiﬁcant eﬀect of injection status (F (%, LX) = LP.]Y, 
P < .QQQ%), but not of mutation status (F (%, LX) = .LL, P = .$]) or an interaction between these factors (F (%, 
LX) = L.L], P = .Q]P). (ii) Expression of marco. Two-tailed ANOVA showed a statistically signiﬁcant eﬀect 
of injection status (F (%, LX) = ]%.lY, P < .QQQ%), but not of mutation status (F (%, LX) = %P, P = .Pm) or an 
interaction between these factors (F (%, LX) = X.%, P = .%P). (C) The total number of cells in the kidney in 
injected and non-injected ﬁsh. Two-way ANOVA was carried out on the reciprocal of the data to fulﬁl the 
requirement of homoscedasticity as measured by Bartlett’s test (before transformation: P = .QQQX, after 
transformation: P = .Qm$). There was a statistically signiﬁcant eﬀect of mutation status (F (%, LX) = Xm.lP, 
P < .QQQ%) and of injection status (F (%, LX) = P.]]l, P = .Q%Y), but not due to an interaction between the 
two (F (%, LX) = X.m$, P = .Qm$). P-value shown on the graph stems from a post-hoc Tukey multiple 
comparison test. For all groups, n is the same as in A. Bars represent mean ± SEM in all graphs. 
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As I previously saw that the WKM hypocellularity was caused by p$R-driven defects, I 
investigated the expression of p$R and its downstream partner p>% in the WKM (Figure 
$.PA). This showed that as before, p$R was decreased in the rad$%-/- ﬁsh before pI:pC 
injection. However, upon pI:pC injection, p$R was massively upregulated exclusively in 
the mutants. A similar pattern was apparent for p>%, albeit not to the same degree. Cell 
viability as measured by PI incorporation during FACS were decreased to the same 
degree upon pI:pC injection in both WT and mutant ﬁsh (Figure $.PB). This indicated 
to me that p$R-driven cell cycle arrest combined with a lot of monocytes leaving the 
WKM was the main driver of WKM hypocellularity in the rad$% mutants upon 
inﬂammation.  
 
Figure B.E: The pB? pathway responds diﬀerently to prolonged inﬂammation in WT and mutant 
ﬁsh. (A) Relative expression of genes linked to apoptosis and proliferation. (i) Expression of p$R. Two-
way ANOVA showed a signiﬁcant inﬂuence of injection status (F (%, LX) = %l.%P, P = .QQQX) and of an 
interaction between mutation status and injection status (F (%, LX) = X$.mm, P < .QQQ%), but not of mutation 
status on its own (F (%, LX) = %.l%, P = .%m). (ii) Expression of p>%.Two-way ANOVA showed a signiﬁcant 
inﬂuence of mutation status (F (%, LX) = l.%$L, P = .QQQL) and of an interaction between mutation status 
and injection status (F (%, LX) = Y.mP, P = .QLL), but not of injection status on its own (F (%, LX) = .]m, P = .Ll). 
P-value shown on the graphs stems from a post-hoc Tukey multiple comparison test. Bars represent 
geometric mean ± m$% CI. (B) Viable cells as determined by PI-staining. Two-way ANOVA revealed a 
signiﬁcant inﬂuence of injection status (F (%, LX) = %QQ.%, P < .QQQ%), but not of mutation status (F (%, 
LX) = .Q%m, P = .ll) or an interaction between the two (F (%, LX) = .QY%, P = .lY). P-values on the graph stem 
from a post-hoc Tukey multiple comparison test. Bars represent mean ± SEM. Numbers are the same as 
in Figure $.$. 
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To test this hypothesis, I conducted another long-term, pI:pC injection experiment, but 
this time I co-injected BrdU (Figure $.]A). Due to constraints in ﬁsh numbers, only three 
groups were used: non-injected rad$%+/+ ﬁsh, pI:pC injected rad$%+/+ ﬁsh and pI:pC 
injected rad$%-/- ﬁsh. During the injection round one day before culling, BrdU was co-
administered as appropriate. Interestingly, pI:pC administration had no eﬀect on 
proliferation rates in WT ﬁsh (Figure $.]B). Furthermore, the results demonstrate that 
even one pI:pC injection was enough to decrease the normally increased proliferation in 
the kidney of rad$%-/- ﬁsh (apart from one outlier demonstrating the normally increased 
proliferation), a change that was maintained after multiple injection rounds. This shows 
that the further reduction in WKM cell numbers was indeed driven by decreased 
proliferation caused by exacerbated p$L/pX% signalling.  
 
Figure B.K: Prolonged inﬂammation can abrogate the excess proliferation in the mutant WKM. 
(A) Injection scheme for determining cell proliferation in pI:pC injected ﬁsh. The experiment was started 
with a cohort of LP WT and %l mutant ﬁsh. %X WT were injected with PBS, %X with pI:pC, P with PBS+BrdU 
and P with pI:pC+BrdU. %X mutants were injected with pI:pC and P with pI:pC+BrdU. On the next day, 
the BrdU co-injected ﬁsh were culled and analysed. On day ], P WT were injected with PBS, P with pI:pC, 
P with PBS+BrdU and P with pI:pC+BrdU. P mutants were injected with pI:pC and P with pI:pC+BrdU. On 
the next day, the BrdU co-injected ﬁsh were culled and analysed. On day %Y, P WT ﬁsh were injected with 
PBS and P with pI:pC. P mutants were injected with pI:pC. On day X%, the same ﬁsh were injected again 
with the same substances and BrdU. All remaining ﬁsh were culled the next day and analysed. (B) 
Percentage of BrdU+ cells in the WKM of wild type (WT) and knockout (KO) ﬁsh in response to pI:pC. 
%I = one injection, XI = two injections, YI = four injections. Bars represent mean ± SEM. Numbers are 
outlined in A. 
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5.2.2 Modelling the role of acetaldehyde-induced damage in FA 
5.2.2.1 Acetaldehyde dose estimation 
I ﬁrst established that WT zebraﬁsh can tolerate doses up to %Q µl %Q% acetaldehyde 
intraperitoneally, albeit showing redness at the site of injection and abdominal muscle 
contractions up to ﬁve minutes after the injection, in combination with signs of stress. 
However, after that initial period, injected ﬁsh generally showed no further impairments. 
5.2.2.2 Aldehyde-derived stress in rad51 mutant zebrafish 
In an initial experiment, I injected nine WT and eight mutant ﬁsh with %Q µl %Q% 
acetaldehyde each. The WT ﬁsh generally tolerated the injections well. The mutants on 
the other hand showed drastic side eﬀects right after injection, including extreme 
arching of the back, bleeding in the abdomen and clear signs of distress and pain. Two 
ﬁsh immediately succumbed to the side eﬀects caused by the injection. Of the remaining 
six mutant ﬁsh, all but one died or had to be culled due to symptoms breaching the 
constraints of the Home Oﬃce licence this work was performed under, whereas only 
one WT had to be culled. This showed that rad$% mutants are more susceptible to the 
acute toxicity of acetaldehyde than their WT siblings. 
Because of the striking symptoms displayed by the injected mutants, I decided to 
drastically limit the dose of injected acetaldehyde for the next experiment. I repeated 
the same injection schedule as for prolonged inﬂammation, but substituted pI:pC with 
%Q µl %% acetaldehyde (Figure $.lA). Out of eight injected WT ﬁsh, none died and out of 
nine injected mutants, only one had to be culled due to adverse eﬀects. After four rounds 
of injections, the ﬁsh were culled and the kidney dissected for WKM cell counts, FACS 
and qPCR analysis. The results were then compared to those obtained from non-injected 
control ﬁsh from the same clutch.  
The number of cells in the diﬀerent blood lineages was not aﬀected in the mutants upon 
injection (Figure $.lB) and neither was overall WKM cellularity (Figure $.lC), whereas 
WT ﬁsh displayed increased numbers in all lineages (Figure $.lB and C). Cell viability, 
however, was lowered in both WT and mutant ﬁsh upon acetaldehyde injection (Figure 
$.lD). The levels of p$R transcription were unaﬀected (Figure $.lE). Overall, these data 
5 — BMF in FA: initial triggers 
	
	 145 
suggest that prolonged acetaldehyde-mediated stress does not aﬀect mutants more than 
their WT siblings, at least where haematological cells are concerned. 
 
 
Figure B.O: Mutation in rad$% does not lead to acetaldehyde sensitivity. (A) Schematic of the 
experimental design. Both wild type and rad$%-/- ﬁsh were injected every seven days with %Q µl %% 
acetaldehyde, four injections in total. All ﬁsh were culled L days after the last injection. Control ﬁsh were 
not injected. (B) Absolute number of cells belonging to diﬀerent blood lineages in the kidney gained by 
combining FACS data with the cell counts shown in A. Statistical tests were carried out individually for 
each cell type, using two-way ANOVA. Erythrocytes: There was a statistically signiﬁcant inﬂuence of 
injection status (F (%,LX) = %L.Pl), P = .QQQl), mutation status (F (%,LX) = %%P.X), P < .QQQ%) and an 
interaction between the two (F (%,LX) = %Y.m%), P = .QQQ$). Progenitors: There was a statistically signiﬁcant 
inﬂuence of injection status (F (%,LX) = %%.Pl), P = QQ%].), mutation status (F (%,LX) = Ym.YP), P < QQQ%.) and 
an interaction between the two (F (%,LX) = %X.Ym), P = .QQ%L). Myeloid cells: There was a statistically 
signiﬁcant eﬀect of mutation status (F (%,LX) = L].Y), P < .QQQ%) and of an interaction between mutation 
and injection status (F(%,LX) = m), P = .QQ$X), but not of injection status on its own (F (%,LX) = %.ml), P = .%]). 
Monocytes: There was a statistically signiﬁcant inﬂuence of injection status (F (%,LX) = %P.%Y), P = .QQQL), 
mutation status (F (%,LX) = Yl.QX), P < .QQQ%) and an interaction between the two (F (%,LX) = %%.Pl), 
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P = .QQ%]). P-value shown on the graph stems from a post-hoc Šidak multiple comparison test, comparing 
non-injected to injected ﬁsh within each genotype. For all groups, n is the same as in A. (C) The total 
number of cells in the kidney in injected and non-injected ﬁsh. Statistical testing was carried out using 
two-way ANOVA. There was a statistically signiﬁcant eﬀect of mutation status (F (%, LX) = m%.X, P < .QQQ%) 
and of injection status (F (%, LX) = %X.Xm, P = .QQ%Y), as well as the interaction between the two (F (%, 
LX) = %l.Ym, P = .QQQ%). P-value shown on the graph is from a post-hoc Tukey multiple comparison test. 
(D) Viable cells as determined by PI-staining. Two-way ANOVA revealed a signiﬁcant inﬂuence of 
mutation status (F (%, LX) = X].Y], P < .QQQ%), as well as injection status (F (%, LX) = L$.Xl, P < .QQQ%), but 
not of an interaction between the two (F (%, LX) = L.%%, P = .Ql]). P-values on the graph stem from a post-
hoc Tukey multiple comparison test. Bars represent mean ± SEM in B, C and D. (E) Relative gene 
expression of p$R. Two-way ANOVA revealed a signiﬁcant inﬂuence of mutation status (F (%, LX) = %P.P], 
P = .QQQL), but not of injection status (F (%, LX) = .Ym, P = .Ym) or an interaction between these factors (F (%, 
LX) = .mX, P = .LY). Bars represent geometric mean ± m$% CI to estimate fold changes. For all graphs, 
rad$%+/+, nNI = m, nI = l; rad$%-/-, nNI = %Q, nI = m. 
5.2.2.3 Alcohol-derived stress in rad51 mutant embryos 
After establishing that aldehyde-derived stress does not play a role in BMF of adult ﬁsh, 
I also considered the eﬀect of similar stress on embryonic development. This was done 
as the main impairments of FA have been proposed to happen during early 
development%LL and the major works studying aldehyde-induced stress utilised genomic 
deletion of aldehyde dehydrogenase, leading to early embryonic death%L–%$,%L%. To estimate 
the eﬀect of aldehyde-induced stress on embryonic rad$% mutants, I treated incrosses of 
rad$%+/- parents with varying concentrations of alcohol. EtOH rather than acetaldehyde 
itself was chosen, as it is metabolised to acetaldehyde and not as volatile as that chemical, 
making the treatment of embryos safer and concentration in solution more consistent. 
Embryos were transiently treated with EtOH and left to recover until Y dpf. At this point, 
pictures were taken, the embryos genotyped and blindly scored. I found that EtOH 
treatment decreases the overall length of the embryos slightly (but statistically 
signiﬁcantly). However, this eﬀect was not inﬂuenced by genotype (Figure $.m). This 
result indicates that while aldehyde mediated damage is harmful to the developing 
embryo, it does not aﬀect rad$% mutants more than their WT siblings. 
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Figure B.Q: Ethanol does not aﬀect rad$% mutant embryos more strongly than their WT siblings. 
(A) Example images of untreated and EtOH treated WT and mutant embryos taken at Y dpf. EtOH was 
added at %.$% between Y and XY hpf. (B) Size measurements of the embryos. The data stems from three 
separate clutches, which were divided into a treatment and a non-treatment group. Each clutch consisted 
of $Q embryos in total. The points plotted represent the mean of that genotype in that condition. Two-
tailed ANOVA showed a statistically signiﬁcant eﬀect of EtOH treatment (F (%, l) = %P.]$, P = .QQY), but 
not of mutation status (F (%, l) = .PX, P = .YP) or an interaction between these factors (F (%, l) = .QmL, 
P = .]]). Bars represent mean ± SEM. Magniﬁcation = %PX. Scale bars = % mm. 
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5.3 Discussion 
In this section of the thesis, I focussed on the eﬀect of inﬂammation- and aldehyde-
induced stress on rad$% mutant ﬁsh, to explore the role of these factors in BMF in FA 
patients. I ﬁrst established an injection scheme for prolonged inﬂammation, which I 
then applied to my mutant model. Subsequently, I adapted this injection schedule for 
acetaldehyde to study the role of aldehydes in FA pathogenesis. 
My results showed that inﬂammation can further exacerbate the haematological 
phenotype of rad$% mutants, driven by p$L-mediated signalling. This ﬁts with previous 
publications, which showed that repeated pI:pC injections can cause BMF in FA mouse 
modelsP$,%LY. In line with the published literature, WT ﬁsh were able to respond to 
inﬂammation by increasing the production of monocytes/macrophages, which was 
stimulated by pI:pC and is associated with chronic inﬂammation$Xl. When I challenged 
ﬁsh with a single pI:pC injection, I saw an upregulation of markers of acute inﬂammation 
(il%b and ilW). In contrast, prolonged inﬂammation led to a decrease in these marker 
genes, coupled to an upregulation of monocyte speciﬁc genes (csfr% and marco), ﬁtting 
with the increase in monocytes. These ﬁndings are consistent with chronic 
inﬂammation, in which the inﬂammatory response shifts from granulocytes to 
mononuclear cells such as monocytes$Xm–$L%. Intriguingly, the mutant ﬁsh were unable to 
respond appropriately to inﬂammation and instead displayed a decline in WKM 
cellularity, resembling the early stages of BMF. This strengthens the case for the 
hypothesis that FA HSCs are more sensitive to inﬂammatory stress%Q,P$,%LY,%Pl,$Q]–$Qm,$%%–$%L 
and is further proof for the suitability of rad$% mutant ﬁsh for the study of FA 
pathogenesis. 
Importantly, neither did mutant ﬁsh express more inﬂammatory cytokines than their 
WT siblings when unstimulated, nor did they show a diﬀerent response upon the 
induction of inﬂammation. This shows that diﬀerences in the expression of 
inﬂammatory cytokines are not the deciding factor in the blood abnormalities in FA, 
going against many previously published studiesPL,%]Q,%]%,%]L,%]Y,$%$–$%]. However, my data ﬁts 
well with more recent clinical evidence that saw no diﬀerence in the amount of 
inﬂammatory cytokines produced by FA patient cells when unchallenged. Similar to 
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rad$% mutant ﬁsh, patient-derived cells increased inﬂammatory cytokine production 
upon challenge with LPS, but to the same degree as healthy cells$%l. Overall, my model 
reﬂects this new clinical data well and provides further evidence that it is cytokine 
hypersensitivity, rather than overexpression that is problematic in FA. 
When I checked for other potential reasons for the decrease in WKM cellularity I saw 
an upregulation of p$R in response to inﬂammation exclusively in the mutant ﬁsh, even 
though they downregulate p$R expression when unchallenged. This data provides yet 
more evidence for the hypothesis that p$L is the major driver in HSC attrition in FA 
patients%LL. 
One apparent diﬀerence between my inﬂammation model and the published literature, 
was a lack of increased proliferation in the rad$% mutants upon pI:pC treatment, whereas 
HSC cycling is increased in mouse models of inﬂammation in WT and FA 
miceP$,%LY,$Q%,$QL,$Q$,$QP,$LX. The most important factor contributing to this diﬀerence is that 
I did not enrich for HSCs when looking at the proliferation rate, in contrast to the 
publications using murine models. It is likely that more mature blood progenitors and 
HSCs respond diﬀerently to inﬂammatory stress, especially since the proliferation rate 
is already increased in the mutant. Judging from my data, additional signals to 
proliferate trigger a p$L response leading to apoptosis and exhaustion of proliferative 
progenitors, which is reﬂected in the decreased WKM cell number. This overall decrease 
in cell numbers, as well as the inability to respond appropriately to chronic inﬂammation 
by making more monocytes suggests a HSC defect.  
There are, however, a few limitations to my inﬂammation model. The eﬀect of 
inﬂammation on the PB is hard to ascertain using this method, as blood smears were 
not quantitative enough to yield conclusive data on the changes in the PB. In addition, 
while I improved the original method of estimating blood lineages in the kidneyL]P using 
single-cell RNA-Seq dataL]], the method is still far from exact and can only be viewed as 
a rough approximation of blood lineages in the WKM. In contrast to previous 
studiesP$,%LY, I was unable to elicit complete BMF during the duration of my experiment. 
Further pI:pC injections might have led to complete ablation of the WKM, but due to 
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animal welfare concerns and the limits of the Home Oﬃce licence, I was unable to 
investigate this any further. 
My model might also have applications in the study of inﬂammatory signalling in 
general. Current inﬂammation models using adult ﬁsh are mostly based on infecting the 
ﬁsh with various microorganisms$LL. The pI:pC injection model oﬀers the advantage of 
decreased risk to staﬀ and other ﬁsh in the facility as well as being more well-deﬁned in 
terms of the inducing agent. 
I went on to explore another major hypothesis explaining BMF in FA, the accumulation 
of excess DNA damage stemming from small aldehydes. My results suggest that rad$% 
mutants are not excessively sensitive to aldehyde-induced stress.  
Initial experiments with very high doses of acetaldehyde showed rapid mortality in rad$% 
mutants. However, this is unlikely to be blood-related due to the fast death of the ﬁsh. 
A more likely cause of death is massive necrosis around the site of injection, consistent 
with the bleeding and reddening at the injection site. This was possibly as the high dose 
of acetaldehyde overwhelmed the capacity of metabolising enzymes. 
Next, I modelled prolonged aldehyde-derived stress in adult ﬁsh using repeated 
injections with a lowered dose of acetaldehyde. This experiment showed no diﬀerence 
in the response between WT and mutant ﬁsh, in contrast to previous research proposing 
aldehydes as the main culprit behind BMF in FA. Previous in-vivo studies looking at the 
role of aldehydes employed double knockout mice in FA genes and aldehyde scavenging 
enzymes%L–%$,%L% saw striking defects starting during early embryonic development, 
especially in aldh>-/- mothers. However, my experiment is not directly comparable to the 
ones carried out on mice. Importantly, my ﬁsh were capable of metabolising harmful 
aldehydes (they did not carry aldh mutations) and my experiment was done solely on 
adult ﬁsh, whereas the mice died in utero or shortly after birth. 
To exclude the possibility of diﬀerential aldehyde sensitivity during embryonic 
development and adulthood, I treated rad$% mutant embryos with EtOH. My results did 
not show a diﬀerence between wild types and mutants. From this outcome, it can be 
concluded that on the organismal level, FA patients are not more susceptible to 
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aldehydes. Due to the large number of enzymes that metabolise aldehydes%Y$, it is a 
reasonable assumption that most, if not all, aldehydes are removed before they can cause 
damage to the genome. If that is the case, the results obtained from Aldh> and Adh$ 
knockout mice%L–%$,%L%, while correct, are not necessarily relevant to FA patients, apart 
from rare cases involving patients carrying ALDH> polymorphisms%Yl,%Ym. These results 
are also compatible with in-vitro studies showing higher susceptibility of FA cells to 
aldehyde%X,%Y, but on an organismal level the aldehydes would be removed before causing 
relevant damage. In conclusion, although aldehyde-derived DNA damage cannot be 
removed eﬃciently in FA cells, the burden of aldehyde-induced damage in-vivo does not 
appear to contribute to BMF in a major way. More studies will be needed to determine 
how much DNA damage by aldehydes contributes to the FA phenotypes in “normal” 
patients.  
The main molecular function of the FA pathway is to remove ICLs, as demonstrated by 
the striking eﬀects of crosslinking agents on FA chromosomes. However, mice with FA 
mutations fail to develop BMF%Q,%LQ,Ll],Lll, unless crosslinking agents are artiﬁcially added, 
the protection against metabolic crosslinkers is removed%L–%$,%L% or the HSCs are forced to 
divideP$,%LY. This poses the question of why division and excess DNA damage lead to the 
same outcome. Walter et al. recently proposed a model in which HSC exit from 
quiescence induces DNA damage%LY and causes the death of the cells. It has also been 
shown that quiescent HSCs accumulate DNA damage that is normally repaired upon re-
entry of the cell cycleY]%, probably because quiescent HSCs use more error-prone repair 
mechanisms, such as NHEJ, rendering them more prone to mutagenesisYP$. Other 
groups have shown that increased HSC cycling leads to excess oxidative stress stemming 
from the mitochondria%LY and that replication stress contributes to functional 
impairments in HSCs in generalYQl. It is probable that a lot of this damage cannot be 
repaired in FA cells, leading to senescence or apoptosis. Together, this evidence suggests 
that excess division of FA HSCs in response to haematopoietic stress triggers BMF due 
to unrepairable DNA damage in their genome. This damage might be the direct result 
of proliferation, or be accumulated during quiescence. 
Overall, this chapter conﬁrmed the role of inﬂammatory stress in BMF. In contrast, my 
data does not indicate a role for small aldehydes in BMF aetiology in FA patients.
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6 Discussion 
6.1 Insights into the aetiology of FA 
6.1.1 A model for BMF in FA 
In chapter L, I outlined the generation and characterisation of the ﬁrst zebraﬁsh FA 
model, utilising rad$% knockout ﬁsh. I then exploited this new model system to 
investigate the cause of BMF in FA patients in chapters Y and $. I found that HSC 
numbers are already decreased early in life and that additional haematopoietic stress 
caused by inﬂammation can lead to further decreases in blood cell numbers. In 
combination with the data discussed above, I propose the following model for FA 
pathogenesis (Figure P.%): During embryonic and foetal development, the HSCs in the 
growing organism accumulate DNA damage due to their inability to undergo eﬃcient 
ICL repairYP$. Previous research has implicated small aldehydes in this process%X–
%Y,%L%,%YP,%Y], but my own data does not support this notion. When HSCs leave quiescence 
during periods of high proliferation, as is normal during early development, the p$L 
signalling pathway is triggered due to the previously sustained DNA damage%LL,$LY. It is 
likely that proliferation itself contributes to the increased DNA damage as well%LY,$QP. 
This induces both apoptosis, as well as cell cycle arrest of the HSCs, leading to a lowered 
number of HSCs at birth. Additional haematopoietic stress, such as infections or 
treatment with growth factorsYX%,$Q%–$QY, trigger further HSC division. Intrinsic 
overexpression of inﬂammatory cytokines does not seem to play a role in this process, 
but rather increased sensitivity of the FA HSCs to such stimuli. Eventually, all functional 
HSCs are exhausted, leading to BMF.  
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Figure E.(: Proposed model of FA pathogenesis. In a healthy person (left), a large number of HSCs is 
formed during embryonic and foetal development in the liver. The number of functional HSCs gradually 
decreases during adult life, but is normally suﬃcient to supply enough blood cells to maintain 
homeostasis, except in a disease context. Conversely in FA patients (right), DNA damage during 
embryonic and foetal development triggers an excess p$L response. This has two potential consequences: 
HSCs stop cycling (which seems to be the main mechanism in FA) or they can undergo apoptosis. Because 
of this, people aﬀected by FA start out with a lowered number of HSCs right after birth, which must divide 
excessively to maintain a normal number of mature blood cells. This leads to their premature exhaustion, 
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triggering BMF. Various factors driving HSC division, such as infections, may contribute to the early BMF 
seen in FA suﬀerers.  
6.1.2 Implications for FA patients 
This model has important implications for the development of novel therapeutics to 
treat FA. The early loss of HSCs during foetal development means that treatment aimed 
at conserving the patient’s own haematopoietic system would have to be started very 
early to protect the HSC pool – ideally already during gestation. There is clearly a risk of 
developmental defects when giving drugs so early, but if treatment was started too late, 
the HSC pool may already be too small to be maintained regardless of treatment. The 
model also suggests that the p$L pathway might be an interesting target for therapeutics. 
Inhibitors for p$L are readily available and have been used with success in mouse models 
without increased tumour developmentY]$,$L$, including an application to increase HSC 
numbersY]$. As the potential for side eﬀects when inhibiting the whole p$L pathway, 
especially in patients already at high risk of malignancies, is considerable, downstream 
targets of p$L might be preferable.  
Another important point is that all drugs that induce HSC cycling, such as growth 
factors and androgens, should be avoided if possible. Although data derived from animal 
models should not be used to change treatment regimens on its own, there is 
considerable clinical evidence highlighting the disadvantages of using such drugs. 
Importantly, some studies have cautioned against the use of androgens unless 
unavoidable, as they have been associated with increased liver cancer rates$P,$l, lower 
BMT success following androgen treatmentPQ and most severely earlier BMF$m. There is 
also evidence for severe side eﬀects caused by growth factors. Long-term administration 
of G-CSF has been associated with BM hypoplasia$L and an increased risk of 
haematological malignancies$Y,$$. Furthermore, G-CSF and thrombopoietin had similar 
eﬃcacy in eliciting BMF compared to pI:pC-induced inﬂammation%LY in FA mice. This 
issue highlights the urgent need for novel FA therapeutics. 
In addition to growth factors and androgens, other unnecessary activation of HSCs 
should be avoided in FA patients. However, as even things such as psychosocial stress$LP 
6 — Discussion 
	
	156
or inﬂammation as it occurs during infectionsP$,%LY,$Q$,$%X,$%L,$LY,$L] can trigger HSC 
activation, this is an almost impossible task. 
6.1.3 Limitations and open questions 
There are, however, some limitations to the proposed model. It adequately describes 
why FA patients experience almost universal BMF, but several gaps in our understanding 
of the disease aetiology remain. Importantly, my model does not explain some of the 
congenital features of the disease, such as decreased stature, which were not rescued 
upon p$R co-mutation in my zebraﬁsh model. It also does not address the diﬀerences 
between FA and healthy cells in terms of autophagy, telomere maintenance and other 
cellular pathways described in earlier chapters. It remains to be elucidated to what 
extent, if at all, these abnormalities contribute to BMF in FA. They are likely implicated 
in some of the congenital features of FA that I found to be p$L-independent. In general, 
the connection between BMF and congenital abnormalities has scarcely been explored. 
Increased data on these features will therefore be vital to develop a model that explains 
the whole disease phenotype rather than just the haematopoietic features. 
It is also not certain what the main ICL-inducing agent is and to what extent ICLs are 
necessary to trigger BMF. Genetic knockout models implicate small aldehydes%X–
%Y,%L%,%YP,%Y], but my own work discussed in chapter $ casts doubt on these earlier ﬁndings. 
If the main cause of ICLs was better understood, it might be possible to develop drugs 
speciﬁcally lowering the ICL burden, thereby extending HSC survival without risking 
tumour development.  
Moreover, it is unclear which downstream signalling from p$L is responsible for 
mediating HSC senescence and apoptosis. Some papers have implicated pX%%LL, but this 
is disputed by others%Ll. My own data was unable to rule out pX%-independent causes, 
but the decreased proliferation of HSCs suggests at least some involvement. 
Understanding the downstream signalling from p$L in FA patients will be vital for the 
creation of eﬀective drugs to combat BMF, as these would likely be better drug targets 
than p$L itself.  
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Finally, it is unclear what other factors, such as the genetic background, diet and others, 
determine the timing of BMF. A better understanding of these factors would lead to 
improvements in the ability to predict the course of the disease and possibly enable 
lifestyle changes, leading to a better quality of life and longer survival. 
Apart from the inherent limitations of the model, there is always the question of how 
well data derived from model organisms will ultimately translate to human patients. In 
general, FA mouse models replicate the features of the disease poorly and few show any 
blood abnormalities. Cellular phenotypes (i.e. abnormal signalling, etc.), conversely, are 
reasonably similarL$l,Ll]. Just like the FA mice do not develop BMF, my ﬁsh do not 
develop kidney marrow failure when unchallenged. Nevertheless, they do show several 
haematological phenotypes, making them closer to the human disease than most mouse 
models. However, studies conﬁrming my ﬁndings in patient-derived samples would be 
appropriate wherever practicable. 
Nevertheless, there is strong evidence that data from zebraﬁsh should be very applicable 
to humans. In general, haematopoiesis is remarkably conserved between zebraﬁsh and 
humans, reaching up to mQ% conservation of gene expression in HSPCsL]]. As HSCs are 
the cell type that is ultimately aﬀected in FA, this indicates that cell-based results 
obtained in zebraﬁsh should be highly analogous to the situation in humans. Moreover, 
the Fanconi genes are almost all conservedL$l, highlighting the similarity in terms of ICL 
repair between ﬁsh and humans. Taking both of these ﬁndings together, there is a high 
degree of conservation in both the cellular, as well of the molecular aspects of FA, 
making the model appropriate. 
6.1.4 Future research on my FA model 
I believe my rad$% knockout FA model can be a valuable asset to the FA ﬁeld. They are 
particularly suitable for investigating the relation between embryonic and adult 
phenotypes, as I demonstrated in the preceding chapters.  
In addition to such studies, zebraﬁsh are also ideal organisms for high-throughput 
screening. Their rapid growth, small size and high fecundity makes them very cheap to 
raise in large numbers$Ll,$Lm. Moreover, zebraﬁsh embryos develop externally and as they 
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are aquatic, drugs for screening can simply be added to the culture medium provided 
they are suﬃciently soluble$YQ. Due to their small size, individual embryos can be 
cultured in mP well plates for up to a week of age, allowing automation of the screening 
process$YQ,$Y%. Pigmentation can be stopped during the ﬁrst days of growthL]Q, facilitating 
the readout of ﬂuorescent reporters$YQ,$Y% due to the optic clarity of the embryos. Apart 
from these purely technical considerations, zebraﬁsh embryos are also more similar to 
humans than immortalised cell lines typically used for these kinds of screenL$m. Drugs 
need to pass the epithelium to enter the embryo, where early precursors of the liver and 
nephric system metabolise and excrete the drugs respectively. Other tissues, such as 
blood and nerve cells, exist as well and allow the study of tissue-speciﬁc eﬀects$Y%. In 
combination with available lines labelling HSPCs in the embryo (Tg(cmyb:EGFP)$YX and 
Tg(runx%+>R:mCherry)LLl), the rad$% mutant line could be straightforwardly used to 
screen for molecules that could alleviate the HSC defects during embryonic 
development. After identifying potential targets, it would be easy to rear drug-treated 
embryos to adulthood, to see whether embryonic changes directly translate to beneﬁts 
in adult animals, a great advantage to cell-based high-throughput screens.  
6.2 Looking beyond FA 
Although the main focus of my work was on characterising the molecular basis of FA, 
the rad$% mutation model also allows insight into a range of other molecular processes, 
including the role of Rad$%, and zebraﬁsh sex determination. This model also 
demonstrates some of the advantages of using zebraﬁsh for research purposes in general. 
In this case, their viability without rad$% was vital to carry out my study. Moreover, the 
ease of investigating embryonic development enabled me to directly visualise the 
developing haematopoietic system, which would have been very diﬃcult, if not 
impossible in other organisms.  
6.2.1 A novel system to study Rad51 
As mouse mutants proved lethal when Rad$% was lostXmP,Xm], zebraﬁsh are the only known 
vertebrates that can survive without rad$%. The survival of these zebraﬁsh, while 
puzzling, might yield insights into the diﬀerences in HR between vertebrates. In this 
document, I considered the functional overlap between rad$% and its paralogues in the 
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survival of my ﬁsh, as well as the mechanism of PARP% inhibition. Other potential 
avenues of investigation include the discovery of non-HR pathways involving Rad$% in 
vertebrate cells, as any pathway involving this protein should be dysfunctional. For 
example, RAD$% has been linked to replication fork protection in ICL repair, before it 
functions in HR%%Y. It would be intriguing if the protein turns out to be involved in other 
pathways as well.  
This study also highlighted the role of Rad$% as a tumour suppressor. The HR pathway 
is defective in many diﬀerent types of cancer, including bowel, prostate, breast and 
ovarian cancer$YL. My model could be useful in further understanding the pathology of 
such malignancies, as well as for the discovery of novel drugs targeting these cancers. 
6.2.2 Zebrafish sex determination and meiosis 
My research on the rad$% mutant line corroborated ﬁndings from previous studies, 
showing that successful ICL repair is necessary for the development of female ﬁshLPL,LPY. 
Increased p$L-driven apoptosis causes the death of immature oocytes, leading to 
virilisation of the ﬁshLPL,LPY. In agreement with the other studies, I also saw a rescue of 
the sex reversal phenotype upon p$R co-mutation. It is possible that other interventions 
preventing the apoptosis of germ cells would lead to similar results. Interestingly, 
meiosis only depends on HR, but not ICL repairLPX. Meiotic defects have been described 
for Brca>$YY and FancaY%Q knockout mice, underlining the applicability of these results 
to mammalian systems. The rad$% mutant line is therefore a suitable model to study the 
role of HR and ICL repair in developing germ cells. 
6.3 Conclusion 
In this thesis, I outlined the generation of the ﬁrst viable vertebrate rad$% mutation 
model. During the characterisation of my model, I showed that these ﬁsh develop many 
symptoms resembling the haematological disease Fanconi anaemia. I went on to utilise 
this system to increase our understanding of the underlying molecular biology of this 
disease. My results implicate a hyperactive p$L response during embryonic development 
as the main cause of the illness, exacerbated by haematopoietic stress that induces HSC 
cycling as the cause of BMF. Based on this evidence, I was able to propose a reﬁned 
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model of how mutations in the FA pathway induce BMF in patients. In doing so, I 
contributed to the literature by developing a useful new tool for studying the cellular 
and molecular pathology of FA. In addition to my ﬁndings on signalling pathways 
involved in FA pathogenesis, I was also able to provide further evidence for the role of 
inﬂammation in triggering BMF. Further research will be needed to make full use of this 
model and apply it to the discovery of new treatment options. Apart from the study of 
FA, there are several other possible uses of this ﬁsh line, including the examination of 
the mechanisms underpinning homologous recombination, as well as meiosis. 
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Appendix 
Table A(: Diﬀerentially upregulated genes in the mutant Tg(itga'b:EGFP) GFPlow population. 
Only genes with a P < .QQ% are shown. FC SE = fold change standard error. ENSEMBL IDs correspond to 
the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000088641 grn2 GRN -3.21064 0.77786 0.00004 
ENSDARG00000105300 BX927081.1  -4.99657 1.28691 0.00010 
ENSDARG00000002670 ATG14 ATG14 -5.38033 1.45565 0.00022 
ENSDARG00000020730 smpd4 SMPD4 -5.10361 1.42013 0.00033 
ENSDARG00000014731 cacybp CACYBP -4.44330 1.25307 0.00039 
ENSDARG00000003495 madd MADD -4.41023 1.24480 0.00040 
ENSDARG00000096127 si:dkey-149m13.1  -3.12261 0.88160 0.00040 
ENSDARG00000055722 bco2a BCO2 -2.65119 0.75876 0.00048 
ENSDARG00000086712 si:dkeyp-97b10.3  -4.90511 1.42738 0.00059 
ENSDARG00000075803 slc41a2a SLC41A2 -4.07510 1.20066 0.00069 
ENSDARG00000008976 mdn1 MDN1 -2.10434 0.63501 0.00092 
ENSDARG00000087536 znf407 ZNF407 -4.78222 1.45507 0.00101 
ENSDARG00000030830 cmtr1 CMTR1 -4.74105 1.49232 0.00149 
ENSDARG00000059130 gata1b GATA1 -2.76686 0.87466 0.00156 
ENSDARG00000102436 WIZ WIZ -3.09365 1.00707 0.00213 
ENSDARG00000075140 CR318653.1  -3.85393 1.25457 0.00213 
ENSDARG00000104255 arhgap27 ARHGAP27 -3.74206 1.23763 0.00250 
ENSDARG00000071196 sdprb SDPR -3.96298 1.31854 0.00265 
ENSDARG00000016481 ptpn2a PTPN2 -3.84578 1.29210 0.00292 
ENSDARG00000019529 parp1 PARP1 -2.59181 0.87399 0.00302 
ENSDARG00000103768 si:dkeyp-28d2.4  -3.86105 1.31415 0.00330 
ENSDARG00000080009 bahcc1 BAHCC1 -2.01429 0.68852 0.00344 
ENSDARG00000099521 CU466240.1  -4.42887 1.51911 0.00355 
ENSDARG00000099359 BX649497.2  -3.48374 1.20492 0.00384 
ENSDARG00000104953 stt3a STT3A -3.96841 1.37532 0.00391 
ENSDARG00000094110 si:ch211-284e20.4  -3.33106 1.15556 0.00394 
ENSDARG00000008904 smarca2 SMARCA2 -2.15960 0.75011 0.00399 
ENSDARG00000063921 mt-nd5 MT-ND5 -1.53059 0.53209 0.00402 
ENSDARG00000045297 phb2a PHB2 -3.51376 1.23111 0.00432 
ENSDARG00000042458 rfc4 RFC4 -3.73948 1.31289 0.00440 
ENSDARG00000058587 ccdc79 CCDC79 -2.68611 0.94630 0.00453 
ENSDARG00000095268 si:dkey-261h17.1  -3.20116 1.12863 0.00456 
ENSDARG00000057787 itgae.2 ITGAE -2.72101 0.97065 0.00506 
ENSDARG00000080001 si:dkey-208m12.2  -3.38500 1.21010 0.00515 
ENSDARG00000011770 dhrs12 DHRS12 -3.86711 1.38465 0.00522 
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ENSDARG00000103787 chd1 CHD1 -2.97632 1.07521 0.00564 
ENSDARG00000075504     -3.66586 1.32956 0.00583 
ENSDARG00000021664 fzd3a FZD3 -2.97876 1.08283 0.00594 
ENSDARG00000007244 acp2 ACP2 -3.18164 1.15667 0.00595 
ENSDARG00000010477 p2rx3a P2RX3 -3.50343 1.27862 0.00614 
ENSDARG00000004184 nf1b NF1 -2.49199 0.91082 0.00622 
ENSDARG00000003449 pde10a PDE10A -3.80209 1.39128 0.00628 
ENSDARG00000016867 rnf128a RNF148 -3.06055 1.12252 0.00640 
ENSDARG00000076586 csf2rb CSF2RB -2.46506 0.90905 0.00669 
ENSDARG00000020606 nfe2 NFE2 -3.41368 1.26319 0.00688 
ENSDARG00000012035 zgc:100832 FBXO44 -2.47787 0.91827 0.00697 
ENSDARG00000016527 helz2 HELZ2 -3.33672 1.23892 0.00708 
ENSDARG00000075980 tmem125b TMEM125 -3.32091 1.24129 0.00746 
ENSDARG00000008333 znfl2a  -2.69356 1.00892 0.00759 
ENSDARG00000078624 arhgef9b ARHGEF9 -2.35210 0.88205 0.00766 
ENSDARG00000056678 trim47 TRIM69 -2.99633 1.13063 0.00805 
ENSDARG00000097533 si:dkey-29l4.4  -2.72300 1.03277 0.00837 
ENSDARG00000052190 fdx1l CTD-2369P2.10 -2.67164 1.01716 0.00863 
ENSDARG00000002369 UBC UBC -1.65672 0.63167 0.00872 
ENSDARG00000062139 eif2ak3 EIF2AK3 -3.04968 1.16479 0.00884 
ENSDARG00000006526 fn1b  -3.67090 1.40806 0.00913 
ENSDARG00000103472 nedd8l  -2.87853 1.11075 0.00956 
	
Table A=: Diﬀerentially downregulated genes in the mutant Tg(itga'b:EGFP) GFPlow population. 
Only genes with a P < .QQ% are shown. FC SE = fold change standard error. ENSEMBL IDs correspond to 
the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000000503 stx1b STX1B 6.11001 1.26110 0.00000 
ENSDARG00000068478 gpx4a GPX4 5.85288 1.26965 0.00000 
ENSDARG00000054578 arl6ip1 ARL6IP1 3.17018 0.69523 0.00001 
ENSDARG00000053517 EML5 EML5 5.36563 1.19444 0.00001 
ENSDARG00000103203 vps28 VPS28 5.40181 1.26452 0.00002 
ENSDARG00000058354 selt1a SELT 4.95022 1.19167 0.00003 
ENSDARG00000099320 si:dkey-284i7.2  4.84260 1.17326 0.00004 
ENSDARG00000031649 sst3  4.71697 1.15214 0.00004 
ENSDARG00000018460 mbnl2 MBNL2 3.90972 0.96295 0.00005 
ENSDARG00000098108 dusp2 DUSP2 5.00010 1.23284 0.00005 
ENSDARG00000036848 slc43a2a SLC43A2 4.18884 1.04068 0.00006 
ENSDARG00000035557 gabarapa GABARAP 3.14521 0.80101 0.00009 
ENSDARG00000100743 si:dkey-190j3.4  4.54120 1.18217 0.00012 
ENSDARG00000079374 tjp1b TJP1 5.40336 1.41540 0.00013 
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ENSDARG00000007923 ptpn1 PTPN1 3.04912 0.80035 0.00014 
ENSDARG00000008370 csnk1da  3.75439 0.98635 0.00014 
ENSDARG00000069404 pln  4.26464 1.13026 0.00016 
ENSDARG00000045909 dynlt1 DYNLT1 3.35902 0.89828 0.00018 
ENSDARG00000005560 ywhah YWHAH 3.13206 0.84600 0.00021 
ENSDARG00000082142 CR753862.1  4.83569 1.32032 0.00025 
ENSDARG00000058606 sik1 CH507-42P11.8 4.50009 1.23093 0.00026 
ENSDARG00000103720 ZFP36 ZFP36 2.25793 0.61872 0.00026 
ENSDARG00000100825 calm3a  2.79360 0.76901 0.00028 
ENSDARG00000014320 gucy2c GUCY2C 3.57602 0.98591 0.00029 
ENSDARG00000104039 errfi1 ERRFI1 3.90807 1.07909 0.00029 
ENSDARG00000004060 bhlhe40 BHLHE40 3.98608 1.12788 0.00041 
ENSDARG00000053656 lypla2 LYPLA2 3.07593 0.87254 0.00042 
ENSDARG00000098994 CR352263.1  4.03432 1.14535 0.00043 
ENSDARG00000098380 BX957331.1    4.66642 1.32830 0.00044 
ENSDARG00000002609 rnf145a RNF145 4.55080 1.30657 0.00050 
ENSDARG00000035253 npr3 NPR3 5.10625 1.46837 0.00051 
ENSDARG00000074527 chst15 CHST15 4.94130 1.42816 0.00054 
ENSDARG00000104077 fcer1gl FCER1G 1.83374 0.53051 0.00055 
ENSDARG00000036700  	 3.67168 1.06811 0.00059 
ENSDARG00000076847 tnrc6c1 TNRC6C 2.26347 0.66105 0.00062 
ENSDARG00000057456 ppp3ccb PPP3CC 3.70745 1.08355 0.00062 
ENSDARG00000020771 tnr TNR 4.20224 1.25383 0.00080 
ENSDARG00000015757 tmem50a TMEM50A 3.72306 1.11352 0.00083 
ENSDARG00000076667 ccng1 CCNG1 1.78161 0.53442 0.00086 
ENSDARG00000103852 si:ch211-215e19.7  3.78015 1.13423 0.00086 
ENSDARG00000018124 psmd3 PSMD3 2.36373 0.71044 0.00088 
ENSDARG00000093303  IFITM10 4.39245 1.32400 0.00091 
ENSDARG00000102998 taf6 TAF6 4.35802 1.31462 0.00092 
ENSDARG00000003938 rpa1 RPA1 2.39537 0.72368 0.00093 
ENSDARG00000104701 map7d1b MAP7D1 3.85718 1.17146 0.00099 
ENSDARG00000042796 yy1a YY1 2.51769 0.76878 0.00106 
ENSDARG00000079616 cramp1l CRAMP1 4.28001 1.31534 0.00114 
ENSDARG00000015059 daam1a DAAM1 4.20451 1.29415 0.00116 
ENSDARG00000053475 ngb NGB 3.98501 1.23484 0.00125 
ENSDARG00000076853 AREG AREG 2.81184 0.87314 0.00128 
ENSDARG00000008548 arhgap12a  4.13406 1.28374 0.00128 
ENSDARG00000013505 ube2kb UBE2K 3.32295 1.03232 0.00129 
ENSDARG00000091917 si:ch73-386o14.1  4.39933 1.38770 0.00152 
ENSDARG00000053753 mff MFF 3.12331 0.98770 0.00157 
ENSDARG00000071107 wnt7bb WNT7B 4.06430 1.28657 0.00158 
ENSDARG00000026865 fam107b FAM107B 2.55375 0.80962 0.00161 
ENSDARG00000018272 wdr33 WDR33 3.48630 1.10922 0.00167 
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ENSDARG00000062987 tyw1 TYW1 3.85641 1.23650 0.00182 
ENSDARG00000104789  KIAA0141 3.97793 1.28532 0.00197 
ENSDARG00000030440 rsrp1  2.90185 0.93956 0.00201 
ENSDARG00000031952 mb MB 3.87995 1.25770 0.00204 
ENSDARG00000041078 chka CHKA 3.56991 1.15888 0.00207 
ENSDARG00000033950 lamb2l  2.73198 0.88842 0.00210 
ENSDARG00000078458 ppp1r37 PPP1R37 2.91519 0.95880 0.00236 
ENSDARG00000092809 hoxc9a HOXC9 4.27298 1.40964 0.00244 
ENSDARG00000037640 aurkb AURKB 2.59699 0.85745 0.00246 
ENSDARG00000010301 b4galt6 B4GALT6 2.45189 0.81276 0.00255 
ENSDARG00000052747 gpatch3 GPATCH3 2.94464 0.98125 0.00269 
ENSDARG00000035521 sfrp1a SFRP1 3.97464 1.32900 0.00278 
ENSDARG00000087688 KLHL29    4.00937 1.34313 0.00283 
ENSDARG00000069752 ckba CKB 4.07256 1.36555 0.00286 
ENSDARG00000005627 CABZ01068209.1 GBP1 3.01889 1.01403 0.00291 
ENSDARG00000003270 dhps DHPS 3.48653 1.17951 0.00312 
ENSDARG00000075853 sh3kbp1 SH3KBP1 2.56670 0.87271 0.00327 
ENSDARG00000018698 carm1 CARM1 2.69504 0.91877 0.00335 
ENSDARG00000057853 atp6v0ca ATP6V0C 2.00666 0.68452 0.00337 
ENSDARG00000068434 h3f3b.1  1.99269 0.68079 0.00342 
ENSDARG00000041750 ccdc92 CCDC92 2.96596 1.01664 0.00353 
ENSDARG00000017744 smc2 SMC2 3.27436 1.13247 0.00384 
ENSDARG00000069696 LRIF1 LRIF1 4.11461 1.42420 0.00386 
ENSDARG00000032614 msi2b MSI2 3.02429 1.05354 0.00410 
ENSDARG00000041068 got2a GOT2 3.07109 1.07143 0.00415 
ENSDARG00000038141 atf4b ATF4 2.64803 0.93231 0.00451 
ENSDARG00000039757 mcfd2 MCFD2 2.67942 0.94462 0.00456 
ENSDARG00000061187 cbx5 CBX5 2.23427 0.78833 0.00459 
ENSDARG00000021149 cbr1l  3.59934 1.27009 0.00460 
ENSDARG00000042368 kif26aa KIF26A 3.68292 1.31071 0.00496 
ENSDARG00000054864 aplp2 SPINT3 2.38178 0.84902 0.00503 
ENSDARG00000078179 fndc3ba FNDC3B 2.52457 0.90295 0.00518 
ENSDARG00000053257 zgc:153733  3.87178 1.38542 0.00520 
ENSDARG00000026582 iscub ISCU 3.17771 1.14118 0.00536 
ENSDARG00000053358 basp1  3.64173 1.30799 0.00537 
ENSDARG00000031200 ppp2r5cb PPP2R5C 2.33917 0.84154 0.00544 
ENSDARG00000027109 zfr ZFR 2.07976 0.75135 0.00564 
ENSDARG00000043795 arhgdia ARHGDIA 1.20001 0.43410 0.00570 
ENSDARG00000100813 nudt12 NUDT12 4.12354 1.49826 0.00592 
ENSDARG00000054063 arpc4 ARPC4 1.74031 0.63423 0.00607 
ENSDARG00000037760 uncx4.1 UNCX 3.46383 1.26492 0.00617 
ENSDARG00000092752 si:ch211-233a1.4  2.96973 1.08822 0.00635 
ENSDARG00000100752 RAB21 RAB21 3.05517 1.12479 0.00660 
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ENSDARG00000057577 mbtps2 MBTPS2 3.29768 1.21522 0.00665 
ENSDARG00000074656 ctssb.1 CTSS 2.61687 0.96532 0.00671 
ENSDARG00000100513 rps27.2 RPS27L 2.22941 0.82704 0.00703 
ENSDARG00000052728 sltm SLTM 1.59747 0.59803 0.00756 
ENSDARG00000012513 sdcbp2 SDCBP2 2.15416 0.81539 0.00824 
ENSDARG00000045417 fam49bb FAM49B 2.25487 0.85663 0.00848 
ENSDARG00000078014 pacsin2 PACSIN2 1.99375 0.75921 0.00864 
ENSDARG00000100823 selk SELK 2.13327 0.81368 0.00875 
ENSDARG00000053668 stag2b STAG2 1.99237 0.76129 0.00887 
ENSDARG00000101755 prkar1ab  2.74281 1.04886 0.00892 
ENSDARG00000000857 mapk14a MAPK14 2.78500 1.06519 0.00893 
ENSDARG00000056653 fhl1b FHL1 3.16148 1.21008 0.00898 
ENSDARG00000032619 tob1a TOB1 2.20784 0.84775 0.00921 
ENSDARG00000052000 cav2 CAV2 3.07262 1.18515 0.00953 
ENSDARG00000053291 pnrc2 PNRC2 1.28908 0.49792 0.00963 
ENSDARG00000040812 ncf4 NCF4 2.20765 0.85344 0.00969 
ENSDARG00000069763 etv5a ETV5 2.31028 0.89377 0.00974 
ENSDARG00000056027 hoxb8a  2.82312 1.09475 0.00992 
	
Table A?: Diﬀerentially upregulated genes in mutant erythrocytes. Only genes with a P < .QQ% are 
shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene.  
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000003383 asb8 ASB8 -6.83710 1.90899 0.00034 
ENSDARG00000069464 cox7a1 COX7A1 -5.66943 1.75500 0.00124 
ENSDARG00000036305 phf23b PHF23 -6.32857 1.98530 0.00143 
ENSDARG00000067717 tomm7 TOMM7 -5.29316 1.68174 0.00165 
ENSDARG00000101216 smarca2 SMARCA2 -4.39017 1.45736 0.00259 
ENSDARG00000008904 meaf6 MEAF6 -6.30431 2.09555 0.00263 
ENSDARG00000015757 tmem50a TMEM50A -5.34355 1.79126 0.00285 
ENSDARG00000069846 zgc:162944  -4.70562 1.58966 0.00308 
ENSDARG00000062058 slc12a7b SLC12A7 -5.68102 1.93342 0.00330 
ENSDARG00000038576 ube2d1b UBE2D1 -5.32100 1.82133 0.00348 
ENSDARG00000098066 si:dkey-92c21.2  -6.05443 2.10732 0.00407 
ENSDARG00000017366 prdm4 PRDM4 -5.12304 1.78681 0.00414 
ENSDARG00000098924 suz12b SUZ12 -6.07905 2.18416 0.00538 
ENSDARG00000041878 rab11ba RAB11B -3.93368 1.42136 0.00565 
ENSDARG00000101275 si:dkey-117a16.1  -5.88954 2.15396 0.00625 
ENSDARG00000102012 ppp1cbl  -4.55539 1.67602 0.00657 
ENSDARG00000058358 krt8 KRT79 -4.29423 1.58676 0.00680 
ERCC-00071 ERCC-00071 NA -4.59143 1.70669 0.00714 
ENSDARG00000061985 gabarapa GABARAP -4.51065 1.70307 0.00808 
ENSDARG00000063612 psma1 RP11-140L24.4 -3.86253 1.45897 0.00811 
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ENSDARG00000019420 rbm47 RBM47 -3.61850 1.37779 0.00863 
ENSDARG00000035557 antxr1c ANTXRL -4.70837 1.79382 0.00867 
ENSDARG00000102555 etnk1 ETNK1 -3.57391 1.36175 0.00868 
ENSDARG00000101560 si:dkey-33i11.9  -4.62968 1.76788 0.00882 
ENSDARG00000063636 galnt11 GALNT11 -4.56470 1.75975 0.00949 
ENSDARG00000035751 ipo7 IPO7 -3.93842 1.52619 0.00986 
	
Table A@: Diﬀerentially downregulated genes in mutant erythrocytes. Only genes with a P < .QQ% 
are shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000056491 ikzf5 IKZF5 8.70139 1.95499 0.00001 
ENSDARG00000006240 slc27a1a SLC27A1 8.55867 2.01008 0.00002 
ENSDARG00000014592 DENND1A DENND1A 8.13607 1.95528 0.00003 
ENSDARG00000024295 slc11a2 SLC11A2 6.79441 1.63499 0.00003 
ENSDARG00000045399 cct5 CCT5 7.55616 1.83902 0.00004 
ENSDARG00000029510 timm17a TIMM17A 7.52138 1.91090 0.00008 
ENSDARG00000034616 mlf2 MLF2 7.83002 2.01881 0.00011 
ENSDARG00000041586 dhx40 DHX40 7.81632 2.03482 0.00012 
ENSDARG00000069031 plac8l1 PLAC8L1 7.93215 2.07402 0.00013 
ENSDARG00000012642 ZNF208  7.72797 2.04018 0.00015 
ENSDARG00000034768 phf3 PHF3 7.55503 2.00503 0.00016 
ENSDARG00000053646 adrb3a ADRB3 7.82148 2.08331 0.00017 
ENSDARG00000033489 ube2j1 UBE2J1 6.63239 1.81152 0.00025 
ENSDARG00000075014 sqstm1 SQSTM1 6.03094 1.64747 0.00025 
ENSDARG00000014582 exoc3 EXOC3 7.64940 2.09107 0.00025 
ENSDARG00000099999 tcf3b TCF3 6.63893 1.82170 0.00027 
ENSDARG00000013931 eif3m EIF3M 5.06388 1.41376 0.00034 
ENSDARG00000032469 ampd3b AMPD3 6.94325 1.94920 0.00037 
ENSDARG00000086416 med11 MED11 7.44857 2.09352 0.00037 
ENSDARG00000025338 hagh HAGH 6.33132 1.79263 0.00041 
ENSDARG00000071037 pex13 PEX13 7.02328 2.00980 0.00047 
ENSDARG00000076483 zgc:198241  6.76603 1.93949 0.00049 
ENSDARG00000016011 gpcpd1 GPCPD1 7.26676 2.09360 0.00052 
ENSDARG00000001220 mycbp2 MYCBP2 4.90150 1.42115 0.00056 
ENSDARG00000104789  KIAA0141 7.21676 2.09622 0.00058 
ENSDARG00000104842 CABZ01085069.1  6.87110 2.00501 0.00061 
ENSDARG00000013946 ivns1abpb IVNS1ABP 6.73798 1.97013 0.00063 
ENSDARG00000044619 birc2 BIRC3 5.30233 1.55471 0.00065 
ENSDARG00000071570 CCDC71 CCDC71 7.33678 2.15912 0.00068 
ENSDARG00000004161 ik IK 5.60836 1.65116 0.00068 
ENSDARG00000057353 EHBP1L1  5.51913 1.65046 0.00083 
ENSDARG00000063229 xpo1b XPO1 5.34107 1.60831 0.00090 
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ENSDARG00000020101 psmc2 PSMC2 7.09585 2.15684 0.00100 
ENSDARG00000012818 csnk2a2a CSNK2A2 6.74061 2.07567 0.00116 
ENSDARG00000038154 isca2 ISCA2 6.15765 1.89681 0.00117 
ENSDARG00000098391 psmg3 PSMG3 6.56397 2.02779 0.00121 
ENSDARG00000013804 capns1b CAPNS2 5.68198 1.75815 0.00123 
ENSDARG00000079238 trim59 TRIM59 6.79111 2.10157 0.00123 
ENSDARG00000019188 ube2l3a UBE2L3 6.97128 2.15738 0.00123 
ENSDARG00000052553 lig3 LIG3 6.97303 2.15859 0.00124 
ENSDARG00000104726 si:ch211-162e15.3 NCBP2-AS2 6.71034 2.09207 0.00134 
ENSDARG00000077405  	 5.41063 1.69949 0.00145 
ENSDARG00000025858 GOLM1 GOLM1 6.65182 2.09286 0.00148 
ENSDARG00000090600 si:ch211-213a13.1  5.34589 1.69011 0.00156 
ENSDARG00000070426 chac1 CHAC1 6.15706 1.95205 0.00161 
ENSDARG00000018742 psme4b PSME4 6.30296 2.00626 0.00168 
ENSDARG00000018190 asna1 ASNA1 5.60296 1.79274 0.00178 
ENSDARG00000011934 gyg1a GYG1 5.43643 1.74558 0.00184 
ENSDARG00000012340 ptpn11b  6.05192 1.94516 0.00186 
ENSDARG00000103343 TRIM14  6.48735 2.09509 0.00196 
ENSDARG00000103203 vps28 VPS28 6.19986 2.00621 0.00200 
ENSDARG00000086618 psma3 PSMA3 6.05933 1.96639 0.00206 
ENSDARG00000044373 atg4c ATG4C 6.40916 2.08831 0.00215 
ENSDARG00000103200 gpr107 GPR107 6.61075 2.15886 0.00220 
ENSDARG00000068698 psenen AC002398.9 6.59402 2.15501 0.00221 
ENSDARG00000023217 crema  6.33146 2.07327 0.00226 
ENSDARG00000071013 arl6ip6 ARL6IP6 6.35279 2.08772 0.00234 
ENSDARG00000012577 waca WAC 5.43223 1.80088 0.00256 
ENSDARG00000093058 C4H7orf73 C7orf73 5.51835 1.83417 0.00262 
ENSDARG00000099896 si:ch211-261o3.3  6.27645 2.09196 0.00270 
ENSDARG00000104609 crebbpa CREBBP 5.74357 1.93843 0.00305 
ENSDARG00000053753 mff MFF 5.53661 1.87577 0.00316 
ENSDARG00000024092 lmbr1 LMBR1 6.33920 2.16069 0.00335 
ENSDARG00000036394 pop7 POP7 6.12563 2.08800 0.00335 
ENSDARG00000102379 FQ378013.1  6.14299 2.09509 0.00337 
ENSDARG00000020926 creb3l3l CREB3 5.54479 1.89895 0.00350 
ENSDARG00000103134 CKN149934.1H1orf52 C1orf52 5.49387 1.88589 0.00358 
ENSDARG00000042728 plaa PLAA 6.24020 2.16254 0.00391 
ENSDARG00000044183 prkab1a PRKAB1 5.11126 1.77144 0.00391 
ENSDARG00000103403 sar1b SAR1B 3.72915 1.29578 0.00400 
ENSDARG00000037012 slc3a2b SLC3A2 5.99717 2.08652 0.00405 
ENSDARG00000059886 fam222ba FAM222B 5.95881 2.08447 0.00425 
ENSDARG00000074759 ccar1 CCAR1 6.15526 2.15986 0.00437 
ENSDARG00000098123 GNG12  6.14288 2.16116 0.00448 
ENSDARG00000062315 sik2b SIK2 5.31550 1.87361 0.00455 
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ENSDARG00000040463 si:dkey-185e18.6 SLC25A51 5.32278 1.87661 0.00456 
ENSDARG00000043562 zgc:65997  5.52189 1.94801 0.00459 
ENSDARG00000078042 il10rb IFNAR1 4.36968 1.54589 0.00470 
ENSDARG00000104216 LOX  4.70709 1.66623 0.00473 
ENSDARG00000071395 camk2g1 CAMK2G 4.84306 1.72252 0.00493 
ENSDARG00000031435 zgc:56493 TXNDC8 3.74212 1.35059 0.00559 
ENSDARG00000076496 frmd4bb FRMD4B 5.08490 1.83585 0.00561 
ENSDARG00000098355 atp5h ATP5H 3.50914 1.26770 0.00564 
ENSDARG00000096091 si:dkey-29j8.3  5.94788 2.16083 0.00591 
ENSDARG00000026072 pdcd5 PDCD5 5.32647 1.93716 0.00597 
ENSDARG00000036482 hexim1 HEXIM1 5.39264 1.97163 0.00624 
ENSDARG00000093538 si:dkey-182g1.5  5.90071 2.15838 0.00626 
ENSDARG00000104373 C4H11orf98 C11orf98 5.89174 2.15932 0.00636 
ENSDARG00000036625 polr2f POLR2F 5.13030 1.90239 0.00700 
ENSDARG00000040930 deptor DEPTOR 4.71366 1.74995 0.00707 
ENSDARG00000090054 znf318 ZNF318 4.59219 1.70692 0.00714 
ENSDARG00000041533 ccdc130 CCDC130 5.79937 2.16610 0.00742 
ENSDARG00000074677 frem3  5.76068 2.16168 0.00770 
ENSDARG00000098317 dync1li1 DYNC1LI1 4.32309 1.62445 0.00778 
ENSDARG00000004160 reep3b REEP3 4.45408 1.68558 0.00823 
ENSDARG00000024874 dock4b DOCK4 4.63719 1.75702 0.00831 
ENSDARG00000063466 rab43 ISY1 5.88273 2.23578 0.00851 
ENSDARG00000061124 srpr SRPRA 5.28088 2.00833 0.00855 
ENSDARG00000051955 brms1 BRMS1 4.88853 1.86231 0.00867 
ENSDARG00000058041 ndufa8 NDUFA8 4.03337 1.53853 0.00875 
ENSDARG00000101828 si:ch211-76m11.11  4.27874 1.63690 0.00895 
ENSDARG00000044601 rtn4a RTN4 4.08898 1.56449 0.00896 
ENSDARG00000034916 hat1 HAT1 4.82198 1.85254 0.00924 
ENSDARG00000098466 ube2a UBE2A 5.01667 1.92801 0.00927 
ENSDARG00000100109 trappc2l TRAPPC2L 5.00664 1.92431 0.00927 
ENSDARG00000069135 ppp1r15a PPP1R15A 5.15301 1.98975 0.00960 
ENSDARG00000057826 si:ch73-61d6.3  3.92563 1.52312 0.00996 
	
Table AB: Diﬀerentially upregulated genes in mutant monocytes. Only genes with a P < .QQ% are 
shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000020711 rrm2 RRM2 -3.44624 0.86919 0.00007 
ENSDARG00000060771 map7d3  -2.56457 0.65275 0.00009 
ENSDARG00000102291 eef1da EEF1D -1.13373 0.30387 0.00019 
ENSDARG00000101406 rplp2  -1.05110 0.28291 0.00020 
ENSDARG00000103436 BX548028.1  -2.12402 0.59261 0.00034 
ENSDARG00000030938 fermt3b FERMT3 -2.20338 0.62982 0.00047 
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ENSDARG00000006691 rpl12 RPL12 -0.84192 0.24670 0.00064 
ENSDARG00000101813 nap1l1 NAP1L1 -1.03719 0.30909 0.00079 
ENSDARG00000058030 hspa14 HSPA14 -2.34247 0.70155 0.00084 
ENSDARG00000019791 prmt3 PRMT3 -4.09064 1.23645 0.00094 
ENSDARG00000030278 idh3a IDH3A -2.76649 0.87102 0.00149 
ENSDARG00000101430 si:dkeyp-3b12.7  -2.83940 0.90711 0.00175 
ENSDARG00000098385 si:dkeyp-3b12.6  -2.83940 0.90711 0.00175 
ENSDARG00000099380 rpl13 RPL13 -1.24589 0.40324 0.00200 
ENSDARG00000076858 C10H8orf4 C8orf4 -1.89253 0.61973 0.00226 
ENSDARG00000070228 cdk6 CDK6 -1.44857 0.47720 0.00240 
ENSDARG00000006818 urod UROD -1.70911 0.56356 0.00242 
ENSDARG00000031795 abcf1 ABCF1 -1.53513 0.51231 0.00273 
ENSDARG00000103846 hspa5  -2.48918 0.83298 0.00281 
ENSDARG00000041811 rps25 RPS25 -0.87198 0.29267 0.00289 
ENSDARG00000040440 snrpd2 SNRPD2 -1.92527 0.64669 0.00291 
ENSDARG00000056600 papss2b PAPSS2 -2.33489 0.81776 0.00430 
ENSDARG00000021339 cpa5 CPA1 -2.05901 0.72302 0.00440 
ENSDARG00000104353 nop58 NOP58 -1.36876 0.48244 0.00455 
ENSDARG00000003098 kdm5bb KDM5B -2.18267 0.77047 0.00461 
ENSDARG00000088959 pdxka PDXK -1.79416 0.63418 0.00467 
ENSDARG00000037017 ube4b UBE4B -1.65157 0.58530 0.00478 
ENSDARG00000074242 serbp1a SERBP1 -0.87561 0.31057 0.00481 
ENSDARG00000011405 rps9 RPS9 -0.84360 0.30042 0.00498 
ENSDARG00000019810 nfe2l3 NFE2L3 -1.90103 0.67873 0.00510 
ENSDARG00000061591 abcb10 ABCB10 -2.07206 0.74475 0.00540 
ENSDARG00000099970 malat1  -0.87279 0.31457 0.00553 
ENSDARG00000032013 pafah1b1a PAFAH1B1 -1.67339 0.60985 0.00607 
ENSDARG00000023532 pinx1 PINX1 -2.05005 0.74858 0.00617 
ENSDARG00000055713 fmnl1a FMNL1 -1.19307 0.43658 0.00628 
ENSDARG00000096770 si:ch73-21k16.6  -1.86988 0.68531 0.00636 
ENSDARG00000104674 CABZ01075268.1  -1.19534 0.44262 0.00692 
ENSDARG00000101637 ccnd1 CCND1 -1.13444 0.42014 0.00693 
ENSDARG00000104011 rps17  -0.86633 0.32114 0.00698 
ENSDARG00000045297 phb2a PHB2 -2.01947 0.75271 0.00730 
ENSDARG00000100677 tmem205 TMEM205 -1.67572 0.62695 0.00752 
ENSDARG00000074245 spen SPEN -1.59626 0.60519 0.00835 
ENSDARG00000095556 si:dkey-238c7.12  -0.62718 0.23817 0.00845 
ENSDARG00000061338 ddx6 DDX6 -2.00092 0.76353 0.00878 
ENSDARG00000031136 moxd1 MOXD1 -1.85914 0.71249 0.00907 
ENSDARG00000080009 bahcc1 BAHCC1 -1.49879 0.58046 0.00982 
ENSDARG00000063626 ddx21 DDX21 -1.14781 0.44461 0.00983 
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Table E: ADiﬀerentially downregulated genes in mutant monocytes. Only genes with a P < .QQ% are 
shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000075980 tmem125b TMEM125 5.81446 1.10879 0.00000 
ENSDARG00000078069 rrm2 RRM2 5.91399 1.14539 0.00000 
ENSDARG00000029445 EIF1B EIF1B 3.72738 0.75153 0.00000 
ENSDARG00000068246 plcb3 PLCB3 3.58165 0.73243 0.00000 
ENSDARG00000009961 rundc3b RUNDC3B 3.82157 0.78281 0.00000 
ENSDARG00000071601 pvalb9 OCM 5.25333 1.07779 0.00000 
ENSDARG00000101840 U3  4.85935 1.00439 0.00000 
ENSDARG00000097202 si:ch211-141i4.3  3.60741 0.75358 0.00000 
ENSDARG00000068456 tmem91 TMEM91 4.32260 0.91603 0.00000 
ENSDARG00000104635 si:busm1-194e12.12 HLA-DRB1 4.25329 0.91949 0.00000 
ENSDARG00000087732 Metazoa_SRP RN7SL480P 4.76687 1.04462 0.00001 
ENSDARG00000008153 serinc5 SERINC5 2.87885 0.64300 0.00001 
ENSDARG00000075421 pttg1  2.95234 0.66814 0.00001 
ENSDARG00000096403 si:dkey-153m14.1  3.13641 0.71024 0.00001 
ENSDARG00000007808 zdhhc16a ZDHHC16 3.12222 0.70810 0.00001 
ENSDARG00000079102 PRRG3 PRRG3 3.65787 0.83205 0.00001 
ENSDARG00000013892 sorl1 SORL1 4.47785 1.05123 0.00002 
ENSDARG00000092337 gas5  2.47073 0.58083 0.00002 
ENSDARG00000099091 si:ch73-158n7.2  2.84406 0.67574 0.00003 
ENSDARG00000081270 rn7sk RN7SKP90 4.56857 1.09563 0.00003 
ENSDARG00000091402 eif2b1 EIF2B1 3.10408 0.74991 0.00003 
ENSDARG00000102311 BX572103.3  3.02770 0.73260 0.00004 
ENSDARG00000083431 U4 RNU4-2 5.30289 1.28466 0.00004 
ENSDARG00000099417 CT027611.1  2.89756 0.71034 0.00005 
ENSDARG00000003017 zgc:55512  2.73266 0.67353 0.00005 
ENSDARG00000071139 zgc:64065  4.54963 1.12680 0.00005 
ENSDARG00000027807 fynrk FRK 3.27901 0.81818 0.00006 
ENSDARG00000040266 sox19b  2.76711 0.69175 0.00006 
ENSDARG00000099359 BX649497.2  4.92607 1.23822 0.00007 
ENSDARG00000099625 si:dkey-97l11.1  2.85659 0.72077 0.00007 
ENSDARG00000100513 rps27.2 RPS27L 2.52503 0.63960 0.00008 
ENSDARG00000104666 BX511215.2 ZNF852 4.44874 1.13166 0.00008 
ENSDARG00000103976 BX544877.1  2.93445 0.74695 0.00009 
ENSDARG00000102436 WIZ WIZ 3.41309 0.89577 0.00014 
ENSDARG00000028295 mkrn4  2.55026 0.67115 0.00014 
ENSDARG00000102805 cyp2aa12  2.90624 0.77187 0.00017 
ENSDARG00000092407 TRIM35    3.50623 0.93314 0.00017 
ENSDARG00000021811 calm1a CALM1 3.17258 0.84453 0.00017 
ENSDARG00000093743 si:ch73-55c23.2  3.90244 1.04293 0.00018 
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ENSDARG00000019260 dhrs9  4.76988 1.27514 0.00018 
ENSDARG00000101770 ACEA_U3 SNORD3D 4.88153 1.31394 0.00020 
ENSDARG00000025436 msrb1a MSRB1 3.01038 0.81042 0.00020 
ENSDARG00000038754 plk3 PLK3 2.11695 0.57288 0.00022 
ENSDARG00000015201 pcmt PCMT1 2.70988 0.73497 0.00023 
ENSDARG00000101777 pdlim5a PDLIM5 2.10829 0.57320 0.00024 
ENSDARG00000091137 CABZ01079258.1  2.33340 0.63461 0.00024 
ENSDARG00000089213 adam15 ADAM15 2.65661 0.72295 0.00024 
ENSDARG00000105109 si:ch1073-329i9.1  3.11309 0.84783 0.00024 
ENSDARG00000058365 hspb8 HSPB8 2.46717 0.67491 0.00026 
ENSDARG00000068787 slc6a17 SLC6A17 2.59182 0.70906 0.00026 
ENSDARG00000031496 ap1ar AP1AR 2.20766 0.60797 0.00028 
ENSDARG00000042824 nfe2l2a NFE2L2 2.23599 0.61790 0.00030 
ENSDARG00000063436 RPH3A    3.83122 1.05892 0.00030 
ENSDARG00000078966 rbm15b RBM15B 3.13042 0.87118 0.00033 
ENSDARG00000094308 si:dkey-247i3.6  3.30516 0.92015 0.00033 
ENSDARG00000083389 SNORA57 SNORA57 4.06864 1.14254 0.00037 
ENSDARG00000038235 pkdccb  2.97945 0.83746 0.00037 
ENSDARG00000040190 qdpra  2.28414 0.64444 0.00039 
ENSDARG00000038668 gbp1 GBP1 3.66357 1.03427 0.00040 
ENSDARG00000071345 mgst2 MGST2 4.12755 1.16722 0.00041 
ENSDARG00000020811 efemp2b EFEMP2 2.17937 0.61643 0.00041 
ENSDARG00000098315 cyp1a CYP1A1 3.60583 1.02078 0.00041 
ENSDARG00000097615 si:ch211-108d22.2  2.92815 0.82906 0.00041 
ENSDARG00000043854 ppil4 PPIL4 3.67245 1.04372 0.00043 
ENSDARG00000105196 CU929447.2  3.51304 0.99993 0.00044 
ENSDARG00000071082 p4ha1b P4HA1 3.10885 0.88642 0.00045 
ENSDARG00000100776 syt8 SYT8 3.58966 1.03220 0.00051 
ENSDARG00000070688 ncalda NCALD 2.08606 0.60047 0.00051 
ENSDARG00000061974 grhl2b GRHL2 3.70947 1.07415 0.00055 
ENSDARG00000030687 phka2 PHKA2 2.58391 0.74836 0.00055 
ENSDARG00000028119 sumo3a SUMO3 2.03891 0.59064 0.00056 
ENSDARG00000095477 si:ch1073-291l11.2  2.96967 0.86226 0.00057 
ENSDARG00000042621 cryaba CRYAB 1.76291 0.51238 0.00058 
ENSDARG00000102549 CR450729.2  2.25224 0.65955 0.00064 
ENSDARG00000097844 si:ch1073-488c15.2  2.10526 0.61866 0.00067 
ENSDARG00000061083 igl4v8 IGKV2-40 4.01903 1.18105 0.00067 
ENSDARG00000087457 ecscr ECSCR 2.54152 0.75094 0.00071 
ENSDARG00000011312 stk3 STK3 1.68585 0.50051 0.00076 
ENSDARG00000101337 zgc:103700 HLA-DRB1 2.39392 0.71807 0.00086 
ENSDARG00000086495 BX546500.1  3.56326 1.06952 0.00086 
ENSDARG00000040725 zgc:114130  2.12957 0.64248 0.00092 
ENSDARG00000078024 CU570881.1  2.83124 0.85458 0.00092 
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ENSDARG00000101828 si:ch211-76m11.11  2.51334 0.75916 0.00093 
ENSDARG00000104572 si:dkey-35h6.1  1.96480 0.59922 0.00104 
ENSDARG00000100731 slc27a2b SLC27A2 2.97019 0.91036 0.00110 
ENSDARG00000039131 atp1a1a.3 ATP1A1 2.50603 0.76815 0.00110 
ENSDARG00000008363 mcl1b MCL1 1.89285 0.58162 0.00114 
ENSDARG00000104715 zgc:171422  3.66249 1.12770 0.00116 
ENSDARG00000098557 BX323564.1  1.85370 0.57157 0.00118 
ENSDARG00000104636 si:dkey-112a7.4  3.22542 0.99946 0.00125 
ENSDARG00000079742 mcf2l2 MCF2L2 3.13285 0.97448 0.00130 
ENSDARG00000044254 anxa3b ANXA3 2.97453 0.92592 0.00132 
ENSDARG00000013990 ube2q2 UBE2Q2 1.95069 0.60749 0.00132 
ENSDARG00000033138 lyrm2 LYRM2 1.63168 0.50865 0.00134 
ENSDARG00000005841 tnni2a.2 TNNI2 1.49179 0.46700 0.00140 
ENSDARG00000059442 smtnb SMTNL1 2.98275 0.93579 0.00144 
ENSDARG00000044339 rp2 RP2 2.81235 0.88378 0.00146 
ENSDARG00000103639 si:dkey-36i7.3  2.32581 0.73134 0.00147 
ENSDARG00000027017 ppp2r5a PPP2R5A 2.91509 0.91685 0.00148 
ENSDARG00000094110 si:ch211-284e20.4  3.10148 0.98634 0.00166 
ENSDARG00000016213 BX088711.1  2.37347 0.75489 0.00167 
ENSDARG00000018478 agxtb AGXT 2.75209 0.87559 0.00167 
ENSDARG00000096655 si:ch211-184m19.3  1.52186 0.48627 0.00175 
ENSDARG00000103925 5S_rRNA  3.94722 1.26256 0.00177 
ENSDARG00000025033 stx5a STX5 3.12122 1.00402 0.00188 
ENSDARG00000026990 klhl6 KLHL6 2.15842 0.69549 0.00191 
ENSDARG00000062577 arhgap35a ARHGAP35 2.05655 0.66282 0.00192 
ENSDARG00000103430 si:ch73-226i7.1  3.40356 1.09759 0.00193 
ENSDARG00000087762 RAB27B RAB27B 1.71326 0.55264 0.00193 
ENSDARG00000079834 kdf1a KDF1 3.09499 0.99896 0.00195 
ENSDARG00000092457 si:ch211-207c6.6  2.41437 0.78082 0.00199 
ENSDARG00000089957 lgi2a LGI2 2.45783 0.79495 0.00199 
ENSDARG00000034700 vegfab VEGFA 3.36542 1.09077 0.00203 
ENSDARG00000041340 mrpl51 MRPL51 2.18989 0.71057 0.00206 
ENSDARG00000005897 dera DERA 2.96361 0.96247 0.00208 
ENSDARG00000062565 kcnh4a KCNH4 3.09797 1.00933 0.00215 
ENSDARG00000070545 top1l TOP1 1.14306 0.37517 0.00231 
ENSDARG00000002897 INPP1 INPP1 2.07384 0.68283 0.00239 
ENSDARG00000105100 si:dkey-3h2.2  1.97695 0.65136 0.00240 
ENSDARG00000074201 flna FLNA 1.25933 0.41531 0.00243 
ENSDARG00000013014 or101-1 OR2AT4 2.15577 0.71766 0.00267 
ENSDARG00000100446 si:ch211-286o17.1  2.72464 0.90852 0.00271 
ENSDARG00000002305 me3 ME3 2.68337 0.89811 0.00281 
ENSDARG00000104084 GPRIN2 GPRIN2 2.10592 0.70607 0.00286 
ENSDARG00000054666 pgpep1  1.41178 0.47345 0.00286 
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ENSDARG00000089142 zgc:113119  3.73601 1.25407 0.00289 
ENSDARG00000100633 APH1A APH1A 1.23375 0.41530 0.00297 
ENSDARG00000102750 cdh1 CDH1 2.17575 0.73288 0.00299 
ENSDARG00000104282 DCC DCC 3.11086 1.04980 0.00304 
ENSDARG00000023712 mao MAOA 2.82992 0.96019 0.00321 
ENSDARG00000013144 atp1b1a ATP1B1 1.08498 0.36936 0.00331 
ENSDARG00000011065 camk2b1 CAMK2B 2.38594 0.81363 0.00336 
ENSDARG00000098099 zgc:64065  2.09562 0.71490 0.00338 
ENSDARG00000071409 arl3 ARL3 2.86959 0.98181 0.00347 
ENSDARG00000053136 b2m B2M 1.39791 0.47872 0.00350 
ENSDARG00000011555 spag7 SPAG7 1.64065 0.56224 0.00352 
ENSDARG00000068738 cox5b2 COX5B 2.62274 0.90115 0.00361 
ENSDARG00000103380 LPIN1    1.53744 0.52853 0.00363 
ENSDARG00000059461 mepce  1.92114 0.66046 0.00363 
ENSDARG00000099546 kynu KYNU 2.57049 0.88654 0.00374 
ENSDARG00000035120 GLDC GLDC 1.38382 0.48015 0.00395 
ENSDARG00000067545 adam19b ADAM19 1.95045 0.67831 0.00403 
ENSDARG00000097300 si:ch211-242h13.4  3.17615 1.10676 0.00411 
ENSDARG00000079034 si:dkey-19b23.11    1.91472 0.67157 0.00436 
ENSDARG00000033046 ccni2 CCNI2 2.84090 0.99650 0.00436 
ENSDARG00000099633 si:dkey-186o21.1 SEC14L3 2.20117 0.77270 0.00439 
ENSDARG00000094133 wu:fc21g02  1.88009 0.66321 0.00458 
ENSDARG00000036117 mchr2  1.78449 0.63216 0.00476 
ENSDARG00000038577 cox6c COX6C 1.63056 0.57819 0.00480 
ENSDARG00000069632 emp1 EMP1 1.77853 0.63126 0.00484 
ENSDARG00000038107 sgcg SGCG 1.62507 0.57783 0.00492 
ENSDARG00000087597 si:dkey-51d8.3  3.03127 1.07917 0.00497 
ENSDARG00000075721 zdhhc6 ZDHHC6 2.65779 0.94692 0.00500 
ENSDARG00000070951 hmga1b HMGA1 1.91093 0.68457 0.00525 
ENSDARG00000090386 cd3eap CD3EAP 2.17912 0.78118 0.00528 
ENSDARG00000102025 znf644b ZNF644 1.91499 0.68683 0.00530 
ENSDARG00000100265 rhcgb RHCG 2.04416 0.73349 0.00532 
ENSDARG00000078302 BRINP1 BRINP1 2.24778 0.80700 0.00535 
ENSDARG00000095273 cox8a  1.39140 0.49954 0.00535 
ENSDARG00000035781 ctdnep1b CTDNEP1 1.43523 0.51553 0.00537 
ENSDARG00000105300 BX927081.1  2.51524 0.90458 0.00543 
ENSDARG00000007141 psmc3 PSMC3 2.55943 0.92434 0.00562 
ENSDARG00000078309 fam83b FAM83B 2.05988 0.74468 0.00567 
ENSDARG00000068708 ifrd1 IFRD1 2.68506 0.97287 0.00578 
ENSDARG00000052652 fermt1 FERMT1 2.05974 0.74808 0.00590 
ENSDARG00000058476 stc1l STC1 3.37701 1.22711 0.00592 
ENSDARG00000060841 pik3c2a PIK3C2A 2.01006 0.73189 0.00603 
ENSDARG00000098171 zgc:162193 TCAF1 3.26928 1.19619 0.00627 
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ENSDARG00000093448 mpc1 MPC1 1.89887 0.69572 0.00635 
ENSDARG00000100374 txnrd1 TXNRD3 2.36426 0.86662 0.00637 
ENSDARG00000075054 RASGRF2    2.08037 0.76273 0.00638 
ENSDARG00000005629 smyd2b  2.16454 0.79362 0.00638 
ENSDARG00000043436 si:dkey-5n18.1  2.03206 0.74733 0.00655 
ENSDARG00000020345 clasp2 CLASP2 2.03636 0.74959 0.00659 
ENSDARG00000095824 si:ch211-207c7.6  3.70881 1.36635 0.00664 
ENSDARG00000007219 actn1 ACTN1 2.61721 0.96445 0.00665 
ENSDARG00000076230 atp10b ATP10B 2.12192 0.78200 0.00666 
ENSDARG00000001870 atp1a1a.4 ATP1A1 1.80662 0.66599 0.00667 
ENSDARG00000092281 FLNB  1.60401 0.59191 0.00673 
ENSDARG00000093549 sepp1a SEPP1 2.16546 0.80113 0.00687 
ENSDARG00000058256 draxin DRAXIN 1.70148 0.63214 0.00711 
ENSDARG00000027063 arpc1b ARPC1B 1.19085 0.44255 0.00713 
ENSDARG00000063916 mt-nd4l MT-ND4L 1.70996 0.63553 0.00713 
ENSDARG00000102911 FO704569.1 IFFO2 2.74555 1.02454 0.00737 
ENSDARG00000019128 tpm4b  1.25233 0.46762 0.00740 
ENSDARG00000036414 CU019646.1 Irs3 1.69193 0.63204 0.00743 
ENSDARG00000063253 hecw2b HECW2 1.74760 0.65442 0.00758 
ENSDARG00000068127 si:ch211-194e1.9  1.92270 0.72004 0.00758 
ENSDARG00000030224 ppp2ca  1.94734 0.72939 0.00759 
ENSDARG00000105287 mpp1 MPP1 1.73671 0.65086 0.00762 
ENSDARG00000081535 U1 Gm25481 3.64861 1.36949 0.00772 
ENSDARG00000090323 U1 Gm25481 3.64861 1.36949 0.00772 
ENSDARG00000074633 gpr35.1 GPR35 3.07977 1.15756 0.00780 
ENSDARG00000103401 CR318592.1  1.32279 0.49729 0.00781 
ENSDARG00000095627 c1qc C1QC 1.73365 0.65331 0.00796 
ENSDARG00000100324 AL627305.1  1.80653 0.68091 0.00798 
ENSDARG00000003157 nfkbil1 NFKBIL1 1.96589 0.74211 0.00807 
ENSDARG00000096072 si:dkey-29j8.4  1.68541 0.63636 0.00808 
ENSDARG00000088141 CU570684.4  2.26242 0.85427 0.00809 
ENSDARG00000102495 CT573234.4  2.69978 1.02324 0.00833 
ENSDARG00000038812 e2f5 E2F5 1.27729 0.48417 0.00834 
ENSDARG00000059483 tead1b TEAD1 2.22345 0.84425 0.00845 
ENSDARG00000016494 ddc DDC 1.42753 0.54379 0.00866 
ENSDARG00000008723 prkcba PRKCB 2.84274 1.08329 0.00869 
ENSDARG00000101394 fam69b FAM69B 1.46925 0.56046 0.00875 
ENSDARG00000058830 zdhhc3b ZDHHC3 1.13491 0.43310 0.00878 
ENSDARG00000014101 pyroxd2 PYROXD2 2.12772 0.81416 0.00897 
ENSDARG00000097197 si:ch211-129i21.3  1.58916 0.60887 0.00905 
ENSDARG00000098488 CABZ01118154.1  2.42216 0.92826 0.00907 
ENSDARG00000089868  TNFRSF25 2.45031 0.93974 0.00912 
ENSDARG00000078176 PHYHIP PHYHIP 1.58381 0.60754 0.00914 
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ENSDARG00000035564 dgcr8 DGCR8 1.49635 0.57442 0.00919 
ENSDARG00000097760 si:dkey-7i4.8  2.04308 0.78593 0.00933 
ENSDARG00000096319 si:ch211-239j9.1  1.41906 0.54591 0.00934 
ENSDARG00000102956 mmp17b  1.70881 0.65781 0.00938 
ENSDARG00000102371 CU570769.1  2.07912 0.80079 0.00942 
ENSDARG00000099177 dok1b DOK1 2.88063 1.10998 0.00945 
ENSDARG00000021398 mul1a  1.44188 0.55821 0.00979 
ENSDARG00000045553 hsd17b2 HSD17B2 1.39776 0.54163 0.00986 
ENSDARG00000079785 si:dkeyp-73a2.2  1.91236 0.74186 0.00994 
ENSDARG00000044345 cyfip1 CYFIP1 2.03627 0.79000 0.00995 
	
Table AK: Diﬀerentially upregulated genes in mutant neutrophils. Only genes with a P < .QQ% are 
shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000042138 selp SELL -3.04896 0.59785 0.00000 
ENSDARG00000033444 map4k6 MAP4K2 -4.01617 0.84634 0.00000 
ERCC-00042 ERCC-00042 NA -4.75380 1.08751 0.00001 
ENSDARG00000104818 CES3 CES3 -2.75097 0.63641 0.00002 
ENSDARG00000043334 ccdc6a CCDC6 -3.61066 0.87577 0.00004 
ENSDARG00000067741 itpkcb ITPKC -2.58164 0.63857 0.00005 
ENSDARG00000098628 si:dkey-9i5.1  -4.16795 1.05068 0.00007 
ENSDARG00000002956 si:dkey-32n7.4 ITGAM -2.79746 0.72569 0.00012 
ENSDARG00000077337 si:ch211-171h4.5  -1.87201 0.50600 0.00022 
ENSDARG00000087564 nek11 NEK11 -4.06295 1.11601 0.00027 
ENSDARG00000103924 zgc:154055  -1.67541 0.46136 0.00028 
ENSDARG00000003216 anxa2a ANXA2 -3.71167 1.02899 0.00031 
ENSDARG00000100114 sf3a3 SF3A3 -2.97638 0.84447 0.00042 
ENSDARG00000031683 fosab FOS -3.51773 1.03765 0.00070 
ERCC-00046 ERCC-00046 NA -1.46786 0.43507 0.00074 
ENSDARG00000036094 PIAS1    -3.43700 1.03159 0.00086 
ENSDARG00000104202 CABZ01077978.1  -2.66810 0.80729 0.00095 
ENSDARG00000097135 si:ch211-63i2.1  -3.10475 0.94695 0.00104 
ENSDARG00000045224 glipr1a GLIPR1L1 -1.36832 0.41844 0.00108 
ENSDARG00000070606 ikbke IKBKE -3.70728 1.14586 0.00121 
ENSDARG00000105273 si:ch73-295i22.2  -2.10778 0.65916 0.00139 
ENSDARG00000030110 myod1 MYOD1 -2.34943 0.73557 0.00140 
ENSDARG00000090730 zgc:158446 XXbac-BPG116M5.17 -1.67997 0.52725 0.00144 
ENSDARG00000060655 BX005421.1 Gvin1 -3.66100 1.16496 0.00167 
ENSDARG00000078547 si:ch211-264f5.2  -2.62420 0.84418 0.00188 
ENSDARG00000095699 dicp1.9  -3.56946 1.16318 0.00215 
ERCC-00113 ERCC-00113 NA -1.63787 0.53447 0.00218 
ENSDARG00000094097 si:ch211-209a2.1  -2.00000 0.65453 0.00225 
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ENSDARG00000007975 fth1b FTMT -2.68808 0.88747 0.00245 
ENSDARG00000101553 CABZ01111555.1  -1.76871 0.59125 0.00278 
ENSDARG00000010756 nod2 NOD2 -3.49984 1.17295 0.00285 
ENSDARG00000105061 si:ch73-261i21.5  -3.47504 1.17061 0.00299 
ENSDARG00000090767 si:ch211-136m16.8  -1.63015 0.54922 0.00300 
ENSDARG00000096403 si:dkey-153m14.1  -1.28642 0.43377 0.00302 
ENSDARG00000063670 gtf2a1l GTF2A1L -3.47369 1.17160 0.00303 
ENSDARG00000056050 kctd17 KCTD17 -2.71101 0.92164 0.00327 
ENSDARG00000103175 CR626875.1  -2.70467 0.92595 0.00349 
ENSDARG00000029063 clpxa CLPX -3.17152 1.08927 0.00360 
ENSDARG00000086173 relb RELB -2.00455 0.69434 0.00389 
ENSDARG00000102043 CABZ01040256.1  -2.06733 0.72042 0.00411 
ENSDARG00000099010 CABZ01004882.1  -2.20407 0.76900 0.00415 
ENSDARG00000099404 CR753902.1  -2.08661 0.72828 0.00417 
ENSDARG00000007601 zmynd8 ZMYND8 -3.07322 1.07482 0.00425 
ENSDARG00000104968 si:ch211-227e10.1  -2.69580 0.94602 0.00438 
ENSDARG00000101315 CABZ01039820.1  -1.78201 0.63195 0.00480 
ENSDARG00000088309 ENDOD1  -2.66792 0.94787 0.00488 
ERCC-00074 ERCC-00074 NA -1.16507 0.41459 0.00495 
ENSDARG00000054799 rfc1 RFC1 -3.11313 1.11136 0.00509 
ENSDARG00000032373 rnf145b RNF145 -2.21101 0.78962 0.00511 
ENSDARG00000089382 zgc:158463  -1.53044 0.54657 0.00511 
ENSDARG00000044235 si:dkey-36h5.1  -3.03557 1.08706 0.00523 
ENSDARG00000076025 dgkzb DGKZ -1.31512 0.47126 0.00526 
ENSDARG00000054616 cldni RP1-4G17.5 -2.93782 1.05553 0.00538 
ENSDARG00000061370 tsen34 TSEN34 -3.26057 1.18956 0.00613 
ENSDARG00000006758 FAM234B FAM234B -2.34959 0.85727 0.00613 
ENSDARG00000011824 pbxip1b  -1.55391 0.56761 0.00619 
ENSDARG00000104308 BX537263.2  -1.57474 0.57796 0.00644 
ENSDARG00000103816 BX537263.1  -1.57474 0.57796 0.00644 
ENSDARG00000040571 ube4a UBE4A -2.99410 1.10350 0.00666 
ENSDARG00000063097 scube1 SCUBE1 -1.72505 0.63592 0.00667 
ENSDARG00000099973 ctage5 CTAGE5 -2.28491 0.84770 0.00703 
ENSDARG00000077297 nbr1 NBR1 -2.71055 1.00819 0.00718 
ENSDARG00000001220 mycbp2 MYCBP2 -1.29957 0.48419 0.00727 
ENSDARG00000009953 med14 MED14 -2.84265 1.05967 0.00731 
ENSDARG00000079104 mfhas1 MFHAS1 -2.94585 1.10042 0.00743 
ENSDARG00000036168 nfatc1 NFATC1 -2.51203 0.93861 0.00744 
ENSDARG00000068214 ccni CCNI -0.90480 0.33808 0.00744 
ENSDARG00000079312 kmt2ca KMT2C -1.00799 0.37769 0.00761 
ENSDARG00000040668 lrtomt Lrrc51 -2.86069 1.07590 0.00784 
ENSDARG00000008153 serinc5 SERINC5 -1.40503 0.52856 0.00785 
ENSDARG00000103635 si:dkeyp-3b12.10  -1.34041 0.50442 0.00788 
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ENSDARG00000077918 dnase2b DNASE2B -2.62891 0.98970 0.00790 
ENSDARG00000040439 rsl24d1 RSL24D1 -1.02622 0.38986 0.00848 
ENSDARG00000017165 slc3a1 SLC3A1 -2.00396 0.76237 0.00857 
ENSDARG00000062385 flcn FLCN -3.11766 1.19854 0.00929 
ENSDARG00000074245 spen SPEN -2.35026 0.90411 0.00933 
ENSDARG00000089706 ANPEP    -1.60632 0.61893 0.00945 
ENSDARG00000020711 rrm2 RRM2 -2.87852 1.11340 0.00973 
	
Table AO: Diﬀerentially downregulated genes in mutant neutrophils. Only genes with a P < .QQ% are 
shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000040252 atp1a1a.5 ATP1A1 4.53260 0.77854 0.00000 
ENSDARG00000098639 pycr1b PYCR1 2.28789 0.54154 0.00002 
ENSDARG00000018574 sf3b4 SF3B4 3.74856 0.92349 0.00005 
ENSDARG00000070076 actr2b ACTR2 3.19605 0.81186 0.00008 
ENSDARG00000101534 rab3db RAB3D 4.29220 1.14278 0.00017 
ENSDARG00000100075 abcg2a ABCG2 3.93941 1.05964 0.00020 
ENSDARG00000008380 brd7 BRD7 3.62897 0.97548 0.00020 
ENSDARG00000053609 pddc1 PDDC1 3.57902 0.94612 0.00016 
ENSDARG00000098231 HHEX HHEX 3.49944 0.93430 0.00018 
ENSDARG00000074667 akt1s1 AKT1S1 3.33291 0.88736 0.00017 
ENSDARG00000053136 b2m B2M 1.92578 0.50926 0.00016 
ENSDARG00000077473 mych  4.26896 1.15675 0.00022 
ENSDARG00000104635 si:busm1-194e12.12 HLA-DRB1 3.61245 1.00462 0.00032 
ENSDARG00000038587 CU929150.1  2.27314 0.65211 0.00049 
ENSDARG00000075881 si:ch211-39k3.2 SERF1B 4.09407 1.18344 0.00054 
ENSDARG00000071694 ndc80 NDC80 4.01394 1.18319 0.00069 
ENSDARG00000074322 si:ch211-194m7.3  3.72320 1.08287 0.00059 
ENSDARG00000100743 si:dkey-190j3.4  3.62591 1.06767 0.00068 
ENSDARG00000055270 si:ch1073-358c10.1  3.59872 1.04720 0.00059 
ENSDARG00000010625 clic2 CLIC2 3.21759 0.94367 0.00065 
ENSDARG00000036700  	 3.20967 0.94815 0.00071 
ENSDARG00000056085 mob4 MOB4 3.15209 0.92973 0.00070 
ENSDARG00000091111 TIFA TIFA 2.88701 0.85511 0.00073 
ENSDARG00000092731 mhc1uka FCGRT 1.80730 0.53178 0.00068 
ENSDARG00000035853 cdkn2aip CDKN2AIP 3.75028 1.12185 0.00083 
ENSDARG00000092124 cox14 COX14 1.85608 0.55714 0.00086 
ENSDARG00000059294 marco MARCO 2.00016 0.60244 0.00090 
ENSDARG00000017034 sqrdl SQRDL 3.15307 0.95952 0.00102 
ENSDARG00000038097 pigq PIGQ 3.57942 1.09799 0.00111 
ENSDARG00000074732 BX682234.1  2.62830 0.80647 0.00112 
ENSDARG00000005536 ubr7 UBR7 3.42568 1.05489 0.00116 
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ENSDARG00000059020 thap1 THAP1 3.26196 1.01481 0.00131 
ENSDARG00000018968 acvr1ba ACVR1B 3.49882 1.09113 0.00134 
ENSDARG00000095746     3.31616 1.03865 0.00141 
ENSDARG00000005098 zgc:86764  3.78900 1.19852 0.00157 
ENSDARG00000013771 ctssb.2 CTSS 2.32041 0.74009 0.00172 
ENSDARG00000088745     2.42336 0.77531 0.00177 
ENSDARG00000011146 uqcrb UQCRB 1.36447 0.43696 0.00179 
ENSDARG00000053990 hmgb2b  1.88566 0.60898 0.00196 
ENSDARG00000055120 ctsba CTSB 1.47301 0.47597 0.00197 
ENSDARG00000097082 im:7152348  3.27231 1.06019 0.00203 
ENSDARG00000094210 zgc:109934  1.58334 0.51601 0.00215 
ENSDARG00000038667 fggy FGGY 3.51797 1.15057 0.00223 
ENSDARG00000033285 gsto2 GSTO2 2.75325 0.90407 0.00232 
ENSDARG00000022303 higd1a HIGD1A 2.19279 0.71917 0.00230 
ENSDARG00000086712 si:dkeyp-97b10.3  3.39558 1.11952 0.00242 
ENSDARG00000089667     3.33877 1.11770 0.00282 
ENSDARG00000101337 zgc:103700 HLA-DRB1 2.45759 0.82070 0.00275 
ENSDARG00000034817 asah1b ASAH1 2.37546 0.79473 0.00280 
ENSDARG00000056583 ndufs6 NDUFS6 1.78485 0.60099 0.00298 
ENSDARG00000002165 psme1 PSME1 1.83852 0.62594 0.00331 
ENSDARG00000055314 mcmbp MCMBP 3.15962 1.08205 0.00350 
ENSDARG00000020252 btbd10b BTBD10 2.58145 0.88568 0.00356 
ENSDARG00000086947 si:ch211-147m6.1  3.10102 1.07946 0.00407 
ENSDARG00000100562 sdc3 SDC3 3.08242 1.06659 0.00385 
ENSDARG00000037283 plrg1 PLRG1 3.01539 1.05339 0.00420 
ENSDARG00000019861 fgl2a FGL2 2.38800 0.83294 0.00414 
ENSDARG00000039579 cfd CFD 2.28427 0.79547 0.00408 
ENSDARG00000090783 mfap4 MFAP4 2.20937 0.77103 0.00416 
ENSDARG00000043154 ucp2 UCP2 1.89722 0.66259 0.00419 
ENSDARG00000067975 atpif1a ATPIF1 1.15120 0.39885 0.00390 
ENSDARG00000099455 ogt.2 OGT 1.89602 0.66800 0.00453 
ENSDARG00000028396 fkbp5 FKBP5 2.24094 0.79050 0.00458 
ENSDARG00000104018 mtpn MTPN 1.65711 0.58819 0.00484 
ENSDARG00000070589 mrpl35 MRPL35 2.78353 0.99224 0.00503 
ENSDARG00000096668 MZT1 MZT1 2.72871 0.97885 0.00531 
ENSDARG00000018328 rhoad RHOC 1.33618 0.48013 0.00539 
ENSDARG00000057853 atp6v0ca ATP6V0C 1.13943 0.40895 0.00533 
ENSDARG00000101831 irx1a IRX1 3.13593 1.12998 0.00552 
ENSDARG00000089505 bod1l1 BOD1L1 2.82611 1.01848 0.00552 
ENSDARG00000100825 calm3a  2.28073 0.82098 0.00547 
ENSDARG00000101791 ccbl2 CCBL2 3.34393 1.21956 0.00611 
ENSDARG00000061896 slco2a1 SLCO2A1 3.20746 1.17497 0.00634 
ENSDARG00000095974 si:ch73-211l13.2  3.18486 1.16298 0.00617 
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ENSDARG00000069961 il21r.1 IL21R 3.03720 1.10633 0.00605 
ENSDARG00000027803 sbds SBDS 2.44424 0.88634 0.00582 
ENSDARG00000014676 bckdhb BCKDHB 2.14469 0.77680 0.00576 
ENSDARG00000017049 adsl RP5-1042K10.14 2.10812 0.77068 0.00623 
ENSDARG00000004173 copa COPA 1.97511 0.72232 0.00625 
ENSDARG00000095627 c1qc C1QC 1.91451 0.69376 0.00579 
ENSDARG00000044267 sumo1 SUMO1 1.65065 0.60515 0.00638 
ENSDARG00000098584 ndufa13 NDUFA13 1.46654 0.53816 0.00643 
ENSDARG00000010149 atp5a1 ATP5A1 1.17689 0.42863 0.00604 
ENSDARG00000005870 mmadhc MMADHC 2.31712 0.85206 0.00654 
ENSDARG00000037238 smad5  2.71075 1.00146 0.00679 
ENSDARG00000036895 dap1b  2.45853 0.90799 0.00678 
ENSDARG00000055592 capn2b CAPN2 2.44983 0.90731 0.00693 
ENSDARG00000100513 rps27.2 RPS27L 1.62017 0.60063 0.00699 
ENSDARG00000014794 uqcrc2a UQCRC2 1.74548 0.64869 0.00713 
ENSDARG00000021346 pdhb PDHB 1.03862 0.38963 0.00768 
ENSDARG00000104537 cox7c COX7C 1.05819 0.40205 0.00849 
ENSDARG00000043687 SAYSD1 SAYSD1 2.45341 0.93739 0.00886 
ENSDARG00000042793 tpp1 TPP1 2.08217 0.79876 0.00914 
ENSDARG00000038938 ssfa2 SSFA2 2.83869 1.09293 0.00940 
ENSDARG00000006260 tuba8l4  1.08866 0.42032 0.00960 
ENSDARG00000056089 nrbp1 NRBP1 2.33396 0.90450 0.00987 
ENSDARG00000039150 lgmn LGMN 1.12194 0.43493 0.00989 
ENSDARG00000042892 paip1 PAIP1 2.68064 1.04039 0.00998 
	
Table AQ: Diﬀerentially upregulated genes in mutant progenitors. Only genes with a P < .QQ% are 
shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000004692 nabp1a NABP1 -6.11321 1.26393 0.00000 
ENSDARG00000100789 plgrkt PLGRKT -4.73613 1.00113 0.00000 
ENSDARG00000091428 FCHSD2 FCHSD2 -2.32393 0.55272 0.00003 
ENSDARG00000100854 ago4 AGO4 -3.28611 0.79013 0.00003 
ENSDARG00000011094 ccna2 CCNA2 -5.45405 1.35635 0.00006 
ENSDARG00000031795 abcf1 ABCF1 -2.27593 0.56599 0.00006 
ENSDARG00000070959 si:ch211-288g17.3  -2.91850 0.76496 0.00014 
ENSDARG00000015394 thoc7 THOC7 -5.09984 1.36451 0.00019 
ENSDARG00000100623 trrap TRRAP -5.09684 1.37027 0.00020 
ENSDARG00000099351 igfbp1a IGFBP1 -3.43624 0.93008 0.00022 
ENSDARG00000100894 si:ch211-193k8.5  -5.18729 1.40925 0.00023 
ENSDARG00000058471 plk1 PLK1 -4.98256 1.36357 0.00026 
ENSDARG00000020711 rrm2 RRM2 -3.58323 1.01127 0.00040 
ENSDARG00000016783 srsf6b SRSF6 -2.04507 0.58187 0.00044 
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ENSDARG00000103028 CABZ01052487.1 GIMAP8 -4.92962 1.40317 0.00044 
ENSDARG00000054007 ppp1r2 PPP1R2 -4.92928 1.41298 0.00049 
ENSDARG00000075795 nol7 NOL7 -4.83986 1.39408 0.00052 
ENSDARG00000031683 fosab FOS -4.58693 1.33680 0.00060 
ENSDARG00000025859 lmf2b LMF2 -4.72071 1.38236 0.00064 
ENSDARG00000051923 ccnb1 CCNB1 -4.10270 1.21056 0.00070 
ENSDARG00000026028 ankrd44 ANKRD44 -2.37154 0.70347 0.00075 
ENSDARG00000008593 nbas NBAS -4.64063 1.37903 0.00077 
ENSDARG00000005468 irf2bp1 IRF2BP1 -4.15585 1.24789 0.00087 
ENSDARG00000051902 prmt7 PRMT7 -4.65158 1.39854 0.00088 
ENSDARG00000095556 si:dkey-238c7.12  -1.39073 0.41958 0.00092 
ENSDARG00000003526 psma5 PSMA5 -3.34648 1.01084 0.00093 
ENSDARG00000035150 si:dkey-261j4.4  -4.52124 1.36972 0.00096 
ENSDARG00000006240 slc27a1a SLC27A1 -4.65038 1.41344 0.00100 
ENSDARG00000060917 anln ANLN -4.65234 1.41432 0.00100 
ENSDARG00000099161 dyx1c1 DYX1C1 -4.74873 1.44434 0.00101 
ENSDARG00000041317 rangap1a RANGAP1 -4.02224 1.22916 0.00107 
ENSDARG00000046002 necap2 NECAP2 -1.76266 0.53903 0.00108 
ENSDARG00000035634 rfc5 RFC5 -3.50785 1.08663 0.00125 
ENSDARG00000007130 mrto4 MRTO4 -4.72355 1.46749 0.00129 
ENSDARG00000101180 mcm7 MCM7 -1.93034 0.60000 0.00129 
ENSDARG00000071341 abch1  -3.83865 1.19412 0.00131 
ENSDARG00000059323 rpn1 RPN1 -2.94994 0.91950 0.00134 
ENSDARG00000003527 mak16 MAK16 -4.51373 1.41019 0.00137 
ENSDARG00000008502 pno1 PNO1 -1.74775 0.55207 0.00155 
ENSDARG00000073850 hdac7b HDAC7 -4.50233 1.42646 0.00160 
ENSDARG00000036995 lsm6 LSM6 -3.63722 1.15902 0.00170 
ENSDARG00000101521 UBE2M UBE2M -4.34394 1.39443 0.00184 
ENSDARG00000078894 hemk1 HEMK1 -4.28099 1.37744 0.00188 
ENSDARG00000021112 c1d C1D -4.34600 1.41480 0.00213 
ENSDARG00000101935 si:ch211-195b11.4  -3.66765 1.19402 0.00213 
ENSDARG00000008447 fkbp4 FKBP4 -4.09399 1.33292 0.00213 
ENSDARG00000104708 ddx24 DDX24 -2.59427 0.84972 0.00226 
ENSDARG00000102590 polr3h POLR3H -3.91086 1.28218 0.00229 
ENSDARG00000005926 ak2 AK2 -1.98585 0.65827 0.00255 
ENSDARG00000003599 rpl3 RPL3 -0.94842 0.31439 0.00256 
ENSDARG00000101134 CABZ01064859.2  -4.42378 1.47488 0.00270 
ENSDARG00000004372 fmnl3 FMNL3 -2.88507 0.96281 0.00273 
ENSDARG00000076509 polr2d POLR2D -2.86996 0.95853 0.00275 
ENSDARG00000087186 ZHX3    -2.95715 0.99073 0.00284 
ENSDARG00000004713 mad2l1 MAD2L1 -4.30140 1.44423 0.00290 
ENSDARG00000030022 nup188 NUP188 -4.03695 1.35589 0.00291 
ENSDARG00000079605 prmt5 PRMT5 -3.34879 1.12803 0.00299 
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ENSDARG00000002403 nusap1 NUSAP1 -3.84951 1.30752 0.00324 
ENSDARG00000074129 edem3 EDEM3 -4.18687 1.42218 0.00324 
ENSDARG00000078315 C5H12orf49 C12orf49 -4.27258 1.45288 0.00327 
ENSDARG00000098787 si:dkey-10p5.7  -2.18830 0.74754 0.00342 
ENSDARG00000004527 pin4 PIN4 -3.52212 1.20992 0.00360 
ENSDARG00000103492 si:ch73-111k22.3  -4.15822 1.44301 0.00396 
ENSDARG00000101942 si:dkey-260j18.2  -4.14188 1.43832 0.00398 
ENSDARG00000091902 b3gnt2b B3GNT2 -2.65345 0.92294 0.00404 
ENSDARG00000043960 rpf2 RPF2 -2.37113 0.82538 0.00407 
ENSDARG00000032157 grk6 GRK6 -3.54695 1.23623 0.00412 
ENSDARG00000043081 ctsz CTSZ -2.25601 0.78818 0.00421 
ENSDARG00000029150 hsp90ab1 HSP90AB1 -0.97299 0.34141 0.00437 
ENSDARG00000042854 ephx1 EPHX1 -4.13382 1.45549 0.00451 
ENSDARG00000104837 nudc NUDC -2.16224 0.76204 0.00455 
ENSDARG00000009743 efhc1 EFHC1 -4.16374 1.46799 0.00456 
ENSDARG00000097421 si:dkeyp-50b9.1  -4.13353 1.46133 0.00468 
ENSDARG00000011405 rps9 RPS9 -0.87277 0.30882 0.00471 
ENSDARG00000069118 ppp2r5eb PPP2R5E -2.44501 0.86553 0.00473 
ENSDARG00000019181 rpsa RPSA -0.94660 0.33510 0.00473 
ENSDARG00000026489 khsrp KHSRP -2.20726 0.78464 0.00491 
ENSDARG00000014329 npm1a NPM1 -1.85758 0.66288 0.00507 
ENSDARG00000035559 tp53 TP53 -2.73582 0.97792 0.00515 
ENSDARG00000016393 arf1l Arf2 -2.20588 0.79011 0.00524 
ENSDARG00000022623 fbxo44 FBXO44 -3.81609 1.36873 0.00530 
ENSDARG00000076889 ralgapa1 RALGAPA1 -2.51200 0.90193 0.00535 
ENSDARG00000059711 nol6 NOL6 -3.84406 1.38421 0.00548 
ENSDARG00000017445 eif3i EIF3I -1.58956 0.57371 0.00559 
ENSDARG00000093708 arhgap20b ARHGAP20 -4.19441 1.51419 0.00560 
ENSDARG00000094646 dyrk2 DYRK2 -2.06285 0.74554 0.00566 
ENSDARG00000045565 noc4l NOC4L -3.49729 1.26635 0.00575 
ENSDARG00000092780 si:ch1073-170o4.1  -4.00759 1.45178 0.00577 
ENSDARG00000052856 khdrbs1a KHDRBS1 -1.12631 0.40868 0.00585 
ENSDARG00000056888  DNAH8 -3.58295 1.30082 0.00588 
ENSDARG00000029533 rpl18 RPL18 -0.82967 0.30137 0.00590 
ENSDARG00000059360 srsf3b SRSF3 -2.17223 0.78919 0.00591 
ENSDARG00000060695 znf346 ZNF346 -3.36929 1.22785 0.00607 
ENSDARG00000057026 ran RAN -1.03358 0.37670 0.00607 
ENSDARG00000032430 ppp2r1b PPP2R1B -3.18154 1.16383 0.00626 
ENSDARG00000076228 kif2c KIF2C -4.07476 1.49078 0.00627 
ENSDARG00000012073 kif15 KIF15 -4.08327 1.49576 0.00634 
ENSDARG00000045843 apex1 APEX1 -2.72842 1.00194 0.00647 
ENSDARG00000079783 isg20 AEN -3.25090 1.19496 0.00652 
ENSDARG00000030665 TCERG1    -4.05933 1.49305 0.00655 
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ENSDARG00000099358 hccsb HCCS -4.00750 1.47419 0.00656 
ENSDARG00000041350 ankrd39 ANKRD39 -4.06922 1.49692 0.00656 
ENSDARG00000061100 nars NARS -1.95386 0.71927 0.00660 
ENSDARG00000094719 si:dkeyp-1h4.9  -1.68042 0.62122 0.00683 
ENSDARG00000075650 dscr3 DSCR3 -2.34635 0.86872 0.00691 
ENSDARG00000055585 c1galt1a  -4.02413 1.49062 0.00694 
ENSDARG00000031108 lrba LRBA -2.57146 0.95263 0.00695 
ENSDARG00000016548 eif5b EIF5B -2.00373 0.74302 0.00700 
ENSDARG00000005791 rpl28 RPL28 -0.83371 0.30959 0.00708 
ENSDARG00000058328 lsm7 LSM7 -2.02065 0.75186 0.00720 
ENSDARG00000089602 si:dkey-217f16.1 Gvin1 -1.77492 0.66119 0.00727 
ENSDARG00000070606 ikbke IKBKE -3.45540 1.28996 0.00739 
ENSDARG00000100427 BX547934.1  -1.94059 0.72476 0.00742 
ENSDARG00000093647 si:dkey-48g21.7  -3.93777 1.47371 0.00754 
ENSDARG00000099243 CR855389.1  -3.38027 1.26747 0.00765 
ENSDARG00000002213 invs INVS -4.00168 1.50186 0.00771 
ENSDARG00000087950 IWS1 IWS1 -2.46194 0.92437 0.00774 
ENSDARG00000100292 fam166b FAM166B -3.93517 1.47793 0.00775 
ENSDARG00000004525 C2H1orf35 C1orf35 -3.03064 1.13854 0.00777 
ENSDARG00000078751 TPP2 TPP2 -1.69170 0.63569 0.00779 
ENSDARG00000016871 smarce1 SMARCE1 -1.77778 0.66941 0.00791 
ENSDARG00000098398 CABZ01079480.1  -3.90717 1.47306 0.00799 
ENSDARG00000101766 ptmab  -1.13536 0.42855 0.00807 
ENSDARG00000055502 cicb CIC -2.56901 0.96991 0.00808 
ENSDARG00000055996 rps8a RPS8 -1.05080 0.39708 0.00814 
ENSDARG00000102640 pdia3 PDIA3 -1.59758 0.60574 0.00835 
ENSDARG00000100514 cfap20 CFAP20 -3.41672 1.29683 0.00842 
ENSDARG00000070617 vhl VHL -3.89672 1.47957 0.00845 
ENSDARG00000088641 grn2  -3.26229 1.23968 0.00850 
ENSDARG00000060089 btaf1 BTAF1 -3.53527 1.34422 0.00854 
ENSDARG00000014634 mbtps1 MBTPS1 -3.33413 1.26796 0.00855 
ENSDARG00000035692 rps3a RPS3A -1.05131 0.40020 0.00861 
ENSDARG00000077584 cln6a CLN6 -3.95042 1.50601 0.00871 
ENSDARG00000010279 scamp2 SCAMP2 -3.00204 1.14562 0.00878 
ENSDARG00000019117 parvb PARVB -3.38174 1.29520 0.00903 
ENSDARG00000077092 elk4 ELK4 -3.90162 1.49554 0.00909 
ENSDARG00000076729 myo9aa MYO9A -3.27436 1.25586 0.00913 
ENSDARG00000057683 mcm6 MCM6 -2.48226 0.95358 0.00924 
ENSDARG00000015862 rpl5b RPL5 -0.92330 0.35486 0.00927 
ENSDARG00000053990 hmgb2b  -1.92119 0.73851 0.00928 
ENSDARG00000056679 morc3a MORC3 -2.83339 1.09068 0.00938 
ENSDARG00000016789 zgc:152891 ALOXE3 -3.89583 1.50064 0.00943 
ENSDARG00000074242 serbp1a SERBP1 -1.01029 0.38917 0.00943 
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ENSDARG00000062116 ctdsplb CTDSPL -2.83024 1.09248 0.00958 
ENSDARG00000068681 crfb1  -3.67630 1.42241 0.00975 
ENSDARG00000021753 ccdc25 CCDC25 -2.85942 1.10738 0.00982 
ENSDARG00000097102 si:ch73-281n10.2  -1.93791 0.75088 0.00986 
ENSDARG00000041875 ube2v1  -1.82376 0.70678 0.00987 
ENSDARG00000074688 fbrs FBRS -3.42459 1.32725 0.00987 
ENSDARG00000006307 shisa4 SHISA4 -3.12270 1.21062 0.00990 
ENSDARG00000096885 si:dkey-74h17.4  -3.93961 1.52801 0.00993 
ENSDARG00000007320 rpl7 RPL7 -0.90308 0.35051 0.00998 
	
Table A(S: Diﬀerentially downregulated genes in mutant progenitors. Only genes with a P < .QQ% 
are shown. FC SE = fold change standard error. ENSEMBL IDs correspond to the zebraﬁsh gene. 
ENSEMBL ID Zebrafish Human Fold change (log2) FC SE P 
ENSDARG00000055523 slc22a6l SLC22A8 4.66096 0.96073 0.00000 
ENSDARG00000101914 metrnl METRNL 4.80443 1.03917 0.00000 
ENSDARG00000040252 atp1a1a.5 ATP1A1 4.42554 1.02970 0.00002 
ENSDARG00000053535 lmo7b LMO7 5.23446 1.24815 0.00003 
ENSDARG00000089917 sh3tc2 SH3TC2 4.95516 1.20801 0.00004 
ENSDARG00000058094 ciarta CIART 4.40436 1.08706 0.00005 
ENSDARG00000099448 sh3d21 SH3D21 5.69812 1.41365 0.00006 
ENSDARG00000006545 rgp1 RGP1 4.79622 1.19113 0.00006 
ENSDARG00000056108 ndufa4  4.24860 1.05673 0.00006 
ENSDARG00000075980 tmem125b TMEM125 4.23016 1.07369 0.00008 
ENSDARG00000037739 zgc:112980  3.77631 0.96407 0.00009 
ENSDARG00000035540 brwd3 BRWD3 5.13085 1.32140 0.00010 
ENSDARG00000028780 gzma GZMK 4.65030 1.19795 0.00010 
ENSDARG00000052170 uap1 UAP1 4.80270 1.26544 0.00015 
ENSDARG00000097300 si:ch211-242h13.4  4.12655 1.08744 0.00015 
ENSDARG00000003219 bin2a BIN2 4.09537 1.08207 0.00015 
ENSDARG00000095717 si:dkey-172k15.6  5.51321 1.46558 0.00017 
ENSDARG00000098686 tmprss2 TMPRSS2 3.93552 1.04955 0.00018 
ENSDARG00000100198 SNCAIP SNCAIP 5.46773 1.46045 0.00018 
ENSDARG00000016519 ctdnep1a CTDNEP1 4.73497 1.27116 0.00020 
ENSDARG00000055648 cpda CPD 3.63825 0.99010 0.00024 
ENSDARG00000102870 si:dkeyp-123a12.2  5.29655 1.44912 0.00026 
ENSDARG00000082142 CR753862.1  5.21744 1.43110 0.00027 
ENSDARG00000042090 PLA2G4C    2.31861 0.63996 0.00029 
ENSDARG00000038475 acy1 ACY1 3.44344 0.95284 0.00030 
ENSDARG00000103144 ppp1r21 PPP1R21 5.14704 1.42489 0.00030 
ENSDARG00000017168 nr2f1b  5.17033 1.43534 0.00032 
ENSDARG00000061180 vps45 VPS45 5.26262 1.46285 0.00032 
ENSDARG00000092346 nfil3-4  5.24512 1.46076 0.00033 
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ENSDARG00000091539 ptprjb.1 PTPRJ 5.23128 1.46032 0.00034 
ENSDARG00000087390 si:ch211-5k11.12 HBD 5.28762 1.49074 0.00039 
ENSDARG00000098817 KCTD5    3.06037 0.87144 0.00044 
ENSDARG00000062154 dip2ca DIP2C 5.09850 1.46084 0.00048 
ENSDARG00000102090 CABZ01021453.1  3.22840 0.92612 0.00049 
ENSDARG00000057681 ZMYM4 RP11-244H3.4 4.68571 1.34969 0.00052 
ENSDARG00000021149 cbr1l  4.09786 1.18203 0.00053 
ENSDARG00000094912 si:dkey-270m17.3  4.16127 1.20372 0.00055 
ENSDARG00000077434 mon1bb MON1B 5.12537 1.49180 0.00059 
ENSDARG00000002339 ccdc101 RP11-347C12.3 5.05534 1.47673 0.00062 
ENSDARG00000101074 glud1b  2.81900 0.82930 0.00068 
ENSDARG00000022660 armc2 ARMC2 2.29186 0.67494 0.00068 
ENSDARG00000033413 si:dkey-183c16.7  4.57798 1.35436 0.00072 
ENSDARG00000043497 scrn2  5.03727 1.49967 0.00078 
ENSDARG00000098631 DST    5.04248 1.50300 0.00079 
ENSDARG00000087394 tshz3a  5.01261 1.50647 0.00088 
ENSDARG00000100776 syt8 SYT8 3.65660 1.10113 0.00090 
ENSDARG00000015224 cd2ap CD2AP 4.92979 1.48781 0.00092 
ENSDARG00000078966 rbm15b RBM15B 3.24245 0.97886 0.00092 
ENSDARG00000009018 rhbg RHBG 2.90792 0.88176 0.00097 
ENSDARG00000105109 si:ch1073-329i9.1  2.82497 0.85698 0.00098 
ENSDARG00000025593 plekhj1 PLEKHJ1 1.64486 0.50070 0.00102 
ENSDARG00000036569 bach2a  4.09674 1.24942 0.00104 
ENSDARG00000041644 TMEM27 TMEM27 2.92272 0.89876 0.00115 
ENSDARG00000073999 tapt1a TAPT1 3.88371 1.20442 0.00126 
ENSDARG00000041078 chka CHKA 3.69334 1.14935 0.00131 
ENSDARG00000061256 FAM195A FAM195A 4.19439 1.30578 0.00132 
ENSDARG00000079102 PRRG3 PRRG3 2.70368 0.84294 0.00134 
ENSDARG00000081270 rn7sk RN7SKP90 3.82521 1.19341 0.00135 
ENSDARG00000070116 nit1 NIT1 3.97214 1.24483 0.00142 
ENSDARG00000052207 c3a.3 C3 4.83490 1.51772 0.00144 
ENSDARG00000068246 plcb3 PLCB3 1.66212 0.52218 0.00146 
ENSDARG00000103716 si:busm1-48c11.3 HLA-DMA 3.41185 1.07293 0.00147 
ENSDARG00000077410 myo9b MYO9B 2.94579 0.93167 0.00157 
ENSDARG00000069339 tbc1d24 TBC1D24 4.85084 1.53465 0.00157 
ENSDARG00000056627 cxcl14 CXCL14 4.79710 1.51903 0.00159 
ENSDARG00000069292 si:dkeyp-89c11.1  4.84071 1.53672 0.00163 
ENSDARG00000052099 agxta AGXT 4.06820 1.29230 0.00164 
ENSDARG00000004141 zgc:92630  4.82741 1.53742 0.00169 
ENSDARG00000062634 kat2b KAT2B 4.75800 1.51569 0.00169 
ENSDARG00000095459 si:ch211-191j22.3  3.24451 1.03372 0.00170 
ENSDARG00000070571 C11H1orf106  4.75955 1.51644 0.00170 
ENSDARG00000100677 tmem205 TMEM205 2.39036 0.76337 0.00174 
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ENSDARG00000015201 pcmt PCMT1 2.71712 0.87260 0.00185 
ENSDARG00000032849 ndrg1a NDRG1 1.79975 0.57849 0.00186 
ENSDARG00000042484 tle2  3.34564 1.07918 0.00193 
ENSDARG00000079497 C5H8orf4 C8orf4 3.82697 1.23668 0.00197 
ENSDARG00000096758 si:dkey-117p18.2  4.71549 1.52645 0.00201 
ENSDARG00000094561 si:ch211-139a5.9  2.15316 0.69866 0.00206 
ENSDARG00000103354 U1 RNU1-108P 4.42013 1.43845 0.00212 
ENSDARG00000061543 ccdc85b CCDC85B 3.84828 1.25495 0.00217 
ENSDARG00000040812 ncf4 NCF4 2.50487 0.81723 0.00218 
ENSDARG00000010571 ezh2 EZH2 2.82572 0.92213 0.00218 
ENSDARG00000104084 GPRIN2 GPRIN2 2.86751 0.93998 0.00228 
ENSDARG00000015915 slc25a36b SLC25A36 2.45524 0.80490 0.00229 
ENSDARG00000002670 ATG14 ATG14 3.95746 1.30007 0.00233 
ENSDARG00000074633 gpr35.1 GPR35 3.83375 1.26477 0.00244 
ENSDARG00000039997 ptp4a3 PTP4A3 3.92112 1.29688 0.00250 
ENSDARG00000105017 CT737138.1  3.68439 1.21903 0.00251 
ENSDARG00000036252 rras2 RRAS2 2.60459 0.86284 0.00254 
ENSDARG00000055043 depdc7 DEPDC7 3.82276 1.26830 0.00258 
ENSDARG00000102805 cyp2aa12  2.54246 0.84782 0.00271 
ENSDARG00000078069 rrm2 RRM2 4.25874 1.42055 0.00272 
ENSDARG00000018073 mrps22 MRPS22 3.49986 1.17109 0.00280 
ENSDARG00000104635 si:busm1-194e12.12 HLA-DRB1 3.00193 1.00511 0.00282 
ENSDARG00000078326 arhgap10 ARHGAP10 3.84371 1.29125 0.00291 
ENSDARG00000041691 bhlhe41 BHLHE41 3.81432 1.28164 0.00292 
ENSDARG00000022261 pdzk1 PDZK1 3.14777 1.05969 0.00297 
ENSDARG00000099139 fbxw5 FBXW5 3.08145 1.03820 0.00300 
ENSDARG00000104178 C3H19orf43 C19orf43 3.11087 1.05047 0.00306 
ENSDARG00000030839 tescb TESC 4.34226 1.46683 0.00307 
ENSDARG00000036041 f2 F2 3.44598 1.16455 0.00309 
ENSDARG00000016875 gys1 GYS1 2.88009 0.97532 0.00315 
ENSDARG00000017565 itk ITK 3.91112 1.32495 0.00316 
ENSDARG00000093549 sepp1a SEPP1 1.95063 0.66150 0.00319 
ENSDARG00000037855 taf11 TAF11 2.33529 0.79356 0.00325 
ENSDARG00000041787 cx32.3  3.32156 1.13020 0.00329 
ENSDARG00000103340 clic1 CLIC1 1.45145 0.49450 0.00333 
ENSDARG00000024090 dnajc4 DNAJC4 2.71008 0.92729 0.00347 
ENSDARG00000086808 ddhd1a DDHD1 3.36063 1.14991 0.00347 
ENSDARG00000055647 ftr82 TRIM29 4.53264 1.55380 0.00353 
ENSDARG00000036232 trpm7 TRPM1 2.48939 0.85363 0.00354 
ENSDARG00000012672 gtf2e2 GTF2E2 3.06320 1.05041 0.00354 
ENSDARG00000092170 apoc1l  4.52724 1.55291 0.00355 
ENSDARG00000090159 si:dkey-37m8.8  2.94296 1.00990 0.00357 
ENSDARG00000102566 fam102aa FAM102A 3.44785 1.18980 0.00376 
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ENSDARG00000069056 ranbp3b RANBP3 2.41843 0.83580 0.00381 
ENSDARG00000087981 SLC6A11 SLC6A11 1.80897 0.62710 0.00392 
ENSDARG00000021494 hnf4a HNF4A 3.04403 1.05653 0.00396 
ENSDARG00000089930 iqce IQCE 3.98109 1.38347 0.00401 
ENSDARG00000058865 endog ENDOG 4.47174 1.55714 0.00408 
ENSDARG00000073726 zbtb32 ZBTB32 2.91736 1.01649 0.00410 
ENSDARG00000007906 lrp2b  4.47300 1.56071 0.00416 
ENSDARG00000079745 si:ch211-166a6.5  3.25856 1.14294 0.00436 
ENSDARG00000042953 cyp2n13 CYP2J2 4.44811 1.56077 0.00437 
ENSDARG00000063436 RPH3A    2.22889 0.78272 0.00440 
ENSDARG00000037810 zgc:112175  3.37278 1.18458 0.00441 
ENSDARG00000008703 apeh APEH 2.66590 0.93651 0.00442 
ENSDARG00000105183 si:ch211-198i6.4  2.65541 0.93517 0.00452 
ENSDARG00000095082 BX571811.1 ITLN1 4.39884 1.54967 0.00453 
ENSDARG00000053257 zgc:153733  4.07124 1.43607 0.00458 
ENSDARG00000043457 gapdh GAPDH 2.41136 0.85079 0.00459 
ENSDARG00000028389 rab44 RAB44 2.41813 0.85506 0.00468 
ENSDARG00000088048 fgf18a FGF18 4.04314 1.43019 0.00470 
ENSDARG00000098661 AL935300.1  3.94111 1.39568 0.00475 
ENSDARG00000103573 si:dkey-48g21.5  1.92027 0.68239 0.00489 
ENSDARG00000044339 rp2 RP2 2.60806 0.92839 0.00497 
ENSDARG00000089885 slc16a12b SLC16A12 4.07096 1.46042 0.00531 
ENSDARG00000038577 cox6c COX6C 1.40727 0.50667 0.00548 
ENSDARG00000057433 st6galnac5b  4.33835 1.56540 0.00558 
ENSDARG00000100731 slc27a2b SLC27A2 2.36937 0.85513 0.00559 
ENSDARG00000059483 tead1b TEAD1 2.17327 0.78505 0.00563 
ENSDARG00000034714 esyt1a ESYT1 1.91368 0.69277 0.00574 
ENSDARG00000019579 ldb2a LDB2 2.37136 0.85868 0.00575 
ERCC-00053 ERCC-00053 NA 4.28651 1.55429 0.00582 
ENSDARG00000056252 sort1b SORT1 2.51930 0.91636 0.00597 
ENSDARG00000104666 BX511215.2 ZNF852 2.99792 1.09143 0.00602 
ENSDARG00000103388 znf609a ZNF609 2.36098 0.86020 0.00606 
ENSDARG00000020364 fbp1b FBP1 2.98153 1.08726 0.00610 
ENSDARG00000061985 rbm47 RBM47 2.08934 0.76235 0.00613 
ENSDARG00000087403 si:ch211-214p13.3  3.62829 1.32446 0.00615 
ENSDARG00000017143 brd9 BRD9 2.01004 0.73564 0.00629 
ENSDARG00000023362 nr5a1b NR5A1 2.93039 1.07251 0.00629 
ENSDARG00000027595 selt1b  3.18588 1.16663 0.00632 
ENSDARG00000096003 USMG5 USMG5 1.88522 0.69071 0.00635 
ENSDARG00000033056 zgc:171927  4.26492 1.56959 0.00658 
ENSDARG00000093354 si:ch211-57i17.2  3.93303 1.44821 0.00661 
ENSDARG00000055253 slc12a10.3  1.85091 0.68210 0.00666 
ENSDARG00000054060 pof1b POF1B 2.52600 0.93096 0.00666 
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ENSDARG00000070688 ncalda NCALD 1.02230 0.37710 0.00671 
ENSDARG00000037476 sorbs3 SORBS3 3.64437 1.34791 0.00686 
ENSDARG00000068474 si:dkey-94e7.2  4.04864 1.49892 0.00691 
ENSDARG00000053563 si:ch73-56d11.4 MS4A18 3.84591 1.42492 0.00695 
ENSDARG00000013087 ndrg3a NDRG3 3.52161 1.30658 0.00703 
ENSDARG00000034600 tmem165 TMEM165 3.96733 1.47496 0.00715 
ENSDARG00000009961 rundc3b RUNDC3B 1.73104 0.64383 0.00717 
ENSDARG00000053636 cracr2b CRACR2B 3.36234 1.25068 0.00718 
ENSDARG00000056331 ahcyl1 AHCYL1 2.19484 0.81691 0.00721 
ENSDARG00000086107 MTERF1 MTERF1 3.85667 1.43568 0.00722 
ENSDARG00000033231 mcm6l  4.22222 1.57297 0.00727 
ENSDARG00000099155 tpst2 TPST2 2.14378 0.79925 0.00731 
ENSDARG00000008884 hprt1 HPRT1 2.01657 0.75188 0.00732 
ENSDARG00000096809 si:ch211-168b3.2  1.91281 0.71344 0.00734 
ENSDARG00000017165 slc3a1 SLC3A1 2.68717 1.00244 0.00735 
ENSDARG00000098497 hrasa HRAS 3.33565 1.24484 0.00737 
ENSDARG00000077737 spsb3a SPSB3 1.70957 0.63807 0.00738 
ENSDARG00000098258 SLC16A7 SLC16A7 2.37630 0.88872 0.00750 
ENSDARG00000094215 si:dkey-240n22.2  3.45112 1.29408 0.00766 
ENSDARG00000095824 si:ch211-207c7.6  3.96139 1.48582 0.00767 
ENSDARG00000102762 pik3r5 PIK3R5 3.90849 1.46716 0.00772 
ENSDARG00000101547 CR354395.1  3.95906 1.48953 0.00786 
ENSDARG00000033046 ccni2 CCNI2 2.17099 0.81756 0.00792 
ENSDARG00000074468 prdm11 PRDM11 2.55153 0.96220 0.00801 
ENSDARG00000073843 myo9ab MYO9A 2.77831 1.04793 0.00802 
ENSDARG00000097082 im:7152348  3.81288 1.43887 0.00805 
ENSDARG00000031434 rcor1 RCOR1 2.63775 0.99633 0.00811 
ENSDARG00000099902 IL17RC IL17RC 2.70142 1.02061 0.00812 
ENSDARG00000043102 lxn RARRES1 1.94432 0.73601 0.00825 
ENSDARG00000010042 dnm1a DNM1 3.04935 1.15554 0.00832 
ENSDARG00000097721 si:dkey-234i14.21  2.28694 0.86694 0.00834 
ENSDARG00000010423 npsn ASTL 2.56409 0.97363 0.00845 
ENSDARG00000091003 il34 IL34 3.37825 1.28368 0.00850 
ENSDARG00000102153 nrp1a NRP1 2.70626 1.02860 0.00851 
ENSDARG00000101979 eps8l3a EPS8L3 2.99633 1.13961 0.00856 
ENSDARG00000012610 saga SAG 1.73437 0.66174 0.00877 
ENSDARG00000017115 kctd10 KCTD10 2.42139 0.92620 0.00894 
ENSDARG00000053129 carhsp1 CARHSP1 3.04557 1.16997 0.00924 
ENSDARG00000069271 kbtbd4 KBTBD4 1.69588 0.65242 0.00934 
ENSDARG00000099546 kynu KYNU 1.81459 0.69864 0.00940 
ENSDARG00000044254 anxa3b ANXA3 2.74201 1.05601 0.00942 
ENSDARG00000003820 nr1d2a  1.92075 0.74014 0.00946 
ENSDARG00000075664 si:ch1073-429i10.1  2.67725 1.03172 0.00946 
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ENSDARG00000075024 KIF1C    2.41031 0.92926 0.00949 
ENSDARG00000103714 rab6a  1.28745 0.49659 0.00953 
ENSDARG00000021147 nipal3 NIPAL3 2.91240 1.12451 0.00960 
ENSDARG00000078508 KCP KCP 2.74329 1.05958 0.00962 
ENSDARG00000061544 ano6 ANO6 1.42371 0.55018 0.00966 
ENSDARG00000095653 si:ch211-32p8.2  1.94806 0.75289 0.00967 
ENSDARG00000070487 MARC2  2.91604 1.12709 0.00967 
ENSDARG00000104387 slc4a5 SLC4A5 2.79011 1.07991 0.00978 
ENSDARG00000053961 slc2a11a AP000350.10 2.86629 1.11143 0.00991 
	
Table A((: GO terms from EnrichR KEGG for genes upregulated in the Tg(itga'b:EGFP) GFPlow 
population in mutants. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Apoptosis Homo sapiens 
hsa04210 3/140 0.00455 0.18208 -1.96126 3.34064 PARP1, EIF2AK3, CSF2RB 
Jak-STAT signaling pathway 
Homo sapiens hsa04630 2/158 0.05603 0.41614 -1.87990 1.64818 CSF2RB, PTPN2 
Wnt signaling pathway Homo 
sapiens hsa04310 2/142 0.04639 0.41614 -1.85411 1.62557 FZD3, CACYBP 
Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
2/169 0.06304 0.41614 -1.71881 1.50694 STT3A, EIF2AK3 
DNA replication Homo sapiens 
hsa03030 1/36 0.08593 0.41614 -1.60585 1.40791 RFC4 
Regulation of autophagy Homo 
sapiens hsa04140 1/39 0.09259 0.41614 -1.53886 1.34917 ATG14 
Sphingolipid metabolism Homo 
sapiens hsa00600 1/47 0.11011 0.41614 -1.52434 1.33644 SMPD4 
Nucleotide excision repair Homo 
sapiens hsa03420 1/47 0.11011 0.41614 -1.51266 1.32620 RFC4 
Mismatch repair Homo sapiens 
hsa03430 1/23 0.05656 0.41614 -1.41293 1.23876 RFC4 
Basal cell carcinoma Homo 
sapiens hsa05217 1/55 0.12731 0.42437 -1.43700 1.23173 FZD3 
Base excision repair Homo 
sapiens hsa03410 1/33 0.07923 0.41614 -1.37029 1.20138 PARP1 
N-Glycan biosynthesis Homo 
sapiens hsa00510 1/49 0.11444 0.41614 -1.32294 1.15987 STT3A 
Ribosome biogenesis in 
eukaryotes Homo sapiens 
hsa03008 
1/89 0.19699 0.48197 -1.55089 1.13197 MDN1 
Taste transduction Homo 
sapiens hsa04742 1/83 0.18509 0.48197 -1.52293 1.11156 P2RX3 
Melanogenesis Homo sapiens 
hsa04916 1/100 0.21839 0.48531 -1.45735 1.05361 FZD3 
Morphine addiction Homo 
sapiens hsa05032 1/91 0.20092 0.48197 -1.42639 1.04110 PDE10A 
PPAR signaling pathway Homo 
sapiens hsa03320 1/69 0.15666 0.48197 -1.32034 0.96369 UBC 
NF-kappa B signaling pathway 
Homo sapiens hsa04064 1/93 0.20484 0.48197 -1.31241 0.95790 PARP1 
Non-alcoholic fatty liver disease 
(NAFLD) Homo sapiens 
hsa04932 
1/151 0.31078 0.50558 -1.39485 0.95136 EIF2AK3 
Measles Homo sapiens 
hsa05162 1/136 0.28473 0.50558 -1.35358 0.92321 EIF2AK3 
Hepatitis C Homo sapiens 
hsa05160 1/133 0.27941 0.50558 -1.35028 0.92095 EIF2AK3 
Lysosome Homo sapiens 
hsa04142 1/123 0.26141 0.50558 -1.32242 0.90195 ACP2 
Influenza A Homo sapiens 
hsa05164 1/175 0.35060 0.50558 -1.32208 0.90172 EIF2AK3 
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Signaling pathways regulating 
pluripotency of stem cells Homo 
sapiens hsa04550 
1/142 0.29526 0.50558 -1.30498 0.89006 FZD3 
Calcium signaling pathway 
Homo sapiens hsa04020 1/180 0.35862 0.50558 -1.27727 0.87116 P2RX3 
Alzheimer's disease Homo 
sapiens hsa05010 1/168 0.33921 0.50558 -1.24114 0.84651 EIF2AK3 
Proteoglycans in cancer Homo 
sapiens hsa05205 1/203 0.39432 0.50881 -1.23684 0.83572 FZD3 
Epstein-Barr virus infection 
Homo sapiens hsa05169 1/202 0.39281 0.50881 -1.23172 0.83226 EIF2AK3 
Hippo signaling pathway Homo 
sapiens hsa04390 1/153 0.31418 0.50558 -1.18322 0.80701 FZD3 
Purine metabolism Homo 
sapiens hsa00230 1/176 0.35221 0.50558 -1.15989 0.79110 PDE10A 
Ras signaling pathway Homo 
sapiens hsa04014 1/227 0.42958 0.52070 -1.18088 0.77061 NF1 
Regulation of actin cytoskeleton 
Homo sapiens hsa04810 1/214 0.41073 0.51341 -1.15421 0.76948 ITGAE 
Herpes simplex infection Homo 
sapiens hsa05168 1/185 0.36655 0.50558 -1.10988 0.75699 EIF2AK3 
MAPK signaling pathway Homo 
sapiens hsa04010 1/255 0.46827 0.53498 -1.15762 0.72412 NF1 
HTLV-I infection Homo sapiens 
hsa05166 1/258 0.47227 0.53498 -1.09368 0.68413 FZD3 
Cytokine-cytokine receptor 
interaction Homo sapiens 
hsa04060 
1/265 0.48148 0.53498 -1.03403 0.64681 CSF2RB 
Neuroactive ligand-receptor 
interaction Homo sapiens 
hsa04080 
1/277 0.49692 0.53721 -1.02367 0.63607 P2RX3 
MicroRNAs in cancer Homo 
sapiens hsa05206 1/297 0.52170 0.54916 -1.01481 0.60824 FZD3 
Pathways in cancer Homo 
sapiens hsa05200 1/397 0.62930 0.64544 -1.09543 0.47961 FZD3 
Metabolic pathways Homo 
sapiens hsa01100 2/1239 0.82956 0.82956 -1.04311 0.19492 SMPD4, STT3A 
	
Table A(=: GO terms from EnrichR KEGG for genes down regulated in the Tg(itga'b:EGFP) GFPlow 
population in mutants. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Epithelial cell signaling in 
Helicobacter pylori infection 
Homo sapiens hsa05120 
3/68 0.01221 0.48782 -1.92319 1.38046 TJP1, MAPK14, ATP6V0C 
Dopaminergic synapse Homo 
sapiens hsa04728 4/129 0.01236 0.48782 -1.84119 1.32161 
PPP3CC, PPP2R5C, 
MAPK14, ATF4 
Tuberculosis Homo sapiens 
hsa05152 5/178 0.00770 0.48782 -1.80427 1.29510 
PPP3CC, FCER1G, 
MAPK14, ATP6V0C, CTSS 
Wnt signaling pathway Homo 
sapiens hsa04310 4/142 0.01690 0.48782 -1.80333 1.29442 
SFRP1, PPP3CC, DAAM1, 
WNT7B 
Vibrio cholerae infection Homo 
sapiens hsa05110 2/51 0.05011 0.48782 -1.61188 1.15700 TJP1, ATP6V0C 
Salmonella infection Homo 
sapiens hsa05132 3/86 0.02229 0.48782 -1.60581 1.15265 TJP1, ARPC4, MAPK14 
Neurotrophin signaling pathway 
Homo sapiens hsa04722 3/120 0.05065 0.48782 -1.59297 1.14343 ARHGDIA, MAPK14, ATF4 
mRNA surveillance pathway 
Homo sapiens hsa03015 3/91 0.02570 0.48782 -1.58746 1.13948 PPP2R5C, MSI2, WDR33 
Arginine and proline metabolism 
Homo sapiens hsa00330 2/50 0.04842 0.48782 -1.57896 1.13337 GOT2, CKB 
Oocyte meiosis Homo sapiens 
hsa04114 3/123 0.05373 0.48782 -1.56583 1.12395 
PPP3CC, PPP2R5C, 
YWHAH 
Osteoclast differentiation Homo 
sapiens hsa04380 3/132 0.06348 0.48782 -1.52768 1.09657 PPP3CC, NCF4, MAPK14 
Sphingolipid signaling pathway 
Homo sapiens hsa04071 3/120 0.05065 0.48782 -1.51833 1.08985 
FCER1G, PPP2R5C, 
MAPK14 
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VEGF signaling pathway Homo 
sapiens hsa04370 2/61 0.06807 0.48782 -1.48416 1.06533 PPP3CC, MAPK14 
Amyotrophic lateral sclerosis 
(ALS) Homo sapiens hsa05014 2/51 0.05011 0.48782 -1.46129 1.04891 PPP3CC, MAPK14 
Fc epsilon RI signaling pathway 
Homo sapiens hsa04664 2/68 0.08171 0.48782 -1.38230 0.99222 FCER1G, MAPK14 
MAPK signaling pathway Homo 
sapiens hsa04010 4/255 0.09825 0.48782 -1.36129 0.97714 
DUSP2, PPP3CC, MAPK14, 
ATF4 
Adrenergic signaling in 
cardiomyocytes Homo sapiens 
hsa04261 
3/148 0.08268 0.48782 -1.35958 0.97590 PPP2R5C, MAPK14, ATF4 
Amphetamine addiction Homo 
sapiens hsa05031 2/67 0.07971 0.48782 -1.35265 0.97093 PPP3CC, ATF4 
Endocytosis Homo sapiens 
hsa04144 4/259 0.10250 0.48782 -1.29895 0.93239 
SH3KBP1, CAV2, ARPC4, 
VPS28 
HTLV-I infection Homo sapiens 
hsa05166 4/258 0.10143 0.48782 -1.29352 0.92849 
ZFP36, PPP3CC, WNT7B, 
ATF4 
Long-term potentiation Homo 
sapiens hsa04720 2/66 0.07773 0.48782 -1.29051 0.92632 PPP3CC, ATF4 
Hippo signaling pathway Homo 
sapiens hsa04390 3/153 0.08914 0.48782 -1.23133 0.88384 WNT7B, AREG, YWHAH 
Phagosome Homo sapiens 
hsa04145 3/154 0.09046 0.48782 -1.17846 0.84590 NCF4, ATP6V0C, CTSS 
Shigellosis Homo sapiens 
hsa05131 2/65 0.07576 0.48782 -1.16493 0.83619 ARPC4, MAPK14 
Synaptic vesicle cycle Homo 
sapiens hsa04721 2/63 0.07188 0.48782 -1.13461 0.81442 STX1B, ATP6V0C 
Leishmaniasis Homo sapiens 
hsa05140 2/73 0.09194 0.48782 -1.11381 0.79949 NCF4, MAPK14 
Adherens junction Homo sapiens 
hsa04520 2/74 0.09402 0.48782 -1.06382 0.76361 TJP1, PTPN1 
Bacterial invasion of epithelial 
cells Homo sapiens hsa05100 2/78 0.10251 0.48782 -0.91517 0.65691 CAV2, ARPC4 
GnRH signaling pathway Homo 
sapiens hsa04912 2/91 0.13144 0.54261 -1.03899 0.63520 MAPK14, ATF4 
Epstein-Barr virus infection 
Homo sapiens hsa05169 3/202 0.16238 0.55787 -1.00941 0.58913 PSMD3, MAPK14, YWHAH 
Proteoglycans in cancer Homo 
sapiens hsa05205 3/203 0.16403 0.55787 -1.00389 0.58591 CAV2, WNT7B, MAPK14 
Glucagon signaling pathway 
Homo sapiens hsa04922 2/101 0.15482 0.55787 -0.90802 0.52995 PPP3CC, ATF4 
T cell receptor signaling pathway 
Homo sapiens hsa04660 2/104 0.16199 0.55787 -0.85738 0.50040 PPP3CC, MAPK14 
PI3K-Akt signaling pathway 
Homo sapiens hsa04151 4/341 0.20615 0.55787 -0.82256 0.48008 
TNR, PPP2R5C, ATF4, 
YWHAH 
TNF signaling pathway Homo 
sapiens hsa04668 2/110 0.17650 0.55787 -0.81075 0.47319 MAPK14, ATF4 
Glycerophospholipid metabolism 
Homo sapiens hsa00564 2/95 0.14069 0.55471 -0.79319 0.46744 LYPLA2, CHKA 
Platelet activation Homo sapiens 
hsa04611 2/122 0.20611 0.55787 -0.67601 0.39454 FCER1G, MAPK14 
Leukocyte transendothelial 
migration Homo sapiens 
hsa04670 
2/118 0.19617 0.55787 -0.57246 0.33411 NCF4, MAPK14 
Lysosome Homo sapiens 
hsa04142 2/123 0.20861 0.55787 -0.54364 0.31729 ATP6V0C, CTSS 
Cell cycle Homo sapiens 
hsa04110 2/124 0.21111 0.55787 -0.46921 0.27385 STAG2, YWHAH 
Apoptosis Homo sapiens 
hsa04210 2/140 0.25142 0.57355 -0.44476 0.24725 CTSS, ATF4 
FoxO signaling pathway Homo 
sapiens hsa04068 2/133 0.23372 0.56974 -0.42847 0.24105 MAPK14, GABARAP 
Natural killer cell mediated 
cytotoxicity Homo sapiens 
hsa04650 
2/135 0.23877 0.56974 -0.42325 0.23811 PPP3CC, FCER1G 
Signaling pathways regulating 
pluripotency of stem cells Homo 
sapiens hsa04550 
2/142 0.25649 0.57355 -0.33216 0.18465 WNT7B, MAPK14 
Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
2/169 0.32483 0.59547 -0.04771 0.02473 MBTPS2, ATF4 
cGMP-PKG signaling pathway 
Homo sapiens hsa04022 2/167 0.31979 0.59547 -0.04469 0.02317 PPP3CC, ATF4 
Phenylalanine, tyrosine and 
tryptophan biosynthesis Homo 
sapiens hsa00400 
1/5 0.04013 0.48782 0.05551 -0.03985 GOT2 
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Focal adhesion Homo sapiens 
hsa04510 2/202 0.40619 0.64994 0.16507 -0.07113 CAV2, TNR 
Viral carcinogenesis Homo 
sapiens hsa05203 2/205 0.41338 0.64994 0.17990 -0.07752 ATF4, YWHAH 
Pathways in cancer Homo 
sapiens hsa05200 1/397 0.93892 0.93892 1.54722 -0.09751 WNT7B 
Metabolic pathways Homo 
sapiens hsa01100 6/1239 0.87351 0.87989 1.36568 -0.17476 
CHKA, GOT2, CKB, 
B4GALT6, ATP6V0C, 
NUDT12 
B cell receptor signaling pathway 
Homo sapiens hsa04662 1/73 0.39807 0.64994 0.73009 -0.31458 PPP3CC 
Prolactin signaling pathway 
Homo sapiens hsa04917 1/72 0.39391 0.64994 0.73334 -0.31598 MAPK14 
MicroRNAs in cancer Homo 
sapiens hsa05206 2/297 0.60984 0.70017 0.91785 -0.32715 CCNG1, TNR 
Rap1 signaling pathway Homo 
sapiens hsa04015 1/211 0.76981 0.78601 1.40573 -0.33849 MAPK14 
Regulation of actin cytoskeleton 
Homo sapiens hsa04810 1/214 0.77462 0.78601 1.41796 -0.34143 ARPC4 
ErbB signaling pathway Homo 
sapiens hsa04012 1/87 0.45352 0.65610 0.83236 -0.35079 AREG 
Progesterone-mediated oocyte 
maturation Homo sapiens 
hsa04914 
1/98 0.49355 0.65610 0.85758 -0.36142 MAPK14 
Aldosterone synthesis and 
secretion Homo sapiens 
hsa04925 
1/81 0.43040 0.65610 0.86422 -0.36422 ATF4 
Inflammatory mediator regulation 
of TRP channels Homo sapiens 
hsa04750 
1/98 0.49355 0.65610 0.88226 -0.37183 MAPK14 
AGE-RAGE signaling pathway in 
diabetic complications Homo 
sapiens hsa04933 
1/101 0.50396 0.65610 0.88454 -0.37279 MAPK14 
Biosynthesis of amino acids 
Homo sapiens hsa01230 1/74 0.40221 0.64994 0.86869 -0.37430 GOT2 
Fc gamma R-mediated 
phagocytosis Homo sapiens 
hsa04666 
1/93 0.47572 0.65610 0.89261 -0.37619 ARPC4 
Purine metabolism Homo 
sapiens hsa00230 1/176 0.70572 0.74068 1.27802 -0.38364 GUCY2C 
Thyroid hormone synthesis 
Homo sapiens hsa04918 1/71 0.38971 0.64994 0.89088 -0.38386 ATF4 
Prostate cancer Homo sapiens 
hsa05215 1/89 0.46102 0.65610 0.91310 -0.38482 ATF4 
p53 signaling pathway Homo 
sapiens hsa04115 1/69 0.38124 0.64994 0.89548 -0.38584 CCNG1 
RNA degradation Homo sapiens 
hsa03018 1/77 0.41445 0.64994 0.89694 -0.38647 TOB1 
Estrogen signaling pathway 
Homo sapiens hsa04915 1/99 0.49704 0.65610 0.92137 -0.38831 ATF4 
Insulin secretion Homo sapiens 
hsa04911 1/85 0.44592 0.65610 0.92184 -0.38851 ATF4 
Longevity regulating pathway - 
mammal Homo sapiens 
hsa04211 
1/94 0.47934 0.65610 0.92617 -0.39033 ATF4 
RIG-I-like receptor signaling 
pathway Homo sapiens 
hsa04622 
1/70 0.38549 0.64994 0.90794 -0.39121 MAPK14 
AMPK signaling pathway Homo 
sapiens hsa04152 1/124 0.57710 0.69859 1.09966 -0.39444 PPP2R5C 
Hepatitis C Homo sapiens 
hsa05160 1/133 0.60274 0.70017 1.11265 -0.39659 MAPK14 
Melanogenesis Homo sapiens 
hsa04916 1/100 0.50051 0.65610 0.94199 -0.39700 WNT7B 
Insulin resistance Homo sapiens 
hsa04931 1/109 0.53070 0.67190 1.00130 -0.39816 PTPN1 
GABAergic synapse Homo 
sapiens hsa04727 1/88 0.45728 0.65610 0.95203 -0.40123 GABARAP 
Alzheimer's disease Homo 
sapiens hsa05010 1/168 0.68878 0.74068 1.33705 -0.40136 PPP3CC 
Jak-STAT signaling pathway 
Homo sapiens hsa04630 1/158 0.66626 0.72397 1.24701 -0.40280 FHL1 
Calcium signaling pathway Homo 
sapiens hsa04020 1/180 0.71385 0.74068 1.34427 -0.40353 PPP3CC 
Influenza A Homo sapiens 
hsa05164 1/175 0.70365 0.74068 1.34444 -0.40358 MAPK14 
Ribosome Homo sapiens 
hsa03010 1/137 0.61365 0.70017 1.13846 -0.40578 RPS27L 
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Alcoholism Homo sapiens 
hsa05034 1/179 0.71184 0.74068 1.35593 -0.40703 ATF4 
Transcriptional misregulation in 
cancer Homo sapiens hsa05202 1/180 0.71385 0.74068 1.35959 -0.40813 ETV5 
Herpes simplex infection Homo 
sapiens hsa05168 1/185 0.72370 0.74530 1.39315 -0.40954 TAF6 
Toll-like receptor signaling 
pathway Homo sapiens 
hsa04620 
1/106 0.52084 0.66552 1.00709 -0.41007 MAPK14 
Rheumatoid arthritis Homo 
sapiens hsa05323 1/90 0.46474 0.65610 0.97429 -0.41061 ATP6V0C 
Axon guidance Homo sapiens 
hsa04360 1/127 0.58582 0.70017 1.15254 -0.41080 PPP3CC 
Renin secretion Homo sapiens 
hsa04924 1/146 0.35955 0.64440 0.93550 -0.41110 PPP3CC 
Hepatitis B Homo sapiens 
hsa05161 1/146 0.63712 0.70906 1.19878 -0.41217 ATF4 
Non-alcoholic fatty liver disease 
(NAFLD) Homo sapiens 
hsa04932 
1/151 0.64955 0.71711 1.24017 -0.41239 ATF4 
Tight junction Homo sapiens 
hsa04530 1/139 0.61899 0.70017 1.16007 -0.41349 TJP1 
Ubiquitin mediated proteolysis 
Homo sapiens hsa04120 1/137 0.61365 0.70017 1.16125 -0.41391 UBE2K 
Cholinergic synapse Homo 
sapiens hsa04725 1/111 0.53717 0.67361 1.05122 -0.41535 ATF4 
Pertussis Homo sapiens 
hsa05133 1/75 0.40632 0.64994 0.96683 -0.41659 MAPK14 
Phospholipase D signaling 
pathway Homo sapiens 
hsa04072 
1/144 0.63203 0.70906 1.21268 -0.41695 FCER1G 
Gap junction Homo sapiens 
hsa04540 1/88 0.45728 0.65610 0.98966 -0.41709 TJP1 
ECM-receptor interaction Homo 
sapiens hsa04512 1/82 0.43432 0.65610 0.99148 -0.41786 TNR 
Oxidative phosphorylation Homo 
sapiens hsa00190 1/133 0.60274 0.70017 1.17610 -0.41920 ATP6V0C 
Choline metabolism in cancer 
Homo sapiens hsa05231 1/101 0.50396 0.65610 1.00503 -0.42356 CHKA 
Oxytocin signaling pathway 
Homo sapiens hsa04921 1/158 0.66626 0.72397 1.32204 -0.42703 PPP3CC 
Insulin signaling pathway Homo 
sapiens hsa04910 1/139 0.61899 0.70017 1.20342 -0.42894 PTPN1 
Chagas disease (American 
trypanosomiasis) Homo sapiens 
hsa05142 
1/104 0.51416 0.66312 1.04955 -0.43115 MAPK14 
Peroxisome Homo sapiens 
hsa04146 1/83 0.43821 0.65610 1.03434 -0.43592 NUDT12 
Glutamatergic synapse Homo 
sapiens hsa04724 1/114 0.54670 0.67361 1.10687 -0.43733 PPP3CC 
Carbon metabolism Homo 
sapiens hsa01200 1/113 0.54354 0.67361 1.13376 -0.44796 GOT2 
Toxoplasmosis Homo sapiens 
hsa05145 1/118 0.55910 0.68280 1.18788 -0.45324 MAPK14 
Antigen processing and 
presentation Homo sapiens 
hsa04612 
1/77 0.41445 0.64994 1.05358 -0.45397 CTSS 
Retrograde endocannabinoid 
signaling Homo sapiens 
hsa04723 
1/101 0.50396 0.65610 1.09017 -0.45945 MAPK14 
Pathogenic Escherichia coli 
infection Homo sapiens 
hsa05130 
1/55 0.31863 0.59547 1.12310 -0.58222 ARPC4 
NOD-like receptor signaling 
pathway Homo sapiens 
hsa04621 
1/57 0.32794 0.59547 1.17225 -0.60771 MAPK14 
Basal cell carcinoma Homo 
sapiens hsa05217 1/55 0.31863 0.59547 1.22080 -0.63287 WNT7B 
Cocaine addiction Homo sapiens 
hsa05030 1/49 0.28993 0.58839 1.21732 -0.64562 ATF4 
Vasopressin-regulated water 
reabsorption Homo sapiens 
hsa04962 
1/44 0.26512 0.57355 1.19236 -0.66285 ARHGDIA 
Asthma Homo sapiens hsa05310 1/31 0.19656 0.55787 1.15504 -0.67413 FCER1G 
Glutathione metabolism Homo 
sapiens hsa00480 1/52 0.30443 0.59547 1.30612 -0.67710 GPX4 
Fanconi anemia pathway Homo 
sapiens hsa03460 1/53 0.30919 0.59547 1.33088 -0.68994 RPA1 
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Hedgehog signaling pathway 
Homo sapiens hsa04340 1/50 0.29480 0.58959 1.31007 -0.69214 WNT7B 
Nicotinate and nicotinamide 
metabolism Homo sapiens 
hsa00760 
1/29 0.18547 0.55787 1.19801 -0.69921 NUDT12 
Basal transcription factors Homo 
sapiens hsa03022 1/45 0.27015 0.57355 1.25830 -0.69951 TAF6 
Nucleotide excision repair Homo 
sapiens hsa03420 1/47 0.28011 0.57694 1.32561 -0.72912 RPA1 
Fat digestion and absorption 
Homo sapiens hsa04975 1/41 0.24982 0.57355 1.33342 -0.74127 GOT2 
Sphingolipid metabolism Homo 
sapiens hsa00600 1/47 0.28011 0.57694 1.42959 -0.78631 B4GALT6 
Homologous recombination 
Homo sapiens hsa03440 1/29 0.18547 0.55787 1.36653 -0.79756 RPA1 
Mismatch repair Homo sapiens 
hsa03430 1/23 0.15130 0.55787 1.37242 -0.80100 RPA1 
Proteasome Homo sapiens 
hsa03050 1/44 0.26512 0.57355 1.47027 -0.81735 PSMD3 
Cysteine and methionine 
metabolism Homo sapiens 
hsa00270 
1/45 0.27015 0.57355 1.47255 -0.81862 GOT2 
Collecting duct acid secretion 
Homo sapiens hsa04966 1/27 0.17423 0.55787 1.45342 -0.84827 ATP6V0C 
Alanine, aspartate and glutamate 
metabolism Homo sapiens 
hsa00250 
1/35 0.21830 0.55787 1.45576 -0.84964 GOT2 
Tyrosine metabolism Homo 
sapiens hsa00350 1/35 0.21830 0.55787 1.47411 -0.86034 GOT2 
Glycosaminoglycan biosynthesis 
- chondroitin sulfate / dermatan 
sulfate Homo sapiens hsa00532 
1/20 0.13369 0.54261 1.40982 -0.86191 CHST15 
Regulation of autophagy Homo 
sapiens hsa04140 1/397 0.23946 0.56974 1.54396 -0.86859 GABARAP 
Circadian rhythm Homo sapiens 
hsa04710 1/30 0.19103 0.55787 1.48911 -0.86910 BHLHE40 
Phenylalanine metabolism Homo 
sapiens hsa00360 1/17 0.11572 0.51514 1.32865 -0.88132 GOT2 
DNA replication Homo sapiens 
hsa03030 1/36 0.22364 0.56113 1.55622 -0.89919 RPA1 
SNARE interactions in vesicular 
transport Homo sapiens 
hsa04130 
1/34 0.21292 0.55787 1.58438 -0.92470 STX1B 
2-Oxocarboxylic acid 
metabolism Homo sapiens 
hsa01210 
1/17 0.11572 0.51514 1.40090 -0.92924 GOT2 
Arginine biosynthesis Homo 
sapiens hsa00220 1/20 0.13369 0.54261 1.54162 -0.94249 GOT2 
	
Table A(?: GO terms from EnrichR KEGG for genes upregulated in mutant erythrocytes. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Vasopressin-regulated water 
reabsorption Homo sapiens 
hsa04962 
1/44 0.05018 0.21163 -1.84738 2.86885 RAB11B 
Regulation of autophagy Homo 
sapiens hsa04140 1/39 0.04472 0.21163 -1.84714 2.86848 GABARAP 
Collecting duct acid secretion 
Homo sapiens hsa04966 1/27 0.03149 0.21163 -1.84280 2.86175 SLC12A7 
GABAergic synapse Homo 
sapiens hsa04727 1/88 0.09711 0.21163 -1.70520 2.64807 GABARAP 
Neurotrophin signaling pathway 
Homo sapiens hsa04722 1/120 0.12995 0.21163 -1.69916 2.63868 PRDM4 
Cardiac muscle contraction 
Homo sapiens hsa04260 1/78 0.08663 0.21163 -1.66888 2.59166 COX7A1 
Mucin type O-Glycan 
biosynthesis Homo sapiens 
hsa00512 
1/31 0.03592 0.21163 -1.66035 2.57841 GALNT11 
Non-alcoholic fatty liver disease 
(NAFLD) Homo sapiens 
hsa04932 
1/151 0.16076 0.21163 -1.62736 2.52718 COX7A1 
Oxidative phosphorylation Homo 
sapiens hsa00190 1/133 0.14299 0.21163 -1.59458 2.47628 COX7A1 
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AMPK signaling pathway Homo 
sapiens hsa04152 1/124 0.13398 0.21163 -1.58752 2.46531 RAB11B 
FoxO signaling pathway Homo 
sapiens hsa04068 1/133 0.14299 0.21163 -1.57211 2.44139 GABARAP 
Glycerophospholipid metabolism 
Homo sapiens hsa00564 1/95 0.10438 0.21163 -1.56249 2.42645 ETNK1 
Alzheimer's disease Homo 
sapiens hsa05010 1/168 0.17725 0.21163 -1.49145 2.31612 COX7A1 
Parkinson's disease Homo 
sapiens hsa05012 1/142 0.15192 0.21163 -1.48113 2.30009 COX7A1 
Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
1/169 0.17821 0.21163 -1.45621 2.26139 UBE2D1 
Huntington's disease Homo 
sapiens hsa05016 1/193 0.20098 0.22463 -1.50423 2.24627 COX7A1 
Ubiquitin mediated proteolysis 
Homo sapiens hsa04120 1/137 0.14697 0.21163 -1.38342 2.14837 UBE2D1 
Endocytosis Homo sapiens 
hsa04144 1/259 0.26078 0.27527 -1.54434 1.99220 RAB11B 
Metabolic pathways Homo 
sapiens hsa01100 2/1239 0.42693 0.42693 -1.56460 1.33168 GALNT11, ETNK1 
	
Table A(@ GO terms from EnrichR KEGG for genes downregulated in mutant erythrocytes. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Glucagon signaling pathway 
Homo sapiens hsa04922 5/101 0.00034 0.03676 -1.91641 6.33064 
CREB3, CREBBP, SIK2, 
PRKAB1, CAMK2G 
Proteasome Homo sapiens 
hsa03050 3/44 0.00248 0.13381 -1.68762 3.39435 PSMA3, PSME4, PSMC2 
Epstein-Barr virus infection 
Homo sapiens hsa05169 5/202 0.00659 0.17751 -1.87394 3.23952 
CREBBP, XPO1, PSMC2, 
CSNK2A2, POLR2F 
Huntington's disease Homo 
sapiens hsa05016 5/193 0.00547 0.17751 -1.85137 3.20050 
CREB3, NDUFA8, CREBBP, 
POLR2F, ATP5H 
Parkinson's disease Homo 
sapiens hsa05012 4/142 0.00986 0.17751 -1.64854 2.84986 
NDUFA8, ATP5H, UBE2L3, 
UBE2J1 
Ubiquitin mediated proteolysis 
Homo sapiens hsa04120 4/137 0.00875 0.17751 -1.54990 2.67934 
UBE2A, UBE2L3, BIRC3, 
UBE2J1 
Ribosome biogenesis in 
eukaryotes Homo sapiens 
hsa03008 
3/89 0.01603 0.23328 -1.80410 2.62588 POP7, XPO1, CSNK2A2 
Influenza A Homo sapiens 
hsa05164 3/89 0.01958 0.23328 -1.76218 2.56487 
IVNS1ABP, CREBBP, XPO1, 
IFNAR1 
Melanogenesis Homo sapiens 
hsa04916 4/175 0.02160 0.23328 -1.68317 2.44986 CREB3, CREBBP, CAMK2G 
Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
3/100 0.01749 0.23328 -1.64719 2.39749 PPP1R15A, SAR1B, PLAA, UBE2J1 
Insulin resistance Homo sapiens 
hsa04931 4/169 0.02686 0.26153 -1.59642 2.14111 CREB3, SLC27A1, PRKAB1 
Vasopressin-regulated water 
reabsorption Homo sapiens 
hsa04962 
3/109 0.02906 0.26153 -1.42810 1.91536 CREB3, DYNC1LI1 
Hepatitis B Homo sapiens 
hsa05161 3/146 0.05499 0.40909 -1.60501 1.43458 CREB3, CREBBP, IFNAR1 
Wnt signaling pathway Homo 
sapiens hsa04310 3/146 0.05146 0.40909 -1.57478 1.40756 
CREBBP, CSNK2A2, 
CAMK2G 
Amphetamine addiction Homo 
sapiens hsa05031 3/142 0.06061 0.40909 -1.46367 1.30825 CREB3, CAMK2G 
Long-term potentiation Homo 
sapiens hsa04720 2/67 0.05906 0.40909 -1.39703 1.24869 CREBBP, CAMK2G 
Adherens junction Homo sapiens 
hsa04520 2/66 0.07180 0.45611 -1.33283 1.04629 CREBBP, CSNK2A2 
Aldosterone synthesis and 
secretion Homo sapiens 
hsa04925 
2/74 0.08360 0.50160 -1.47507 1.01773 CREB3, CAMK2G 
Prostate cancer Homo sapiens 
hsa05215 2/81 0.09776 0.50215 -1.37705 0.94859 CREB3, CREBBP 
Insulin secretion Homo sapiens 
hsa04911 2/89 0.09060 0.50215 -1.34608 0.92725 CREB3, CAMK2G 
cAMP signaling pathway Homo 
sapiens hsa04024 3/199 0.11192 0.50366 -1.35006 0.92594 CREB3, CREBBP, CAMK2G 
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Herpes simplex infection Homo 
sapiens hsa05168 3/185 0.09519 0.50215 -1.32443 0.91234 
CREBBP, CSNK2A2, 
IFNAR1 
Longevity regulating pathway - 
mammal Homo sapiens 
hsa04211 
2/94 0.10694 0.50215 -1.28346 0.88412 CREB3, PRKAB1 
Cholinergic synapse Homo 
sapiens hsa04725 2/111 0.13971 0.53620 -1.31869 0.82187 CREB3, CAMK2G 
NF-kappa B signaling pathway 
Homo sapiens hsa04064 2/93 0.10509 0.50215 -1.17033 0.80619 CSNK2A2, BIRC3 
TNF signaling pathway Homo 
sapiens hsa04668 2/110 0.13772 0.53620 -1.24154 0.77379 CREB3, BIRC3 
HIF-1 signaling pathway Homo 
sapiens hsa04066 2/103 0.12401 0.53573 -1.19770 0.74751 CREBBP, CAMK2G 
Dopaminergic synapse Homo 
sapiens hsa04728 2/129 0.17644 0.53620 -1.09346 0.68150 CREB3, CAMK2G 
AMPK signaling pathway Homo 
sapiens hsa04152 2/124 0.16607 0.53620 -1.07568 0.67041 CREB3, PRKAB1 
HTLV-I infection Homo sapiens 
hsa05166 3/258 0.19285 0.53620 -1.04372 0.65050 CREBBP, XPO1, TCF3 
Osteoclast differentiation Homo 
sapiens hsa04380 2/132 0.18272 0.53620 -1.03592 0.64564 SQSTM1, IFNAR1 
FoxO signaling pathway Homo 
sapiens hsa04068 2/133 0.18481 0.53620 -0.98759 0.61551 CREBBP, PRKAB1 
Measles Homo sapiens 
hsa05162 2/136 0.19113 0.53620 -0.97521 0.60780 CSNK2A2, IFNAR1 
Oxidative phosphorylation Homo 
sapiens hsa00190 2/133 0.18481 0.53620 -0.94723 0.59036 NDUFA8, ATP5H 
Non-alcoholic fatty liver disease 
(NAFLD) Homo sapiens 
hsa04932 
2/151 0.22313 0.53620 -0.90402 0.56343 NDUFA8, PRKAB1 
Oxytocin signaling pathway 
Homo sapiens hsa04921 2/158 0.23823 0.53620 -0.87330 0.54429 PRKAB1, CAMK2G 
Adrenergic signaling in 
cardiomyocytes Homo sapiens 
hsa04261 
2/148 0.21669 0.53620 -0.85994 0.53595 CREB3, CAMK2G 
Jak-STAT signaling pathway 
Homo sapiens hsa04630 2/158 0.23823 0.53620 -0.83760 0.52203 CREBBP, IFNAR1 
Tight junction Homo sapiens 
hsa04530 2/139 0.19748 0.53620 -0.81618 0.50868 CSNK2A2, EXOC3 
cGMP-PKG signaling pathway 
Homo sapiens hsa04022 2/167 0.25773 0.53620 -0.74667 0.46536 CREB3, ADRB3 
RNA transport Homo sapiens 
hsa03013 2/172 0.26859 0.53620 -0.67870 0.42300 POP7, XPO1 
Alzheimer's disease Homo 
sapiens hsa05010 2/168 0.25991 0.53620 -0.66542 0.41472 NDUFA8, ATP5H 
Purine metabolism Homo 
sapiens hsa00230 2/176 0.27728 0.53620 -0.59183 0.36886 POLR2F, AMPD3 
Calcium signaling pathway Homo 
sapiens hsa04020 2/180 0.28597 0.53620 -0.57147 0.35617 ADRB3, CAMK2G 
Alcoholism Homo sapiens 
hsa05034 2/179 0.28380 0.53620 -0.54928 0.34234 CREB3, HAT1 
Tuberculosis Homo sapiens 
hsa05152 2/178 0.28163 0.53620 -0.53751 0.33500 CREBBP, CAMK2G 
Transcriptional misregulation in 
cancer Homo sapiens hsa05202 2/180 0.28597 0.53620 -0.43063 0.26839 TCF3, BIRC3 
Viral carcinogenesis Homo 
sapiens hsa05203 2/205 0.33996 0.55496 -0.35430 0.20863 CREB3, CREBBP 
Endocytosis Homo sapiens 
hsa04144 2/259 0.45179 0.58787 0.05069 -0.02693 ADRB3, VPS28 
Metabolic pathways Homo 
sapiens hsa01100 4/1239 0.94701 0.94701 0.64553 -0.03515 
NDUFA8, POLR2F, ATP5H, 
AMPD3 
Olfactory transduction Homo 
sapiens hsa04740 1/415 0.91796 0.92654 0.60400 -0.04608 CAMK2G 
Regulation of lipolysis in 
adipocytes Homo sapiens 
hsa04923 
1/56 0.28376 0.53620 0.12920 -0.08052 ADRB3 
RNA polymerase Homo sapiens 
hsa03020 1/32 0.17542 0.53620 0.14636 -0.09122 POLR2F 
Circadian rhythm Homo sapiens 
hsa04710 1/30 0.16571 0.53620 0.15158 -0.09447 PRKAB1 
MicroRNAs in cancer Homo 
sapiens hsa05206 1/297 0.83062 0.84630 0.62795 -0.10480 CREBBP 
Neuroactive ligand-receptor 
interaction Homo sapiens 
hsa04080 
1/277 0.80872 0.83183 0.61911 -0.11400 ADRB3 
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Cytokine-cytokine receptor 
interaction Homo sapiens 
hsa04060 
1/265 0.79428 0.82483 0.60411 -0.11634 IFNAR1 
Cocaine addiction Homo sapiens 
hsa05030 1/49 0.25369 0.53620 0.19589 -0.12209 CREB3 
Longevity regulating pathway - 
multiple species Homo sapiens 
hsa04213 
1/64 0.31669 0.55496 0.22086 -0.13005 PRKAB1 
TGF-beta signaling pathway 
Homo sapiens hsa04350 1/84 0.39267 0.58526 0.24659 -0.13210 CREBBP 
Notch signaling pathway Homo 
sapiens hsa04330 1/48 0.24929 0.53620 0.22075 -0.13758 CREBBP 
Legionellosis Homo sapiens 
hsa05134 1/55 0.27954 0.53620 0.22745 -0.14176 SAR1B 
Glioma Homo sapiens hsa05214 1/65 0.32070 0.55496 0.24086 -0.14183 CAMK2G 
ErbB signaling pathway Homo 
sapiens hsa04012 1/87 0.40333 0.58526 0.26810 -0.14362 CAMK2G 
Inflammatory mediator regulation 
of TRP channels Homo sapiens 
hsa04750 
1/98 0.44089 0.58787 0.29701 -0.15779 CAMK2G 
GnRH signaling pathway Homo 
sapiens hsa04912 1/91 0.41727 0.58526 0.29505 -0.15806 CAMK2G 
Gastric acid secretion Homo 
sapiens hsa04971 1/74 0.35577 0.56505 0.28313 -0.16163 CAMK2G 
Pathways in cancer Homo 
sapiens hsa05200 2/397 0.68336 0.73803 0.53287 -0.16187 CREBBP, BIRC3 
Circadian entrainment Homo 
sapiens hsa04713 1/95 0.43088 0.58787 0.31712 -0.16847 CAMK2G 
Rap1 signaling pathway Homo 
sapiens hsa04015 1/211 0.71500 0.74971 0.60165 -0.17332 DOCK4 
Estrogen signaling pathway 
Homo sapiens hsa04915 1/99 0.44419 0.58787 0.32971 -0.17516 CREB3 
Focal adhesion Homo sapiens 
hsa04510 1/202 0.69916 0.74220 0.59254 -0.17666 BIRC3 
Renal cell carcinoma Homo 
sapiens hsa05211 1/66 0.32468 0.55496 0.30055 -0.17698 CREBBP 
Proteoglycans in cancer Homo 
sapiens hsa05205 1/203 0.70096 0.74220 0.60086 -0.17914 CAMK2G 
Base excision repair Homo 
sapiens hsa03410 1/33 0.18024 0.53620 0.29537 -0.18409 LIG3 
Salivary secretion Homo sapiens 
hsa04970 1/89 0.41034 0.58526 0.34851 -0.18670 ADRB3 
Choline metabolism in cancer 
Homo sapiens hsa05231 1/101 0.45072 0.58787 0.35270 -0.18737 GPCPD1 
Small cell lung cancer Homo 
sapiens hsa05222 1/86 0.39980 0.58526 0.35745 -0.19149 BIRC3 
Peroxisome Homo sapiens 
hsa04146 1/83 0.38908 0.58526 0.36089 -0.19333 PEX13 
Toll-like receptor signaling 
pathway Homo sapiens 
hsa04620 
1/106 0.46674 0.59304 0.38164 -0.19941 IFNAR1 
Renin secretion Homo sapiens 
hsa04924 1/64 0.31669 0.55496 0.33950 -0.19992 ADRB3 
PI3K-Akt signaling pathway 
Homo sapiens hsa04151 2/341 0.59999 0.65454 0.47378 -0.20080 CREB3, IFNAR1 
Thyroid hormone signaling 
pathway Homo sapiens 
hsa04919 
1/118 0.50335 0.61800 0.41932 -0.20181 CREBBP 
Neurotrophin signaling pathway 
Homo sapiens hsa04722 1/120 0.50921 0.61800 0.42468 -0.20438 CAMK2G 
Salmonella infection Homo 
sapiens hsa05132 1/86 0.39980 0.58526 0.38909 -0.20844 DYNC1LI1 
Lysosome Homo sapiens 
hsa04142 1/123 0.51787 0.61800 0.43611 -0.20988 SLC11A2 
Adipocytokine signaling pathway 
Homo sapiens hsa04920 1/70 0.34041 0.55496 0.36521 -0.21506 PRKAB1 
Spliceosome Homo sapiens 
hsa03040 1/134 0.54837 0.63312 0.47115 -0.21537 ISY1 
Hypertrophic cardiomyopathy 
(HCM) Homo sapiens hsa05410 1/83 0.38908 0.58526 0.40863 -0.21891 PRKAB1 
Apoptosis Homo sapiens 
hsa04210 1/140 0.56420 0.63392 0.48055 -0.21905 BIRC3 
Glycerophospholipid metabolism 
Homo sapiens hsa00564 1/95 0.43088 0.58787 0.41572 -0.22085 GPCPD1 
Toxoplasmosis Homo sapiens 
hsa05145 1/118 0.50335 0.61800 0.46390 -0.22326 BIRC3 
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Hepatitis C Homo sapiens 
hsa05160 1/133 0.54567 0.63312 0.49692 -0.22714 IFNAR1 
Oocyte meiosis Homo sapiens 
hsa04114 1/123 0.51787 0.61800 0.47418 -0.22821 CAMK2G 
Regulation of autophagy Homo 
sapiens hsa04140 1/39 0.20857 0.53620 0.37249 -0.23215 ATG4C 
Mineral absorption Homo 
sapiens hsa04978 1/51 0.26240 0.53620 0.37635 -0.23456 SLC11A2 
Cytosolic DNA-sensing pathway 
Homo sapiens hsa04623 1/64 0.31669 0.55496 0.39971 -0.23538 POLR2F 
Natural killer cell mediated 
cytotoxicity Homo sapiens 
hsa04650 
1/135 0.55104 0.63312 0.51746 -0.23653 IFNAR1 
Insulin signaling pathway Homo 
sapiens hsa04910 1/139 0.56160 0.63392 0.53938 -0.24586 PRKAB1 
PPAR signaling pathway Homo 
sapiens hsa03320 1/69 0.33651 0.55496 0.41849 -0.24644 SLC27A1 
Pyruvate metabolism Homo 
sapiens hsa00620 1/40 0.21320 0.53620 0.39797 -0.24803 HAGH 
Pyrimidine metabolism Homo 
sapiens hsa00240 1/105 0.46357 0.59304 0.47608 -0.24875 POLR2F 
Thyroid hormone synthesis 
Homo sapiens hsa04918 1/71 0.34428 0.55496 0.43361 -0.25534 CREB3 
Signaling pathways regulating 
pluripotency of stem cells Homo 
sapiens hsa04550 
1/142 0.56936 0.63392 0.56582 -0.25792 TCF3 
Cell cycle Homo sapiens 
hsa04110 1/124 0.52072 0.61800 0.54199 -0.26084 CREBBP 
Phagosome Homo sapiens 
hsa04145 1/154 0.59907 0.65454 0.62199 -0.26362 DYNC1LI1 
Protein digestion and absorption 
Homo sapiens hsa04974 1/90 0.41381 0.58526 0.52272 -0.28002 SLC3A2 
NOD-like receptor signaling 
pathway Homo sapiens 
hsa04621 
1/57 0.28796 0.53620 0.45680 -0.28470 BIRC3 
	
	
Table A@: GO terms from EnrichR KEGG for genes upregulated in mutant monocytes. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Ribosome Homo sapiens 
hsa03010 4/137 0.00059 0.02954 -1.74614 6.15014 
RPS25, RPS9, RPL12, 
RPL13 
p53 signaling pathway Homo 
sapiens hsa04115 3/69 0.00104 0.02954 -1.73739 6.11932 CDK6, RRM2, CCND1 
Non-small cell lung cancer Homo 
sapiens hsa05223 2/56 0.01156 0.14075 -2.02977 3.97997 CDK6, CCND1 
Glioma Homo sapiens hsa05214 2/65 0.01522 0.14075 -2.02243 3.96558 CDK6, CCND1 
Pancreatic cancer Homo sapiens 
hsa05212 2/66 0.01566 0.14075 -1.86302 3.65301 CDK6, CCND1 
Melanoma Homo sapiens 
hsa05218 2/71 0.01791 0.14075 -1.78760 3.50513 CDK6, CCND1 
Chronic myeloid leukemia Homo 
sapiens hsa05220 2/73 0.01885 0.14075 -1.74118 3.41411 CDK6, CCND1 
Small cell lung cancer Homo 
sapiens hsa05222 2/86 0.02543 0.16107 -1.63486 2.98511 CDK6, CCND1 
Cell cycle Homo sapiens 
hsa04110 2/124 0.04907 0.21944 -1.48040 2.24527 CDK6, CCND1 
Measles Homo sapiens 
hsa05162 2/136 0.05772 0.23501 -1.53016 2.21583 CDK6, CCND1 
Hepatitis B Homo sapiens 
hsa05161 2/146 0.06532 0.24821 -1.57952 2.20105 CDK6, CCND1 
Viral carcinogenesis Homo 
sapiens hsa05203 2/205 0.11599 0.30279 -1.47358 1.76053 CDK6, CCND1 
Purine metabolism Homo 
sapiens hsa00230 2/176 0.08995 0.28485 -1.37291 1.72411 RRM2, PAPSS2 
Metabolic pathways Homo 
sapiens hsa01100 6/1239 0.12749 0.30279 -1.44043 1.72093 
PDXK, RRM2, UROD, 
PAPSS2, PAFAH1B1, IDH3A 
Bladder cancer Homo sapiens 
hsa05219 1/41 0.11309 0.30279 -0.99388 1.18741 CCND1 
Thyroid cancer Homo sapiens 
hsa05216 1/29 0.08208 0.28401 -0.92694 1.16678 CCND1 
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MicroRNAs in cancer Homo 
sapiens hsa05206 2/297 0.20815 0.35954 -1.13560 1.16165 CDK6, CCND1 
Acute myeloid leukemia Homo 
sapiens hsa05221 1/57 0.15288 0.32111 -0.96977 1.10164 CCND1 
Endometrial cancer Homo 
sapiens hsa05213 1/52 0.14063 0.30831 -0.93250 1.09722 CCND1 
PI3K-Akt signaling pathway 
Homo sapiens hsa04151 2/341 0.25500 0.37270 -1.08182 1.06775 CDK6, CCND1 
Prolactin signaling pathway 
Homo sapiens hsa04917 1/72 0.18865 0.35543 -0.99399 1.02820 CCND1 
Colorectal cancer Homo sapiens 
hsa05210 1/62 0.16497 0.32425 -0.90190 1.01577 CCND1 
Prostate cancer Homo sapiens 
hsa05215 1/89 0.22744 0.36364 -0.98009 0.99144 CCND1 
AGE-RAGE signaling pathway in 
diabetic complications Homo 
sapiens hsa04933 
1/101 0.25376 0.37270 -1.00367 0.99061 CCND1 
Porphyrin and chlorophyll 
metabolism Homo sapiens 
hsa00860 
1/42 0.11563 0.30279 -0.82529 0.98600 UROD 
Viral myocarditis Homo sapiens 
hsa05416 1/59 0.15774 0.32111 -0.81879 0.93013 CCND1 
Ribosome biogenesis in 
eukaryotes Homo sapiens 
hsa03008 
1/89 0.22744 0.36364 -0.91788 0.92851 NOP58 
Glutathione metabolism Homo 
sapiens hsa00480 1/52 0.14063 0.30831 -0.78077 0.91870 RRM2 
RNA degradation Homo sapiens 
hsa03018 1/77 0.20025 0.35669 -0.87351 0.90049 DDX6 
Pathways in cancer Homo 
sapiens hsa05200 2/397 0.31522 0.38914 -0.93527 0.88271 CDK6, CCND1 
ABC transporters Homo sapiens 
hsa02010 1/44 0.12068 0.30279 -0.71895 0.85895 ABCB10 
Ether lipid metabolism Homo 
sapiens hsa00565 1/45 0.12320 0.30279 -0.71146 0.85001 PAFAH1B1 
Biosynthesis of amino acids 
Homo sapiens hsa01230 1/74 0.19330 0.35543 -0.80559 0.83332 IDH3A 
Selenocompound metabolism 
Homo sapiens hsa00450 1/17 0.05005 0.21944 -0.52446 0.79543 PAPSS2 
Platelet activation Homo sapiens 
hsa04611 1/122 0.29778 0.38914 -0.80795 0.76254 FERMT3 
Pancreatic secretion Homo 
sapiens hsa04972 1/96 0.24290 0.37270 -0.73547 0.72590 CPA1 
Thyroid hormone signaling 
pathway Homo sapiens 
hsa04919 
1/118 0.28959 0.38914 -0.76140 0.71862 CCND1 
Citrate cycle (TCA cycle) Homo 
sapiens hsa00020 1/30 0.08470 0.28401 -0.56962 0.71700 IDH3A 
Pyrimidine metabolism Homo 
sapiens hsa00240 1/105 0.26234 0.37384 -0.72489 0.71324 RRM2 
Protein digestion and absorption 
Homo sapiens hsa04974 1/90 0.22967 0.36364 -0.67328 0.68108 CPA1 
AMPK signaling pathway Homo 
sapiens hsa04152 1/124 0.30184 0.38914 -0.69179 0.65292 CCND1 
FoxO signaling pathway Homo 
sapiens hsa04068 1/133 0.31984 0.38914 -0.68262 0.64426 CCND1 
Carbon metabolism Homo 
sapiens hsa01200 1/113 0.27923 0.38819 -0.67733 0.64093 IDH3A 
Spliceosome Homo sapiens 
hsa03040 1/134 0.32181 0.38914 -0.66273 0.62549 SNRPD2 
Wnt signaling pathway Homo 
sapiens hsa04310 1/142 0.33740 0.39249 -0.66058 0.61781 CCND1 
Oxytocin signaling pathway 
Homo sapiens hsa04921 1/158 0.36756 0.40290 -0.66422 0.60382 CCND1 
Jak-STAT signaling pathway 
Homo sapiens hsa04630 1/158 0.36756 0.40290 -0.63422 0.57655 CCND1 
Hippo signaling pathway Homo 
sapiens hsa04390 1/153 0.35828 0.40290 -0.55780 0.50707 CCND1 
Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
1/169 0.38753 0.41678 -0.57291 0.50141 UBE4B 
Ubiquitin mediated proteolysis 
Homo sapiens hsa04120 1/137 0.32770 0.38914 -0.52727 0.49764 UBE4B 
Appendix 
	 237 
2-Oxocarboxylic acid 
metabolism Homo sapiens 
hsa01210 
1/17 0.05005 0.21944 -0.31871 0.48338 IDH3A 
Proteoglycans in cancer Homo 
sapiens hsa05205 1/203 0.44554 0.45350 -0.58976 0.46636 CCND1 
Focal adhesion Homo sapiens 
hsa04510 1/202 0.44391 0.45350 -0.56415 0.44611 CCND1 
Herpes simplex infection Homo 
sapiens hsa05168 1/185 0.41551 0.43860 -0.51392 0.42356 EEF1D 
HTLV-I infection Homo sapiens 
hsa05166 1/258 0.52848 0.52848 -0.54412 0.34701 CCND1 
Sulfur metabolism Homo sapiens 
hsa00920 1/10 0.03087 0.17599 0.07236 -0.12571 PAPSS2 
Vitamin B6 metabolism Homo 
sapiens hsa00750 1/6 0.01975 0.14075 0.17640 -0.34588 PDXK 
	
Table A(E: GO terms from EnrichR KEGG for genes downregulated in mutant monocytes. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Gastric acid secretion Homo 
sapiens hsa04971 6/74 0.00005 0.00840 -2.02272 9.66656 
CAMK2B, PLCB3, PRKCB, 
ATP1A1, ATP1B1, CALM1 
Dopaminergic synapse Homo 
sapiens hsa04728 7/129 0.00012 0.01071 -1.86790 8.47353 
CAMK2B, PLCB3, DDC, 
PRKCB, MAOA, PPP2R5A, 
CALM1 
Amphetamine addiction Homo 
sapiens hsa05031 5/67 0.00031 0.01794 -1.94473 7.81935 
CAMK2B, DDC, MAOA, 
PRKCB, CALM1 
Tryptophan metabolism Homo 
sapiens hsa00380 4/40 0.00046 0.02004 -1.84865 7.22868 
DDC, MAOA, KYNU, 
CYP1A1 
Endocrine and other factor-
regulated calcium reabsorption 
Homo sapiens hsa04961 
4/47 0.00082 0.02513 -1.81165 6.67366 PLCB3, PRKCB, ATP1A1, ATP1B1 
Insulin secretion Homo sapiens 
hsa04911 5/85 0.00087 0.02513 -1.74995 6.44637 
CAMK2B, PLCB3, PRKCB, 
ATP1A1, ATP1B1 
Salivary secretion Homo sapiens 
hsa04970 5/89 0.00106 0.02623 -1.67567 6.10108 
PLCB3, PRKCB, ATP1A1, 
ATP1B1, CALM1 
Phosphatidylinositol signaling 
system Homo sapiens hsa04070 5/98 0.00160 0.02916 -1.63960 5.79573 
PLCB3, INPP1, PRKCB, 
CALM1, PIK3C2A 
Adrenergic signaling in 
cardiomyocytes Homo sapiens 
hsa04261 
6/148 0.00169 0.02916 -1.63438 5.77728 
CAMK2B, PLCB3, 
PPP2R5A, ATP1A1, 
ATP1B1, CALM1 
Pancreatic secretion Homo 
sapiens hsa04972 5/96 0.00146 0.02916 -1.53503 5.42610 
PLCB3, PRKCB, RAB27B, 
ATP1A1, ATP1B1 
Long-term potentiation Homo 
sapiens hsa04720 4/66 0.00266 0.04189 -1.53906 4.88311 
CAMK2B, PLCB3, PRKCB, 
CALM1 
Thyroid hormone synthesis 
Homo sapiens hsa04918 4/71 0.00342 0.04935 -1.50101 4.51624 
PLCB3, PRKCB, ATP1A1, 
ATP1B1 
Aldosterone synthesis and 
secretion Homo sapiens 
hsa04925 
4/81 0.00536 0.05815 -1.57392 4.47728 CAMK2B, PLCB3, PRKCB, CALM1 
Cardiac muscle contraction 
Homo sapiens hsa04260 4/78 0.00472 0.05815 -1.41091 4.01357 
ATP1A1, ATP1B1, COX6C, 
COX5B 
GnRH signaling pathway Homo 
sapiens hsa04912 4/91 0.00793 0.07618 -1.45402 3.74365 
CAMK2B, PLCB3, PRKCB, 
CALM1 
Inflammatory mediator regulation 
of TRP channels Homo sapiens 
hsa04750 
4/98 0.01013 0.08418 -1.45874 3.61009 CAMK2B, PLCB3, PRKCB, CALM1 
Circadian entrainment Homo 
sapiens hsa04713 4/95 0.00914 0.08326 -1.41906 3.52748 
CAMK2B, PLCB3, PRKCB, 
CALM1 
Aldosterone-regulated sodium 
reabsorption Homo sapiens 
hsa04960 
3/39 0.00503 0.05815 -1.19737 3.40612 PRKCB, ATP1A1, ATP1B1 
Melanogenesis Homo sapiens 
hsa04916 4/100 0.01083 0.08418 -1.34444 3.32720 
CAMK2B, PLCB3, PRKCB, 
CALM1 
Glucagon signaling pathway 
Homo sapiens hsa04922 4/101 0.01119 0.08418 -1.30017 3.21766 
CAMK2B, PLCB3, CALM1, 
PHKA2 
Glycine, serine and threonine 
metabolism Homo sapiens 
hsa00260 
3/40 0.00538 0.05815 -1.05552 3.00260 GLDC, MAOA, AGXT 
Alzheimer's disease Homo 
sapiens hsa05010 5/168 0.01429 0.10303 -1.26617 2.87761 
APH1A, PLCB3, CALM1, 
COX6C, COX5B 
Carbohydrate digestion and 
absorption Homo sapiens 
hsa04973 
3/45 0.00732 0.07448 -1.08935 2.82924 PRKCB, ATP1A1, ATP1B1 
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Calcium signaling pathway Homo 
sapiens hsa04020 5/180 0.01861 0.11252 -1.27727 2.79037 
CAMK2B, PLCB3, PRKCB, 
CALM1, PHKA2 
Serotonergic synapse Homo 
sapiens hsa04726 4/112 0.01567 0.10844 -1.22251 2.71594 
PLCB3, DDC, PRKCB, 
MAOA 
Thyroid hormone signaling 
pathway Homo sapiens 
hsa04919 
4/118 0.01853 0.11252 -1.16392 2.54275 PLCB3, PRKCB, ATP1A1, ATP1B1 
Glioma Homo sapiens hsa05214 3/65 0.01886 0.11252 -1.04687 2.28704 CAMK2B, PRKCB, CALM1 
Focal adhesion Homo sapiens 
hsa04510 5/202 0.02859 0.14989 -1.11735 2.12054 
PRKCB, ACTN1, FLNA, 
ARHGAP35, VEGFA 
Rap1 signaling pathway Homo 
sapiens hsa04015 5/211 0.03350 0.17047 -1.13215 2.00298 
PLCB3, PRKCB, CDH1, 
CALM1, VEGFA 
Inositol phosphate metabolism 
Homo sapiens hsa00562 5/71 0.02356 0.13146 -0.90590 1.83809 PLCB3, INPP1, PIK3C2A 
Oxytocin signaling pathway 
Homo sapiens hsa04921 4/158 0.04571 0.21371 -1.03011 1.58963 
CAMK2B, PLCB3, PRKCB, 
CALM1 
cGMP-PKG signaling pathway 
Homo sapiens hsa04022 4/167 0.05384 0.23465 -0.95466 1.38395 
PLCB3, ATP1A1, ATP1B1, 
CALM1 
AGE-RAGE signaling pathway in 
diabetic complications Homo 
sapiens hsa04933 
3/101 0.05561 0.23465 -0.91784 1.33058 PLCB3, PRKCB, VEGFA 
RNA transport Homo sapiens 
hsa03013 4/172 0.05867 0.23606 -0.84848 1.22493 
CYFIP1, SUMO3, EIF2B1, 
EIF1B 
Amoebiasis Homo sapiens 
hsa05146 3/100 0.05432 0.23465 -0.77741 1.12700 PLCB3, PRKCB, ACTN1 
Cholinergic synapse Homo 
sapiens hsa04725 3/111 0.06932 0.24993 -0.77618 1.07622 CAMK2B, PLCB3, PRKCB 
HIF-1 signaling pathway Homo 
sapiens hsa04066 3/103 0.05824 0.23606 -0.74035 1.06882 CAMK2B, PRKCB, VEGFA 
Tuberculosis Homo sapiens 
hsa05152 4/178 0.06478 0.24993 -0.75676 1.04929 
CAMK2B, PLK3, CALM1, 
HLA-DRB1 
Metabolic pathways Homo 
sapiens hsa01100 15/1239 0.08772 0.25477 -0.59611 0.81513 
DDC, RRM2, INPP1, GLDC, 
MAOA, COX6C, COX5B, 
PIK3C2A, PLCB3, P4HA1, 
KYNU, HSD17B2, CYP1A1, 
ME3, AGXT 
Carbon metabolism Homo 
sapiens hsa01200 3/113 0.07224 0.24993 -0.44448 0.61629 GLDC, ME3, AGXT 
cAMP signaling pathway Homo 
sapiens hsa04024 4/199 0.08866 0.25477 -0.44539 0.60902 
CAMK2B, ATP1A1, CALM1, 
ATP1B1 
Proteoglycans in cancer Homo 
sapiens hsa05205 4/203 0.09363 0.25477 -0.43446 0.59409 
CAMK2B, PRKCB, FLNA, 
VEGFA 
Vascular smooth muscle 
contraction Homo sapiens 
hsa04270 
3/120 0.08285 0.25477 -0.43263 0.59158 PLCB3, PRKCB, CALM1 
Leukocyte transendothelial 
migration Homo sapiens 
hsa04670 
3/118 0.07975 0.25477 -0.41863 0.57244 PRKCB, ACTN1, ARHGAP35 
Oocyte meiosis Homo sapiens 
hsa04114 3/123 0.08760 0.25477 -0.40011 0.54711 CAMK2B, PPP2R5A, CALM1 
Sphingolipid signaling pathway 
Homo sapiens hsa04071 3/120 0.08285 0.25477 -0.38943 0.53251 PLCB3, PRKCB, PPP2R5A 
Regulation of actin cytoskeleton 
Homo sapiens hsa04810 4/214 0.10800 0.27476 -0.26384 0.34085 
CYFIP1, ACTN1, ARPC1B, 
ARHGAP35 
Wnt signaling pathway Homo 
sapiens hsa04310 3/142 0.12019 0.29703 -0.12729 0.15453 CAMK2B, PLCB3, PRKCB 
Systemic lupus erythematosus 
Homo sapiens hsa05322 3/135 0.10770 0.27476 -0.09852 0.12728 ACTN1, HLA-DRB1, C1QC 
Bladder cancer Homo sapiens 
hsa05219 2/41 0.04971 0.22631 -0.01682 0.02499 CDH1, VEGFA 
Hippo signaling pathway Homo 
sapiens hsa04390 3/153 0.14084 0.30841 0.13979 -0.16444 CDH1, TEAD1, STK3 
Ovarian steroidogenesis Homo 
sapiens hsa04913 2/50 0.06963 0.24993 0.13080 -0.18136 HSD17B2, CYP1A1 
Cocaine addiction Homo sapiens 
hsa05030 2/49 0.06730 0.24993 0.14946 -0.20724 DDC, MAOA 
Neuroactive ligand-receptor 
interaction Homo sapiens 
hsa04080 
1/277 0.90718 0.90718 2.26189 -0.22034 GPR35 
Endocytosis Homo sapiens 
hsa04144 1/259 0.89142 0.89660 2.23466 -0.24390 ARPC1B 
HTLV-I infection Homo sapiens 
hsa05166 1/258 0.89047 0.89660 2.30360 -0.25143 HLA-DRB1 
African trypanosomiasis Homo 
sapiens hsa05143 2/35 0.03784 0.18184 0.16861 -0.28741 PLCB3, PRKCB 
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Alcoholism Homo sapiens 
hsa05034 3/179 0.19379 0.37669 0.30305 -0.29588 DDC, MAOA, CALM1 
Arginine and proline metabolism 
Homo sapiens hsa00330 2/50 0.06963 0.24993 0.26149 -0.36258 P4HA1, MAOA 
Tyrosine metabolism Homo 
sapiens hsa00350 2/35 0.03784 0.18184 0.22707 -0.38706 DDC, MAOA 
Viral carcinogenesis Homo 
sapiens hsa05203 1/205 0.82661 0.84119 2.31671 -0.40064 ACTN1 
Huntington's disease Homo 
sapiens hsa05016 3/193 0.22415 0.40036 0.45466 -0.41619 PLCB3, COX6C, COX5B 
Pathogenic Escherichia coli 
infection Homo sapiens 
hsa05130 
2/55 0.08164 0.25477 0.32319 -0.44193 CDH1, ARPC1B 
Pathways in cancer Homo 
sapiens hsa05200 5/397 0.24338 0.42106 0.53287 -0.46093 
PLCB3, PRKCB, CDH1, 
DCC, VEGFA 
Herpes simplex infection Homo 
sapiens hsa05168 1/185 0.79398 0.81277 2.22749 -0.46177 HLA-DRB1 
Purine metabolism Homo 
sapiens hsa00230 1/176 0.77739 0.80053 2.17745 -0.48444 RRM2 
Mineral absorption Homo 
sapiens hsa04978 2/51 0.07198 0.24993 0.37635 -0.52184 ATP1A1, ATP1B1 
mTOR signaling pathway Homo 
sapiens hsa04150 2/60 0.09425 0.25477 0.38661 -0.52865 PRKCB, VEGFA 
Estrogen signaling pathway 
Homo sapiens hsa04915 2/99 0.20605 0.39607 0.58328 -0.54021 PLCB3, CALM1 
Staphylococcus aureus infection 
Homo sapiens hsa05150 2/56 0.08412 0.25477 0.39649 -0.54217 HLA-DRB1, C1QC 
Leishmaniasis Homo sapiens 
hsa05140 2/73 0.12931 0.30476 0.47892 -0.56907 PRKCB, HLA-DRB1 
Glutathione metabolism Homo 
sapiens hsa00480 2/52 0.07436 0.25224 0.42499 -0.58537 RRM2, MGST2 
Cytokine-cytokine receptor 
interaction Homo sapiens 
hsa04060 
2/265 0.65920 0.72868 1.85680 -0.58771 TNFRSF25, VEGFA 
ErbB signaling pathway Homo 
sapiens hsa04012 2/87 0.16983 0.34977 0.56508 -0.59361 CAMK2B, PRKCB 
VEGF signaling pathway Homo 
sapiens hsa04370 2/61 0.09683 0.25773 0.44214 -0.59948 PRKCB, VEGFA 
Ras signaling pathway Homo 
sapiens hsa04014 3/227 0.30107 0.47350 0.81076 -0.60613 PRKCB, CALM1, VEGFA 
Fc gamma R-mediated 
phagocytosis Homo sapiens 
hsa04666 
2/93 0.18781 0.36922 0.60879 -0.60658 PRKCB, ARPC1B 
Jak-STAT signaling pathway 
Homo sapiens hsa04630 1/158 0.74019 0.76679 2.28931 -0.60792 MCL1 
Chagas disease (American 
trypanosomiasis) Homo sapiens 
hsa05142 
2/104 0.22140 0.40036 0.66879 -0.61221 PLCB3, C1QC 
Phagosome Homo sapiens 
hsa04145 1/154 0.73113 0.76196 2.25440 -0.61288 HLA-DRB1 
Proximal tubule bicarbonate 
reclamation Homo sapiens 
hsa04964 
2/23 0.01816 0.11252 0.28545 -0.62361 ATP1A1, ATP1B1 
Retrograde endocannabinoid 
signaling Homo sapiens 
hsa04723 
2/101 0.21217 0.39898 0.68590 -0.63024 PLCB3, PRKCB 
Long-term depression Homo 
sapiens hsa04730 2/60 0.09425 0.25477 0.46636 -0.63771 PLCB3, PRKCB 
Insulin resistance Homo sapiens 
hsa04931 2/109 0.23684 0.41387 0.73622 -0.64949 PRKCB, SLC27A2 
Hepatitis B Homo sapiens 
hsa05161 1/146 0.71206 0.74659 2.24382 -0.65574 PRKCB 
Measles Homo sapiens 
hsa05162 1/136 0.68635 0.73581 2.15267 -0.66042 DOK1 
Ribosome Homo sapiens 
hsa03010 1/137 0.68902 0.73581 2.15655 -0.66161 RPS27L 
Phospholipase D signaling 
pathway Homo sapiens 
hsa04072 
1/144 0.70709 0.74590 2.25765 -0.66188 PLCB3 
Ubiquitin mediated proteolysis 
Homo sapiens hsa04120 1/137 0.68902 0.73581 2.16009 -0.66269 UBE2Q2 
FoxO signaling pathway Homo 
sapiens hsa04068 1/133 0.67821 0.73581 2.16377 -0.66382 PLK3 
Apoptosis Homo sapiens 
hsa04210 1/140 0.69690 0.73965 2.20268 -0.66428 MCL1 
Natural killer cell mediated 
cytotoxicity Homo sapiens 
hsa04650 
1/135 0.68366 0.73581 2.17007 -0.66575 PRKCB 
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Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
2/169 0.41990 0.56511 1.16980 -0.66764 CRYAB, NFE2L2 
AMPK signaling pathway Homo 
sapiens hsa04152 1/124 0.65250 0.72828 2.12334 -0.67325 PPP2R5A 
Glutamatergic synapse Homo 
sapiens hsa04724 2/114 0.25235 0.43210 0.80501 -0.67547 PLCB3, PRKCB 
Platelet activation Homo sapiens 
hsa04611 2/122 0.27722 0.45184 0.85448 -0.67882 PLCB3, ARHGAP35 
Renin secretion Homo sapiens 
hsa04924 2/64 0.10471 0.27447 0.52575 -0.67975 PLCB3, CALM1 
Cell cycle Homo sapiens 
hsa04110 1/124 0.65250 0.72828 2.15989 -0.68484 E2F5 
Drug metabolism - cytochrome 
P450 Homo sapiens hsa00982 2/69 0.11821 0.29638 0.56944 -0.69250 MAOA, MGST2 
Adherens junction Homo sapiens 
hsa04520 2/74 0.13212 0.30476 0.58388 -0.69379 CDH1, ACTN1 
Tight junction Homo sapiens 
hsa04530 2/139 0.32986 0.49293 0.99340 -0.70272 PRKCB, ACTN1 
Neurotrophin signaling pathway 
Homo sapiens hsa04722 2/120 0.27100 0.44651 0.87599 -0.70631 CAMK2B, CALM1 
Axon guidance Homo sapiens 
hsa04360 1/127 0.66129 0.72868 2.23170 -0.70638 DCC 
Metabolism of xenobiotics by 
cytochrome P450 Homo sapiens 
hsa00980 
2/73 0.12931 0.30476 0.59447 -0.70638 CYP1A1, MGST2 
Bile secretion Homo sapiens 
hsa04976 2/71 0.12373 0.30148 0.59089 -0.70851 ATP1A1, ATP1B1 
Rheumatoid arthritis Homo 
sapiens hsa05323 2/90 0.17878 0.35551 0.68793 -0.71146 HLA-DRB1, VEGFA 
MAPK signaling pathway Homo 
sapiens hsa04010 3/255 0.36563 0.51543 1.08284 -0.71766 PRKCB, FLNA, STK3 
Gap junction Homo sapiens 
hsa04540 2/88 0.17281 0.35171 0.69273 -0.72386 PLCB3, PRKCB 
Insulin signaling pathway Homo 
sapiens hsa04910 2/139 0.32986 0.49293 1.03126 -0.72950 CALM1, PHKA2 
Olfactory transduction Homo 
sapiens hsa04740 4/415 0.46642 0.58050 1.34406 -0.73098 
CAMK2B, OR2AT4, CALM1, 
NCALD 
Viral myocarditis Homo sapiens 
hsa05416 2/59 0.09168 0.25477 0.54179 -0.74085 HLA-DRB1, SGCG 
Parkinson's disease Homo 
sapiens hsa05012 2/142 0.33907 0.49293 1.05398 -0.74557 COX6C, COX5B 
MicroRNAs in cancer Homo 
sapiens hsa05206 3/297 0.46049 0.58050 1.37686 -0.74882 PRKCB, VEGFA, MCL1 
Salmonella infection Homo 
sapiens hsa05132 2/86 0.16686 0.34780 0.71661 -0.75683 ARPC1B, FLNA 
Pyrimidine metabolism Homo 
sapiens hsa00240 2/105 0.22448 0.40036 0.83092 -0.76062 RRM2, TXNRD3 
Toxoplasmosis Homo sapiens 
hsa05145 1/118 0.63426 0.71717 2.30170 -0.76518 HLA-DRB1 
Oxidative phosphorylation Homo 
sapiens hsa00190 2/133 0.31136 0.48093 1.04663 -0.76616 COX6C, COX5B 
Epstein-Barr virus infection 
Homo sapiens hsa05169 2/202 0.51166 0.61470 1.58417 -0.77089 PSMC3, HLA-DRB1 
Cell adhesion molecules (CAMs) 
Homo sapiens hsa04514 2/142 0.33907 0.49293 1.09076 -0.77159 CDH1, HLA-DRB1 
Chemical carcinogenesis Homo 
sapiens hsa05204 2/82 0.15510 0.33126 0.71261 -0.78733 CYP1A1, MGST2 
Non-alcoholic fatty liver disease 
(NAFLD) Homo sapiens 
hsa04932 
2/151 0.36646 0.51543 1.18850 -0.78769 COX6C, COX5B 
Pertussis Homo sapiens 
hsa05133 2/75 0.13495 0.30718 0.67711 -0.79921 CALM1, C1QC 
Bacterial invasion of epithelial 
cells Homo sapiens hsa05100 2/78 0.14351 0.31033 0.68372 -0.80003 CDH1, ARPC1B 
Influenza A Homo sapiens 
hsa05164 2/175 0.43723 0.56873 1.44800 -0.81717 PRKCB, HLA-DRB1 
Steroid hormone biosynthesis 
Homo sapiens hsa00140 2/58 0.08914 0.25477 0.60624 -0.82898 HSD17B2, CYP1A1 
PI3K-Akt signaling pathway 
Homo sapiens hsa04151 3/341 0.55323 0.63383 1.82197 -0.83076 PPP2R5A, VEGFA, MCL1 
Peroxisome Homo sapiens 
hsa04146 2/83 0.15802 0.33339 0.75883 -0.83354 AGXT, SLC27A2 
Protein digestion and absorption 
Homo sapiens hsa04974 2/90 0.17878 0.35551 0.82172 -0.84982 ATP1A1, ATP1B1 
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Antigen processing and 
presentation Homo sapiens 
hsa04612 
2/77 0.14064 0.30841 0.72633 -0.85439 B2M, HLA-DRB1 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) Homo 
sapiens hsa05412 
2/74 0.13212 0.30476 0.73568 -0.87417 ACTN1, SGCG 
Chemokine signaling pathway 
Homo sapiens hsa04062 2/187 0.47107 0.58210 1.67726 -0.90758 PLCB3, PRKCB 
Phenylalanine metabolism Homo 
sapiens hsa00360 2/17 0.01069 0.08418 0.38353 -0.94916 DDC, MAOA 
Choline metabolism in cancer 
Homo sapiens hsa05231 1/101 0.57730 0.65706 2.33805 -0.98195 PRKCB 
Glyoxylate and dicarboxylate 
metabolism Homo sapiens 
hsa00630 
2/28 0.02565 0.13866 0.51500 -1.01749 GLDC, AGXT 
Morphine addiction Homo 
sapiens hsa05032 1/91 0.53981 0.62676 2.40071 -1.12161 PRKCB 
mRNA surveillance pathway 
Homo sapiens hsa03015 1/91 0.53981 0.62676 2.40336 -1.12284 PPP2R5A 
NF-kappa B signaling pathway 
Homo sapiens hsa04064 1/93 0.54756 0.63152 2.46684 -1.13384 PRKCB 
Hematopoietic cell lineage Homo 
sapiens hsa04640 1/88 0.52794 0.62557 2.45225 -1.15034 HLA-DRB1 
GABAergic synapse Homo 
sapiens hsa04727 1/88 0.52794 0.62557 2.49202 -1.16900 PRKCB 
Dilated cardiomyopathy Homo 
sapiens hsa05414 1/90 0.53588 0.62676 2.52122 -1.17791 SGCG 
TGF-beta signaling pathway 
Homo sapiens hsa04350 1/84 0.51164 0.61470 2.42831 -1.18166 E2F5 
Hypertrophic cardiomyopathy 
(HCM) Homo sapiens hsa05410 1/83 0.50748 0.61470 2.76593 -1.34596 SGCG 
Complement and coagulation 
cascades Homo sapiens 
hsa04610 
1/79 0.49049 0.60180 2.74107 -1.39199 C1QC 
B cell receptor signaling pathway 
Homo sapiens hsa04662 1/73 0.46391 0.58050 2.61589 -1.42268 PRKCB 
Melanoma Homo sapiens 
hsa05218 1/71 0.45475 0.57847 2.63492 -1.44225 CDH1 
Histidine metabolism Homo 
sapiens hsa00340 2/24 0.01957 0.11288 0.67195 -1.46582 DDC, MAOA 
Longevity regulating pathway - 
multiple species Homo sapiens 
hsa04213 
1/64 0.42148 0.56511 2.76325 -1.57707 CRYAB 
Renal cell carcinoma Homo 
sapiens hsa05211 1/66 0.43118 0.56511 2.77114 -1.58158 VEGFA 
p53 signaling pathway Homo 
sapiens hsa04115 1/69 0.44544 0.57083 2.83549 -1.58977 RRM2 
PPAR signaling pathway Homo 
sapiens hsa03320 1/69 0.44544 0.57083 2.83923 -1.59186 SLC27A2 
Pancreatic cancer Homo sapiens 
hsa05212 1/66 0.43118 0.56511 2.79242 -1.59372 VEGFA 
Colorectal cancer Homo sapiens 
hsa05210 1/62 0.41161 0.56511 2.88049 -1.64399 DCC 
Shigellosis Homo sapiens 
hsa05131 1/65 0.42635 0.56511 2.88353 -1.64572 ARPC1B 
Retinol metabolism Homo 
sapiens hsa00830 1/65 0.42635 0.56511 2.90737 -1.65933 CYP1A1 
Inflammatory bowel disease (IBD) 
Homo sapiens hsa05321 1/65 0.42635 0.56511 2.96544 -1.69247 HLA-DRB1 
Non-small cell lung cancer Homo 
sapiens hsa05223 1/56 0.38100 0.53155 3.17328 -2.00536 PRKCB 
Endometrial cancer Homo 
sapiens hsa05213 1/52 0.35973 0.51543 3.10137 -2.05547 CDH1 
Autoimmune thyroid disease 
Homo sapiens hsa05320 1/53 0.36511 0.51543 3.50050 -2.31999 HLA-DRB1 
Notch signaling pathway Homo 
sapiens hsa04330 1/48 0.33774 0.49293 3.47977 -2.46154 APH1A 
Intestinal immune network for IgA 
production Homo sapiens 
hsa04672 
1/48 0.33774 0.49293 3.68536 -2.60697 HLA-DRB1 
Type I diabetes mellitus Homo 
sapiens hsa04940 1/43 0.30920 0.48093 4.01150 -2.93652 HLA-DRB1 
Proteasome Homo sapiens 
hsa03050 1/44 0.31500 0.48226 4.05871 -2.95987 PSMC3 
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Graft-versus-host disease Homo 
sapiens hsa05332 1/41 0.29745 0.47211 4.10757 -3.08294 HLA-DRB1 
Prion diseases Homo sapiens 
hsa05020 1/35 0.26102 0.43419 4.04942 -3.37831 C1QC 
Pyruvate metabolism Homo 
sapiens hsa00620 1/40 0.29151 0.46695 4.51685 -3.43972 ME3 
Allograft rejection Homo sapiens 
hsa05330 1/38 0.27946 0.45184 4.34520 -3.45194 HLA-DRB1 
Thyroid cancer Homo sapiens 
hsa05216 1/29 0.22272 0.40036 3.92208 -3.59025 CDH1 
Pentose phosphate pathway 
Homo sapiens hsa00030 1/29 0.22272 0.40036 3.96137 -3.62622 DERA 
Asthma Homo sapiens hsa05310 1/31 0.23570 0.41387 4.23748 -3.73828 HLA-DRB1 
Alanine, aspartate and glutamate 
metabolism Homo sapiens 
hsa00250 
1/35 0.26102 0.43419 4.65382 -3.88254 AGXT 
SNARE interactions in vesicular 
transport Homo sapiens 
hsa04130 
1/34 0.25477 0.43210 4.99315 -4.18971 STX5 
Phototransduction Homo sapiens 
hsa04744 1/27 0.20953 0.39834 5.04511 -4.64379 CALM1 
Selenocompound metabolism 
Homo sapiens hsa00450 1/17 0.14019 0.30841 7.67439 -9.02749 TXNRD3 
	
Table A(K: GO terms from EnrichR KEGG for genes upregulated in mutant neutrophils. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
MAPK signaling pathway Homo 
sapiens hsa04010 4/255 0.00779 0.26103 -1.99779 2.68328 
MAP4K2, NFATC1, FOS, 
RELB 
Hepatitis B Homo sapiens 
hsa05161 3/146 0.01069 0.26103 -1.88539 2.53231 NFATC1, FOS, IKBKE 
B cell receptor signaling pathway 
Homo sapiens hsa04662 2/73 0.02259 0.26103 -1.86290 2.50211 NFATC1, FOS 
Inflammatory bowel disease (IBD) 
Homo sapiens hsa05321 2/65 0.01827 0.26103 -1.85842 2.49610 NFATC1, NOD2 
Osteoclast differentiation Homo 
sapiens hsa04380 3/132 0.00816 0.26103 -1.83827 2.46903 NFATC1, FOS, RELB 
Leishmaniasis Homo sapiens 
hsa05140 2/73 0.02259 0.26103 -1.71108 2.29820 ITGAM, FOS 
Choline metabolism in cancer 
Homo sapiens hsa05231 2/101 0.04057 0.27964 -1.71774 2.18885 FOS, DGKZ 
HTLV-I infection Homo sapiens 
hsa05166 3/258 0.04623 0.27964 -1.66822 2.12576 NFATC1, FOS, RELB 
Phosphatidylinositol signaling 
system Homo sapiens hsa04070 2/98 0.03845 0.27964 -1.66814 2.12565 ITPKC, DGKZ 
T cell receptor signaling pathway 
Homo sapiens hsa04660 2/104 0.04274 0.27964 -1.63202 2.07963 NFATC1, FOS 
Toll-like receptor signaling 
pathway Homo sapiens 
hsa04620 
2/106 0.04421 0.27964 -1.63066 2.07790 FOS, IKBKE 
Pertussis Homo sapiens 
hsa05133 2/75 0.02373 0.26103 -1.54410 2.07392 ITGAM, FOS 
TNF signaling pathway Homo 
sapiens hsa04668 2/110 0.04721 0.27964 -1.59156 2.02807 NOD2, FOS 
Oxytocin signaling pathway 
Homo sapiens hsa04921 2/158 0.08835 0.40718 -1.57895 1.41867 NFATC1, FOS 
Cell adhesion molecules (CAMs) 
Homo sapiens hsa04514 2/142 0.07367 0.37817 -1.38877 1.35044 ITGAM, SELL 
cAMP signaling pathway Homo 
sapiens hsa04024 2/199 0.12942 0.41622 -1.42760 1.25136 NFATC1, FOS 
Tuberculosis Homo sapiens 
hsa05152 2/178 0.10783 0.41622 -1.39014 1.21852 ITGAM, NOD2 
Herpes simplex infection Homo 
sapiens hsa05168 2/185 0.11491 0.41622 -1.32443 1.16092 FOS, IKBKE 
Thyroid cancer Homo sapiens 
hsa05216 1/29 0.08990 0.40718 -0.86556 0.77769 CCDC6 
Lysine degradation Homo 
sapiens hsa00310 1/52 0.15354 0.41622 -0.87910 0.77058 KMT2C 
Legionellosis Homo sapiens 
hsa05134 1/55 0.16152 0.41622 -0.86736 0.76028 ITGAM 
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Colorectal cancer Homo sapiens 
hsa05210 1/62 0.17986 0.41622 -0.86250 0.75603 FOS 
Basal transcription factors Homo 
sapiens hsa03022 1/45 0.13463 0.41622 -0.83935 0.73573 GTF2A1L 
Glutathione metabolism Homo 
sapiens hsa00480 1/52 0.15354 0.41622 -0.82715 0.72504 RRM2 
Nucleotide excision repair Homo 
sapiens hsa03420 1/47 0.14008 0.41622 -0.81554 0.71486 RFC1 
DNA replication Homo sapiens 
hsa03030 1/36 0.10974 0.41622 -0.81534 0.71468 RFC1 
Glycerolipid metabolism Homo 
sapiens hsa00561 1/59 0.17205 0.41622 -0.80999 0.71000 DGKZ 
Amphetamine addiction Homo 
sapiens hsa05031 1/67 0.19273 0.41622 -0.79759 0.69912 FOS 
Staphylococcus aureus infection 
Homo sapiens hsa05150 1/56 0.16416 0.41622 -0.77751 0.68152 ITGAM 
Renal cell carcinoma Homo 
sapiens hsa05211 1/66 0.19017 0.41622 -0.77363 0.67812 FLCN 
NOD-like receptor signaling 
pathway Homo sapiens 
hsa04621 
1/57 0.16680 0.41622 -0.73562 0.64480 NOD2 
Prolactin signaling pathway 
Homo sapiens hsa04917 1/72 0.20541 0.41622 -0.72303 0.63377 FOS 
Inositol phosphate metabolism 
Homo sapiens hsa00562 1/71 0.20289 0.41622 -0.69605 0.61012 ITPKC 
AGE-RAGE signaling pathway in 
diabetic complications Homo 
sapiens hsa04933 
1/101 0.27525 0.42941 -0.68897 0.58241 NFATC1 
Cytosolic DNA-sensing pathway 
Homo sapiens hsa04623 1/64 0.18503 0.41622 -0.63227 0.55421 IKBKE 
Circadian entrainment Homo 
sapiens hsa04713 1/95 0.26130 0.42941 -0.65397 0.55283 FOS 
Shigellosis Homo sapiens 
hsa05131 1/65 0.18761 0.41622 -0.62273 0.54585 NOD2 
Estrogen signaling pathway 
Homo sapiens hsa04915 1/99 0.27063 0.42941 -0.62822 0.53106 FOS 
Mismatch repair Homo sapiens 
hsa03430 1/23 0.07256 0.37817 -0.54251 0.52753 RFC1 
Hematopoietic cell lineage Homo 
sapiens hsa04640 1/88 0.24470 0.42941 -0.61749 0.52199 ITGAM 
p53 signaling pathway Homo 
sapiens hsa04115 1/69 0.19782 0.41622 -0.59417 0.52082 RRM2 
Cholinergic synapse Homo 
sapiens hsa04725 1/111 0.29795 0.42949 -0.60486 0.51120 FOS 
Complement and coagulation 
cascades Homo sapiens 
hsa04610 
1/79 0.22283 0.42941 -0.58501 0.49453 ITGAM 
Rheumatoid arthritis Homo 
sapiens hsa05323 1/90 0.24948 0.42941 -0.57203 0.48356 FOS 
RIG-I-like receptor signaling 
pathway Homo sapiens 
hsa04622 
1/70 0.20036 0.41622 -0.54805 0.48039 IKBKE 
Salmonella infection Homo 
sapiens hsa05132 1/86 0.23989 0.42941 -0.56370 0.47652 FOS 
Amoebiasis Homo sapiens 
hsa05146 1/100 0.27295 0.42941 -0.55237 0.46694 ITGAM 
NF-kappa B signaling pathway 
Homo sapiens hsa04064 1/93 0.25659 0.42941 -0.54519 0.46087 RELB 
Chagas disease (American 
trypanosomiasis) Homo sapiens 
hsa05142 
1/104 0.28214 0.42941 -0.50068 0.42324 FOS 
Protein digestion and absorption 
Homo sapiens hsa04974 1/90 0.24948 0.42941 -0.49388 0.41750 SLC3A1 
Glycerophospholipid metabolism 
Homo sapiens hsa00564 1/95 0.26130 0.42941 -0.49096 0.41503 DGKZ 
Thyroid hormone signaling 
pathway Homo sapiens 
hsa04919 
1/118 0.31343 0.42949 -0.46622 0.39403 MED14 
Pathways in cancer Homo 
sapiens hsa05200 2/397 0.35741 0.42949 -0.45479 0.38437 CCDC6, FOS 
Dopaminergic synapse Homo 
sapiens hsa04728 1/129 0.33710 0.42949 -0.42585 0.35991 FOS 
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Pyrimidine metabolism Homo 
sapiens hsa00240 1/105 0.28442 0.42941 -0.42464 0.35897 RRM2 
Lysosome Homo sapiens 
hsa04142 1/123 0.32429 0.42949 -0.41803 0.35331 DNASE2B 
Hepatitis C Homo sapiens 
hsa05160 1/133 0.34552 0.42949 -0.40102 0.33893 IKBKE 
Spliceosome Homo sapiens 
hsa03040 1/134 0.34761 0.42949 -0.39159 0.33095 SF3A3 
Natural killer cell mediated 
cytotoxicity Homo sapiens 
hsa04650 
1/135 0.34969 0.42949 -0.37240 0.31474 NFATC1 
Measles Homo sapiens 
hsa05162 1/136 0.35176 0.42949 -0.36982 0.31255 IKBKE 
Leukocyte transendothelial 
migration Homo sapiens 
hsa04670 
1/118 0.31343 0.42949 -0.36736 0.31048 ITGAM 
Apoptosis Homo sapiens 
hsa04210 1/140 0.36000 0.42949 -0.34195 0.28900 FOS 
Ribosome Homo sapiens 
hsa03010 1/137 0.35383 0.42949 -0.26748 0.22606 RSL24D1 
Wnt signaling pathway Homo 
sapiens hsa04310 1/142 0.36408 0.42949 -0.25427 0.21490 NFATC1 
Phospholipase D signaling 
pathway Homo sapiens 
hsa04072 
1/144 0.36813 0.42949 -0.24007 0.20290 DGKZ 
Ubiquitin mediated proteolysis 
Homo sapiens hsa04120 1/137 0.35383 0.42949 -0.21811 0.18433 UBE4A 
Influenza A Homo sapiens 
hsa05164 1/175 0.42792 0.46739 -0.20887 0.15886 IKBKE 
cGMP-PKG signaling pathway 
Homo sapiens hsa04022 1/167 0.41303 0.46739 -0.20068 0.15263 NFATC1 
Calcium signaling pathway Homo 
sapiens hsa04020 1/180 0.43704 0.46739 -0.16815 0.12790 ITPKC 
Epstein-Barr virus infection 
Homo sapiens hsa05169 1/202 0.47556 0.50010 -0.16959 0.11752 RELB 
Purine metabolism Homo 
sapiens hsa00230 1/176 0.42976 0.46739 -0.14212 0.10809 RRM2 
Phagosome Homo sapiens 
hsa04145 1/154 0.38804 0.44596 -0.12220 0.09868 ITGAM 
Viral carcinogenesis Homo 
sapiens hsa05203 1/205 0.48061 0.50010 -0.12536 0.08687 GTF2A1L 
Transcriptional misregulation in 
cancer Homo sapiens hsa05202 1/180 0.43704 0.46739 -0.10085 0.07671 ITGAM 
Rap1 signaling pathway Homo 
sapiens hsa04015 1/211 0.49058 0.50201 -0.10192 0.07024 ITGAM 
Regulation of actin cytoskeleton 
Homo sapiens hsa04810 1/214 0.49549 0.50201 -0.06598 0.04547 ITGAM 
Metabolic pathways Homo 
sapiens hsa01100 3/1239 0.77310 0.77310 -0.12429 0.03198 ITPKC, RRM2, DGKZ 
	
Table A(O: GO terms from EnrichR KEGG for genes downregulated in mutant neutrophils. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Oxidative phosphorylation Homo 
sapiens hsa00190 7/133 0.00002 0.00091 -1.80174 12.61986 
NDUFA13, UQCRB, 
NDUFS6, ATP5A1, 
UQCRC2, ATP6V0C, 
COX7C 
Antigen processing and 
presentation Homo sapiens 
hsa04612 
6/77 0.00001 0.00091 -1.79354 12.56244 PSME1, B2M, CTSS, HLA-DRB1, CTSB, LGMN 
Alzheimer's disease Homo 
sapiens hsa05010 7/168 0.00008 0.00254 -1.79182 10.70583 
NDUFA13, UQCRB, 
NDUFS6, ATP5A1, CAPN2, 
UQCRC2, COX7C 
Lysosome Homo sapiens 
hsa04142 6/123 0.00012 0.00286 -1.69925 9.95417 
ASAH1, TPP1, ATP6V0C, 
CTSS, LGMN, CTSB 
Parkinson's disease Homo 
sapiens hsa05012 6/142 0.00025 0.00486 -1.67246 8.90974 
NDUFA13, UQCRB, 
NDUFS6, ATP5A1, 
UQCRC2, COX7C 
Huntington's disease Homo 
sapiens hsa05016 6/193 0.00119 0.01950 -1.77698 6.99661 
NDUFA13, UQCRB, 
NDUFS6, ATP5A1, 
UQCRC2, COX7C 
Non-alcoholic fatty liver disease 
(NAFLD) Homo sapiens hsa04932 5/151 0.00243 0.02971 -1.78236 6.26729 
NDUFA13, UQCRB, 
NDUFS6, UQCRC2, COX7C 
Cardiac muscle contraction Homo 
sapiens hsa04260 4/78 0.00148 0.02077 -1.60439 6.21545 
UQCRB, UQCRC2, ATP1A1, 
COX7C 
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Staphylococcus aureus infection 
Homo sapiens hsa05150 4/154 0.00541 0.05893 -1.50620 4.26461 CFD, HLA-DRB1, C1QC 
Phagosome Homo sapiens 
hsa04145 4/154 0.01518 0.14881 -1.49054 2.83964 
MARCO, ATP6V0C, HLA-
DRB1, CTSS 
Metabolic pathways Homo 
sapiens hsa01100 13/1239 0.03146 0.28027 -1.76326 2.24288 
ASAH1, NDUFA13, UQCRB, 
PIGQ, ATP5A1, BCKDHB, 
CCBL2, PYCR1, PDHB, 
COX7C, NDUFS6, UQCRC2, 
ATP6V0C 
Apoptosis Homo sapiens 
hsa04210 3/140 0.05590 0.45571 -1.67852 1.31916 CAPN2, CTSS, CTSB 
Inflammatory bowel disease (IBD) 
Homo sapiens hsa05321 2/65 0.06257 0.45571 -1.50830 1.18538 IL21R, HLA-DRB1 
Bile secretion Homo sapiens 
hsa04976 2/71 0.07270 0.47499 -1.29529 0.96430 ATP1A1, ABCG2 
Tuberculosis Homo sapiens 
hsa05152 3/178 0.09734 0.52833 -1.39014 0.88696 
ATP6V0C, HLA-DRB1, 
CTSS 
Complement and coagulation 
cascades Homo sapiens 
hsa04610 
2/79 0.08697 0.52833 -1.33501 0.85178 CFD, C1QC 
Rheumatoid arthritis Homo 
sapiens hsa05323 2/90 0.10782 0.52833 -1.23065 0.78520 ATP6V0C, HLA-DRB1 
Chemical carcinogenesis Homo 
sapiens hsa05204 2/82 0.09253 0.52833 -1.21160 0.77304 GSTO2, CCBL2 
Pancreatic secretion Homo 
sapiens hsa04972 2/96 0.11971 0.53051 -1.17661 0.74588 RAB3D, ATP1A1 
Spliceosome Homo sapiens 
hsa03040 2/134 0.20089 0.53051 -1.05713 0.67014 SF3B4, PLRG1 
Systemic lupus erythematosus 
Homo sapiens hsa05322 2/135 0.20312 0.53051 -0.97280 0.61668 HLA-DRB1, C1QC 
Ribosome Homo sapiens 
hsa03010 2/137 0.20759 0.53051 -0.97045 0.61519 RPS27L, MRPL35 
Cell adhesion molecules (CAMs) 
Homo sapiens hsa04514 2/142 0.21881 0.53051 -0.88323 0.55990 SDC3, HLA-DRB1 
RNA transport Homo sapiens 
hsa03013 2/172 0.28691 0.53051 -0.60593 0.38411 SUMO1, PAIP1 
Prion diseases Homo sapiens 
hsa05020 1/35 0.19804 0.53051 -0.17510 0.11100 C1QC 
Aldosterone-regulated sodium 
reabsorption Homo sapiens 
hsa04960 
1/39 0.21753 0.53051 -0.09396 0.05957 ATP1A1 
Asthma Homo sapiens hsa05310 1/31 0.17809 0.53051 -0.05376 0.03408 HLA-DRB1 
Proximal tubule bicarbonate 
reclamation Homo sapiens 
hsa04964 
1/23 0.13671 0.53051 -0.02721 0.01725 ATP1A1 
Propanoate metabolism Homo 
sapiens hsa00640 1/32 0.18312 0.53051 0.00892 -0.00566 BCKDHB 
Cytokine-cytokine receptor 
interaction Homo sapiens 
hsa04060 
2/265 0.48847 0.59568 0.02594 -0.01344 IL21R, ACVR1B 
Citrate cycle (TCA cycle) Homo 
sapiens hsa00020 1/30 0.17303 0.53051 0.04938 -0.03130 PDHB 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis Homo 
sapiens hsa00563 
1/25 0.14724 0.53051 0.05272 -0.03342 PIGQ 
Other types of O-glycan 
biosynthesis Homo sapiens 
hsa00514 
1/31 0.17809 0.53051 0.06049 -0.03835 OGT 
Allograft rejection Homo sapiens 
hsa05330 1/38 0.21270 0.53051 0.06117 -0.03878 HLA-DRB1 
Maturity onset diabetes of the 
young Homo sapiens hsa04950 1/26 0.15246 0.53051 0.07479 -0.04741 HHEX 
mTOR signaling pathway Homo 
sapiens hsa04150 1/60 0.31246 0.53797 0.08047 -0.04989 AKT1S1 
Collecting duct acid secretion 
Homo sapiens hsa04966 1/27 0.15765 0.53051 0.13493 -0.08554 ATP6V0C 
Tryptophan metabolism Homo 
sapiens hsa00380 1/40 0.22232 0.53051 0.13998 -0.08874 CCBL2 
Longevity regulating pathway - 
multiple species Homo sapiens 
hsa04213 
1/64 0.32922 0.53797 0.14497 -0.08987 AKT1S1 
Central carbon metabolism in 
cancer Homo sapiens hsa05230 1/67 0.34153 0.53797 0.14544 -0.09017 PDHB 
Endocrine and other factor-
regulated calcium reabsorption 
Homo sapiens hsa04961 
1/47 0.25511 0.53051 0.15233 -0.09657 ATP1A1 
Estrogen signaling pathway Homo 
sapiens hsa04915 1/99 0.45984 0.59090 0.18884 -0.09935 FKBP5 
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TGF-beta signaling pathway 
Homo sapiens hsa04350 1/84 0.40722 0.56793 0.18599 -0.10523 ACVR1B 
HTLV-I infection Homo sapiens 
hsa05166 1/258 0.80084 0.80084 0.48006 -0.10662 HLA-DRB1 
Glucagon signaling pathway 
Homo sapiens hsa04922 1/101 0.46650 0.59090 0.21242 -0.11175 PDHB 
Carbohydrate digestion and 
absorption Homo sapiens 
hsa04973 
1/45 0.24589 0.53051 0.17665 -0.11198 ATP1A1 
Jak-STAT signaling pathway 
Homo sapiens hsa04630 1/158 0.62598 0.68928 0.30639 -0.11401 IL21R 
Renin secretion Homo sapiens 
hsa04924 1/64 0.32922 0.53797 0.19050 -0.11810 CTSB 
Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
1/169 0.65087 0.70094 0.33425 -0.11877 CAPN2 
HIF-1 signaling pathway Homo 
sapiens hsa04066 1/103 0.47308 0.59090 0.22818 -0.12005 PDHB 
Type I diabetes mellitus Homo 
sapiens hsa04940 1/43 0.23655 0.53051 0.19371 -0.12279 HLA-DRB1 
Longevity regulating pathway - 
mammal Homo sapiens hsa04211 1/94 0.44283 0.57863 0.22839 -0.12495 AKT1S1 
Adrenergic signaling in 
cardiomyocytes Homo sapiens 
hsa04261 
1/148 0.60185 0.67024 0.31422 -0.12573 ATP1A1 
Vibrio cholerae infection Homo 
sapiens hsa05110 1/51 0.27324 0.53051 0.20007 -0.12683 ATP6V0C 
Epstein-Barr virus infection Homo 
sapiens hsa05169 1/202 0.71623 0.72362 0.39853 -0.12892 HLA-DRB1 
Signaling pathways regulating 
pluripotency of stem cells Homo 
sapiens hsa04550 
1/142 0.58664 0.66082 0.31638 -0.13107 ACVR1B 
cGMP-PKG signaling pathway 
Homo sapiens hsa04022 1/167 0.64647 0.70094 0.37130 -0.13194 ATP1A1 
Leishmaniasis Homo sapiens 
hsa05140 1/73 0.36549 0.53797 0.21346 -0.13234 HLA-DRB1 
Influenza A Homo sapiens 
hsa05164 1/175 0.66376 0.70705 0.38657 -0.13401 HLA-DRB1 
Insulin resistance Homo sapiens 
hsa04931 1/109 0.49235 0.59568 0.25909 -0.13422 OGT 
Insulin secretion Homo sapiens 
hsa04911 1/85 0.41088 0.56793 0.23836 -0.13485 ATP1A1 
Pyruvate metabolism Homo 
sapiens hsa00620 1/40 0.22232 0.53051 0.21626 -0.13709 PDHB 
Valine, leucine and isoleucine 
degradation Homo sapiens 
hsa00280 
1/48 0.25969 0.53051 0.21862 -0.13859 BCKDHB 
Glycolysis / Gluconeogenesis 
Homo sapiens hsa00010 1/67 0.34153 0.53797 0.22769 -0.14116 PDHB 
Transcriptional misregulation in 
cancer Homo sapiens hsa05202 1/180 0.67414 0.71039 0.41737 -0.14272 HHEX 
Graft-versus-host disease Homo 
sapiens hsa05332 1/41 0.22709 0.53051 0.22542 -0.14290 HLA-DRB1 
Ribosome biogenesis in 
eukaryotes Homo sapiens 
hsa03008 
1/89 0.42529 0.56793 0.25321 -0.14326 SBDS 
Hematopoietic cell lineage Homo 
sapiens hsa04640 1/88 0.42172 0.56793 0.25958 -0.14686 HLA-DRB1 
Herpes simplex infection Homo 
sapiens hsa05168 1/185 0.68421 0.71333 0.43961 -0.14851 HLA-DRB1 
Sphingolipid metabolism Homo 
sapiens hsa00600 1/47 0.25511 0.53051 0.23765 -0.15065 ASAH1 
Chagas disease (American 
trypanosomiasis) Homo sapiens 
hsa05142 
1/104 0.47634 0.59090 0.28803 -0.15154 C1QC 
Gastric acid secretion Homo 
sapiens hsa04971 1/74 0.36940 0.53797 0.24872 -0.15419 ATP1A1 
cAMP signaling pathway Homo 
sapiens hsa04024 1/199 0.71082 0.72362 0.48514 -0.15694 ATP1A1 
Viral myocarditis Homo sapiens 
hsa05416 1/59 0.30821 0.53797 0.25318 -0.15696 HLA-DRB1 
Focal adhesion Homo sapiens 
hsa04510 1/202 0.71623 0.72362 0.49196 -0.15915 CAPN2 
Salivary secretion Homo sapiens 
hsa04970 1/89 0.42529 0.56793 0.28898 -0.16349 ATP1A1 
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Arginine and proline metabolism 
Homo sapiens hsa00330 1/50 0.26875 0.53051 0.26149 -0.16577 PYCR1 
Epithelial cell signaling in 
Helicobacter pylori infection 
Homo sapiens hsa05120 
1/68 0.34558 0.53797 0.26754 -0.16586 ATP6V0C 
Thyroid hormone signaling 
pathway Homo sapiens hsa04919 1/118 0.51997 0.60634 0.33882 -0.16952 ATP1A1 
Thyroid hormone synthesis Homo 
sapiens hsa04918 1/71 0.35760 0.53797 0.29291 -0.18159 ATP1A1 
AMPK signaling pathway Homo 
sapiens hsa04152 1/124 0.53756 0.61257 0.38308 -0.18774 AKT1S1 
Sphingolipid signaling pathway 
Homo sapiens hsa04071 1/120 0.52590 0.60634 0.38027 -0.19026 ASAH1 
Toxoplasmosis Homo sapiens 
hsa05145 1/118 0.51997 0.60634 0.38036 -0.19030 HLA-DRB1 
Carbon metabolism Homo 
sapiens hsa01200 1/113 0.50481 0.60331 0.38345 -0.19377 PDHB 
Drug metabolism - cytochrome 
P450 Homo sapiens hsa00982 1/69 0.34961 0.53797 0.31631 -0.19610 GSTO2 
Biosynthesis of amino acids 
Homo sapiens hsa01230 1/74 0.36940 0.53797 0.32133 -0.19921 PYCR1 
ABC transporters Homo sapiens 
hsa02010 1/44 0.24123 0.53051 0.31745 -0.20124 ABCG2 
Metabolism of xenobiotics by 
cytochrome P450 Homo sapiens 
hsa00980 
1/73 0.36549 0.53797 0.32493 -0.20144 GSTO2 
Proteasome Homo sapiens 
hsa03050 1/44 0.24123 0.53051 0.33136 -0.21006 PSME1 
Intestinal immune network for IgA 
production Homo sapiens 
hsa04672 
1/48 0.25969 0.53051 0.33896 -0.21488 HLA-DRB1 
Selenocompound metabolism 
Homo sapiens hsa00450 1/17 0.10435 0.52833 0.35849 -0.22873 CCBL2 
Synaptic vesicle cycle Homo 
sapiens hsa04721 1/63 0.32507 0.53797 0.39277 -0.24350 ATP6V0C 
Autoimmune thyroid disease 
Homo sapiens hsa05320 1/53 0.28214 0.53051 0.38866 -0.24638 HLA-DRB1 
Pertussis Homo sapiens 
hsa05133 1/75 0.37329 0.53797 0.41958 -0.26012 C1QC 
Protein digestion and absorption 
Homo sapiens hsa04974 1/90 0.42884 0.56793 0.46292 -0.26190 ATP1A1 
Mineral absorption Homo sapiens 
hsa04978 1/51 0.27324 0.53051 0.42188 -0.26744 ATP1A1 
Glutathione metabolism Homo 
sapiens hsa00480 1/52 0.27770 0.53051 0.42499 -0.26941 GSTO2 
Sulfur metabolism Homo sapiens 
hsa00920 1/10 0.06510 0.45571 0.77183 -0.60659 SQRDL 
	
Table A(Q: GO terms from EnrichR KEGG for genes upregulated in mutant progenitors. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
Ribosome Homo sapiens 
hsa03010 9/137 0.00000 0.00039 -1.74614 13.71052 
RPL5, RPS9, RPL3, RPS8, 
RPSA, RPS3A, RPL18, 
RPL28, RPL7 
Cell cycle Homo sapiens 
hsa04110 7/124 0.00012 0.00636 -1.70792 8.63898 
CCNA2, CCNB1, MCM7, 
PLK1, MCM6, TP53, 
MAD2L1 
RNA transport Homo sapiens 
hsa03013 7/172 0.00082 0.02854 -1.81865 6.46798 
EIF5B, PRMT5, NUP188, 
EIF3I, RANGAP1, RAN, 
THOC7 
Progesterone-mediated oocyte 
maturation Homo sapiens 
hsa04914 
5/98 0.00185 0.04867 -1.85638 5.61125 CCNA2, CCNB1, HSP90AB1, PLK1, MAD2L1 
Oocyte meiosis Homo sapiens 
hsa04114 5/123 0.00476 0.08323 -1.75128 4.35402 
CCNB1, PPP2R1B, 
PPP2R5E, PLK1, MAD2L1 
DNA replication Homo sapiens 
hsa03030 3/36 0.00448 0.08323 -1.73761 4.32002 RFC5, MCM7, MCM6 
HTLV-I infection Homo sapiens 
hsa05166 6/258 0.02552 0.25810 -1.71818 2.32711 
ELK4, TRRAP, FOS, TP53, 
RAN, MAD2L1 
Protein processing in 
endoplasmic reticulum Homo 
sapiens hsa04141 
5/169 0.01669 0.25041 -1.67106 2.31386 PDIA3, EDEM3, MBTPS1, HSP90AB1, RPN1 
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Epstein-Barr virus infection 
Homo sapiens hsa05169 5/202 0.03240 0.25810 -1.65163 2.23698 
CCNA2, POLR2D, POLR3H, 
TP53, RAN 
Herpes simplex infection Homo 
sapiens hsa05168 5/185 0.02347 0.25810 -1.61049 2.18125 
SRSF3, FOS, SRSF6, TP53, 
IKBKE 
Spliceosome Homo sapiens 
hsa03040 4/134 0.03077 0.25810 -1.55012 2.09949 
LSM7, LSM6, SRSF3, 
SRSF6 
RNA degradation Homo sapiens 
hsa03018 3/77 0.03139 0.25810 -1.51730 2.05504 LSM7, LSM6, C1D 
p53 signaling pathway Homo 
sapiens hsa04115 3/69 0.02391 0.25810 -1.49489 2.02468 CCNB1, RRM2, TP53 
Hepatitis B Homo sapiens 
hsa05161 4/146 0.03997 0.27979 -1.57952 2.01189 CCNA2, FOS, TP53, IKBKE 
Estrogen signaling pathway 
Homo sapiens hsa04915 3/99 0.05750 0.37734 -1.50163 1.46352 HSP90AB1, FOS, FKBP4 
RNA polymerase Homo sapiens 
hsa03020 2/32 0.03441 0.25810 -1.01856 1.37954 POLR2D, POLR3H 
Purine metabolism Homo 
sapiens hsa00230 4/176 0.06914 0.40331 -1.37291 1.24666 
RRM2, POLR2D, AK2, 
POLR3H 
Pyrimidine metabolism Homo 
sapiens hsa00240 3/105 0.06597 0.40331 -1.35267 1.22828 RRM2, POLR2D, POLR3H 
Dopaminergic synapse Homo 
sapiens hsa04728 3/129 0.10501 0.49112 -1.36051 0.96742 PPP2R1B, PPP2R5E, FOS 
Sphingolipid signaling pathway 
Homo sapiens hsa04071 3/120 0.08945 0.49112 -1.31307 0.93369 PPP2R1B, PPP2R5E, TP53 
AMPK signaling pathway Homo 
sapiens hsa04152 3/124 0.09624 0.49112 -1.30601 0.92866 
CCNA2, PPP2R1B, 
PPP2R5E 
Hepatitis C Homo sapiens 
hsa05160 3/133 0.11226 0.49112 -1.24765 0.88717 PPP2R1B, TP53, IKBKE 
Apoptosis Homo sapiens 
hsa04210 3/140 0.12538 0.52329 -1.34438 0.87065 CTSZ, FOS, TP53 
Colorectal cancer Homo sapiens 
hsa05210 2/62 0.10511 0.49112 -1.17770 0.83743 FOS, TP53 
Cytosolic DNA-sensing pathway 
Homo sapiens hsa04623 2/64 0.11065 0.49112 -0.92712 0.65925 POLR3H, IKBKE 
Antigen processing and 
presentation Homo sapiens 
hsa04612 
2/77 0.14828 0.57666 -0.94268 0.51894 PDIA3, HSP90AB1 
Ribosome biogenesis in 
eukaryotes Homo sapiens 
hsa03008 
2/89 0.18497 0.64768 -1.13943 0.49493 RAN, NOL6 
Prostate cancer Homo sapiens 
hsa05215 2/89 0.18497 0.64768 -1.13277 0.49203 HSP90AB1, TP53 
Viral carcinogenesis Homo 
sapiens hsa05203 3/205 0.26674 0.67409 -1.04113 0.41061 CCNA2, TP53, HDAC7 
Huntington's disease Homo 
sapiens hsa05016 3/193 0.23880 0.67409 -1.03310 0.40744 DNAH8, POLR2D, TP53 
mRNA surveillance pathway 
Homo sapiens hsa03015 2/91 0.19122 0.64768 -0.88977 0.38648 PPP2R1B, PPP2R5E 
Toll-like receptor signaling 
pathway Homo sapiens 
hsa04620 
2/106 0.23879 0.67409 -0.97802 0.38572 FOS, IKBKE 
Chagas disease (American 
trypanosomiasis) Homo sapiens 
hsa05142 
2/104 0.23240 0.67409 -0.93583 0.36908 PPP2R1B, FOS 
PI3K-Akt signaling pathway 
Homo sapiens hsa04151 4/341 0.34719 0.67409 -0.90034 0.35508 
HSP90AB1, PPP2R1B, 
PPP2R5E, TP53 
Measles Homo sapiens 
hsa05162 2/136 0.33488 0.67409 -0.79864 0.31497 TP53, IKBKE 
FoxO signaling pathway Homo 
sapiens hsa04068 2/133 0.32535 0.67409 -0.78427 0.30931 CCNB1, PLK1 
Wnt signaling pathway Homo 
sapiens hsa04310 2/142 0.35382 0.67409 -0.68597 0.27054 INVS, TP53 
MAPK signaling pathway Homo 
sapiens hsa04010 3/255 0.38550 0.67409 -0.67388 0.26577 ELK4, FOS, TP53 
Ubiquitin mediated proteolysis 
Homo sapiens hsa04120 2/137 0.33805 0.67409 -0.62240 0.24547 VHL, UBE2M 
Adrenergic signaling in 
cardiomyocytes Homo sapiens 
hsa04261 
2/148 0.37259 0.67409 -0.58513 0.23077 PPP2R1B, PPP2R5E 
Pathways in cancer Homo 
sapiens hsa05200 4/397 0.45785 0.67409 -0.40140 0.15831 HSP90AB1, FOS, VHL, TP53 
Transcriptional misregulation in 
cancer Homo sapiens hsa05202 2/180 0.46856 0.67409 -0.14796 0.05836 ELK4, TP53 
Bladder cancer Homo sapiens 
hsa05219 1/41 0.30578 0.67409 0.03460 -0.01365 TP53 
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Metabolic pathways Homo 
sapiens hsa01100 6/1239 0.96953 0.96953 0.57103 -0.01767 
RRM2, RPN1, POLR2D, 
AK2, B3GNT2, POLR3H 
Glioma Homo sapiens hsa05214 1/65 0.43701 0.67409 0.08477 -0.03343 TP53 
MicroRNAs in cancer Homo 
sapiens hsa05206 1/297 0.92849 0.93742 0.57964 -0.03746 TP53 
Endometrial cancer Homo 
sapiens hsa05213 1/52 0.36929 0.67409 0.09743 -0.03842 TP53 
Thyroid cancer Homo sapiens 
hsa05216 1/297 0.22931 0.67409 0.11652 -0.04596 TP53 
Endocytosis Homo sapiens 
hsa04144 1/259 0.89926 0.91672 0.54147 -0.04708 GRK6 
Renal cell carcinoma Homo 
sapiens hsa05211 1/66 0.44191 0.67409 0.19313 -0.07617 VHL 
Long-term depression Homo 
sapiens hsa04730 1/60 0.41186 0.67409 0.19736 -0.07784 PPP2R1B 
Pancreatic cancer Homo sapiens 
hsa05212 1/66 0.44191 0.67409 0.20606 -0.08127 TP53 
Non-small cell lung cancer Homo 
sapiens hsa05223 1/56 0.39094 0.67409 0.20625 -0.08134 TP53 
Influenza A Homo sapiens 
hsa05164 1/175 0.78651 0.85068 0.51601 -0.08345 IKBKE 
Central carbon metabolism in 
cancer Homo sapiens hsa05230 1/67 0.44677 0.67409 0.21445 -0.08458 TP53 
Alcoholism Homo sapiens 
hsa05034 1/179 0.79397 0.85068 0.52867 -0.08550 HDAC7 
Focal adhesion Homo sapiens 
hsa04510 1/202 0.83213 0.85814 0.59254 -0.09065 PARVB 
Proteoglycans in cancer Homo 
sapiens hsa05205 1/203 0.83362 0.85814 0.60086 -0.09193 TP53 
cAMP signaling pathway Homo 
sapiens hsa04024 1/199 0.82758 0.85814 0.61437 -0.09399 FOS 
Chemokine signaling pathway 
Homo sapiens hsa04062 1/187 0.80812 0.85710 0.61379 -0.09465 GRK6 
Oxytocin signaling pathway 
Homo sapiens hsa04921 1/158 0.75175 0.82222 0.51185 -0.10019 FOS 
Hippo signaling pathway Homo 
sapiens hsa04390 1/153 0.74050 0.81845 0.52467 -0.10511 PPP2R1B 
Amphetamine addiction Homo 
sapiens hsa05031 1/67 0.44677 0.67409 0.27555 -0.10867 FOS 
Nucleotide excision repair Homo 
sapiens hsa03420 1/47 0.34116 0.67409 0.27993 -0.11040 RFC5 
Amyotrophic lateral sclerosis 
(ALS) Homo sapiens hsa05014 1/51 0.36376 0.67409 0.28710 -0.11323 TP53 
Aminoacyl-tRNA biosynthesis 
Homo sapiens hsa00970 1/66 0.44191 0.67409 0.29128 -0.11488 NARS 
Porphyrin and chlorophyll 
metabolism Homo sapiens 
hsa00860 
1/42 0.31180 0.67409 0.29680 -0.11705 HCCS 
Tight junction Homo sapiens 
hsa04530 1/139 0.70628 0.78893 0.51719 -0.12262 PPP2R1B 
Melanoma Homo sapiens 
hsa05218 1/71 0.46580 0.67409 0.32160 -0.12683 TP53 
Choline metabolism in cancer 
Homo sapiens hsa05231 1/101 0.58941 0.73267 0.40942 -0.12735 FOS 
Insulin resistance Homo sapiens 
hsa04931 1/109 0.61731 0.73616 0.41813 -0.12808 SLC27A1 
HIF-1 signaling pathway Homo 
sapiens hsa04066 1/103 0.59656 0.73267 0.41650 -0.12955 VHL 
Proteasome Homo sapiens 
hsa03050 1/44 0.32370 0.67409 0.33136 -0.13068 PSMA5 
Osteoclast differentiation Homo 
sapiens hsa04380 1/132 0.68754 0.77626 0.51700 -0.13094 FOS 
TNF signaling pathway Homo 
sapiens hsa04668 1/110 0.62066 0.73616 0.42776 -0.13103 FOS 
Cholinergic synapse Homo 
sapiens hsa04725 1/111 0.62398 0.73616 0.45161 -0.13833 FOS 
N-Glycan biosynthesis Homo 
sapiens hsa00510 1/49 0.35256 0.67409 0.35326 -0.13932 RPN1 
Chronic myeloid leukemia Homo 
sapiens hsa05220 1/73 0.47507 0.67409 0.35467 -0.13988 TP53 
Prolactin signaling pathway 
Homo sapiens hsa04917 1/72 0.47046 0.67409 0.36078 -0.14229 FOS 
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Neurotrophin signaling pathway 
Homo sapiens hsa04722 1/120 0.65264 0.75305 0.50432 -0.14304 TP53 
Longevity regulating pathway - 
mammal Homo sapiens 
hsa04211 
1/94 0.56336 0.71751 0.43191 -0.14338 TP53 
Lysosome Homo sapiens 
hsa04142 1/123 0.66171 0.75522 0.51147 -0.14360 CTSZ 
T cell receptor signaling pathway 
Homo sapiens hsa04660 1/104 0.60010 0.73267 0.47058 -0.14637 FOS 
NOD-like receptor signaling 
pathway Homo sapiens 
hsa04621 
1/57 0.39623 0.67409 0.37731 -0.14881 HSP90AB1 
TGF-beta signaling pathway 
Homo sapiens hsa04350 1/84 0.52331 0.70655 0.42840 -0.14881 PPP2R1B 
Thyroid hormone signaling 
pathway Homo sapiens 
hsa04919 
1/118 0.64647 0.75305 0.52666 -0.14937 TP53 
Morphine addiction Homo 
sapiens hsa05032 1/91 0.55171 0.71517 0.45817 -0.15359 GRK6 
Circadian entrainment Homo 
sapiens hsa04713 1/95 0.56718 0.71751 0.46425 -0.15411 FOS 
Basal cell carcinoma Homo 
sapiens hsa05217 1/55 0.38560 0.67409 0.39296 -0.15498 TP53 
Rheumatoid arthritis Homo 
sapiens hsa05323 1/90 0.54775 0.71517 0.48749 -0.16342 FOS 
PPAR signaling pathway Homo 
sapiens hsa03320 1/69 0.45637 0.67409 0.41849 -0.16505 SLC27A1 
Glutathione metabolism Homo 
sapiens hsa00480 1/52 0.36929 0.67409 0.42499 -0.16761 RRM2 
B cell receptor signaling pathway 
Homo sapiens hsa04662 1/73 0.47507 0.67409 0.42701 -0.16841 FOS 
Small cell lung cancer Homo 
sapiens hsa05222 1/86 0.53160 0.70655 0.51310 -0.17823 TP53 
Bile secretion Homo sapiens 
hsa04976 1/71 0.46580 0.67409 0.45616 -0.17990 EPHX1 
RIG-I-like receptor signaling 
pathway Homo sapiens 
hsa04622 
1/70 0.46111 0.67409 0.46776 -0.18448 IKBKE 
Leishmaniasis Homo sapiens 
hsa05140 1/73 0.47507 0.67409 0.47892 -0.18888 FOS 
Chemical carcinogenesis Homo 
sapiens hsa05204 1/82 0.51488 0.70655 0.56228 -0.19531 EPHX1 
Salmonella infection Homo 
sapiens hsa05132 1/86 0.53160 0.70655 0.59751 -0.20755 FOS 
Base excision repair Homo 
sapiens hsa03410 1/33 0.25567 0.67409 0.61569 -0.24282 APEX1 
Metabolism of xenobiotics by 
cytochrome P450 Homo sapiens 
hsa00980 
1/73 0.47507 0.67409 0.62816 -0.24774 EPHX1 
Pertussis Homo sapiens 
hsa05133 1/75 0.48419 0.67786 0.64492 -0.25075 FOS 
Glycosphingolipid biosynthesis - 
lacto and neolacto series Homo 
sapiens hsa00601 
1/26 0.20893 0.67409 0.67754 -0.26722 B3GNT2 
Mismatch repair Homo sapiens 
hsa03430 1/23 0.18802 0.64768 0.85017 -0.36928 RFC5 
Glycosaminoglycan biosynthesis 
- keratan sulfate Homo sapiens 
hsa00533 
1/15 0.12958 0.52329 1.44988 -0.93897 B3GNT2 
	
Table A=S: GO terms from EnrichR KEGG for genes downregulated in mutant progenitors. 
Term Overlap P-value Adjusted P-value Z-score 
Combined 
Score Genes 
HTLV-I infection Homo sapiens 
hsa05166 8/258 0.00095 0.16325 -1.94300 3.52169 
KAT2B, NRP1, HLA-DMA, 
RANBP3, RRAS2, HRAS, 
HLA-DRB1, PIK3R5 
Thyroid hormone signaling 
pathway Homo sapiens 
hsa04919 
5/118 0.00256 0.16325 -1.83479 3.32556 KAT2B, PLCB3, ATP1A1, HRAS, PIK3R5 
Leishmaniasis Homo sapiens 
hsa05140 4/73 0.00292 0.16325 -1.81063 3.28176 
C3, HLA-DMA, NCF4, HLA-
DRB1 
Bacterial invasion of epithelial 
cells Homo sapiens hsa05100 4/78 0.00367 0.16325 -1.69894 3.07933 
ARHGAP10, DNM1, PIK3R5, 
CD2AP 
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Phospholipase D signaling 
pathway Homo sapiens 
hsa04072 
5/144 0.00581 0.20048 -1.79478 2.88431 PLCB3, RRAS2, HRAS, DNM1, PIK3R5 
Endocrine and other factor-
regulated calcium reabsorption 
Homo sapiens hsa04961 
3/47 0.00676 0.20048 -1.76255 2.83252 PLCB3, ATP1A1, DNM1 
Chemokine signaling pathway 
Homo sapiens hsa04062 5/187 0.01631 0.30527 -1.74660 2.07246 
ITK, PLCB3, CXCL14, HRAS, 
PIK3R5 
Staphylococcus aureus infection 
Homo sapiens hsa05150 3/56 0.01067 0.27134 -1.58716 2.07024 C3, HLA-DMA, HLA-DRB1 
Viral carcinogenesis Homo 
sapiens hsa05203 5/205 0.02309 0.30527 -1.70252 2.02016 
C3, KAT2B, HRAS, GTF2E2, 
PIK3R5 
Melanoma Homo sapiens 
hsa05218 3/71 0.01961 0.30527 -1.61751 1.91928 FGF18, HRAS, PIK3R5 
AMPK signaling pathway Homo 
sapiens hsa04152 4/124 0.01721 0.30527 -1.58752 1.88370 
GYS1, HNF4A, FBP1, 
PIK3R5 
Regulation of actin cytoskeleton 
Homo sapiens hsa04810 5/214 0.02708 0.30527 -1.57466 1.86844 
FGF18, RRAS2, F2, HRAS, 
PIK3R5 
Inflammatory mediator regulation 
of TRP channels Homo sapiens 
hsa04750 
3/98 0.04357 0.30527 -1.48801 1.76562 CYP2J2, PLCB3, PIK3R5 
Insulin signaling pathway Homo 
sapiens hsa04910 4/139 0.02474 0.30527 -1.47736 1.75298 GYS1, FBP1, HRAS, PIK3R5 
Bile secretion Homo sapiens 
hsa04976 3/71 0.01961 0.30527 -1.46370 1.73678 ATP1A1, SLC22A8, SLC4A5 
AGE-RAGE signaling pathway in 
diabetic complications Homo 
sapiens hsa04933 
3/101 0.04685 0.30527 -1.46142 1.73407 PLCB3, HRAS, PIK3R5 
Estrogen signaling pathway 
Homo sapiens hsa04915 3/99 0.04465 0.30527 -1.36076 1.61463 PLCB3, HRAS, PIK3R5 
Phagosome Homo sapiens 
hsa04145 4/154 0.03401 0.30527 -1.34650 1.59772 
C3, HLA-DMA, NCF4, HLA-
DRB1 
Influenza A Homo sapiens 
hsa05164 4/175 0.04999 0.30527 -1.32208 1.56873 
HLA-DMA, TMPRSS2, HLA-
DRB1, PIK3R5 
Choline metabolism in cancer 
Homo sapiens hsa05231 3/101 0.04685 0.30527 -1.32067 1.56706 CHKA, HRAS, PIK3R5 
Glucagon signaling pathway 
Homo sapiens hsa04922 3/101 0.04685 0.30527 -1.27216 1.50951 GYS1, PLCB3, FBP1 
T cell receptor signaling pathway 
Homo sapiens hsa04660 3/104 0.05024 0.30527 -1.16170 1.37844 ITK, HRAS, PIK3R5 
Cholinergic synapse Homo 
sapiens hsa04725 3/111 0.05863 0.30527 -1.14737 1.36143 PLCB3, HRAS, PIK3R5 
Chagas disease (American 
trypanosomiasis) Homo sapiens 
hsa05142 
3/104 0.05024 0.30527 -1.09901 1.30405 C3, PLCB3, PIK3R5 
Insulin resistance Homo sapiens 
hsa04931 3/109 0.05617 0.30527 -1.06628 1.26521 GYS1, SLC27A2, PIK3R5 
Aldosterone-regulated sodium 
reabsorption Homo sapiens 
hsa04960 
3/39 0.04021 0.30527 -0.98720 1.17137 ATP1A1, PIK3R5 
Serotonergic synapse Homo 
sapiens hsa04726 3/112 0.05988 0.30527 -0.97446 1.15627 CYP2J2, PLCB3, HRAS 
Allograft rejection Homo sapiens 
hsa05330 3/38 0.03844 0.30527 -0.93648 1.11120 HLA-DMA, HLA-DRB1 
Toxoplasmosis Homo sapiens 
hsa05145 3/118 0.06763 0.30527 -0.92837 1.10158 
HLA-DMA, HLA-DRB1, 
PIK3R5 
Asthma Homo sapiens hsa05310 3/31 0.02693 0.30527 -0.83948 0.99609 HLA-DMA, HLA-DRB1 
Carbon metabolism Homo 
sapiens hsa01200 3/113 0.06114 0.30527 -0.83257 0.98790 AGXT, FBP1, GAPDH 
Graft-versus-host disease Homo 
sapiens hsa05332 2/41 0.04385 0.30527 -0.82831 0.98285 HLA-DMA, HLA-DRB1 
Neurotrophin signaling pathway 
Homo sapiens hsa04722 3/120 0.07031 0.30527 -0.82308 0.97663 SORT1, HRAS, PIK3R5 
Rap1 signaling pathway Homo 
sapiens hsa04015 4/211 0.08550 0.31794 -0.83062 0.95180 
PLCB3, FGF18, HRAS, 
PIK3R5 
Leukocyte transendothelial 
migration Homo sapiens 
hsa04670 
3/118 0.06763 0.30527 -0.77757 0.92264 ITK, NCF4, PIK3R5 
Sphingolipid signaling pathway 
Homo sapiens hsa04071 3/120 0.07031 0.30527 -0.77428 0.91874 PLCB3, HRAS, PIK3R5 
Type I diabetes mellitus Homo 
sapiens hsa04940 2/43 0.04760 0.30527 -0.61287 0.72721 HLA-DMA, HLA-DRB1 
Apoptosis Homo sapiens 
hsa04210 3/140 0.09968 0.31794 -0.59898 0.68637 ENDOG, HRAS, PIK3R5 
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Systemic lupus erythematosus 
Homo sapiens hsa05322 3/135 0.09192 0.31794 -0.57313 0.65674 C3, HLA-DMA, HLA-DRB1 
Ras signaling pathway Homo 
sapiens hsa04014 4/227 0.10443 0.31794 -0.53425 0.61218 
FGF18, RRAS2, HRAS, 
PIK3R5 
Endometrial cancer Homo 
sapiens hsa05213 2/52 0.06585 0.30527 -0.50336 0.59728 HRAS, PIK3R5 
Basal transcription factors Homo 
sapiens hsa03022 2/45 0.05147 0.30527 -0.48974 0.58112 TAF11, GTF2E2 
Carbohydrate digestion and 
absorption Homo sapiens 
hsa04973 
2/45 0.05147 0.30527 -0.45635 0.54149 ATP1A1, PIK3R5 
Intestinal immune network for IgA 
production Homo sapiens 
hsa04672 
2/48 0.05748 0.30527 -0.38851 0.46100 HLA-DMA, HLA-DRB1 
Adrenergic signaling in 
cardiomyocytes Homo sapiens 
hsa04261 
3/148 0.11262 0.31794 -0.38528 0.44148 PLCB3, ATP1A1, PIK3R5 
Non-small cell lung cancer Homo 
sapiens hsa05223 2/56 0.07459 0.31614 -0.35276 0.40622 HRAS, PIK3R5 
Acute myeloid leukemia Homo 
sapiens hsa05221 2/57 0.07684 0.31794 -0.31015 0.35540 HRAS, PIK3R5 
Long-term depression Homo 
sapiens hsa04730 2/60 0.08369 0.31794 -0.26378 0.30226 PLCB3, HRAS 
VEGF signaling pathway Homo 
sapiens hsa04370 2/61 0.08602 0.31794 -0.25133 0.28799 HRAS, PIK3R5 
Autoimmune thyroid disease 
Homo sapiens hsa05320 2/53 0.06800 0.30527 -0.19763 0.23450 HLA-DMA, HLA-DRB1 
Longevity regulating pathway - 
multiple species Homo sapiens 
hsa04213 
2/64 0.09311 0.31794 -0.19655 0.22522 HRAS, PIK3R5 
Glioma Homo sapiens hsa05214 2/65 0.09551 0.31794 -0.18838 0.21587 HRAS, PIK3R5 
Oxytocin signaling pathway 
Homo sapiens hsa04921 3/158 0.12965 0.32937 -0.19379 0.21522 PLCB3, HRAS, PIK3R5 
Viral myocarditis Homo sapiens 
hsa05416 2/59 0.08139 0.31794 -0.15911 0.18233 HLA-DMA, HLA-DRB1 
Long-term potentiation Homo 
sapiens hsa04720 2/66 0.09793 0.31794 -0.08323 0.09538 PLCB3, HRAS 
Inflammatory bowel disease (IBD) 
Homo sapiens hsa05321 2/65 0.09551 0.31794 -0.06893 0.07898 HLA-DMA, HLA-DRB1 
Fc epsilon RI signaling pathway 
Homo sapiens hsa04664 2/68 0.10283 0.31794 -0.06652 0.07623 HRAS, PIK3R5 
cGMP-PKG signaling pathway 
Homo sapiens hsa04022 3/167 0.14573 0.34671 -0.07068 0.07487 PLCB3, ATP1A1, PIK3R5 
Renal cell carcinoma Homo 
sapiens hsa05211 2/66 0.09793 0.31794 -0.05751 0.06590 HRAS, PIK3R5 
Central carbon metabolism in 
cancer Homo sapiens hsa05230 2/67 0.10037 0.31794 0.00743 -0.00851 HRAS, PIK3R5 
Alzheimer's disease Homo 
sapiens hsa05010 3/168 0.14755 0.34671 0.01041 -0.01103 PLCB3, COX6C, GAPDH 
Metabolic pathways Homo 
sapiens hsa01100 13/1239 0.16361 0.34671 0.04954 -0.05248 
CYP2J2, AHCYL1, RRM2, 
ACY1, CHKA, UAP1, 
COX6C, PLCB3, KYNU, 
HPRT1, AGXT, GAPDH, 
FBP1 
Prolactin signaling pathway 
Homo sapiens hsa04917 2/72 0.11281 0.31794 0.05596 -0.06412 HRAS, PIK3R5 
Chronic myeloid leukemia Homo 
sapiens hsa05220 2/73 0.11534 0.31794 0.05994 -0.06869 HRAS, PIK3R5 
Olfactory transduction Homo 
sapiens hsa04740 1/415 0.96495 0.96495 2.24601 -0.08014 NCALD 
Glycolysis / Gluconeogenesis 
Homo sapiens hsa00010 2/67 0.10037 0.31794 0.07128 -0.08168 FBP1, GAPDH 
B cell receptor signaling pathway 
Homo sapiens hsa04662 2/73 0.11534 0.31794 0.09026 -0.10343 HRAS, PIK3R5 
Thyroid hormone synthesis 
Homo sapiens hsa04918 2/71 0.11029 0.31794 0.15221 -0.17442 PLCB3, ATP1A1 
Gastric acid secretion Homo 
sapiens hsa04971 2/74 0.11789 0.31794 0.21430 -0.24556 PLCB3, ATP1A1 
Tuberculosis Homo sapiens 
hsa05152 3/178 0.16622 0.34808 0.24203 -0.25542 C3, HLA-DMA, HLA-DRB1 
Cytokine-cytokine receptor 
interaction Homo sapiens 
hsa04060 
1/265 0.87985 0.88482 2.36269 -0.28912 CXCL14 
Biosynthesis of amino acids 
Homo sapiens hsa01230 2/74 0.11789 0.31794 0.25693 -0.29442 ACY1, GAPDH 
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Adherens junction Homo sapiens 
hsa04520 2/74 0.11789 0.31794 0.28124 -0.32227 LMO7, PTPRJ 
Herpes simplex infection Homo 
sapiens hsa05168 3/185 0.17969 0.35937 0.32042 -0.32792 C3, HLA-DMA, HLA-DRB1 
ErbB signaling pathway Homo 
sapiens hsa04012 2/87 0.15220 0.34671 0.35719 -0.37837 HRAS, PIK3R5 
Insulin secretion Homo sapiens 
hsa04911 2/85 0.14680 0.34671 0.36263 -0.38412 PLCB3, ATP1A1 
Cardiac muscle contraction 
Homo sapiens hsa04260 2/78 0.12822 0.32937 0.36268 -0.40278 ATP1A1, COX6C 
Antigen processing and 
presentation Homo sapiens 
hsa04612 
2/77 0.12562 0.32937 0.36635 -0.40686 HLA-DMA, HLA-DRB1 
Huntington's disease Homo 
sapiens hsa05016 3/193 0.19544 0.36505 0.40507 -0.40820 PLCB3, COX6C, RCOR1 
Prostate cancer Homo sapiens 
hsa05215 2/89 0.15765 0.34671 0.39400 -0.41736 HRAS, PIK3R5 
Complement and coagulation 
cascades Homo sapiens 
hsa04610 
2/79 0.13084 0.32937 0.42586 -0.47295 C3, F2 
Peroxisome Homo sapiens 
hsa04146 2/83 0.14143 0.34671 0.45272 -0.47956 AGXT, SLC27A2 
GnRH signaling pathway Homo 
sapiens hsa04912 2/91 0.16313 0.34671 0.47292 -0.50095 PLCB3, HRAS 
Gap junction Homo sapiens 
hsa04540 2/88 0.15492 0.34671 0.48487 -0.51361 PLCB3, HRAS 
Salivary secretion Homo sapiens 
hsa04970 2/89 0.15765 0.34671 0.49735 -0.52683 PLCB3, ATP1A1 
Epstein-Barr virus infection 
Homo sapiens hsa05169 3/202 0.21357 0.36902 0.54673 -0.54505 HLA-DRB1, GTF2E2, PIK3R5 
cAMP signaling pathway Homo 
sapiens hsa04024 3/199 0.20748 0.36901 0.56268 -0.56094 RRAS2, ATP1A1, PIK3R5 
Rheumatoid arthritis Homo 
sapiens hsa05323 2/90 0.16039 0.34671 0.54476 -0.57705 HLA-DMA, HLA-DRB1 
Longevity regulating pathway - 
mammal Homo sapiens 
hsa04211 
2/94 0.17142 0.35073 0.57728 -0.60484 HRAS, PIK3R5 
Transcriptional misregulation in 
cancer Homo sapiens hsa05202 1/180 0.76140 0.77005 2.37248 -0.61991 TMPRSS2 
Calcium signaling pathway Homo 
sapiens hsa04020 1/180 0.76140 0.77005 2.42818 -0.63447 PLCB3 
Alcoholism Homo sapiens 
hsa05034 1/179 0.75948 0.77005 2.43387 -0.63595 HRAS 
Melanogenesis Homo sapiens 
hsa04916 2/100 0.18821 0.36415 0.63149 -0.63792 PLCB3, HRAS 
Proteoglycans in cancer Homo 
sapiens hsa05205 3/203 0.21560 0.36902 0.65263 -0.65061 RRAS2, HRAS, PIK3R5 
Amoebiasis Homo sapiens 
hsa05146 2/100 0.18821 0.36415 0.65727 -0.66397 PLCB3, PIK3R5 
Phosphatidylinositol signaling 
system Homo sapiens hsa04070 2/98 0.18259 0.36112 0.67201 -0.68448 PLCB3, PIK3R5 
Pancreatic secretion Homo 
sapiens hsa04972 2/96 0.17699 0.35801 0.67066 -0.68890 PLCB3, ATP1A1 
HIF-1 signaling pathway Homo 
sapiens hsa04066 2/103 0.19669 0.36505 0.68553 -0.69084 GAPDH, PIK3R5 
Protein digestion and absorption 
Homo sapiens hsa04974 2/90 0.16039 0.34671 0.67222 -0.71207 SLC3A1, ATP1A1 
PI3K-Akt signaling pathway 
Homo sapiens hsa04151 4/341 0.28065 0.43084 0.88860 -0.74822 
GYS1, FGF18, HRAS, 
PIK3R5 
MicroRNAs in cancer Homo 
sapiens hsa05206 2/297 0.68314 0.70697 2.22240 -0.77065 HRAS, EZH2 
Hippo signaling pathway Homo 
sapiens hsa04390 1/153 0.70383 0.72418 2.40093 -0.77483 TEAD1 
Platelet activation Homo sapiens 
hsa04611 2/122 0.25129 0.41416 0.90725 -0.79976 PLCB3, PIK3R5 
Neuroactive ligand-receptor 
interaction Homo sapiens 
hsa04080 
2/277 0.64550 0.68392 2.14110 -0.81343 GPR35, F2 
Axon guidance Homo sapiens 
hsa04360 2/127 0.26579 0.43084 0.99837 -0.84064 NRP1, HRAS 
Wnt signaling pathway Homo 
sapiens hsa04310 1/142 0.67665 0.70435 2.43754 -0.85431 PLCB3 
Osteoclast differentiation Homo 
sapiens hsa04380 2/132 0.28029 0.43084 1.03464 -0.87118 NCF4, PIK3R5 
Measles Homo sapiens 
hsa05162 1/136 0.66080 0.69190 2.40491 -0.88576 PIK3R5 
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Tight junction Homo sapiens 
hsa04530 2/139 0.30058 0.44392 1.11245 -0.90343 RRAS2, HRAS 
Parkinson's disease Homo 
sapiens hsa05012 2/142 0.30925 0.44392 1.12573 -0.91421 COX6C, SNCAIP 
FoxO signaling pathway Homo 
sapiens hsa04068 2/133 0.28319 0.43084 1.09638 -0.92317 HRAS, PIK3R5 
Natural killer cell mediated 
cytotoxicity Homo sapiens 
hsa04650 
2/135 0.28899 0.43594 1.12765 -0.93624 HRAS, PIK3R5 
Oxidative phosphorylation Homo 
sapiens hsa00190 1/133 0.65260 0.68735 2.52260 -0.94574 COX6C 
Lysosome Homo sapiens 
hsa04142 1/123 0.62381 0.66891 2.37049 -0.95320 SORT1 
Hepatitis C Homo sapiens 
hsa05160 2/133 0.28319 0.43084 1.13831 -0.95847 HRAS, PIK3R5 
Dopaminergic synapse Homo 
sapiens hsa04728 1/129 0.64135 0.68360 2.53836 -0.96555 PLCB3 
Cell adhesion molecules (CAMs) 
Homo sapiens hsa04514 2/142 0.30925 0.44392 1.21113 -0.98357 HLA-DMA, HLA-DRB1 
Endocytosis Homo sapiens 
hsa04144 3/259 0.33422 0.44853 1.22856 -0.98503 VPS45, HRAS, DNM1 
Signaling pathways regulating 
pluripotency of stem cells Homo 
sapiens hsa04550 
2/142 0.30925 0.44392 1.23931 -1.00645 HRAS, PIK3R5 
MAPK signaling pathway Homo 
sapiens hsa04010 3/255 0.32560 0.44853 1.26106 -1.01109 FGF18, RRAS2, HRAS 
Hepatitis B Homo sapiens 
hsa05161 2/146 0.32078 0.44609 1.30073 -1.05000 HRAS, PIK3R5 
Vascular smooth muscle 
contraction Homo sapiens 
hsa04270 
1/120 0.61473 0.66316 2.57930 -1.05941 PLCB3 
Focal adhesion Homo sapiens 
hsa04510 2/202 0.47474 0.55638 1.84982 -1.08455 HRAS, PIK3R5 
Glutamatergic synapse Homo 
sapiens hsa04724 1/114 0.59591 0.64678 2.53383 -1.10411 PLCB3 
TNF signaling pathway Homo 
sapiens hsa04668 1/110 0.58287 0.63651 2.44708 -1.10550 PIK3R5 
Jak-STAT signaling pathway 
Homo sapiens hsa04630 2/158 0.35510 0.46515 1.47581 -1.12959 HRAS, PIK3R5 
Purine metabolism Homo sapiens 
hsa00230 2/176 0.40542 0.49769 1.63306 -1.13953 RRM2, HPRT1 
Non-alcoholic fatty liver disease 
(NAFLD) Homo sapiens 
hsa04932 
2/151 0.33514 0.44853 1.44684 -1.16004 COX6C, PIK3R5 
Pathways in cancer Homo 
sapiens hsa05200 4/397 0.38082 0.48419 1.60060 -1.16089 
PLCB3, FGF18, HRAS, 
PIK3R5 
Toll-like receptor signaling 
pathway Homo sapiens 
hsa04620 
1/106 0.56941 0.62565 2.47553 -1.16094 PIK3R5 
Pyrimidine metabolism Homo 
sapiens hsa00240 1/105 0.56598 0.62565 2.57778 -1.20889 RRM2 
Progesterone-mediated oocyte 
maturation Homo sapiens 
hsa04914 
1/98 0.54121 0.60588 2.48037 -1.24285 PIK3R5 
Retrograde endocannabinoid 
signaling Homo sapiens 
hsa04723 
1/101 0.55199 0.61409 2.64948 -1.29193 PLCB3 
Fc gamma R-mediated 
phagocytosis Homo sapiens 
hsa04666 
1/93 0.52267 0.59637 2.53877 -1.31225 PIK3R5 
Glycerophospholipid metabolism 
Homo sapiens hsa00564 1/95 0.53017 0.59728 2.58625 -1.33288 CHKA 
Circadian entrainment Homo 
sapiens hsa04713 1/95 0.53017 0.59728 2.64183 -1.36153 PLCB3 
Hematopoietic cell lineage Homo 
sapiens hsa04640 1/88 0.50339 0.57809 2.68613 -1.47209 HLA-DRB1 
GABAergic synapse Homo 
sapiens hsa04727 1/88 0.50339 0.57809 2.79398 -1.53119 SLC6A11 
Small cell lung cancer Homo 
sapiens hsa05222 1/86 0.49547 0.57643 2.84785 -1.56891 PIK3R5 
Aldosterone synthesis and 
secretion Homo sapiens 
hsa04925 
1/81 0.47511 0.55638 2.93992 -1.72367 PLCB3 
Pertussis Homo sapiens 
hsa05133 1/75 0.44962 0.53355 3.05927 -1.92183 C3 
Inositol phosphate metabolism 
Homo sapiens hsa00562 1/71 0.43196 0.51603 3.22123 -2.13113 PLCB3 
PPAR signaling pathway Homo 
sapiens hsa03320 1/69 0.42292 0.50865 3.24836 -2.19591 SLC27A2 
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p53 signaling pathway Homo 
sapiens hsa04115 1/69 0.42292 0.50865 3.32049 -2.24467 RRM2 
Pancreatic cancer Homo sapiens 
hsa05212 1/66 0.40909 0.49876 3.34664 -2.32804 PIK3R5 
mTOR signaling pathway Homo 
sapiens hsa04150 1/60 0.38046 0.48419 3.29492 -2.38976 PIK3R5 
Renin secretion Homo sapiens 
hsa04924 1/64 0.39970 0.49407 3.43124 -2.41930 PLCB3 
Colorectal cancer Homo sapiens 
hsa05210 1/62 0.39015 0.48906 3.55029 -2.53938 PIK3R5 
Regulation of lipolysis in 
adipocytes Homo sapiens 
hsa04923 
1/56 0.36062 0.46515 3.38324 -2.58954 PIK3R5 
Synaptic vesicle cycle Homo 
sapiens hsa04721 1/63 0.39494 0.49161 3.71483 -2.63781 DNM1 
Arachidonic acid metabolism 
Homo sapiens hsa00590 1/62 0.39015 0.48906 3.93436 -2.81409 CYP2J2 
Legionellosis Homo sapiens 
hsa05134 1/55 0.35556 0.46515 3.76453 -2.88138 C3 
Starch and sucrose metabolism 
Homo sapiens hsa00500 1/56 0.36062 0.46515 4.08474 -3.12647 GYS1 
Notch signaling pathway Homo 
sapiens hsa04330 1/48 0.31905 0.44609 3.88715 -3.13786 KAT2B 
Ovarian steroidogenesis Homo 
sapiens hsa04913 1/50 0.32968 0.44853 4.03806 -3.23763 CYP2J2 
Amino sugar and nucleotide 
sugar metabolism Homo sapiens 
hsa00520 
1/48 0.31905 0.44609 4.01121 -3.23801 UAP1 
Bladder cancer Homo sapiens 
hsa05219 1/41 0.28050 0.43084 3.89141 -3.27662 HRAS 
Type II diabetes mellitus Homo 
sapiens hsa04930 1/48 0.31905 0.44609 4.12303 -3.32828 PIK3R5 
Mineral absorption Homo 
sapiens hsa04978 1/51 0.33494 0.44853 4.15519 -3.33155 ATP1A1 
Glutathione metabolism Homo 
sapiens hsa00480 1/52 0.34015 0.45185 4.27414 -3.39543 RRM2 
Drug metabolism - other 
enzymes Homo sapiens 
hsa00983 
1/46 0.30825 0.44392 4.25038 -3.45176 HPRT1 
Cysteine and methionine 
metabolism Homo sapiens 
hsa00270 
1/45 0.30278 0.44392 4.38106 -3.55788 AHCYL1 
Tryptophan metabolism Homo 
sapiens hsa00380 1/40 0.27482 0.43084 4.46818 -3.76227 KYNU 
Glycine, serine and threonine 
metabolism Homo sapiens 
hsa00260 
1/40 0.27482 0.43084 4.62082 -3.89079 AGXT 
African trypanosomiasis Homo 
sapiens hsa05143 1/35 0.24577 0.40885 4.35659 -3.89661 PLCB3 
Regulation of autophagy Homo 
sapiens hsa04140 1/39 0.26910 0.43084 4.75008 -3.99963 ATG14 
Thyroid cancer Homo sapiens 
hsa05216 1/29 0.20938 0.36901 4.22898 -4.21595 HRAS 
Pentose phosphate pathway 
Homo sapiens hsa00030 1/29 0.20938 0.36901 4.25791 -4.24479 FBP1 
Alanine, aspartate and glutamate 
metabolism Homo sapiens 
hsa00250 
1/35 0.24577 0.40885 4.77923 -4.27464 AGXT 
Fructose and mannose 
metabolism Homo sapiens 
hsa00051 
1/32 0.22779 0.38615 4.99270 -4.75068 FBP1 
Linoleic acid metabolism Homo 
sapiens hsa00591 1/29 0.20938 0.36901 4.89436 -4.87928 CYP2J2 
Glyoxylate and dicarboxylate 
metabolism Homo sapiens 
hsa00630 
1/28 0.20316 0.36901 4.93064 -4.91545 AGXT 
Proximal tubule bicarbonate 
reclamation Homo sapiens 
hsa04964 
1/23 0.17128 0.35073 4.97539 -5.21289 ATP1A1 
Phototransduction Homo sapiens 
hsa04744 1/27 0.19688 0.36505 5.43863 -5.48068 SAG 
2-Oxocarboxylic acid 
metabolism Homo sapiens 
hsa01210 
1/17 0.13138 0.32937 5.22227 -5.79976 ACY1 
Maturity onset diabetes of the 
young Homo sapiens hsa04950 1/26 0.19055 0.36471 5.81982 -5.87010 HNF4A 
Circadian rhythm Homo sapiens 
hsa04710 1/30 0.21557 0.36902 6.05243 -6.03376 BHLHE41 
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Arginine biosynthesis Homo 
sapiens hsa00220 1/20 0.15156 0.34671 6.17173 -6.53756 ACY1 
 
